[{
  "_id": {
    "$oid": "63e345920717205c0e0fa9f2"
  },
  "level": "LEVEL_1",
  "gene": "EZH2",
  "alteration": "A692V",
  "alteration_name": "A692V",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Follicular Lymphoma",
  "drug": [
    "Tazemetostat"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33035457",
      "title": "Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Nov",
      "volume": "21",
      "issue": "11",
      "pages": "1433-1442",
      "authors": "Morschhauser F et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30441-1",
      "link": null,
      "reference": "Morschhauser F et al. The Lancet. Oncology. 2020 Nov;21(11)1433-1442.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fa9f3"
  },
  "level": "LEVEL_1",
  "gene": "EZH2",
  "alteration": "Y646H",
  "alteration_name": "Y646H",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Follicular Lymphoma",
  "drug": [
    "Tazemetostat"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33035457",
      "title": "Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Nov",
      "volume": "21",
      "issue": "11",
      "pages": "1433-1442",
      "authors": "Morschhauser F et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30441-1",
      "link": null,
      "reference": "Morschhauser F et al. The Lancet. Oncology. 2020 Nov;21(11)1433-1442.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fa9f4"
  },
  "level": "LEVEL_1",
  "gene": "EZH2",
  "alteration": "Y646S",
  "alteration_name": "Y646S",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Follicular Lymphoma",
  "drug": [
    "Tazemetostat"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33035457",
      "title": "Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Nov",
      "volume": "21",
      "issue": "11",
      "pages": "1433-1442",
      "authors": "Morschhauser F et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30441-1",
      "link": null,
      "reference": "Morschhauser F et al. The Lancet. Oncology. 2020 Nov;21(11)1433-1442.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fa9f5"
  },
  "level": "LEVEL_1",
  "gene": "EZH2",
  "alteration": "Y646C",
  "alteration_name": "Y646C",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Follicular Lymphoma",
  "drug": [
    "Tazemetostat"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33035457",
      "title": "Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Nov",
      "volume": "21",
      "issue": "11",
      "pages": "1433-1442",
      "authors": "Morschhauser F et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30441-1",
      "link": null,
      "reference": "Morschhauser F et al. The Lancet. Oncology. 2020 Nov;21(11)1433-1442.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fa9f6"
  },
  "level": "LEVEL_1",
  "gene": "EZH2",
  "alteration": "Y646F",
  "alteration_name": "Y646F",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Follicular Lymphoma",
  "drug": [
    "Tazemetostat"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33035457",
      "title": "Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Nov",
      "volume": "21",
      "issue": "11",
      "pages": "1433-1442",
      "authors": "Morschhauser F et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30441-1",
      "link": null,
      "reference": "Morschhauser F et al. The Lancet. Oncology. 2020 Nov;21(11)1433-1442.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fa9f7"
  },
  "level": "LEVEL_1",
  "gene": "EZH2",
  "alteration": "Y646N",
  "alteration_name": "Y646N",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Follicular Lymphoma",
  "drug": [
    "Tazemetostat"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33035457",
      "title": "Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Nov",
      "volume": "21",
      "issue": "11",
      "pages": "1433-1442",
      "authors": "Morschhauser F et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30441-1",
      "link": null,
      "reference": "Morschhauser F et al. The Lancet. Oncology. 2020 Nov;21(11)1433-1442.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fa9f8"
  },
  "level": "LEVEL_1",
  "gene": "EZH2",
  "alteration": "A682G",
  "alteration_name": "A682G",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Follicular Lymphoma",
  "drug": [
    "Tazemetostat"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33035457",
      "title": "Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Nov",
      "volume": "21",
      "issue": "11",
      "pages": "1433-1442",
      "authors": "Morschhauser F et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30441-1",
      "link": null,
      "reference": "Morschhauser F et al. The Lancet. Oncology. 2020 Nov;21(11)1433-1442.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fa9f9"
  },
  "level": "LEVEL_1",
  "gene": "Other Biomarkers",
  "alteration": "MSI-H",
  "alteration_name": "Microsatellite Instability-High",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Nivolumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31765263",
      "title": "Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2020 Jan 20",
      "volume": "38",
      "issue": "3",
      "pages": "214-222",
      "authors": "Azad NS et al",
      "elocationId": "doi: 10.1200/JCO.19.00818",
      "link": null,
      "reference": "Azad NS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Jan 20;38(3)214-222.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/155742/abstract",
      "reference": "null. null. .",
      "abstract": "Andre et al. Abstract# 553, GCS 2018"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3510",
      "reference": "null. null. .",
      "abstract": "Overman et al. Abstract# 3510, ASCO 2022"
    },
    {
      "pmid": "28734759",
      "title": "Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2017 Sep",
      "volume": "18",
      "issue": "9",
      "pages": "1182-1191",
      "authors": "Overman MJ et al",
      "elocationId": "doi: 10.1016/S1470-2045(17)30422-9",
      "link": null,
      "reference": "Overman MJ et al. The Lancet. Oncology. 2017 Sep;18(9)1182-1191.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fa9fa"
  },
  "level": "LEVEL_1",
  "gene": "ABL1",
  "alteration": "T315I",
  "alteration_name": "T315I",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Ponatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23190221",
      "title": "Ponatinib in refractory Philadelphia chromosome-positive leukemias.",
      "journal": "The New England journal of medicine",
      "pubDate": "2012 Nov 29",
      "volume": "367",
      "issue": "22",
      "pages": "2075-88",
      "authors": "Cortes JE et al",
      "elocationId": "doi: 10.1056/NEJMoa1205127",
      "link": null,
      "reference": "Cortes JE et al. The New England journal of medicine. 2012 Nov 29;367(22)2075-88.",
      "abstract": null
    },
    {
      "pmid": "24180494",
      "title": "A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.",
      "journal": "The New England journal of medicine",
      "pubDate": "2013 Nov 7",
      "volume": "369",
      "issue": "19",
      "pages": "1783-96",
      "authors": "Cortes JE et al",
      "elocationId": "doi: 10.1056/NEJMoa1306494",
      "link": null,
      "reference": "Cortes JE et al. The New England journal of medicine. 2013 Nov 7;369(19)1783-96.",
      "abstract": null
    },
    {
      "pmid": "19878872",
      "title": "AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.",
      "journal": "Cancer cell",
      "pubDate": "2009 Nov 6",
      "volume": "16",
      "issue": "5",
      "pages": "401-12",
      "authors": "O'Hare T et al",
      "elocationId": "doi: 10.1016/j.ccr.2009.09.028",
      "link": null,
      "reference": "O'Hare T et al. Cancer cell. 2009 Nov 6;16(5)401-12.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fa9fb"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600K",
  "alteration_name": "V600K",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Binimetinib",
    "Encorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "35862871",
      "title": "COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2022 Jul 21",
      "volume": "",
      "issue": "",
      "pages": "JCO2102659",
      "authors": "Dummer R et al",
      "elocationId": "doi: 10.1200/JCO.21.02659",
      "link": null,
      "reference": "Dummer R et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Jul 21;()JCO2102659.",
      "abstract": null
    },
    {
      "pmid": "29573941",
      "title": "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2018 May",
      "volume": "19",
      "issue": "5",
      "pages": "603-615",
      "authors": "Dummer R et al",
      "elocationId": "doi: 10.1016/S1470-2045(18)30142-6",
      "link": null,
      "reference": "Dummer R et al. The Lancet. Oncology. 2018 May;19(5)603-615.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fa9fc"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Binimetinib",
    "Encorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "35862871",
      "title": "COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2022 Jul 21",
      "volume": "",
      "issue": "",
      "pages": "JCO2102659",
      "authors": "Dummer R et al",
      "elocationId": "doi: 10.1200/JCO.21.02659",
      "link": null,
      "reference": "Dummer R et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Jul 21;()JCO2102659.",
      "abstract": null
    },
    {
      "pmid": "29573941",
      "title": "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2018 May",
      "volume": "19",
      "issue": "5",
      "pages": "603-615",
      "authors": "Dummer R et al",
      "elocationId": "doi: 10.1016/S1470-2045(18)30142-6",
      "link": null,
      "reference": "Dummer R et al. The Lancet. Oncology. 2018 May;19(5)603-615.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fa9fd"
  },
  "level": "LEVEL_1",
  "gene": "ROS1",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "25264305",
      "title": "Crizotinib in ROS1-rearranged non-small-cell lung cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2014 Nov 20",
      "volume": "371",
      "issue": "21",
      "pages": "1963-71",
      "authors": "Shaw AT et al",
      "elocationId": "doi: 10.1056/NEJMoa1406766",
      "link": null,
      "reference": "Shaw AT et al. The New England journal of medicine. 2014 Nov 20;371(21)1963-71.",
      "abstract": null
    },
    {
      "pmid": "29596029",
      "title": "Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 May 10",
      "volume": "36",
      "issue": "14",
      "pages": "1405-1411",
      "authors": "Wu YL et al",
      "elocationId": "doi: 10.1200/JCO.2017.75.5587",
      "link": null,
      "reference": "Wu YL et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 May 10;36(14)1405-1411.",
      "abstract": null
    },
    {
      "pmid": "30980071",
      "title": "Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2019 Jul 1",
      "volume": "30",
      "issue": "7",
      "pages": "1121-1126",
      "authors": "Shaw AT et al",
      "elocationId": "doi: 10.1093/annonc/mdz131",
      "link": null,
      "reference": "Shaw AT et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Jul 1;30(7)1121-1126.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fa9fe"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "L858R",
  "alteration_name": "L858R",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Afatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22452895",
      "title": "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2012 May",
      "volume": "13",
      "issue": "5",
      "pages": "539-48",
      "authors": "Yang JC et al",
      "elocationId": "doi: 10.1016/S1470-2045(12)70086-4",
      "link": null,
      "reference": "Yang JC et al. The Lancet. Oncology. 2012 May;13(5)539-48.",
      "abstract": null
    },
    {
      "pmid": "25589191",
      "title": "Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2015 Feb",
      "volume": "16",
      "issue": "2",
      "pages": "141-51",
      "authors": "Yang JC et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)71173-8",
      "link": null,
      "reference": "Yang JC et al. The Lancet. Oncology. 2015 Feb;16(2)141-51.",
      "abstract": null
    },
    {
      "pmid": "23816960",
      "title": "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 20",
      "volume": "31",
      "issue": "27",
      "pages": "3327-34",
      "authors": "Sequist LV et al",
      "elocationId": "doi: 10.1200/JCO.2012.44.2806",
      "link": null,
      "reference": "Sequist LV et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 20;31(27)3327-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fa9ff"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "729_761del",
  "alteration_name": "Exon 19 in-frame deletions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Afatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22452895",
      "title": "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2012 May",
      "volume": "13",
      "issue": "5",
      "pages": "539-48",
      "authors": "Yang JC et al",
      "elocationId": "doi: 10.1016/S1470-2045(12)70086-4",
      "link": null,
      "reference": "Yang JC et al. The Lancet. Oncology. 2012 May;13(5)539-48.",
      "abstract": null
    },
    {
      "pmid": "25589191",
      "title": "Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2015 Feb",
      "volume": "16",
      "issue": "2",
      "pages": "141-51",
      "authors": "Yang JC et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)71173-8",
      "link": null,
      "reference": "Yang JC et al. The Lancet. Oncology. 2015 Feb;16(2)141-51.",
      "abstract": null
    },
    {
      "pmid": "23816960",
      "title": "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 20",
      "volume": "31",
      "issue": "27",
      "pages": "3327-34",
      "authors": "Sequist LV et al",
      "elocationId": "doi: 10.1200/JCO.2012.44.2806",
      "link": null,
      "reference": "Sequist LV et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 20;31(27)3327-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa00"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24882434",
      "title": "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 Jul",
      "volume": "15",
      "issue": "8",
      "pages": "852-61",
      "authors": "Ledermann J et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70228-1",
      "link": null,
      "reference": "Ledermann J et al. The Lancet. Oncology. 2014 Jul;15(8)852-61.",
      "abstract": null
    },
    {
      "pmid": "25366685",
      "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Jan 20",
      "volume": "33",
      "issue": "3",
      "pages": "244-50",
      "authors": "Kaufman B et al",
      "elocationId": "doi: 10.1200/JCO.2014.56.2728",
      "link": null,
      "reference": "Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.",
      "abstract": null
    },
    {
      "pmid": "36082969",
      "title": "Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2022 Sep 9",
      "volume": "",
      "issue": "",
      "pages": "JCO2201549",
      "authors": "DiSilvestro P et al",
      "elocationId": "doi: 10.1200/JCO.22.01549",
      "link": null,
      "reference": "DiSilvestro P et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Sep 9;()JCO2201549.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa01"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Bevacizumab",
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24882434",
      "title": "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 Jul",
      "volume": "15",
      "issue": "8",
      "pages": "852-61",
      "authors": "Ledermann J et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70228-1",
      "link": null,
      "reference": "Ledermann J et al. The Lancet. Oncology. 2014 Jul;15(8)852-61.",
      "abstract": null
    },
    {
      "pmid": "25366685",
      "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Jan 20",
      "volume": "33",
      "issue": "3",
      "pages": "244-50",
      "authors": "Kaufman B et al",
      "elocationId": "doi: 10.1200/JCO.2014.56.2728",
      "link": null,
      "reference": "Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.",
      "abstract": null
    },
    {
      "pmid": "36082969",
      "title": "Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2022 Sep 9",
      "volume": "",
      "issue": "",
      "pages": "JCO2201549",
      "authors": "DiSilvestro P et al",
      "elocationId": "doi: 10.1200/JCO.22.01549",
      "link": null,
      "reference": "DiSilvestro P et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Sep 9;()JCO2201549.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa02"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian/Fallopian Tube Cancer, NOS",
  "cancer_sub_type": "Ovary/Fallopian Tube",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24882434",
      "title": "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 Jul",
      "volume": "15",
      "issue": "8",
      "pages": "852-61",
      "authors": "Ledermann J et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70228-1",
      "link": null,
      "reference": "Ledermann J et al. The Lancet. Oncology. 2014 Jul;15(8)852-61.",
      "abstract": null
    },
    {
      "pmid": "25366685",
      "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Jan 20",
      "volume": "33",
      "issue": "3",
      "pages": "244-50",
      "authors": "Kaufman B et al",
      "elocationId": "doi: 10.1200/JCO.2014.56.2728",
      "link": null,
      "reference": "Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.",
      "abstract": null
    },
    {
      "pmid": "36082969",
      "title": "Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2022 Sep 9",
      "volume": "",
      "issue": "",
      "pages": "JCO2201549",
      "authors": "DiSilvestro P et al",
      "elocationId": "doi: 10.1200/JCO.22.01549",
      "link": null,
      "reference": "DiSilvestro P et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Sep 9;()JCO2201549.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa03"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian/Fallopian Tube Cancer, NOS",
  "cancer_sub_type": "Ovary/Fallopian Tube",
  "drug": [
    "Bevacizumab",
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24882434",
      "title": "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 Jul",
      "volume": "15",
      "issue": "8",
      "pages": "852-61",
      "authors": "Ledermann J et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70228-1",
      "link": null,
      "reference": "Ledermann J et al. The Lancet. Oncology. 2014 Jul;15(8)852-61.",
      "abstract": null
    },
    {
      "pmid": "25366685",
      "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Jan 20",
      "volume": "33",
      "issue": "3",
      "pages": "244-50",
      "authors": "Kaufman B et al",
      "elocationId": "doi: 10.1200/JCO.2014.56.2728",
      "link": null,
      "reference": "Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.",
      "abstract": null
    },
    {
      "pmid": "36082969",
      "title": "Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2022 Sep 9",
      "volume": "",
      "issue": "",
      "pages": "JCO2201549",
      "authors": "DiSilvestro P et al",
      "elocationId": "doi: 10.1200/JCO.22.01549",
      "link": null,
      "reference": "DiSilvestro P et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Sep 9;()JCO2201549.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa04"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Peritoneal Cancer, NOS",
  "cancer_sub_type": "Peritoneal Serous Carcinoma",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24882434",
      "title": "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 Jul",
      "volume": "15",
      "issue": "8",
      "pages": "852-61",
      "authors": "Ledermann J et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70228-1",
      "link": null,
      "reference": "Ledermann J et al. The Lancet. Oncology. 2014 Jul;15(8)852-61.",
      "abstract": null
    },
    {
      "pmid": "25366685",
      "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Jan 20",
      "volume": "33",
      "issue": "3",
      "pages": "244-50",
      "authors": "Kaufman B et al",
      "elocationId": "doi: 10.1200/JCO.2014.56.2728",
      "link": null,
      "reference": "Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.",
      "abstract": null
    },
    {
      "pmid": "36082969",
      "title": "Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2022 Sep 9",
      "volume": "",
      "issue": "",
      "pages": "JCO2201549",
      "authors": "DiSilvestro P et al",
      "elocationId": "doi: 10.1200/JCO.22.01549",
      "link": null,
      "reference": "DiSilvestro P et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Sep 9;()JCO2201549.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa05"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Peritoneal Cancer, NOS",
  "cancer_sub_type": "Peritoneal Serous Carcinoma",
  "drug": [
    "Bevacizumab",
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24882434",
      "title": "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 Jul",
      "volume": "15",
      "issue": "8",
      "pages": "852-61",
      "authors": "Ledermann J et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70228-1",
      "link": null,
      "reference": "Ledermann J et al. The Lancet. Oncology. 2014 Jul;15(8)852-61.",
      "abstract": null
    },
    {
      "pmid": "25366685",
      "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Jan 20",
      "volume": "33",
      "issue": "3",
      "pages": "244-50",
      "authors": "Kaufman B et al",
      "elocationId": "doi: 10.1200/JCO.2014.56.2728",
      "link": null,
      "reference": "Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.",
      "abstract": null
    },
    {
      "pmid": "36082969",
      "title": "Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2022 Sep 9",
      "volume": "",
      "issue": "",
      "pages": "JCO2201549",
      "authors": "DiSilvestro P et al",
      "elocationId": "doi: 10.1200/JCO.22.01549",
      "link": null,
      "reference": "DiSilvestro P et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Sep 9;()JCO2201549.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa06"
  },
  "level": "LEVEL_1",
  "gene": "FGFR2",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Bladder Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erdafitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    },
    {
      "pmid": "26324363",
      "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Oct 20",
      "volume": "33",
      "issue": "30",
      "pages": "3401-8",
      "authors": "Tabernero J et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.7341",
      "link": null,
      "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa07"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600",
  "alteration_name": "V600",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Vemurafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29188284",
      "title": "Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.",
      "journal": "JAMA oncology",
      "pubDate": "2018 Mar 1",
      "volume": "4",
      "issue": "3",
      "pages": "384-388",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1001/jamaoncol.2017.5029",
      "link": null,
      "reference": "Diamond EL et al. JAMA oncology. 2018 Mar 1;4(3)384-388.",
      "abstract": null
    },
    {
      "pmid": "26287849",
      "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Aug 20",
      "volume": "373",
      "issue": "8",
      "pages": "726-36",
      "authors": "Hyman DM et al",
      "elocationId": "doi: 10.1056/NEJMoa1502309",
      "link": null,
      "reference": "Hyman DM et al. The New England journal of medicine. 2015 Aug 20;373(8)726-36.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa08"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Ado-Trastuzumab Emtansine"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30516102",
      "title": "Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Feb 14",
      "volume": "380",
      "issue": "7",
      "pages": "617-628",
      "authors": "von Minckwitz G et al",
      "elocationId": "doi: 10.1056/NEJMoa1814017",
      "link": null,
      "reference": "von Minckwitz G et al. The New England journal of medicine. 2019 Feb 14;380(7)617-628.",
      "abstract": null
    },
    {
      "pmid": "23020162",
      "title": "Trastuzumab emtansine for HER2-positive advanced breast cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2012 Nov 8",
      "volume": "367",
      "issue": "19",
      "pages": "1783-91",
      "authors": "Verma S et al",
      "elocationId": "doi: 10.1056/NEJMoa1209124",
      "link": null,
      "reference": "Verma S et al. The New England journal of medicine. 2012 Nov 8;367(19)1783-91.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa09"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "T790M",
  "alteration_name": "T790M",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Osimertinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "25923549",
      "title": "AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Apr 30",
      "volume": "372",
      "issue": "18",
      "pages": "1689-99",
      "authors": "Jänne PA et al",
      "elocationId": "doi: 10.1056/NEJMoa1411817",
      "link": null,
      "reference": "Jänne PA et al. The New England journal of medicine. 2015 Apr 30;372(18)1689-99.",
      "abstract": null
    },
    {
      "pmid": "30059262",
      "title": "CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Sep 10",
      "volume": "36",
      "issue": "26",
      "pages": "2702-2709",
      "authors": "Wu YL et al",
      "elocationId": "doi: 10.1200/JCO.2018.77.9363",
      "link": null,
      "reference": "Wu YL et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Sep 10;36(26)2702-2709.",
      "abstract": null
    },
    {
      "pmid": "29151359",
      "title": "Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Jan 11",
      "volume": "378",
      "issue": "2",
      "pages": "113-125",
      "authors": "Soria JC et al",
      "elocationId": "doi: 10.1056/NEJMoa1713137",
      "link": null,
      "reference": "Soria JC et al. The New England journal of medicine. 2018 Jan 11;378(2)113-125.",
      "abstract": null
    },
    {
      "pmid": "27751847",
      "title": "Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2016 Dec",
      "volume": "17",
      "issue": "12",
      "pages": "1643-1652",
      "authors": "Goss G et al",
      "elocationId": "doi: 10.1016/S1470-2045(16)30508-3",
      "link": null,
      "reference": "Goss G et al. The Lancet. Oncology. 2016 Dec;17(12)1643-1652.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa0a"
  },
  "level": "LEVEL_1",
  "gene": "ABL1",
  "alteration": "T315I",
  "alteration_name": "T315I",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Asciminib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ash.confex.com/ash/2020/webprogram/Paper143816.html",
      "reference": "null. null. .",
      "abstract": "Hochhaus et al. Abstract #LBA-4, ASH 2020"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa0b"
  },
  "level": "LEVEL_1",
  "gene": "PIK3CA",
  "alteration": "C420R",
  "alteration_name": "C420R",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alpelisib",
    "Fulvestrant"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30543347",
      "title": "Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Feb 1",
      "volume": "5",
      "issue": "2",
      "pages": "e184475",
      "authors": "Juric D et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.4475",
      "link": null,
      "reference": "Juric D et al. JAMA oncology. 2019 Feb 1;5(2)e184475.",
      "abstract": null
    },
    {
      "pmid": "31091374",
      "title": "Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 May 16",
      "volume": "380",
      "issue": "20",
      "pages": "1929-1940",
      "authors": "André F et al",
      "elocationId": "doi: 10.1056/NEJMoa1813904",
      "link": null,
      "reference": "André F et al. The New England journal of medicine. 2019 May 16;380(20)1929-1940.",
      "abstract": null
    },
    {
      "pmid": "25877889",
      "title": "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2015 Apr 15",
      "volume": "7",
      "issue": "283",
      "pages": "283ra51",
      "authors": "Bosch A et al",
      "elocationId": "doi: 10.1126/scitranslmed.aaa4442",
      "link": null,
      "reference": "Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa0c"
  },
  "level": "LEVEL_1",
  "gene": "PIK3CA",
  "alteration": "E542K",
  "alteration_name": "E542K",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alpelisib",
    "Fulvestrant"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30543347",
      "title": "Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Feb 1",
      "volume": "5",
      "issue": "2",
      "pages": "e184475",
      "authors": "Juric D et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.4475",
      "link": null,
      "reference": "Juric D et al. JAMA oncology. 2019 Feb 1;5(2)e184475.",
      "abstract": null
    },
    {
      "pmid": "31091374",
      "title": "Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 May 16",
      "volume": "380",
      "issue": "20",
      "pages": "1929-1940",
      "authors": "André F et al",
      "elocationId": "doi: 10.1056/NEJMoa1813904",
      "link": null,
      "reference": "André F et al. The New England journal of medicine. 2019 May 16;380(20)1929-1940.",
      "abstract": null
    },
    {
      "pmid": "25877889",
      "title": "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2015 Apr 15",
      "volume": "7",
      "issue": "283",
      "pages": "283ra51",
      "authors": "Bosch A et al",
      "elocationId": "doi: 10.1126/scitranslmed.aaa4442",
      "link": null,
      "reference": "Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa0d"
  },
  "level": "LEVEL_1",
  "gene": "PIK3CA",
  "alteration": "E545A",
  "alteration_name": "E545A",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alpelisib",
    "Fulvestrant"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30543347",
      "title": "Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Feb 1",
      "volume": "5",
      "issue": "2",
      "pages": "e184475",
      "authors": "Juric D et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.4475",
      "link": null,
      "reference": "Juric D et al. JAMA oncology. 2019 Feb 1;5(2)e184475.",
      "abstract": null
    },
    {
      "pmid": "31091374",
      "title": "Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 May 16",
      "volume": "380",
      "issue": "20",
      "pages": "1929-1940",
      "authors": "André F et al",
      "elocationId": "doi: 10.1056/NEJMoa1813904",
      "link": null,
      "reference": "André F et al. The New England journal of medicine. 2019 May 16;380(20)1929-1940.",
      "abstract": null
    },
    {
      "pmid": "25877889",
      "title": "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2015 Apr 15",
      "volume": "7",
      "issue": "283",
      "pages": "283ra51",
      "authors": "Bosch A et al",
      "elocationId": "doi: 10.1126/scitranslmed.aaa4442",
      "link": null,
      "reference": "Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa0e"
  },
  "level": "LEVEL_1",
  "gene": "PIK3CA",
  "alteration": "E545D",
  "alteration_name": "E545D",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alpelisib",
    "Fulvestrant"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30543347",
      "title": "Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Feb 1",
      "volume": "5",
      "issue": "2",
      "pages": "e184475",
      "authors": "Juric D et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.4475",
      "link": null,
      "reference": "Juric D et al. JAMA oncology. 2019 Feb 1;5(2)e184475.",
      "abstract": null
    },
    {
      "pmid": "31091374",
      "title": "Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 May 16",
      "volume": "380",
      "issue": "20",
      "pages": "1929-1940",
      "authors": "André F et al",
      "elocationId": "doi: 10.1056/NEJMoa1813904",
      "link": null,
      "reference": "André F et al. The New England journal of medicine. 2019 May 16;380(20)1929-1940.",
      "abstract": null
    },
    {
      "pmid": "25877889",
      "title": "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2015 Apr 15",
      "volume": "7",
      "issue": "283",
      "pages": "283ra51",
      "authors": "Bosch A et al",
      "elocationId": "doi: 10.1126/scitranslmed.aaa4442",
      "link": null,
      "reference": "Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa0f"
  },
  "level": "LEVEL_1",
  "gene": "PIK3CA",
  "alteration": "E545G",
  "alteration_name": "E545G",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alpelisib",
    "Fulvestrant"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30543347",
      "title": "Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Feb 1",
      "volume": "5",
      "issue": "2",
      "pages": "e184475",
      "authors": "Juric D et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.4475",
      "link": null,
      "reference": "Juric D et al. JAMA oncology. 2019 Feb 1;5(2)e184475.",
      "abstract": null
    },
    {
      "pmid": "31091374",
      "title": "Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 May 16",
      "volume": "380",
      "issue": "20",
      "pages": "1929-1940",
      "authors": "André F et al",
      "elocationId": "doi: 10.1056/NEJMoa1813904",
      "link": null,
      "reference": "André F et al. The New England journal of medicine. 2019 May 16;380(20)1929-1940.",
      "abstract": null
    },
    {
      "pmid": "25877889",
      "title": "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2015 Apr 15",
      "volume": "7",
      "issue": "283",
      "pages": "283ra51",
      "authors": "Bosch A et al",
      "elocationId": "doi: 10.1126/scitranslmed.aaa4442",
      "link": null,
      "reference": "Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa10"
  },
  "level": "LEVEL_1",
  "gene": "PIK3CA",
  "alteration": "E545K",
  "alteration_name": "E545K",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alpelisib",
    "Fulvestrant"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30543347",
      "title": "Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Feb 1",
      "volume": "5",
      "issue": "2",
      "pages": "e184475",
      "authors": "Juric D et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.4475",
      "link": null,
      "reference": "Juric D et al. JAMA oncology. 2019 Feb 1;5(2)e184475.",
      "abstract": null
    },
    {
      "pmid": "31091374",
      "title": "Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 May 16",
      "volume": "380",
      "issue": "20",
      "pages": "1929-1940",
      "authors": "André F et al",
      "elocationId": "doi: 10.1056/NEJMoa1813904",
      "link": null,
      "reference": "André F et al. The New England journal of medicine. 2019 May 16;380(20)1929-1940.",
      "abstract": null
    },
    {
      "pmid": "25877889",
      "title": "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2015 Apr 15",
      "volume": "7",
      "issue": "283",
      "pages": "283ra51",
      "authors": "Bosch A et al",
      "elocationId": "doi: 10.1126/scitranslmed.aaa4442",
      "link": null,
      "reference": "Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa11"
  },
  "level": "LEVEL_1",
  "gene": "PIK3CA",
  "alteration": "Q546E",
  "alteration_name": "Q546E",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alpelisib",
    "Fulvestrant"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30543347",
      "title": "Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Feb 1",
      "volume": "5",
      "issue": "2",
      "pages": "e184475",
      "authors": "Juric D et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.4475",
      "link": null,
      "reference": "Juric D et al. JAMA oncology. 2019 Feb 1;5(2)e184475.",
      "abstract": null
    },
    {
      "pmid": "31091374",
      "title": "Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 May 16",
      "volume": "380",
      "issue": "20",
      "pages": "1929-1940",
      "authors": "André F et al",
      "elocationId": "doi: 10.1056/NEJMoa1813904",
      "link": null,
      "reference": "André F et al. The New England journal of medicine. 2019 May 16;380(20)1929-1940.",
      "abstract": null
    },
    {
      "pmid": "25877889",
      "title": "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2015 Apr 15",
      "volume": "7",
      "issue": "283",
      "pages": "283ra51",
      "authors": "Bosch A et al",
      "elocationId": "doi: 10.1126/scitranslmed.aaa4442",
      "link": null,
      "reference": "Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa12"
  },
  "level": "LEVEL_1",
  "gene": "PIK3CA",
  "alteration": "Q546R",
  "alteration_name": "Q546R",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alpelisib",
    "Fulvestrant"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30543347",
      "title": "Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Feb 1",
      "volume": "5",
      "issue": "2",
      "pages": "e184475",
      "authors": "Juric D et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.4475",
      "link": null,
      "reference": "Juric D et al. JAMA oncology. 2019 Feb 1;5(2)e184475.",
      "abstract": null
    },
    {
      "pmid": "31091374",
      "title": "Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 May 16",
      "volume": "380",
      "issue": "20",
      "pages": "1929-1940",
      "authors": "André F et al",
      "elocationId": "doi: 10.1056/NEJMoa1813904",
      "link": null,
      "reference": "André F et al. The New England journal of medicine. 2019 May 16;380(20)1929-1940.",
      "abstract": null
    },
    {
      "pmid": "25877889",
      "title": "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2015 Apr 15",
      "volume": "7",
      "issue": "283",
      "pages": "283ra51",
      "authors": "Bosch A et al",
      "elocationId": "doi: 10.1126/scitranslmed.aaa4442",
      "link": null,
      "reference": "Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa13"
  },
  "level": "LEVEL_1",
  "gene": "PIK3CA",
  "alteration": "H1047L",
  "alteration_name": "H1047L",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alpelisib",
    "Fulvestrant"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30543347",
      "title": "Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Feb 1",
      "volume": "5",
      "issue": "2",
      "pages": "e184475",
      "authors": "Juric D et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.4475",
      "link": null,
      "reference": "Juric D et al. JAMA oncology. 2019 Feb 1;5(2)e184475.",
      "abstract": null
    },
    {
      "pmid": "31091374",
      "title": "Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 May 16",
      "volume": "380",
      "issue": "20",
      "pages": "1929-1940",
      "authors": "André F et al",
      "elocationId": "doi: 10.1056/NEJMoa1813904",
      "link": null,
      "reference": "André F et al. The New England journal of medicine. 2019 May 16;380(20)1929-1940.",
      "abstract": null
    },
    {
      "pmid": "25877889",
      "title": "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2015 Apr 15",
      "volume": "7",
      "issue": "283",
      "pages": "283ra51",
      "authors": "Bosch A et al",
      "elocationId": "doi: 10.1126/scitranslmed.aaa4442",
      "link": null,
      "reference": "Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa14"
  },
  "level": "LEVEL_1",
  "gene": "PIK3CA",
  "alteration": "H1047R",
  "alteration_name": "H1047R",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alpelisib",
    "Fulvestrant"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30543347",
      "title": "Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Feb 1",
      "volume": "5",
      "issue": "2",
      "pages": "e184475",
      "authors": "Juric D et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.4475",
      "link": null,
      "reference": "Juric D et al. JAMA oncology. 2019 Feb 1;5(2)e184475.",
      "abstract": null
    },
    {
      "pmid": "31091374",
      "title": "Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 May 16",
      "volume": "380",
      "issue": "20",
      "pages": "1929-1940",
      "authors": "André F et al",
      "elocationId": "doi: 10.1056/NEJMoa1813904",
      "link": null,
      "reference": "André F et al. The New England journal of medicine. 2019 May 16;380(20)1929-1940.",
      "abstract": null
    },
    {
      "pmid": "25877889",
      "title": "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2015 Apr 15",
      "volume": "7",
      "issue": "283",
      "pages": "283ra51",
      "authors": "Bosch A et al",
      "elocationId": "doi: 10.1126/scitranslmed.aaa4442",
      "link": null,
      "reference": "Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa15"
  },
  "level": "LEVEL_1",
  "gene": "PIK3CA",
  "alteration": "H1047Y",
  "alteration_name": "H1047Y",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alpelisib",
    "Fulvestrant"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30543347",
      "title": "Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Feb 1",
      "volume": "5",
      "issue": "2",
      "pages": "e184475",
      "authors": "Juric D et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.4475",
      "link": null,
      "reference": "Juric D et al. JAMA oncology. 2019 Feb 1;5(2)e184475.",
      "abstract": null
    },
    {
      "pmid": "31091374",
      "title": "Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 May 16",
      "volume": "380",
      "issue": "20",
      "pages": "1929-1940",
      "authors": "André F et al",
      "elocationId": "doi: 10.1056/NEJMoa1813904",
      "link": null,
      "reference": "André F et al. The New England journal of medicine. 2019 May 16;380(20)1929-1940.",
      "abstract": null
    },
    {
      "pmid": "25877889",
      "title": "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2015 Apr 15",
      "volume": "7",
      "issue": "283",
      "pages": "283ra51",
      "authors": "Bosch A et al",
      "elocationId": "doi: 10.1126/scitranslmed.aaa4442",
      "link": null,
      "reference": "Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa16"
  },
  "level": "LEVEL_1",
  "gene": "RAD51B",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa17"
  },
  "level": "LEVEL_1",
  "gene": "RAD51B",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa18"
  },
  "level": "LEVEL_1",
  "gene": "IDH1",
  "alteration": "R132C",
  "alteration_name": "R132C",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Olutasidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ashpublications.org/blood/article/140/Supplement%201/6193/487212",
      "reference": "null. null. .",
      "abstract": "Cortes et al. Abstract #6193, ASH 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa19"
  },
  "level": "LEVEL_1",
  "gene": "IDH1",
  "alteration": "R132H",
  "alteration_name": "R132H",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Olutasidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ashpublications.org/blood/article/140/Supplement%201/6193/487212",
      "reference": "null. null. .",
      "abstract": "Cortes et al. Abstract #6193, ASH 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa1a"
  },
  "level": "LEVEL_1",
  "gene": "IDH1",
  "alteration": "R132G",
  "alteration_name": "R132G",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Olutasidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ashpublications.org/blood/article/140/Supplement%201/6193/487212",
      "reference": "null. null. .",
      "abstract": "Cortes et al. Abstract #6193, ASH 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa1b"
  },
  "level": "LEVEL_1",
  "gene": "IDH1",
  "alteration": "R132S",
  "alteration_name": "R132S",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Olutasidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ashpublications.org/blood/article/140/Supplement%201/6193/487212",
      "reference": "null. null. .",
      "abstract": "Cortes et al. Abstract #6193, ASH 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa1c"
  },
  "level": "LEVEL_1",
  "gene": "IDH1",
  "alteration": "R132L",
  "alteration_name": "R132L",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Olutasidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ashpublications.org/blood/article/140/Supplement%201/6193/487212",
      "reference": "null. null. .",
      "abstract": "Cortes et al. Abstract #6193, ASH 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa1d"
  },
  "level": "LEVEL_1",
  "gene": "NTRK2",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Larotrectinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26216294",
      "title": "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.",
      "journal": "Cancer discovery",
      "pubDate": "2015 Oct",
      "volume": "5",
      "issue": "10",
      "pages": "1049-57",
      "authors": "Doebele RC et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0443",
      "link": null,
      "reference": "Doebele RC et al. Cancer discovery. 2015 Oct;5(10)1049-57.",
      "abstract": null
    },
    {
      "pmid": "29466156",
      "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Feb 22",
      "volume": "378",
      "issue": "8",
      "pages": "731-739",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1056/NEJMoa1714448",
      "link": null,
      "reference": "Drilon A et al. The New England journal of medicine. 2018 Feb 22;378(8)731-739.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa1e"
  },
  "level": "LEVEL_1",
  "gene": "FGFR2",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Hepatobiliary Cancer",
  "cancer_sub_type": "Cholangiocarcinoma",
  "drug": [
    "Infigratinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.3_suppl.265?af=R",
      "reference": "null. null. .",
      "abstract": "Javle et al. Abstract# 265, ASCO 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa1f"
  },
  "level": "LEVEL_1",
  "gene": "RAD51C",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa20"
  },
  "level": "LEVEL_1",
  "gene": "RAD51C",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa21"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Chemotherapy",
    "Margetuximab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.1000",
      "reference": "null. null. .",
      "abstract": "Rugo et al. Abstract# 1000, ASCO 2019"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa22"
  },
  "level": "LEVEL_1",
  "gene": "ALK",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alectinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29668860",
      "title": "Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2018 Jun 1",
      "volume": "29",
      "issue": "6",
      "pages": "1409-1416",
      "authors": "Novello S et al",
      "elocationId": "doi: 10.1093/annonc/mdy121",
      "link": null,
      "reference": "Novello S et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Jun 1;29(6)1409-1416.",
      "abstract": null
    },
    {
      "pmid": "30215676",
      "title": "Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2018 Nov 1",
      "volume": "29",
      "issue": "11",
      "pages": "2214-2222",
      "authors": "Gadgeel S et al",
      "elocationId": "doi: 10.1093/annonc/mdy405",
      "link": null,
      "reference": "Gadgeel S et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Nov 1;29(11)2214-2222.",
      "abstract": null
    },
    {
      "pmid": "28586279",
      "title": "Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Aug 31",
      "volume": "377",
      "issue": "9",
      "pages": "829-838",
      "authors": "Peters S et al",
      "elocationId": "doi: 10.1056/NEJMoa1704795",
      "link": null,
      "reference": "Peters S et al. The New England journal of medicine. 2017 Aug 31;377(9)829-838.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa23"
  },
  "level": "LEVEL_1",
  "gene": "MET",
  "alteration": "963_1010del",
  "alteration_name": "Exon 14 in-frame deletions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Tepotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32469185",
      "title": "Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 Sep 3",
      "volume": "383",
      "issue": "10",
      "pages": "931-943",
      "authors": "Paik PK et al",
      "elocationId": "doi: 10.1056/NEJMoa2004407",
      "link": null,
      "reference": "Paik PK et al. The New England journal of medicine. 2020 Sep 3;383(10)931-943.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa24"
  },
  "level": "LEVEL_1",
  "gene": "MET",
  "alteration": "Exon 14 Deletion",
  "alteration_name": "Exon 14 Deletion",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Tepotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32469185",
      "title": "Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 Sep 3",
      "volume": "383",
      "issue": "10",
      "pages": "931-943",
      "authors": "Paik PK et al",
      "elocationId": "doi: 10.1056/NEJMoa2004407",
      "link": null,
      "reference": "Paik PK et al. The New England journal of medicine. 2020 Sep 3;383(10)931-943.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa25"
  },
  "level": "LEVEL_1",
  "gene": "MET",
  "alteration": "D1010",
  "alteration_name": "D1010",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Tepotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32469185",
      "title": "Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 Sep 3",
      "volume": "383",
      "issue": "10",
      "pages": "931-943",
      "authors": "Paik PK et al",
      "elocationId": "doi: 10.1056/NEJMoa2004407",
      "link": null,
      "reference": "Paik PK et al. The New England journal of medicine. 2020 Sep 3;383(10)931-943.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa26"
  },
  "level": "LEVEL_1",
  "gene": "MET",
  "alteration": "963_1010splice",
  "alteration_name": "Exon 14 splice mutations",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Tepotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32469185",
      "title": "Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 Sep 3",
      "volume": "383",
      "issue": "10",
      "pages": "931-943",
      "authors": "Paik PK et al",
      "elocationId": "doi: 10.1056/NEJMoa2004407",
      "link": null,
      "reference": "Paik PK et al. The New England journal of medicine. 2020 Sep 3;383(10)931-943.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa27"
  },
  "level": "LEVEL_1",
  "gene": "FGFR3",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Bladder Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erdafitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    },
    {
      "pmid": "26324363",
      "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Oct 20",
      "volume": "33",
      "issue": "30",
      "pages": "3401-8",
      "authors": "Tabernero J et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.7341",
      "link": null,
      "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa28"
  },
  "level": "LEVEL_1",
  "gene": "PDGFRA",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Myelodysplastic/Myeloproliferative Neoplasms",
  "cancer_sub_type": "Myelodysplastic/Myeloproliferative Neoplasms",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "17555450",
      "title": "Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia.",
      "journal": "British journal of haematology",
      "pubDate": "2007 Jul",
      "volume": "138",
      "issue": "1",
      "pages": "77-81",
      "authors": "Curtis CE et al",
      "elocationId": "",
      "link": null,
      "reference": "Curtis CE et al. British journal of haematology. 2007 Jul;138(1)77-81.",
      "abstract": null
    },
    {
      "pmid": "15034867",
      "title": "Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia.",
      "journal": "Genes, chromosomes & cancer",
      "pubDate": "2004 May",
      "volume": "40",
      "issue": "1",
      "pages": "44-50",
      "authors": "Safley AM et al",
      "elocationId": "",
      "link": null,
      "reference": "Safley AM et al. Genes, chromosomes & cancer. 2004 May;40(1)44-50.",
      "abstract": null
    },
    {
      "pmid": "12660384",
      "title": "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.",
      "journal": "The New England journal of medicine",
      "pubDate": "2003 Mar 27",
      "volume": "348",
      "issue": "13",
      "pages": "1201-14",
      "authors": "Cools J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cools J et al. The New England journal of medicine. 2003 Mar 27;348(13)1201-14.",
      "abstract": null
    },
    {
      "pmid": "14504092",
      "title": "Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.",
      "journal": "Blood",
      "pubDate": "2004 Jan 15",
      "volume": "103",
      "issue": "2",
      "pages": "473-8",
      "authors": "Klion AD et al",
      "elocationId": "",
      "link": null,
      "reference": "Klion AD et al. Blood. 2004 Jan 15;103(2)473-8.",
      "abstract": null
    },
    {
      "pmid": "12944919",
      "title": "Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec.",
      "journal": "Oncogene",
      "pubDate": "2003 Aug 28",
      "volume": "22",
      "issue": "36",
      "pages": "5702-6",
      "authors": "Trempat P et al",
      "elocationId": "",
      "link": null,
      "reference": "Trempat P et al. Oncogene. 2003 Aug 28;22(36)5702-6.",
      "abstract": null
    },
    {
      "pmid": "16845659",
      "title": "Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.",
      "journal": "Genes, chromosomes & cancer",
      "pubDate": "2006 Oct",
      "volume": "45",
      "issue": "10",
      "pages": "950-6",
      "authors": "Walz C et al",
      "elocationId": "",
      "link": null,
      "reference": "Walz C et al. Genes, chromosomes & cancer. 2006 Oct;45(10)950-6.",
      "abstract": null
    },
    {
      "pmid": "18950453",
      "title": "Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.",
      "journal": "British journal of haematology",
      "pubDate": "2008 Dec",
      "volume": "143",
      "issue": "5",
      "pages": "707-15",
      "authors": "Metzgeroth G et al",
      "elocationId": "doi: 10.1111/j.1365-2141.2008.07294.x",
      "link": null,
      "reference": "Metzgeroth G et al. British journal of haematology. 2008 Dec;143(5)707-15.",
      "abstract": null
    },
    {
      "pmid": "16498388",
      "title": "Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.",
      "journal": "Leukemia",
      "pubDate": "2006 May",
      "volume": "20",
      "issue": "5",
      "pages": "827-32",
      "authors": "Score J et al",
      "elocationId": "",
      "link": null,
      "reference": "Score J et al. Leukemia. 2006 May;20(5)827-32.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa29"
  },
  "level": "LEVEL_1",
  "gene": "CDK12",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa2a"
  },
  "level": "LEVEL_1",
  "gene": "CDK12",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa2b"
  },
  "level": "LEVEL_1",
  "gene": "RET",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Thyroid Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Pralsetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109",
      "reference": "null. null. .",
      "abstract": "Subbiah et al. Abstract# 109, ASCO 2020"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy",
      "reference": "null. null. .",
      "abstract": "Hu et al. Abstract# 19130, ESMO 2020"
    },
    {
      "pmid": "29657135",
      "title": "Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers.",
      "journal": "Cancer discovery",
      "pubDate": "2018 Jul",
      "volume": "8",
      "issue": "7",
      "pages": "836-849",
      "authors": "Subbiah V et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0338",
      "link": null,
      "reference": "Subbiah V et al. Cancer discovery. 2018 Jul;8(7)836-849.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa2c"
  },
  "level": "LEVEL_1",
  "gene": "ABL1",
  "alteration": "BCR-ABL1 Fusion",
  "alteration_name": "BCR-ABL1 Fusion",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    },
    {
      "pmid": "24345751",
      "title": "Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2014 Feb 27",
      "volume": "123",
      "issue": "9",
      "pages": "1309-18",
      "authors": "Kantarjian HM et al",
      "elocationId": "doi: 10.1182/blood-2013-07-513937",
      "link": null,
      "reference": "Kantarjian HM et al. Blood. 2014 Feb 27;123(9)1309-18.",
      "abstract": null
    },
    {
      "pmid": "29091516",
      "title": "Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Jan 20",
      "volume": "36",
      "issue": "3",
      "pages": "231-237",
      "authors": "Cortes JE et al",
      "elocationId": "doi: 10.1200/JCO.2017.74.7162",
      "link": null,
      "reference": "Cortes JE et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Jan 20;36(3)231-237.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa2d"
  },
  "level": "LEVEL_1",
  "gene": "FGFR3",
  "alteration": "G370C",
  "alteration_name": "G370C",
  "cancer_main_type": "Bladder Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erdafitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    },
    {
      "pmid": "26324363",
      "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Oct 20",
      "volume": "33",
      "issue": "30",
      "pages": "3401-8",
      "authors": "Tabernero J et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.7341",
      "link": null,
      "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa2e"
  },
  "level": "LEVEL_1",
  "gene": "FGFR3",
  "alteration": "R248C",
  "alteration_name": "R248C",
  "cancer_main_type": "Bladder Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erdafitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    },
    {
      "pmid": "26324363",
      "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Oct 20",
      "volume": "33",
      "issue": "30",
      "pages": "3401-8",
      "authors": "Tabernero J et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.7341",
      "link": null,
      "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa2f"
  },
  "level": "LEVEL_1",
  "gene": "FGFR3",
  "alteration": "S249C",
  "alteration_name": "S249C",
  "cancer_main_type": "Bladder Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erdafitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    },
    {
      "pmid": "26324363",
      "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Oct 20",
      "volume": "33",
      "issue": "30",
      "pages": "3401-8",
      "authors": "Tabernero J et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.7341",
      "link": null,
      "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa30"
  },
  "level": "LEVEL_1",
  "gene": "FGFR3",
  "alteration": "Y373C",
  "alteration_name": "Y373C",
  "cancer_main_type": "Bladder Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erdafitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    },
    {
      "pmid": "26324363",
      "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Oct 20",
      "volume": "33",
      "issue": "30",
      "pages": "3401-8",
      "authors": "Tabernero J et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.7341",
      "link": null,
      "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa31"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30425037",
      "title": "<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
      "journal": "Cancer discovery",
      "pubDate": "2019 Feb",
      "volume": "9",
      "issue": "2",
      "pages": "210-219",
      "authors": "Lin KK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0715",
      "link": null,
      "reference": "Lin KK et al. Cancer discovery. 2019 Feb;9(2)210-219.",
      "abstract": null
    },
    {
      "pmid": "28882436",
      "title": "Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.",
      "journal": "Gynecologic oncology",
      "pubDate": "2017 Nov",
      "volume": "147",
      "issue": "2",
      "pages": "267-275",
      "authors": "Oza AM et al",
      "elocationId": "doi: 10.1016/j.ygyno.2017.08.022",
      "link": null,
      "reference": "Oza AM et al. Gynecologic oncology. 2017 Nov;147(2)267-275.",
      "abstract": null
    },
    {
      "pmid": "28916367",
      "title": "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2017 Oct 28",
      "volume": "390",
      "issue": "10106",
      "pages": "1949-1961",
      "authors": "Coleman RL et al",
      "elocationId": "doi: 10.1016/S0140-6736(17)32440-6",
      "link": null,
      "reference": "Coleman RL et al. Lancet (London, England). 2017 Oct 28;390(10106)1949-1961.",
      "abstract": null
    },
    {
      "pmid": "32359490",
      "title": "Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 May",
      "volume": "21",
      "issue": "5",
      "pages": "710-722",
      "authors": "Ledermann JA et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30061-9",
      "link": null,
      "reference": "Ledermann JA et al. The Lancet. Oncology. 2020 May;21(5)710-722.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa32"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian/Fallopian Tube Cancer, NOS",
  "cancer_sub_type": "Ovary/Fallopian Tube",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30425037",
      "title": "<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
      "journal": "Cancer discovery",
      "pubDate": "2019 Feb",
      "volume": "9",
      "issue": "2",
      "pages": "210-219",
      "authors": "Lin KK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0715",
      "link": null,
      "reference": "Lin KK et al. Cancer discovery. 2019 Feb;9(2)210-219.",
      "abstract": null
    },
    {
      "pmid": "28882436",
      "title": "Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.",
      "journal": "Gynecologic oncology",
      "pubDate": "2017 Nov",
      "volume": "147",
      "issue": "2",
      "pages": "267-275",
      "authors": "Oza AM et al",
      "elocationId": "doi: 10.1016/j.ygyno.2017.08.022",
      "link": null,
      "reference": "Oza AM et al. Gynecologic oncology. 2017 Nov;147(2)267-275.",
      "abstract": null
    },
    {
      "pmid": "28916367",
      "title": "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2017 Oct 28",
      "volume": "390",
      "issue": "10106",
      "pages": "1949-1961",
      "authors": "Coleman RL et al",
      "elocationId": "doi: 10.1016/S0140-6736(17)32440-6",
      "link": null,
      "reference": "Coleman RL et al. Lancet (London, England). 2017 Oct 28;390(10106)1949-1961.",
      "abstract": null
    },
    {
      "pmid": "32359490",
      "title": "Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 May",
      "volume": "21",
      "issue": "5",
      "pages": "710-722",
      "authors": "Ledermann JA et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30061-9",
      "link": null,
      "reference": "Ledermann JA et al. The Lancet. Oncology. 2020 May;21(5)710-722.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa33"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Peritoneal Cancer, NOS",
  "cancer_sub_type": "Peritoneal Serous Carcinoma",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30425037",
      "title": "<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
      "journal": "Cancer discovery",
      "pubDate": "2019 Feb",
      "volume": "9",
      "issue": "2",
      "pages": "210-219",
      "authors": "Lin KK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0715",
      "link": null,
      "reference": "Lin KK et al. Cancer discovery. 2019 Feb;9(2)210-219.",
      "abstract": null
    },
    {
      "pmid": "28882436",
      "title": "Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.",
      "journal": "Gynecologic oncology",
      "pubDate": "2017 Nov",
      "volume": "147",
      "issue": "2",
      "pages": "267-275",
      "authors": "Oza AM et al",
      "elocationId": "doi: 10.1016/j.ygyno.2017.08.022",
      "link": null,
      "reference": "Oza AM et al. Gynecologic oncology. 2017 Nov;147(2)267-275.",
      "abstract": null
    },
    {
      "pmid": "28916367",
      "title": "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2017 Oct 28",
      "volume": "390",
      "issue": "10106",
      "pages": "1949-1961",
      "authors": "Coleman RL et al",
      "elocationId": "doi: 10.1016/S0140-6736(17)32440-6",
      "link": null,
      "reference": "Coleman RL et al. Lancet (London, England). 2017 Oct 28;390(10106)1949-1961.",
      "abstract": null
    },
    {
      "pmid": "32359490",
      "title": "Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 May",
      "volume": "21",
      "issue": "5",
      "pages": "710-722",
      "authors": "Ledermann JA et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30061-9",
      "link": null,
      "reference": "Ledermann JA et al. The Lancet. Oncology. 2020 May;21(5)710-722.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa34"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Esophagogastric Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Chemotherapy",
    "Trastuzumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "20728210",
      "title": "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2010 Aug 28",
      "volume": "376",
      "issue": "9742",
      "pages": "687-97",
      "authors": "Bang YJ et al",
      "elocationId": "doi: 10.1016/S0140-6736(10)61121-X",
      "link": null,
      "reference": "Bang YJ et al. Lancet (London, England). 2010 Aug 28;376(9742)687-97.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa35"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "L861Q",
  "alteration_name": "L861Q",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "Non-Small Cell Lung Cancer",
  "drug": [
    "Afatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28336552",
      "title": "Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.",
      "journal": "Cancer discovery",
      "pubDate": "2017 Jun",
      "volume": "7",
      "issue": "6",
      "pages": "596-609",
      "authors": "Jordan EJ et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-16-1337",
      "link": null,
      "reference": "Jordan EJ et al. Cancer discovery. 2017 Jun;7(6)596-609.",
      "abstract": null
    },
    {
      "pmid": "26051236",
      "title": "Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2015 Jul",
      "volume": "16",
      "issue": "7",
      "pages": "830-8",
      "authors": "Yang JC et al",
      "elocationId": "doi: 10.1016/S1470-2045(15)00026-1",
      "link": null,
      "reference": "Yang JC et al. The Lancet. Oncology. 2015 Jul;16(7)830-8.",
      "abstract": null
    },
    {
      "pmid": "22452895",
      "title": "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2012 May",
      "volume": "13",
      "issue": "5",
      "pages": "539-48",
      "authors": "Yang JC et al",
      "elocationId": "doi: 10.1016/S1470-2045(12)70086-4",
      "link": null,
      "reference": "Yang JC et al. The Lancet. Oncology. 2012 May;13(5)539-48.",
      "abstract": null
    },
    {
      "pmid": "21531810",
      "title": "Effectiveness of tyrosine kinase inhibitors on \"uncommon\" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2011 Jun 1",
      "volume": "17",
      "issue": "11",
      "pages": "3812-21",
      "authors": "Wu JY et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-10-3408",
      "link": null,
      "reference": "Wu JY et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Jun 1;17(11)3812-21.",
      "abstract": null
    },
    {
      "pmid": "25589191",
      "title": "Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2015 Feb",
      "volume": "16",
      "issue": "2",
      "pages": "141-51",
      "authors": "Yang JC et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)71173-8",
      "link": null,
      "reference": "Yang JC et al. The Lancet. Oncology. 2015 Feb;16(2)141-51.",
      "abstract": null
    },
    {
      "pmid": "23816960",
      "title": "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 20",
      "volume": "31",
      "issue": "27",
      "pages": "3327-34",
      "authors": "Sequist LV et al",
      "elocationId": "doi: 10.1200/JCO.2012.44.2806",
      "link": null,
      "reference": "Sequist LV et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 20;31(27)3327-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa36"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600K",
  "alteration_name": "V600K",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Dabrafenib",
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23020132",
      "title": "Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.",
      "journal": "The New England journal of medicine",
      "pubDate": "2012 Nov 1",
      "volume": "367",
      "issue": "18",
      "pages": "1694-703",
      "authors": "Flaherty KT et al",
      "elocationId": "doi: 10.1056/NEJMoa1210093",
      "link": null,
      "reference": "Flaherty KT et al. The New England journal of medicine. 2012 Nov 1;367(18)1694-703.",
      "abstract": null
    },
    {
      "pmid": "29361468",
      "title": "Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2018 Feb",
      "volume": "19",
      "issue": "2",
      "pages": "181-193",
      "authors": "Amaria RN et al",
      "elocationId": "doi: 10.1016/S1470-2045(18)30015-9",
      "link": null,
      "reference": "Amaria RN et al. The Lancet. Oncology. 2018 Feb;19(2)181-193.",
      "abstract": null
    },
    {
      "pmid": "25287827",
      "title": "Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2014 Nov 20",
      "volume": "32",
      "issue": "33",
      "pages": "3697-704",
      "authors": "Johnson DB et al",
      "elocationId": "doi: 10.1200/JCO.2014.57.3535",
      "link": null,
      "reference": "Johnson DB et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Nov 20;32(33)3697-704.",
      "abstract": null
    },
    {
      "pmid": "28891408",
      "title": "Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Nov 9",
      "volume": "377",
      "issue": "19",
      "pages": "1813-1823",
      "authors": "Long GV et al",
      "elocationId": "doi: 10.1056/NEJMoa1708539",
      "link": null,
      "reference": "Long GV et al. The New England journal of medicine. 2017 Nov 9;377(19)1813-1823.",
      "abstract": null
    },
    {
      "pmid": "31171876",
      "title": "Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.",
      "journal": "Nature medicine",
      "pubDate": "2019 Jun",
      "volume": "25",
      "issue": "6",
      "pages": "929-935",
      "authors": "Sullivan RJ et al",
      "elocationId": "doi: 10.1038/s41591-019-0474-7",
      "link": null,
      "reference": "Sullivan RJ et al. Nature medicine. 2019 Jun;25(6)929-935.",
      "abstract": null
    },
    {
      "pmid": "28991513",
      "title": "Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Mar 1",
      "volume": "36",
      "issue": "7",
      "pages": "667-673",
      "authors": "Long GV et al",
      "elocationId": "doi: 10.1200/JCO.2017.74.1025",
      "link": null,
      "reference": "Long GV et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Mar 1;36(7)667-673.",
      "abstract": null
    },
    {
      "pmid": "31171878",
      "title": "Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.",
      "journal": "Nature medicine",
      "pubDate": "2019 Jun",
      "volume": "25",
      "issue": "6",
      "pages": "941-946",
      "authors": "Ascierto PA et al",
      "elocationId": "doi: 10.1038/s41591-019-0448-9",
      "link": null,
      "reference": "Ascierto PA et al. Nature medicine. 2019 Jun;25(6)941-946.",
      "abstract": null
    },
    {
      "pmid": "31171879",
      "title": "Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.",
      "journal": "Nature medicine",
      "pubDate": "2019 Jun",
      "volume": "25",
      "issue": "6",
      "pages": "936-940",
      "authors": "Ribas A et al",
      "elocationId": "doi: 10.1038/s41591-019-0476-5",
      "link": null,
      "reference": "Ribas A et al. Nature medicine. 2019 Jun;25(6)936-940.",
      "abstract": null
    },
    {
      "pmid": "25399551",
      "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Jan 1",
      "volume": "372",
      "issue": "1",
      "pages": "30-9",
      "authors": "Robert C et al",
      "elocationId": "doi: 10.1056/NEJMoa1412690",
      "link": null,
      "reference": "Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.",
      "abstract": null
    },
    {
      "pmid": "25265492",
      "title": "Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2014 Nov 13",
      "volume": "371",
      "issue": "20",
      "pages": "1877-88",
      "authors": "Long GV et al",
      "elocationId": "doi: 10.1056/NEJMoa1406037",
      "link": null,
      "reference": "Long GV et al. The New England journal of medicine. 2014 Nov 13;371(20)1877-88.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa37"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Dabrafenib",
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23020132",
      "title": "Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.",
      "journal": "The New England journal of medicine",
      "pubDate": "2012 Nov 1",
      "volume": "367",
      "issue": "18",
      "pages": "1694-703",
      "authors": "Flaherty KT et al",
      "elocationId": "doi: 10.1056/NEJMoa1210093",
      "link": null,
      "reference": "Flaherty KT et al. The New England journal of medicine. 2012 Nov 1;367(18)1694-703.",
      "abstract": null
    },
    {
      "pmid": "29361468",
      "title": "Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2018 Feb",
      "volume": "19",
      "issue": "2",
      "pages": "181-193",
      "authors": "Amaria RN et al",
      "elocationId": "doi: 10.1016/S1470-2045(18)30015-9",
      "link": null,
      "reference": "Amaria RN et al. The Lancet. Oncology. 2018 Feb;19(2)181-193.",
      "abstract": null
    },
    {
      "pmid": "25287827",
      "title": "Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2014 Nov 20",
      "volume": "32",
      "issue": "33",
      "pages": "3697-704",
      "authors": "Johnson DB et al",
      "elocationId": "doi: 10.1200/JCO.2014.57.3535",
      "link": null,
      "reference": "Johnson DB et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Nov 20;32(33)3697-704.",
      "abstract": null
    },
    {
      "pmid": "28891408",
      "title": "Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Nov 9",
      "volume": "377",
      "issue": "19",
      "pages": "1813-1823",
      "authors": "Long GV et al",
      "elocationId": "doi: 10.1056/NEJMoa1708539",
      "link": null,
      "reference": "Long GV et al. The New England journal of medicine. 2017 Nov 9;377(19)1813-1823.",
      "abstract": null
    },
    {
      "pmid": "31171876",
      "title": "Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.",
      "journal": "Nature medicine",
      "pubDate": "2019 Jun",
      "volume": "25",
      "issue": "6",
      "pages": "929-935",
      "authors": "Sullivan RJ et al",
      "elocationId": "doi: 10.1038/s41591-019-0474-7",
      "link": null,
      "reference": "Sullivan RJ et al. Nature medicine. 2019 Jun;25(6)929-935.",
      "abstract": null
    },
    {
      "pmid": "28991513",
      "title": "Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Mar 1",
      "volume": "36",
      "issue": "7",
      "pages": "667-673",
      "authors": "Long GV et al",
      "elocationId": "doi: 10.1200/JCO.2017.74.1025",
      "link": null,
      "reference": "Long GV et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Mar 1;36(7)667-673.",
      "abstract": null
    },
    {
      "pmid": "31171878",
      "title": "Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.",
      "journal": "Nature medicine",
      "pubDate": "2019 Jun",
      "volume": "25",
      "issue": "6",
      "pages": "941-946",
      "authors": "Ascierto PA et al",
      "elocationId": "doi: 10.1038/s41591-019-0448-9",
      "link": null,
      "reference": "Ascierto PA et al. Nature medicine. 2019 Jun;25(6)941-946.",
      "abstract": null
    },
    {
      "pmid": "31171879",
      "title": "Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.",
      "journal": "Nature medicine",
      "pubDate": "2019 Jun",
      "volume": "25",
      "issue": "6",
      "pages": "936-940",
      "authors": "Ribas A et al",
      "elocationId": "doi: 10.1038/s41591-019-0476-5",
      "link": null,
      "reference": "Ribas A et al. Nature medicine. 2019 Jun;25(6)936-940.",
      "abstract": null
    },
    {
      "pmid": "25399551",
      "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Jan 1",
      "volume": "372",
      "issue": "1",
      "pages": "30-9",
      "authors": "Robert C et al",
      "elocationId": "doi: 10.1056/NEJMoa1412690",
      "link": null,
      "reference": "Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.",
      "abstract": null
    },
    {
      "pmid": "25265492",
      "title": "Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2014 Nov 13",
      "volume": "371",
      "issue": "20",
      "pages": "1877-88",
      "authors": "Long GV et al",
      "elocationId": "doi: 10.1056/NEJMoa1406037",
      "link": null,
      "reference": "Long GV et al. The New England journal of medicine. 2014 Nov 13;371(20)1877-88.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa38"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24882434",
      "title": "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 Jul",
      "volume": "15",
      "issue": "8",
      "pages": "852-61",
      "authors": "Ledermann J et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70228-1",
      "link": null,
      "reference": "Ledermann J et al. The Lancet. Oncology. 2014 Jul;15(8)852-61.",
      "abstract": null
    },
    {
      "pmid": "30345884",
      "title": "Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Dec 27",
      "volume": "379",
      "issue": "26",
      "pages": "2495-2505",
      "authors": "Moore K et al",
      "elocationId": "doi: 10.1056/NEJMoa1810858",
      "link": null,
      "reference": "Moore K et al. The New England journal of medicine. 2018 Dec 27;379(26)2495-2505.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/173435/abstract",
      "reference": "null. null. .",
      "abstract": "Penson et al. Abstract# 5506, ASCO 2019"
    },
    {
      "pmid": "25366685",
      "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Jan 20",
      "volume": "33",
      "issue": "3",
      "pages": "244-50",
      "authors": "Kaufman B et al",
      "elocationId": "doi: 10.1200/JCO.2014.56.2728",
      "link": null,
      "reference": "Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.",
      "abstract": null
    },
    {
      "pmid": "30285518",
      "title": "First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Nov 20",
      "volume": "36",
      "issue": "33",
      "pages": "3298-3306",
      "authors": "Strickler JH et al",
      "elocationId": "doi: 10.1200/JCO.2018.78.7697",
      "link": null,
      "reference": "Strickler JH et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Nov 20;36(33)3298-3306.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa39"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Bevacizumab",
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24882434",
      "title": "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 Jul",
      "volume": "15",
      "issue": "8",
      "pages": "852-61",
      "authors": "Ledermann J et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70228-1",
      "link": null,
      "reference": "Ledermann J et al. The Lancet. Oncology. 2014 Jul;15(8)852-61.",
      "abstract": null
    },
    {
      "pmid": "30345884",
      "title": "Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Dec 27",
      "volume": "379",
      "issue": "26",
      "pages": "2495-2505",
      "authors": "Moore K et al",
      "elocationId": "doi: 10.1056/NEJMoa1810858",
      "link": null,
      "reference": "Moore K et al. The New England journal of medicine. 2018 Dec 27;379(26)2495-2505.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/173435/abstract",
      "reference": "null. null. .",
      "abstract": "Penson et al. Abstract# 5506, ASCO 2019"
    },
    {
      "pmid": "25366685",
      "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Jan 20",
      "volume": "33",
      "issue": "3",
      "pages": "244-50",
      "authors": "Kaufman B et al",
      "elocationId": "doi: 10.1200/JCO.2014.56.2728",
      "link": null,
      "reference": "Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.",
      "abstract": null
    },
    {
      "pmid": "30285518",
      "title": "First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Nov 20",
      "volume": "36",
      "issue": "33",
      "pages": "3298-3306",
      "authors": "Strickler JH et al",
      "elocationId": "doi: 10.1200/JCO.2018.78.7697",
      "link": null,
      "reference": "Strickler JH et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Nov 20;36(33)3298-3306.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa3a"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian/Fallopian Tube Cancer, NOS",
  "cancer_sub_type": "Ovary/Fallopian Tube",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24882434",
      "title": "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 Jul",
      "volume": "15",
      "issue": "8",
      "pages": "852-61",
      "authors": "Ledermann J et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70228-1",
      "link": null,
      "reference": "Ledermann J et al. The Lancet. Oncology. 2014 Jul;15(8)852-61.",
      "abstract": null
    },
    {
      "pmid": "30345884",
      "title": "Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Dec 27",
      "volume": "379",
      "issue": "26",
      "pages": "2495-2505",
      "authors": "Moore K et al",
      "elocationId": "doi: 10.1056/NEJMoa1810858",
      "link": null,
      "reference": "Moore K et al. The New England journal of medicine. 2018 Dec 27;379(26)2495-2505.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/173435/abstract",
      "reference": "null. null. .",
      "abstract": "Penson et al. Abstract# 5506, ASCO 2019"
    },
    {
      "pmid": "25366685",
      "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Jan 20",
      "volume": "33",
      "issue": "3",
      "pages": "244-50",
      "authors": "Kaufman B et al",
      "elocationId": "doi: 10.1200/JCO.2014.56.2728",
      "link": null,
      "reference": "Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.",
      "abstract": null
    },
    {
      "pmid": "30285518",
      "title": "First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Nov 20",
      "volume": "36",
      "issue": "33",
      "pages": "3298-3306",
      "authors": "Strickler JH et al",
      "elocationId": "doi: 10.1200/JCO.2018.78.7697",
      "link": null,
      "reference": "Strickler JH et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Nov 20;36(33)3298-3306.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa3b"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian/Fallopian Tube Cancer, NOS",
  "cancer_sub_type": "Ovary/Fallopian Tube",
  "drug": [
    "Bevacizumab",
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24882434",
      "title": "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 Jul",
      "volume": "15",
      "issue": "8",
      "pages": "852-61",
      "authors": "Ledermann J et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70228-1",
      "link": null,
      "reference": "Ledermann J et al. The Lancet. Oncology. 2014 Jul;15(8)852-61.",
      "abstract": null
    },
    {
      "pmid": "30345884",
      "title": "Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Dec 27",
      "volume": "379",
      "issue": "26",
      "pages": "2495-2505",
      "authors": "Moore K et al",
      "elocationId": "doi: 10.1056/NEJMoa1810858",
      "link": null,
      "reference": "Moore K et al. The New England journal of medicine. 2018 Dec 27;379(26)2495-2505.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/173435/abstract",
      "reference": "null. null. .",
      "abstract": "Penson et al. Abstract# 5506, ASCO 2019"
    },
    {
      "pmid": "25366685",
      "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Jan 20",
      "volume": "33",
      "issue": "3",
      "pages": "244-50",
      "authors": "Kaufman B et al",
      "elocationId": "doi: 10.1200/JCO.2014.56.2728",
      "link": null,
      "reference": "Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.",
      "abstract": null
    },
    {
      "pmid": "30285518",
      "title": "First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Nov 20",
      "volume": "36",
      "issue": "33",
      "pages": "3298-3306",
      "authors": "Strickler JH et al",
      "elocationId": "doi: 10.1200/JCO.2018.78.7697",
      "link": null,
      "reference": "Strickler JH et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Nov 20;36(33)3298-3306.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa3c"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Peritoneal Cancer, NOS",
  "cancer_sub_type": "Peritoneal Serous Carcinoma",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24882434",
      "title": "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 Jul",
      "volume": "15",
      "issue": "8",
      "pages": "852-61",
      "authors": "Ledermann J et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70228-1",
      "link": null,
      "reference": "Ledermann J et al. The Lancet. Oncology. 2014 Jul;15(8)852-61.",
      "abstract": null
    },
    {
      "pmid": "30345884",
      "title": "Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Dec 27",
      "volume": "379",
      "issue": "26",
      "pages": "2495-2505",
      "authors": "Moore K et al",
      "elocationId": "doi: 10.1056/NEJMoa1810858",
      "link": null,
      "reference": "Moore K et al. The New England journal of medicine. 2018 Dec 27;379(26)2495-2505.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/173435/abstract",
      "reference": "null. null. .",
      "abstract": "Penson et al. Abstract# 5506, ASCO 2019"
    },
    {
      "pmid": "25366685",
      "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Jan 20",
      "volume": "33",
      "issue": "3",
      "pages": "244-50",
      "authors": "Kaufman B et al",
      "elocationId": "doi: 10.1200/JCO.2014.56.2728",
      "link": null,
      "reference": "Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.",
      "abstract": null
    },
    {
      "pmid": "30285518",
      "title": "First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Nov 20",
      "volume": "36",
      "issue": "33",
      "pages": "3298-3306",
      "authors": "Strickler JH et al",
      "elocationId": "doi: 10.1200/JCO.2018.78.7697",
      "link": null,
      "reference": "Strickler JH et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Nov 20;36(33)3298-3306.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa3d"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Peritoneal Cancer, NOS",
  "cancer_sub_type": "Peritoneal Serous Carcinoma",
  "drug": [
    "Bevacizumab",
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24882434",
      "title": "Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 Jul",
      "volume": "15",
      "issue": "8",
      "pages": "852-61",
      "authors": "Ledermann J et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70228-1",
      "link": null,
      "reference": "Ledermann J et al. The Lancet. Oncology. 2014 Jul;15(8)852-61.",
      "abstract": null
    },
    {
      "pmid": "30345884",
      "title": "Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Dec 27",
      "volume": "379",
      "issue": "26",
      "pages": "2495-2505",
      "authors": "Moore K et al",
      "elocationId": "doi: 10.1056/NEJMoa1810858",
      "link": null,
      "reference": "Moore K et al. The New England journal of medicine. 2018 Dec 27;379(26)2495-2505.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/173435/abstract",
      "reference": "null. null. .",
      "abstract": "Penson et al. Abstract# 5506, ASCO 2019"
    },
    {
      "pmid": "25366685",
      "title": "Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Jan 20",
      "volume": "33",
      "issue": "3",
      "pages": "244-50",
      "authors": "Kaufman B et al",
      "elocationId": "doi: 10.1200/JCO.2014.56.2728",
      "link": null,
      "reference": "Kaufman B et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Jan 20;33(3)244-50.",
      "abstract": null
    },
    {
      "pmid": "30285518",
      "title": "First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Nov 20",
      "volume": "36",
      "issue": "33",
      "pages": "3298-3306",
      "authors": "Strickler JH et al",
      "elocationId": "doi: 10.1200/JCO.2018.78.7697",
      "link": null,
      "reference": "Strickler JH et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Nov 20;36(33)3298-3306.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa3e"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30425037",
      "title": "<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
      "journal": "Cancer discovery",
      "pubDate": "2019 Feb",
      "volume": "9",
      "issue": "2",
      "pages": "210-219",
      "authors": "Lin KK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0715",
      "link": null,
      "reference": "Lin KK et al. Cancer discovery. 2019 Feb;9(2)210-219.",
      "abstract": null
    },
    {
      "pmid": "28882436",
      "title": "Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.",
      "journal": "Gynecologic oncology",
      "pubDate": "2017 Nov",
      "volume": "147",
      "issue": "2",
      "pages": "267-275",
      "authors": "Oza AM et al",
      "elocationId": "doi: 10.1016/j.ygyno.2017.08.022",
      "link": null,
      "reference": "Oza AM et al. Gynecologic oncology. 2017 Nov;147(2)267-275.",
      "abstract": null
    },
    {
      "pmid": "28916367",
      "title": "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2017 Oct 28",
      "volume": "390",
      "issue": "10106",
      "pages": "1949-1961",
      "authors": "Coleman RL et al",
      "elocationId": "doi: 10.1016/S0140-6736(17)32440-6",
      "link": null,
      "reference": "Coleman RL et al. Lancet (London, England). 2017 Oct 28;390(10106)1949-1961.",
      "abstract": null
    },
    {
      "pmid": "32359490",
      "title": "Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 May",
      "volume": "21",
      "issue": "5",
      "pages": "710-722",
      "authors": "Ledermann JA et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30061-9",
      "link": null,
      "reference": "Ledermann JA et al. The Lancet. Oncology. 2020 May;21(5)710-722.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa3f"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian/Fallopian Tube Cancer, NOS",
  "cancer_sub_type": "Ovary/Fallopian Tube",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30425037",
      "title": "<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
      "journal": "Cancer discovery",
      "pubDate": "2019 Feb",
      "volume": "9",
      "issue": "2",
      "pages": "210-219",
      "authors": "Lin KK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0715",
      "link": null,
      "reference": "Lin KK et al. Cancer discovery. 2019 Feb;9(2)210-219.",
      "abstract": null
    },
    {
      "pmid": "28882436",
      "title": "Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.",
      "journal": "Gynecologic oncology",
      "pubDate": "2017 Nov",
      "volume": "147",
      "issue": "2",
      "pages": "267-275",
      "authors": "Oza AM et al",
      "elocationId": "doi: 10.1016/j.ygyno.2017.08.022",
      "link": null,
      "reference": "Oza AM et al. Gynecologic oncology. 2017 Nov;147(2)267-275.",
      "abstract": null
    },
    {
      "pmid": "28916367",
      "title": "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2017 Oct 28",
      "volume": "390",
      "issue": "10106",
      "pages": "1949-1961",
      "authors": "Coleman RL et al",
      "elocationId": "doi: 10.1016/S0140-6736(17)32440-6",
      "link": null,
      "reference": "Coleman RL et al. Lancet (London, England). 2017 Oct 28;390(10106)1949-1961.",
      "abstract": null
    },
    {
      "pmid": "32359490",
      "title": "Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 May",
      "volume": "21",
      "issue": "5",
      "pages": "710-722",
      "authors": "Ledermann JA et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30061-9",
      "link": null,
      "reference": "Ledermann JA et al. The Lancet. Oncology. 2020 May;21(5)710-722.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa40"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Peritoneal Cancer, NOS",
  "cancer_sub_type": "Peritoneal Serous Carcinoma",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30425037",
      "title": "<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
      "journal": "Cancer discovery",
      "pubDate": "2019 Feb",
      "volume": "9",
      "issue": "2",
      "pages": "210-219",
      "authors": "Lin KK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0715",
      "link": null,
      "reference": "Lin KK et al. Cancer discovery. 2019 Feb;9(2)210-219.",
      "abstract": null
    },
    {
      "pmid": "28882436",
      "title": "Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.",
      "journal": "Gynecologic oncology",
      "pubDate": "2017 Nov",
      "volume": "147",
      "issue": "2",
      "pages": "267-275",
      "authors": "Oza AM et al",
      "elocationId": "doi: 10.1016/j.ygyno.2017.08.022",
      "link": null,
      "reference": "Oza AM et al. Gynecologic oncology. 2017 Nov;147(2)267-275.",
      "abstract": null
    },
    {
      "pmid": "28916367",
      "title": "Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2017 Oct 28",
      "volume": "390",
      "issue": "10106",
      "pages": "1949-1961",
      "authors": "Coleman RL et al",
      "elocationId": "doi: 10.1016/S0140-6736(17)32440-6",
      "link": null,
      "reference": "Coleman RL et al. Lancet (London, England). 2017 Oct 28;390(10106)1949-1961.",
      "abstract": null
    },
    {
      "pmid": "32359490",
      "title": "Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 May",
      "volume": "21",
      "issue": "5",
      "pages": "710-722",
      "authors": "Ledermann JA et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30061-9",
      "link": null,
      "reference": "Ledermann JA et al. The Lancet. Oncology. 2020 May;21(5)710-722.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa41"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Niraparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30948273",
      "title": "Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 May",
      "volume": "20",
      "issue": "5",
      "pages": "636-648",
      "authors": "Moore KN et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30029-4",
      "link": null,
      "reference": "Moore KN et al. The Lancet. Oncology. 2019 May;20(5)636-648.",
      "abstract": null
    },
    {
      "pmid": "27717299",
      "title": "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2016 Dec 1",
      "volume": "375",
      "issue": "22",
      "pages": "2154-2164",
      "authors": "Mirza MR et al",
      "elocationId": "",
      "link": null,
      "reference": "Mirza MR et al. The New England journal of medicine. 2016 Dec 1;375(22)2154-2164.",
      "abstract": null
    },
    {
      "pmid": "31562799",
      "title": "Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Dec 19",
      "volume": "381",
      "issue": "25",
      "pages": "2391-2402",
      "authors": "González-Martín A et al",
      "elocationId": "doi: 10.1056/NEJMoa1910962",
      "link": null,
      "reference": "González-Martín A et al. The New England journal of medicine. 2019 Dec 19;381(25)2391-2402.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa42"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian/Fallopian Tube Cancer, NOS",
  "cancer_sub_type": "Ovary/Fallopian Tube",
  "drug": [
    "Niraparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30948273",
      "title": "Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 May",
      "volume": "20",
      "issue": "5",
      "pages": "636-648",
      "authors": "Moore KN et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30029-4",
      "link": null,
      "reference": "Moore KN et al. The Lancet. Oncology. 2019 May;20(5)636-648.",
      "abstract": null
    },
    {
      "pmid": "27717299",
      "title": "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2016 Dec 1",
      "volume": "375",
      "issue": "22",
      "pages": "2154-2164",
      "authors": "Mirza MR et al",
      "elocationId": "",
      "link": null,
      "reference": "Mirza MR et al. The New England journal of medicine. 2016 Dec 1;375(22)2154-2164.",
      "abstract": null
    },
    {
      "pmid": "31562799",
      "title": "Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Dec 19",
      "volume": "381",
      "issue": "25",
      "pages": "2391-2402",
      "authors": "González-Martín A et al",
      "elocationId": "doi: 10.1056/NEJMoa1910962",
      "link": null,
      "reference": "González-Martín A et al. The New England journal of medicine. 2019 Dec 19;381(25)2391-2402.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa43"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Peritoneal Cancer, NOS",
  "cancer_sub_type": "Peritoneal Serous Carcinoma",
  "drug": [
    "Niraparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30948273",
      "title": "Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 May",
      "volume": "20",
      "issue": "5",
      "pages": "636-648",
      "authors": "Moore KN et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30029-4",
      "link": null,
      "reference": "Moore KN et al. The Lancet. Oncology. 2019 May;20(5)636-648.",
      "abstract": null
    },
    {
      "pmid": "27717299",
      "title": "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2016 Dec 1",
      "volume": "375",
      "issue": "22",
      "pages": "2154-2164",
      "authors": "Mirza MR et al",
      "elocationId": "",
      "link": null,
      "reference": "Mirza MR et al. The New England journal of medicine. 2016 Dec 1;375(22)2154-2164.",
      "abstract": null
    },
    {
      "pmid": "31562799",
      "title": "Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Dec 19",
      "volume": "381",
      "issue": "25",
      "pages": "2391-2402",
      "authors": "González-Martín A et al",
      "elocationId": "doi: 10.1056/NEJMoa1910962",
      "link": null,
      "reference": "González-Martín A et al. The New England journal of medicine. 2019 Dec 19;381(25)2391-2402.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa44"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "762_823ins",
  "alteration_name": "Exon 20 in-frame insertions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Amivantamab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "34339292",
      "title": "Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2021 Oct 20",
      "volume": "39",
      "issue": "30",
      "pages": "3391-3402",
      "authors": "Park K et al",
      "elocationId": "doi: 10.1200/JCO.21.00662",
      "link": null,
      "reference": "Park K et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Oct 20;39(30)3391-3402.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa45"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "L858R",
  "alteration_name": "L858R",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Gefitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19692680",
      "title": "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2009 Sep 3",
      "volume": "361",
      "issue": "10",
      "pages": "947-57",
      "authors": "Mok TS et al",
      "elocationId": "doi: 10.1056/NEJMoa0810699",
      "link": null,
      "reference": "Mok TS et al. The New England journal of medicine. 2009 Sep 3;361(10)947-57.",
      "abstract": null
    },
    {
      "pmid": "20022809",
      "title": "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2010 Feb",
      "volume": "11",
      "issue": "2",
      "pages": "121-8",
      "authors": "Mitsudomi T et al",
      "elocationId": "doi: 10.1016/S1470-2045(09)70364-X",
      "link": null,
      "reference": "Mitsudomi T et al. The Lancet. Oncology. 2010 Feb;11(2)121-8.",
      "abstract": null
    },
    {
      "pmid": "21670455",
      "title": "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2011 Jul 20",
      "volume": "29",
      "issue": "21",
      "pages": "2866-74",
      "authors": "Fukuoka M et al",
      "elocationId": "doi: 10.1200/JCO.2010.33.4235",
      "link": null,
      "reference": "Fukuoka M et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Jul 20;29(21)2866-74.",
      "abstract": null
    },
    {
      "pmid": "22370314",
      "title": "First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2012 Apr 1",
      "volume": "30",
      "issue": "10",
      "pages": "1122-8",
      "authors": "Han JY et al",
      "elocationId": "doi: 10.1200/JCO.2011.36.8456",
      "link": null,
      "reference": "Han JY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Apr 1;30(10)1122-8.",
      "abstract": null
    },
    {
      "pmid": "31682542",
      "title": "Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2020 Jan 10",
      "volume": "38",
      "issue": "2",
      "pages": "115-123",
      "authors": "Hosomi Y et al",
      "elocationId": "doi: 10.1200/JCO.19.01488",
      "link": null,
      "reference": "Hosomi Y et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Jan 10;38(2)115-123.",
      "abstract": null
    },
    {
      "pmid": "20573926",
      "title": "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.",
      "journal": "The New England journal of medicine",
      "pubDate": "2010 Jun 24",
      "volume": "362",
      "issue": "25",
      "pages": "2380-8",
      "authors": "Maemondo M et al",
      "elocationId": "doi: 10.1056/NEJMoa0909530",
      "link": null,
      "reference": "Maemondo M et al. The New England journal of medicine. 2010 Jun 24;362(25)2380-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa46"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "729_761del",
  "alteration_name": "Exon 19 in-frame deletions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Gefitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19692680",
      "title": "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2009 Sep 3",
      "volume": "361",
      "issue": "10",
      "pages": "947-57",
      "authors": "Mok TS et al",
      "elocationId": "doi: 10.1056/NEJMoa0810699",
      "link": null,
      "reference": "Mok TS et al. The New England journal of medicine. 2009 Sep 3;361(10)947-57.",
      "abstract": null
    },
    {
      "pmid": "20022809",
      "title": "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2010 Feb",
      "volume": "11",
      "issue": "2",
      "pages": "121-8",
      "authors": "Mitsudomi T et al",
      "elocationId": "doi: 10.1016/S1470-2045(09)70364-X",
      "link": null,
      "reference": "Mitsudomi T et al. The Lancet. Oncology. 2010 Feb;11(2)121-8.",
      "abstract": null
    },
    {
      "pmid": "21670455",
      "title": "Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2011 Jul 20",
      "volume": "29",
      "issue": "21",
      "pages": "2866-74",
      "authors": "Fukuoka M et al",
      "elocationId": "doi: 10.1200/JCO.2010.33.4235",
      "link": null,
      "reference": "Fukuoka M et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Jul 20;29(21)2866-74.",
      "abstract": null
    },
    {
      "pmid": "22370314",
      "title": "First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2012 Apr 1",
      "volume": "30",
      "issue": "10",
      "pages": "1122-8",
      "authors": "Han JY et al",
      "elocationId": "doi: 10.1200/JCO.2011.36.8456",
      "link": null,
      "reference": "Han JY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Apr 1;30(10)1122-8.",
      "abstract": null
    },
    {
      "pmid": "31682542",
      "title": "Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2020 Jan 10",
      "volume": "38",
      "issue": "2",
      "pages": "115-123",
      "authors": "Hosomi Y et al",
      "elocationId": "doi: 10.1200/JCO.19.01488",
      "link": null,
      "reference": "Hosomi Y et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Jan 10;38(2)115-123.",
      "abstract": null
    },
    {
      "pmid": "20573926",
      "title": "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.",
      "journal": "The New England journal of medicine",
      "pubDate": "2010 Jun 24",
      "volume": "362",
      "issue": "25",
      "pages": "2380-8",
      "authors": "Maemondo M et al",
      "elocationId": "doi: 10.1056/NEJMoa0909530",
      "link": null,
      "reference": "Maemondo M et al. The New England journal of medicine. 2010 Jun 24;362(25)2380-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa47"
  },
  "level": "LEVEL_1",
  "gene": "KIT",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "Gastrointestinal Stromal Tumor",
  "drug": [
    "Sunitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "17046465",
      "title": "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2006 Oct 14",
      "volume": "368",
      "issue": "9544",
      "pages": "1329-38",
      "authors": "Demetri GD et al",
      "elocationId": "",
      "link": null,
      "reference": "Demetri GD et al. Lancet (London, England). 2006 Oct 14;368(9544)1329-38.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa48"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Chemotherapy",
    "Pertuzumab",
    "Trastuzumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22149875",
      "title": "Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2012 Jan 12",
      "volume": "366",
      "issue": "2",
      "pages": "109-19",
      "authors": "Baselga J et al",
      "elocationId": "doi: 10.1056/NEJMoa1113216",
      "link": null,
      "reference": "Baselga J et al. The New England journal of medicine. 2012 Jan 12;366(2)109-19.",
      "abstract": null
    },
    {
      "pmid": "29320312",
      "title": "Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Feb 20",
      "volume": "36",
      "issue": "6",
      "pages": "536-542",
      "authors": "Hainsworth JD et al",
      "elocationId": "doi: 10.1200/JCO.2017.75.3780",
      "link": null,
      "reference": "Hainsworth JD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Feb 20;36(6)536-542.",
      "abstract": null
    },
    {
      "pmid": "22153890",
      "title": "Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2012 Jan",
      "volume": "13",
      "issue": "1",
      "pages": "25-32",
      "authors": "Gianni L et al",
      "elocationId": "doi: 10.1016/S1470-2045(11)70336-9",
      "link": null,
      "reference": "Gianni L et al. The Lancet. Oncology. 2012 Jan;13(1)25-32.",
      "abstract": null
    },
    {
      "pmid": "31647503",
      "title": "Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2020 Mar 1",
      "volume": "6",
      "issue": "3",
      "pages": "e193692",
      "authors": "Shao Z et al",
      "elocationId": "doi: 10.1001/jamaoncol.2019.3692",
      "link": null,
      "reference": "Shao Z et al. JAMA oncology. 2020 Mar 1;6(3)e193692.",
      "abstract": null
    },
    {
      "pmid": "32171426",
      "title": "Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Apr",
      "volume": "21",
      "issue": "4",
      "pages": "519-530",
      "authors": "Swain SM et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30863-0",
      "link": null,
      "reference": "Swain SM et al. The Lancet. Oncology. 2020 Apr;21(4)519-530.",
      "abstract": null
    },
    {
      "pmid": "23602601",
      "title": "Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2013 May",
      "volume": "14",
      "issue": "6",
      "pages": "461-71",
      "authors": "Swain SM et al",
      "elocationId": "doi: 10.1016/S1470-2045(13)70130-X",
      "link": null,
      "reference": "Swain SM et al. The Lancet. Oncology. 2013 May;14(6)461-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa49"
  },
  "level": "LEVEL_1",
  "gene": "FLT3",
  "alteration": "572_630ins",
  "alteration_name": "Internal tandem duplication",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Gilteritinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31665578",
      "title": "Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Oct 31",
      "volume": "381",
      "issue": "18",
      "pages": "1728-1740",
      "authors": "Perl AE et al",
      "elocationId": "doi: 10.1056/NEJMoa1902688",
      "link": null,
      "reference": "Perl AE et al. The New England journal of medicine. 2019 Oct 31;381(18)1728-1740.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/173640/abstract",
      "reference": "null. null. .",
      "abstract": "Levis et al. Abstract# 7000, ASCO 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(22",
      "reference": "null. null. .",
      "abstract": "Prazt et al. Abstract# AML-256, Clinical Lymphoma, Myeloma & Leukemia 2022"
    },
    {
      "pmid": "28645776",
      "title": "Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2017 Aug",
      "volume": "18",
      "issue": "8",
      "pages": "1061-1075",
      "authors": "Perl AE et al",
      "elocationId": "doi: 10.1016/S1470-2045(17)30416-3",
      "link": null,
      "reference": "Perl AE et al. The Lancet. Oncology. 2017 Aug;18(8)1061-1075.",
      "abstract": null
    },
    {
      "pmid": "28516360",
      "title": "Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.",
      "journal": "Investigational new drugs",
      "pubDate": "2017 Oct",
      "volume": "35",
      "issue": "5",
      "pages": "556-565",
      "authors": "Mori M et al",
      "elocationId": "doi: 10.1007/s10637-017-0470-z",
      "link": null,
      "reference": "Mori M et al. Investigational new drugs. 2017 Oct;35(5)556-565.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa4a"
  },
  "level": "LEVEL_1",
  "gene": "FLT3",
  "alteration": "D835",
  "alteration_name": "D835",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Gilteritinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31665578",
      "title": "Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Oct 31",
      "volume": "381",
      "issue": "18",
      "pages": "1728-1740",
      "authors": "Perl AE et al",
      "elocationId": "doi: 10.1056/NEJMoa1902688",
      "link": null,
      "reference": "Perl AE et al. The New England journal of medicine. 2019 Oct 31;381(18)1728-1740.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/173640/abstract",
      "reference": "null. null. .",
      "abstract": "Levis et al. Abstract# 7000, ASCO 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(22",
      "reference": "null. null. .",
      "abstract": "Prazt et al. Abstract# AML-256, Clinical Lymphoma, Myeloma & Leukemia 2022"
    },
    {
      "pmid": "28645776",
      "title": "Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2017 Aug",
      "volume": "18",
      "issue": "8",
      "pages": "1061-1075",
      "authors": "Perl AE et al",
      "elocationId": "doi: 10.1016/S1470-2045(17)30416-3",
      "link": null,
      "reference": "Perl AE et al. The Lancet. Oncology. 2017 Aug;18(8)1061-1075.",
      "abstract": null
    },
    {
      "pmid": "28516360",
      "title": "Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.",
      "journal": "Investigational new drugs",
      "pubDate": "2017 Oct",
      "volume": "35",
      "issue": "5",
      "pages": "556-565",
      "authors": "Mori M et al",
      "elocationId": "doi: 10.1007/s10637-017-0470-z",
      "link": null,
      "reference": "Mori M et al. Investigational new drugs. 2017 Oct;35(5)556-565.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa4b"
  },
  "level": "LEVEL_1",
  "gene": "FLT3",
  "alteration": "I836",
  "alteration_name": "I836",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Gilteritinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31665578",
      "title": "Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Oct 31",
      "volume": "381",
      "issue": "18",
      "pages": "1728-1740",
      "authors": "Perl AE et al",
      "elocationId": "doi: 10.1056/NEJMoa1902688",
      "link": null,
      "reference": "Perl AE et al. The New England journal of medicine. 2019 Oct 31;381(18)1728-1740.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/173640/abstract",
      "reference": "null. null. .",
      "abstract": "Levis et al. Abstract# 7000, ASCO 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(22",
      "reference": "null. null. .",
      "abstract": "Prazt et al. Abstract# AML-256, Clinical Lymphoma, Myeloma & Leukemia 2022"
    },
    {
      "pmid": "28645776",
      "title": "Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2017 Aug",
      "volume": "18",
      "issue": "8",
      "pages": "1061-1075",
      "authors": "Perl AE et al",
      "elocationId": "doi: 10.1016/S1470-2045(17)30416-3",
      "link": null,
      "reference": "Perl AE et al. The Lancet. Oncology. 2017 Aug;18(8)1061-1075.",
      "abstract": null
    },
    {
      "pmid": "28516360",
      "title": "Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.",
      "journal": "Investigational new drugs",
      "pubDate": "2017 Oct",
      "volume": "35",
      "issue": "5",
      "pages": "556-565",
      "authors": "Mori M et al",
      "elocationId": "doi: 10.1007/s10637-017-0470-z",
      "link": null,
      "reference": "Mori M et al. Investigational new drugs. 2017 Oct;35(5)556-565.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa4c"
  },
  "level": "LEVEL_1",
  "gene": "CHEK2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa4d"
  },
  "level": "LEVEL_1",
  "gene": "CHEK2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa4e"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "S768I",
  "alteration_name": "S768I",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Afatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "25521405",
      "title": "Clinical and in vivo evidence that EGFR S768I mutant lung adenocarcinomas are sensitive to erlotinib.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2014 Oct",
      "volume": "9",
      "issue": "10",
      "pages": "e73-4",
      "authors": "Hellmann MD et al",
      "elocationId": "doi: 10.1097/JTO.0000000000000221",
      "link": null,
      "reference": "Hellmann MD et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Oct;9(10)e73-4.",
      "abstract": null
    },
    {
      "pmid": "28336552",
      "title": "Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.",
      "journal": "Cancer discovery",
      "pubDate": "2017 Jun",
      "volume": "7",
      "issue": "6",
      "pages": "596-609",
      "authors": "Jordan EJ et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-16-1337",
      "link": null,
      "reference": "Jordan EJ et al. Cancer discovery. 2017 Jun;7(6)596-609.",
      "abstract": null
    },
    {
      "pmid": "17285735",
      "title": "Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.",
      "journal": "The oncologist",
      "pubDate": "2007 Jan",
      "volume": "12",
      "issue": "1",
      "pages": "90-8",
      "authors": "Sequist LV et al",
      "elocationId": "",
      "link": null,
      "reference": "Sequist LV et al. The oncologist. 2007 Jan;12(1)90-8.",
      "abstract": null
    },
    {
      "pmid": "26051236",
      "title": "Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2015 Jul",
      "volume": "16",
      "issue": "7",
      "pages": "830-8",
      "authors": "Yang JC et al",
      "elocationId": "doi: 10.1016/S1470-2045(15)00026-1",
      "link": null,
      "reference": "Yang JC et al. The Lancet. Oncology. 2015 Jul;16(7)830-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa4f"
  },
  "level": "LEVEL_1",
  "gene": "KIT",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "Gastrointestinal Stromal Tumor",
  "drug": [
    "Regorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23177515",
      "title": "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2013 Jan 26",
      "volume": "381",
      "issue": "9863",
      "pages": "295-302",
      "authors": "Demetri GD et al",
      "elocationId": "doi: 10.1016/S0140-6736(12)61857-1",
      "link": null,
      "reference": "Demetri GD et al. Lancet (London, England). 2013 Jan 26;381(9863)295-302.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa50"
  },
  "level": "LEVEL_1",
  "gene": "Other Biomarkers",
  "alteration": "MSI-H",
  "alteration_name": "Microsatellite Instability-High",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Ipilimumab",
    "Nivolumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3510",
      "reference": "null. null. .",
      "abstract": "Overman et al. Abstract# 3510, ASCO 2022"
    },
    {
      "pmid": "29355075",
      "title": "Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Mar 10",
      "volume": "36",
      "issue": "8",
      "pages": "773-779",
      "authors": "Overman MJ et al",
      "elocationId": "doi: 10.1200/JCO.2017.76.9901",
      "link": null,
      "reference": "Overman MJ et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Mar 10;36(8)773-779.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa51"
  },
  "level": "LEVEL_1",
  "gene": "Other Biomarkers",
  "alteration": "MSI-H",
  "alteration_name": "Microsatellite Instability-High",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Pembrolizumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28596308",
      "title": "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.",
      "journal": "Science (New York, N.Y.)",
      "pubDate": "2017 Jul 28",
      "volume": "357",
      "issue": "6349",
      "pages": "409-413",
      "authors": "Le DT et al",
      "elocationId": "doi: 10.1126/science.aan6733",
      "link": null,
      "reference": "Le DT et al. Science (New York, N.Y.). 2017 Jul 28;357(6349)409-413.",
      "abstract": null
    },
    {
      "pmid": "30589920",
      "title": "Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Apr 1",
      "volume": "5",
      "issue": "4",
      "pages": "471-478",
      "authors": "Abida W et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.5801",
      "link": null,
      "reference": "Abida W et al. JAMA oncology. 2019 Apr 1;5(4)471-478.",
      "abstract": null
    },
    {
      "pmid": "31725351",
      "title": "Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2020 Jan 1",
      "volume": "38",
      "issue": "1",
      "pages": "11-19",
      "authors": "Le DT et al",
      "elocationId": "doi: 10.1200/JCO.19.02107",
      "link": null,
      "reference": "Le DT et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Jan 1;38(1)11-19.",
      "abstract": null
    },
    {
      "pmid": "26028255",
      "title": "PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Jun 25",
      "volume": "372",
      "issue": "26",
      "pages": "2509-20",
      "authors": "Le DT et al",
      "elocationId": "doi: 10.1056/NEJMoa1500596",
      "link": null,
      "reference": "Le DT et al. The New England journal of medicine. 2015 Jun 25;372(26)2509-20.",
      "abstract": null
    },
    {
      "pmid": "34990208",
      "title": "Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2022 Mar 1",
      "volume": "40",
      "issue": "7",
      "pages": "752-761",
      "authors": "O'Malley DM et al",
      "elocationId": "doi: 10.1200/JCO.21.01874",
      "link": null,
      "reference": "O'Malley DM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Mar 1;40(7)752-761.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa52"
  },
  "level": "LEVEL_1",
  "gene": "Other Biomarkers",
  "alteration": "TMB-H",
  "alteration_name": "Tumor Mutational Burden-High",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Pembrolizumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.sciencedirect.com/science/article/pii/S0923753419594042",
      "reference": "null. null. .",
      "abstract": "Marabelle et al. Abstract# 1192O, ESMO 2019"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa53"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Cetuximab",
    "Encorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31566309",
      "title": "Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Oct 24",
      "volume": "381",
      "issue": "17",
      "pages": "1632-1643",
      "authors": "Kopetz S et al",
      "elocationId": "doi: 10.1056/NEJMoa1908075",
      "link": null,
      "reference": "Kopetz S et al. The New England journal of medicine. 2019 Oct 24;381(17)1632-1643.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa54"
  },
  "level": "LEVEL_1",
  "gene": "ABL1",
  "alteration": "BCR-ABL1 Fusion",
  "alteration_name": "BCR-ABL1 Fusion",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "11287973",
      "title": "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.",
      "journal": "The New England journal of medicine",
      "pubDate": "2001 Apr 5",
      "volume": "344",
      "issue": "14",
      "pages": "1038-42",
      "authors": "Druker BJ et al",
      "elocationId": "",
      "link": null,
      "reference": "Druker BJ et al. The New England journal of medicine. 2001 Apr 5;344(14)1038-42.",
      "abstract": null
    },
    {
      "pmid": "24441288",
      "title": "Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.",
      "journal": "Leukemia",
      "pubDate": "2014 Jul",
      "volume": "28",
      "issue": "7",
      "pages": "1467-71",
      "authors": "Schultz KR et al",
      "elocationId": "doi: 10.1038/leu.2014.30",
      "link": null,
      "reference": "Schultz KR et al. Leukemia. 2014 Jul;28(7)1467-71.",
      "abstract": null
    },
    {
      "pmid": "12200353",
      "title": "A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.",
      "journal": "Blood",
      "pubDate": "2002 Sep 15",
      "volume": "100",
      "issue": "6",
      "pages": "1965-71",
      "authors": "Ottmann OG et al",
      "elocationId": "",
      "link": null,
      "reference": "Ottmann OG et al. Blood. 2002 Sep 15;100(6)1965-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa55"
  },
  "level": "LEVEL_1",
  "gene": "ABL1",
  "alteration": "BCR-ABL1 Fusion",
  "alteration_name": "BCR-ABL1 Fusion",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "20131302",
      "title": "Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.",
      "journal": "American journal of hematology",
      "pubDate": "2010 Mar",
      "volume": "85",
      "issue": "3",
      "pages": "164-70",
      "authors": "Lilly MB et al",
      "elocationId": "doi: 10.1002/ajh.21615",
      "link": null,
      "reference": "Lilly MB et al. American journal of hematology. 2010 Mar;85(3)164-70.",
      "abstract": null
    },
    {
      "pmid": "17496201",
      "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.",
      "journal": "Blood",
      "pubDate": "2007 Oct 1",
      "volume": "110",
      "issue": "7",
      "pages": "2309-15",
      "authors": "Ottmann O et al",
      "elocationId": "",
      "link": null,
      "reference": "Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/130/Suppl_1/98",
      "reference": "null. null. .",
      "abstract": "Hunger et al. ASH 2017"
    },
    {
      "pmid": "21931113",
      "title": "Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.",
      "journal": "Blood",
      "pubDate": "2011 Dec 15",
      "volume": "118",
      "issue": "25",
      "pages": "6521-8",
      "authors": "Foà R et al",
      "elocationId": "doi: 10.1182/blood-2011-05-351403",
      "link": null,
      "reference": "Foà R et al. Blood. 2011 Dec 15;118(25)6521-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa56"
  },
  "level": "LEVEL_1",
  "gene": "KRAS",
  "alteration": "Wildtype",
  "alteration_name": "Wildtype",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Panitumumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27736842",
      "title": "A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.",
      "journal": "British journal of cancer",
      "pubDate": "2016 Nov 8",
      "volume": "115",
      "issue": "10",
      "pages": "1206-1214",
      "authors": "Kim TW et al",
      "elocationId": "doi: 10.1038/bjc.2016.309",
      "link": null,
      "reference": "Kim TW et al. British journal of cancer. 2016 Nov 8;115(10)1206-1214.",
      "abstract": null
    },
    {
      "pmid": "15677699",
      "title": "Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2005 Mar 20",
      "volume": "23",
      "issue": "9",
      "pages": "1803-10",
      "authors": "Chung KY et al",
      "elocationId": "",
      "link": null,
      "reference": "Chung KY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Mar 20;23(9)1803-10.",
      "abstract": null
    },
    {
      "pmid": "20921462",
      "title": "Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2010 Nov 1",
      "volume": "28",
      "issue": "31",
      "pages": "4706-13",
      "authors": "Peeters M et al",
      "elocationId": "doi: 10.1200/JCO.2009.27.6055",
      "link": null,
      "reference": "Peeters M et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Nov 1;28(31)4706-13.",
      "abstract": null
    },
    {
      "pmid": "31609637",
      "title": "FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2019 Dec 10",
      "volume": "37",
      "issue": "35",
      "pages": "3401-3411",
      "authors": "Modest DP et al",
      "elocationId": "doi: 10.1200/JCO.19.01340",
      "link": null,
      "reference": "Modest DP et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Dec 10;37(35)3401-3411.",
      "abstract": null
    },
    {
      "pmid": "24739896",
      "title": "Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 May",
      "volume": "15",
      "issue": "6",
      "pages": "569-79",
      "authors": "Price TJ et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70118-4",
      "link": null,
      "reference": "Price TJ et al. The Lancet. Oncology. 2014 May;15(6)569-79.",
      "abstract": null
    },
    {
      "pmid": "31268481",
      "title": "Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Jul 3",
      "volume": "",
      "issue": "",
      "pages": "",
      "authors": "Pietrantonio F et al",
      "elocationId": "doi: 10.1001/jamaoncol.2019.1467",
      "link": null,
      "reference": "Pietrantonio F et al. JAMA oncology. 2019 Jul 3;().",
      "abstract": null
    },
    {
      "pmid": "20921465",
      "title": "Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2010 Nov 1",
      "volume": "28",
      "issue": "31",
      "pages": "4697-705",
      "authors": "Douillard JY et al",
      "elocationId": "doi: 10.1200/JCO.2009.27.4860",
      "link": null,
      "reference": "Douillard JY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Nov 1;28(31)4697-705.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa57"
  },
  "level": "LEVEL_1",
  "gene": "KRAS",
  "alteration": "Wildtype",
  "alteration_name": "Wildtype",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Chemotherapy",
    "Panitumumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27736842",
      "title": "A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.",
      "journal": "British journal of cancer",
      "pubDate": "2016 Nov 8",
      "volume": "115",
      "issue": "10",
      "pages": "1206-1214",
      "authors": "Kim TW et al",
      "elocationId": "doi: 10.1038/bjc.2016.309",
      "link": null,
      "reference": "Kim TW et al. British journal of cancer. 2016 Nov 8;115(10)1206-1214.",
      "abstract": null
    },
    {
      "pmid": "15677699",
      "title": "Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2005 Mar 20",
      "volume": "23",
      "issue": "9",
      "pages": "1803-10",
      "authors": "Chung KY et al",
      "elocationId": "",
      "link": null,
      "reference": "Chung KY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Mar 20;23(9)1803-10.",
      "abstract": null
    },
    {
      "pmid": "20921462",
      "title": "Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2010 Nov 1",
      "volume": "28",
      "issue": "31",
      "pages": "4706-13",
      "authors": "Peeters M et al",
      "elocationId": "doi: 10.1200/JCO.2009.27.6055",
      "link": null,
      "reference": "Peeters M et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Nov 1;28(31)4706-13.",
      "abstract": null
    },
    {
      "pmid": "31609637",
      "title": "FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109).",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2019 Dec 10",
      "volume": "37",
      "issue": "35",
      "pages": "3401-3411",
      "authors": "Modest DP et al",
      "elocationId": "doi: 10.1200/JCO.19.01340",
      "link": null,
      "reference": "Modest DP et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Dec 10;37(35)3401-3411.",
      "abstract": null
    },
    {
      "pmid": "24739896",
      "title": "Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 May",
      "volume": "15",
      "issue": "6",
      "pages": "569-79",
      "authors": "Price TJ et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70118-4",
      "link": null,
      "reference": "Price TJ et al. The Lancet. Oncology. 2014 May;15(6)569-79.",
      "abstract": null
    },
    {
      "pmid": "31268481",
      "title": "Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Jul 3",
      "volume": "",
      "issue": "",
      "pages": "",
      "authors": "Pietrantonio F et al",
      "elocationId": "doi: 10.1001/jamaoncol.2019.1467",
      "link": null,
      "reference": "Pietrantonio F et al. JAMA oncology. 2019 Jul 3;().",
      "abstract": null
    },
    {
      "pmid": "20921465",
      "title": "Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2010 Nov 1",
      "volume": "28",
      "issue": "31",
      "pages": "4697-705",
      "authors": "Douillard JY et al",
      "elocationId": "doi: 10.1200/JCO.2009.27.4860",
      "link": null,
      "reference": "Douillard JY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Nov 1;28(31)4697-705.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa58"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Neratinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26874901",
      "title": "Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2016 Mar",
      "volume": "17",
      "issue": "3",
      "pages": "367-377",
      "authors": "Chan A et al",
      "elocationId": "doi: 10.1016/S1470-2045(15)00551-3",
      "link": null,
      "reference": "Chan A et al. The Lancet. Oncology. 2016 Mar;17(3)367-377.",
      "abstract": null
    },
    {
      "pmid": "30860945",
      "title": "TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2019 May 1",
      "volume": "37",
      "issue": "13",
      "pages": "1081-1089",
      "authors": "Freedman RA et al",
      "elocationId": "doi: 10.1200/JCO.18.01511",
      "link": null,
      "reference": "Freedman RA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 May 1;37(13)1081-1089.",
      "abstract": null
    },
    {
      "pmid": "29146401",
      "title": "Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2017 Dec",
      "volume": "18",
      "issue": "12",
      "pages": "1688-1700",
      "authors": "Martin M et al",
      "elocationId": "doi: 10.1016/S1470-2045(17)30717-9",
      "link": null,
      "reference": "Martin M et al. The Lancet. Oncology. 2017 Dec;18(12)1688-1700.",
      "abstract": null
    },
    {
      "pmid": "30274983",
      "title": "Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER<sup>+</sup>/HER2<sup>+</sup> Breast Cancers: Implications to the ExteNET Trial.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Jan 15",
      "volume": "25",
      "issue": "2",
      "pages": "771-783",
      "authors": "Sudhan DR et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1131",
      "link": null,
      "reference": "Sudhan DR et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jan 15;25(2)771-783.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa59"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Capecitabine",
    "Neratinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26874901",
      "title": "Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2016 Mar",
      "volume": "17",
      "issue": "3",
      "pages": "367-377",
      "authors": "Chan A et al",
      "elocationId": "doi: 10.1016/S1470-2045(15)00551-3",
      "link": null,
      "reference": "Chan A et al. The Lancet. Oncology. 2016 Mar;17(3)367-377.",
      "abstract": null
    },
    {
      "pmid": "30860945",
      "title": "TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2019 May 1",
      "volume": "37",
      "issue": "13",
      "pages": "1081-1089",
      "authors": "Freedman RA et al",
      "elocationId": "doi: 10.1200/JCO.18.01511",
      "link": null,
      "reference": "Freedman RA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 May 1;37(13)1081-1089.",
      "abstract": null
    },
    {
      "pmid": "29146401",
      "title": "Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2017 Dec",
      "volume": "18",
      "issue": "12",
      "pages": "1688-1700",
      "authors": "Martin M et al",
      "elocationId": "doi: 10.1016/S1470-2045(17)30717-9",
      "link": null,
      "reference": "Martin M et al. The Lancet. Oncology. 2017 Dec;18(12)1688-1700.",
      "abstract": null
    },
    {
      "pmid": "30274983",
      "title": "Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER<sup>+</sup>/HER2<sup>+</sup> Breast Cancers: Implications to the ExteNET Trial.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Jan 15",
      "volume": "25",
      "issue": "2",
      "pages": "771-783",
      "authors": "Sudhan DR et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1131",
      "link": null,
      "reference": "Sudhan DR et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jan 15;25(2)771-783.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa5a"
  },
  "level": "LEVEL_1",
  "gene": "RET",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Thyroid Cancer",
  "cancer_sub_type": "Medullary Thyroid Cancer",
  "drug": [
    "Selpercatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.sciencedirect.com/science/article/pii/S0923753419604539",
      "reference": "null. null. .",
      "abstract": "Wirth et al. Abstract# LBA93, ESMO 2019"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa5b"
  },
  "level": "LEVEL_1",
  "gene": "PDGFB",
  "alteration": "COL1A1-PDGFB Fusion",
  "alteration_name": "COL1A1-PDGFB Fusion",
  "cancer_main_type": "Skin Cancer, Non-Melanoma",
  "cancer_sub_type": "Dermatofibrosarcoma Protuberans",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19620561",
      "title": "Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.",
      "journal": "Archives of dermatology",
      "pubDate": "2009 Jul",
      "volume": "145",
      "issue": "7",
      "pages": "792-6",
      "authors": "Han A et al",
      "elocationId": "doi: 10.1001/archdermatol.2009.140",
      "link": null,
      "reference": "Han A et al. Archives of dermatology. 2009 Jul;145(7)792-6.",
      "abstract": null
    },
    {
      "pmid": "20439456",
      "title": "Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2010 Jun 15",
      "volume": "16",
      "issue": "12",
      "pages": "3288-95",
      "authors": "Kérob D et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-09-3401",
      "link": null,
      "reference": "Kérob D et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Jun 15;16(12)3288-95.",
      "abstract": null
    },
    {
      "pmid": "15746584",
      "title": "Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate.",
      "journal": "Anti-cancer drugs",
      "pubDate": "2005 Apr",
      "volume": "16",
      "issue": "4",
      "pages": "461-6",
      "authors": "Labropoulos SV et al",
      "elocationId": "",
      "link": null,
      "reference": "Labropoulos SV et al. Anti-cancer drugs. 2005 Apr;16(4)461-6.",
      "abstract": null
    },
    {
      "pmid": "18451237",
      "title": "Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2008 May 1",
      "volume": "14",
      "issue": "9",
      "pages": "2717-25",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-07-4575",
      "link": null,
      "reference": "Heinrich MC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 May 1;14(9)2717-25.",
      "abstract": null
    },
    {
      "pmid": "15503291",
      "title": "Imatinib mesylate: an attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2005 May",
      "volume": "44",
      "issue": "5",
      "pages": "511-5",
      "authors": "Price VE et al",
      "elocationId": "",
      "link": null,
      "reference": "Price VE et al. Pediatric blood & cancer. 2005 May;44(5)511-5.",
      "abstract": null
    },
    {
      "pmid": "15681532",
      "title": "Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2005 Feb 1",
      "volume": "23",
      "issue": "4",
      "pages": "866-73",
      "authors": "McArthur GA et al",
      "elocationId": "",
      "link": null,
      "reference": "McArthur GA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Feb 1;23(4)866-73.",
      "abstract": null
    },
    {
      "pmid": "21128251",
      "title": "Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.",
      "journal": "International journal of cancer",
      "pubDate": "2011 Oct 1",
      "volume": "129",
      "issue": "7",
      "pages": "1761-72",
      "authors": "Stacchiotti S et al",
      "elocationId": "doi: 10.1002/ijc.25826",
      "link": null,
      "reference": "Stacchiotti S et al. International journal of cancer. 2011 Oct 1;129(7)1761-72.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa5c"
  },
  "level": "LEVEL_1",
  "gene": "CHEK1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa5d"
  },
  "level": "LEVEL_1",
  "gene": "CHEK1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa5e"
  },
  "level": "LEVEL_1",
  "gene": "TSC1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Glioma",
  "cancer_sub_type": "Encapsulated Glioma",
  "drug": [
    "Everolimus"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23158522",
      "title": "Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2013 Jan 12",
      "volume": "381",
      "issue": "9861",
      "pages": "125-32",
      "authors": "Franz DN et al",
      "elocationId": "doi: 10.1016/S0140-6736(12)61134-9",
      "link": null,
      "reference": "Franz DN et al. Lancet (London, England). 2013 Jan 12;381(9861)125-32.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa5f"
  },
  "level": "LEVEL_1",
  "gene": "ABL1",
  "alteration": "BCR-ABL1 Fusion",
  "alteration_name": "BCR-ABL1 Fusion",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Ponatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24180494",
      "title": "A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.",
      "journal": "The New England journal of medicine",
      "pubDate": "2013 Nov 7",
      "volume": "369",
      "issue": "19",
      "pages": "1783-96",
      "authors": "Cortes JE et al",
      "elocationId": "doi: 10.1056/NEJMoa1306494",
      "link": null,
      "reference": "Cortes JE et al. The New England journal of medicine. 2013 Nov 7;369(19)1783-96.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa60"
  },
  "level": "LEVEL_1",
  "gene": "IDH1",
  "alteration": "R132C",
  "alteration_name": "R132C",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Ivosidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29860938",
      "title": "Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Jun 21",
      "volume": "378",
      "issue": "25",
      "pages": "2386-2398",
      "authors": "DiNardo CD et al",
      "elocationId": "doi: 10.1056/NEJMoa1716984",
      "link": null,
      "reference": "DiNardo CD et al. The New England journal of medicine. 2018 Jun 21;378(25)2386-2398.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/124/21/3734?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Hansen et al. Abstract# 3734, ASH 2014"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7042",
      "reference": "null. null. .",
      "abstract": "Dohner et al. Abstract# 7042, ASCO 2022"
    },
    {
      "pmid": "23393090",
      "title": "(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.",
      "journal": "Science (New York, N.Y.)",
      "pubDate": "2013 Mar 29",
      "volume": "339",
      "issue": "6127",
      "pages": "1621-5",
      "authors": "Losman JA et al",
      "elocationId": "doi: 10.1126/science.1231677",
      "link": null,
      "reference": "Losman JA et al. Science (New York, N.Y.). 2013 Mar 29;339(6127)1621-5.",
      "abstract": null
    },
    {
      "pmid": "23558169",
      "title": "An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.",
      "journal": "Science (New York, N.Y.)",
      "pubDate": "2013 May 3",
      "volume": "340",
      "issue": "6132",
      "pages": "626-30",
      "authors": "Rohle D et al",
      "elocationId": "doi: 10.1126/science.1236062",
      "link": null,
      "reference": "Rohle D et al. Science (New York, N.Y.). 2013 May 3;340(6132)626-30.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa61"
  },
  "level": "LEVEL_1",
  "gene": "IDH1",
  "alteration": "R132H",
  "alteration_name": "R132H",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Ivosidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29860938",
      "title": "Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Jun 21",
      "volume": "378",
      "issue": "25",
      "pages": "2386-2398",
      "authors": "DiNardo CD et al",
      "elocationId": "doi: 10.1056/NEJMoa1716984",
      "link": null,
      "reference": "DiNardo CD et al. The New England journal of medicine. 2018 Jun 21;378(25)2386-2398.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/124/21/3734?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Hansen et al. Abstract# 3734, ASH 2014"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7042",
      "reference": "null. null. .",
      "abstract": "Dohner et al. Abstract# 7042, ASCO 2022"
    },
    {
      "pmid": "23393090",
      "title": "(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.",
      "journal": "Science (New York, N.Y.)",
      "pubDate": "2013 Mar 29",
      "volume": "339",
      "issue": "6127",
      "pages": "1621-5",
      "authors": "Losman JA et al",
      "elocationId": "doi: 10.1126/science.1231677",
      "link": null,
      "reference": "Losman JA et al. Science (New York, N.Y.). 2013 Mar 29;339(6127)1621-5.",
      "abstract": null
    },
    {
      "pmid": "23558169",
      "title": "An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.",
      "journal": "Science (New York, N.Y.)",
      "pubDate": "2013 May 3",
      "volume": "340",
      "issue": "6132",
      "pages": "626-30",
      "authors": "Rohle D et al",
      "elocationId": "doi: 10.1126/science.1236062",
      "link": null,
      "reference": "Rohle D et al. Science (New York, N.Y.). 2013 May 3;340(6132)626-30.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa62"
  },
  "level": "LEVEL_1",
  "gene": "IDH1",
  "alteration": "R132G",
  "alteration_name": "R132G",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Ivosidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29860938",
      "title": "Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Jun 21",
      "volume": "378",
      "issue": "25",
      "pages": "2386-2398",
      "authors": "DiNardo CD et al",
      "elocationId": "doi: 10.1056/NEJMoa1716984",
      "link": null,
      "reference": "DiNardo CD et al. The New England journal of medicine. 2018 Jun 21;378(25)2386-2398.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/124/21/3734?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Hansen et al. Abstract# 3734, ASH 2014"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7042",
      "reference": "null. null. .",
      "abstract": "Dohner et al. Abstract# 7042, ASCO 2022"
    },
    {
      "pmid": "23393090",
      "title": "(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.",
      "journal": "Science (New York, N.Y.)",
      "pubDate": "2013 Mar 29",
      "volume": "339",
      "issue": "6127",
      "pages": "1621-5",
      "authors": "Losman JA et al",
      "elocationId": "doi: 10.1126/science.1231677",
      "link": null,
      "reference": "Losman JA et al. Science (New York, N.Y.). 2013 Mar 29;339(6127)1621-5.",
      "abstract": null
    },
    {
      "pmid": "23558169",
      "title": "An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.",
      "journal": "Science (New York, N.Y.)",
      "pubDate": "2013 May 3",
      "volume": "340",
      "issue": "6132",
      "pages": "626-30",
      "authors": "Rohle D et al",
      "elocationId": "doi: 10.1126/science.1236062",
      "link": null,
      "reference": "Rohle D et al. Science (New York, N.Y.). 2013 May 3;340(6132)626-30.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa63"
  },
  "level": "LEVEL_1",
  "gene": "IDH1",
  "alteration": "R132S",
  "alteration_name": "R132S",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Ivosidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29860938",
      "title": "Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Jun 21",
      "volume": "378",
      "issue": "25",
      "pages": "2386-2398",
      "authors": "DiNardo CD et al",
      "elocationId": "doi: 10.1056/NEJMoa1716984",
      "link": null,
      "reference": "DiNardo CD et al. The New England journal of medicine. 2018 Jun 21;378(25)2386-2398.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/124/21/3734?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Hansen et al. Abstract# 3734, ASH 2014"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7042",
      "reference": "null. null. .",
      "abstract": "Dohner et al. Abstract# 7042, ASCO 2022"
    },
    {
      "pmid": "23393090",
      "title": "(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.",
      "journal": "Science (New York, N.Y.)",
      "pubDate": "2013 Mar 29",
      "volume": "339",
      "issue": "6127",
      "pages": "1621-5",
      "authors": "Losman JA et al",
      "elocationId": "doi: 10.1126/science.1231677",
      "link": null,
      "reference": "Losman JA et al. Science (New York, N.Y.). 2013 Mar 29;339(6127)1621-5.",
      "abstract": null
    },
    {
      "pmid": "23558169",
      "title": "An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.",
      "journal": "Science (New York, N.Y.)",
      "pubDate": "2013 May 3",
      "volume": "340",
      "issue": "6132",
      "pages": "626-30",
      "authors": "Rohle D et al",
      "elocationId": "doi: 10.1126/science.1236062",
      "link": null,
      "reference": "Rohle D et al. Science (New York, N.Y.). 2013 May 3;340(6132)626-30.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa64"
  },
  "level": "LEVEL_1",
  "gene": "IDH1",
  "alteration": "R132L",
  "alteration_name": "R132L",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Ivosidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29860938",
      "title": "Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Jun 21",
      "volume": "378",
      "issue": "25",
      "pages": "2386-2398",
      "authors": "DiNardo CD et al",
      "elocationId": "doi: 10.1056/NEJMoa1716984",
      "link": null,
      "reference": "DiNardo CD et al. The New England journal of medicine. 2018 Jun 21;378(25)2386-2398.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/124/21/3734?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Hansen et al. Abstract# 3734, ASH 2014"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7042",
      "reference": "null. null. .",
      "abstract": "Dohner et al. Abstract# 7042, ASCO 2022"
    },
    {
      "pmid": "23393090",
      "title": "(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible.",
      "journal": "Science (New York, N.Y.)",
      "pubDate": "2013 Mar 29",
      "volume": "339",
      "issue": "6127",
      "pages": "1621-5",
      "authors": "Losman JA et al",
      "elocationId": "doi: 10.1126/science.1231677",
      "link": null,
      "reference": "Losman JA et al. Science (New York, N.Y.). 2013 Mar 29;339(6127)1621-5.",
      "abstract": null
    },
    {
      "pmid": "23558169",
      "title": "An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.",
      "journal": "Science (New York, N.Y.)",
      "pubDate": "2013 May 3",
      "volume": "340",
      "issue": "6132",
      "pages": "626-30",
      "authors": "Rohle D et al",
      "elocationId": "doi: 10.1126/science.1236062",
      "link": null,
      "reference": "Rohle D et al. Science (New York, N.Y.). 2013 May 3;340(6132)626-30.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa65"
  },
  "level": "LEVEL_1",
  "gene": "ALK",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Ceritinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://academic.oup.com/annonc/article/30/Supplement_5/mdz260/5576390",
      "reference": "null. null. .",
      "abstract": "Chow et al. Abstract# 1478O, ESMO 2019"
    },
    {
      "pmid": "28126333",
      "title": "First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.",
      "journal": "Lancet (London, England)",
      "pubDate": "2017 Mar 4",
      "volume": "389",
      "issue": "10072",
      "pages": "917-929",
      "authors": "Soria JC et al",
      "elocationId": "doi: 10.1016/S0140-6736(17)30123-X",
      "link": null,
      "reference": "Soria JC et al. Lancet (London, England). 2017 Mar 4;389(10072)917-929.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa66"
  },
  "level": "LEVEL_1",
  "gene": "ROS1",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Entrectinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28183697",
      "title": "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).",
      "journal": "Cancer discovery",
      "pubDate": "2017 Apr",
      "volume": "7",
      "issue": "4",
      "pages": "400-409",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-16-1237",
      "link": null,
      "reference": "Drilon A et al. Cancer discovery. 2017 Apr;7(4)400-409.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060",
      "reference": "null. null. .",
      "abstract": "Drilon et al. Abstract# CT060, AACR 2017"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397",
      "reference": "null. null. .",
      "abstract": "Braud et al. Abstract# 64P, ESMO 2019"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa67"
  },
  "level": "LEVEL_1",
  "gene": "NTRK3",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Entrectinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28183697",
      "title": "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).",
      "journal": "Cancer discovery",
      "pubDate": "2017 Apr",
      "volume": "7",
      "issue": "4",
      "pages": "400-409",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-16-1237",
      "link": null,
      "reference": "Drilon A et al. Cancer discovery. 2017 Apr;7(4)400-409.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583",
      "reference": "null. null. .",
      "abstract": "Demetri et al. Abstract# LBA17, ESMO 2018 Congress"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407",
      "reference": "null. null. .",
      "abstract": "Rolfo et al. Abstract# 65P, ESMO 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/155954/abstract",
      "reference": "null. null. .",
      "abstract": "Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018"
    },
    {
      "pmid": "31838007",
      "title": "Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Feb",
      "volume": "21",
      "issue": "2",
      "pages": "271-282",
      "authors": "Doebele RC et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30691-6",
      "link": null,
      "reference": "Doebele RC et al. The Lancet. Oncology. 2020 Feb;21(2)271-282.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa68"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Esophagogastric Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Trastuzumab Deruxtecan"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32469182",
      "title": "Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 Jun 18",
      "volume": "382",
      "issue": "25",
      "pages": "2419-2430",
      "authors": "Shitara K et al",
      "elocationId": "doi: 10.1056/NEJMoa2004413",
      "link": null,
      "reference": "Shitara K et al. The New England journal of medicine. 2020 Jun 18;382(25)2419-2430.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa69"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Biliary Tract Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Dabrafenib",
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23020132",
      "title": "Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.",
      "journal": "The New England journal of medicine",
      "pubDate": "2012 Nov 1",
      "volume": "367",
      "issue": "18",
      "pages": "1694-703",
      "authors": "Flaherty KT et al",
      "elocationId": "doi: 10.1056/NEJMoa1210093",
      "link": null,
      "reference": "Flaherty KT et al. The New England journal of medicine. 2012 Nov 1;367(18)1694-703.",
      "abstract": null
    },
    {
      "pmid": "34838156",
      "title": "Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2022 Jan",
      "volume": "23",
      "issue": "1",
      "pages": "53-64",
      "authors": "Wen PY et al",
      "elocationId": "doi: 10.1016/S1470-2045(21)00578-7",
      "link": null,
      "reference": "Wen PY et al. The Lancet. Oncology. 2022 Jan;23(1)53-64.",
      "abstract": null
    },
    {
      "pmid": "32758030",
      "title": "Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF<sup>V600E</sup></i> Mutations: Results of the NCI-MATCH Trial Subprotocol H.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2020 Nov 20",
      "volume": "38",
      "issue": "33",
      "pages": "3895-3904",
      "authors": "Salama AKS et al",
      "elocationId": "doi: 10.1200/JCO.20.00762",
      "link": null,
      "reference": "Salama AKS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Nov 20;38(33)3895-3904.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/",
      "reference": "null. null. .",
      "abstract": "Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020"
    },
    {
      "pmid": "32818466",
      "title": "Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Sep",
      "volume": "21",
      "issue": "9",
      "pages": "1234-1243",
      "authors": "Subbiah V et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30321-1",
      "link": null,
      "reference": "Subbiah V et al. The Lancet. Oncology. 2020 Sep;21(9)1234-1243.",
      "abstract": null
    },
    {
      "pmid": "25399551",
      "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Jan 1",
      "volume": "372",
      "issue": "1",
      "pages": "30-9",
      "authors": "Robert C et al",
      "elocationId": "doi: 10.1056/NEJMoa1412690",
      "link": null,
      "reference": "Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.",
      "abstract": null
    },
    {
      "pmid": "27283860",
      "title": "Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2016 Jul",
      "volume": "17",
      "issue": "7",
      "pages": "984-993",
      "authors": "Planchard D et al",
      "elocationId": "doi: 10.1016/S1470-2045(16)30146-2",
      "link": null,
      "reference": "Planchard D et al. The Lancet. Oncology. 2016 Jul;17(7)984-993.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa6a"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Dabrafenib",
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23020132",
      "title": "Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.",
      "journal": "The New England journal of medicine",
      "pubDate": "2012 Nov 1",
      "volume": "367",
      "issue": "18",
      "pages": "1694-703",
      "authors": "Flaherty KT et al",
      "elocationId": "doi: 10.1056/NEJMoa1210093",
      "link": null,
      "reference": "Flaherty KT et al. The New England journal of medicine. 2012 Nov 1;367(18)1694-703.",
      "abstract": null
    },
    {
      "pmid": "34838156",
      "title": "Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2022 Jan",
      "volume": "23",
      "issue": "1",
      "pages": "53-64",
      "authors": "Wen PY et al",
      "elocationId": "doi: 10.1016/S1470-2045(21)00578-7",
      "link": null,
      "reference": "Wen PY et al. The Lancet. Oncology. 2022 Jan;23(1)53-64.",
      "abstract": null
    },
    {
      "pmid": "32758030",
      "title": "Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF<sup>V600E</sup></i> Mutations: Results of the NCI-MATCH Trial Subprotocol H.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2020 Nov 20",
      "volume": "38",
      "issue": "33",
      "pages": "3895-3904",
      "authors": "Salama AKS et al",
      "elocationId": "doi: 10.1200/JCO.20.00762",
      "link": null,
      "reference": "Salama AKS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Nov 20;38(33)3895-3904.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/",
      "reference": "null. null. .",
      "abstract": "Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.17_suppl.LBA2002",
      "reference": "null. null. .",
      "abstract": "Bouffet et al. Abstract# LBA2002, ASCO 2022"
    },
    {
      "pmid": "32818466",
      "title": "Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Sep",
      "volume": "21",
      "issue": "9",
      "pages": "1234-1243",
      "authors": "Subbiah V et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30321-1",
      "link": null,
      "reference": "Subbiah V et al. The Lancet. Oncology. 2020 Sep;21(9)1234-1243.",
      "abstract": null
    },
    {
      "pmid": "25399551",
      "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Jan 1",
      "volume": "372",
      "issue": "1",
      "pages": "30-9",
      "authors": "Robert C et al",
      "elocationId": "doi: 10.1056/NEJMoa1412690",
      "link": null,
      "reference": "Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.",
      "abstract": null
    },
    {
      "pmid": "27283860",
      "title": "Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2016 Jul",
      "volume": "17",
      "issue": "7",
      "pages": "984-993",
      "authors": "Planchard D et al",
      "elocationId": "doi: 10.1016/S1470-2045(16)30146-2",
      "link": null,
      "reference": "Planchard D et al. The Lancet. Oncology. 2016 Jul;17(7)984-993.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa6b"
  },
  "level": "LEVEL_1",
  "gene": "IDH2",
  "alteration": "R172S",
  "alteration_name": "R172S",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Enasidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30967620",
      "title": "Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.",
      "journal": "Leukemia",
      "pubDate": "2019 Nov",
      "volume": "33",
      "issue": "11",
      "pages": "2575-2584",
      "authors": "Pollyea DA et al",
      "elocationId": "doi: 10.1038/s41375-019-0472-2",
      "link": null,
      "reference": "Pollyea DA et al. Leukemia. 2019 Nov;33(11)2575-2584.",
      "abstract": null
    },
    {
      "pmid": "28588020",
      "title": "Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia.",
      "journal": "Blood",
      "pubDate": "2017 Aug 10",
      "volume": "130",
      "issue": "6",
      "pages": "722-731",
      "authors": "Stein EM et al",
      "elocationId": "doi: 10.1182/blood-2017-04-779405",
      "link": null,
      "reference": "Stein EM et al. Blood. 2017 Aug 10;130(6)722-731.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa6c"
  },
  "level": "LEVEL_1",
  "gene": "IDH2",
  "alteration": "R140L",
  "alteration_name": "R140L",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Enasidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30967620",
      "title": "Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.",
      "journal": "Leukemia",
      "pubDate": "2019 Nov",
      "volume": "33",
      "issue": "11",
      "pages": "2575-2584",
      "authors": "Pollyea DA et al",
      "elocationId": "doi: 10.1038/s41375-019-0472-2",
      "link": null,
      "reference": "Pollyea DA et al. Leukemia. 2019 Nov;33(11)2575-2584.",
      "abstract": null
    },
    {
      "pmid": "28588020",
      "title": "Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia.",
      "journal": "Blood",
      "pubDate": "2017 Aug 10",
      "volume": "130",
      "issue": "6",
      "pages": "722-731",
      "authors": "Stein EM et al",
      "elocationId": "doi: 10.1182/blood-2017-04-779405",
      "link": null,
      "reference": "Stein EM et al. Blood. 2017 Aug 10;130(6)722-731.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa6d"
  },
  "level": "LEVEL_1",
  "gene": "IDH2",
  "alteration": "R140G",
  "alteration_name": "R140G",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Enasidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30967620",
      "title": "Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.",
      "journal": "Leukemia",
      "pubDate": "2019 Nov",
      "volume": "33",
      "issue": "11",
      "pages": "2575-2584",
      "authors": "Pollyea DA et al",
      "elocationId": "doi: 10.1038/s41375-019-0472-2",
      "link": null,
      "reference": "Pollyea DA et al. Leukemia. 2019 Nov;33(11)2575-2584.",
      "abstract": null
    },
    {
      "pmid": "28588020",
      "title": "Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia.",
      "journal": "Blood",
      "pubDate": "2017 Aug 10",
      "volume": "130",
      "issue": "6",
      "pages": "722-731",
      "authors": "Stein EM et al",
      "elocationId": "doi: 10.1182/blood-2017-04-779405",
      "link": null,
      "reference": "Stein EM et al. Blood. 2017 Aug 10;130(6)722-731.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa6e"
  },
  "level": "LEVEL_1",
  "gene": "IDH2",
  "alteration": "R140W",
  "alteration_name": "R140W",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Enasidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30967620",
      "title": "Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.",
      "journal": "Leukemia",
      "pubDate": "2019 Nov",
      "volume": "33",
      "issue": "11",
      "pages": "2575-2584",
      "authors": "Pollyea DA et al",
      "elocationId": "doi: 10.1038/s41375-019-0472-2",
      "link": null,
      "reference": "Pollyea DA et al. Leukemia. 2019 Nov;33(11)2575-2584.",
      "abstract": null
    },
    {
      "pmid": "28588020",
      "title": "Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia.",
      "journal": "Blood",
      "pubDate": "2017 Aug 10",
      "volume": "130",
      "issue": "6",
      "pages": "722-731",
      "authors": "Stein EM et al",
      "elocationId": "doi: 10.1182/blood-2017-04-779405",
      "link": null,
      "reference": "Stein EM et al. Blood. 2017 Aug 10;130(6)722-731.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa6f"
  },
  "level": "LEVEL_1",
  "gene": "IDH2",
  "alteration": "R172W",
  "alteration_name": "R172W",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Enasidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30967620",
      "title": "Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.",
      "journal": "Leukemia",
      "pubDate": "2019 Nov",
      "volume": "33",
      "issue": "11",
      "pages": "2575-2584",
      "authors": "Pollyea DA et al",
      "elocationId": "doi: 10.1038/s41375-019-0472-2",
      "link": null,
      "reference": "Pollyea DA et al. Leukemia. 2019 Nov;33(11)2575-2584.",
      "abstract": null
    },
    {
      "pmid": "28588020",
      "title": "Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia.",
      "journal": "Blood",
      "pubDate": "2017 Aug 10",
      "volume": "130",
      "issue": "6",
      "pages": "722-731",
      "authors": "Stein EM et al",
      "elocationId": "doi: 10.1182/blood-2017-04-779405",
      "link": null,
      "reference": "Stein EM et al. Blood. 2017 Aug 10;130(6)722-731.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa70"
  },
  "level": "LEVEL_1",
  "gene": "IDH2",
  "alteration": "R140Q",
  "alteration_name": "R140Q",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Enasidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30967620",
      "title": "Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.",
      "journal": "Leukemia",
      "pubDate": "2019 Nov",
      "volume": "33",
      "issue": "11",
      "pages": "2575-2584",
      "authors": "Pollyea DA et al",
      "elocationId": "doi: 10.1038/s41375-019-0472-2",
      "link": null,
      "reference": "Pollyea DA et al. Leukemia. 2019 Nov;33(11)2575-2584.",
      "abstract": null
    },
    {
      "pmid": "28588020",
      "title": "Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia.",
      "journal": "Blood",
      "pubDate": "2017 Aug 10",
      "volume": "130",
      "issue": "6",
      "pages": "722-731",
      "authors": "Stein EM et al",
      "elocationId": "doi: 10.1182/blood-2017-04-779405",
      "link": null,
      "reference": "Stein EM et al. Blood. 2017 Aug 10;130(6)722-731.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa71"
  },
  "level": "LEVEL_1",
  "gene": "IDH2",
  "alteration": "R172G",
  "alteration_name": "R172G",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Enasidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30967620",
      "title": "Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.",
      "journal": "Leukemia",
      "pubDate": "2019 Nov",
      "volume": "33",
      "issue": "11",
      "pages": "2575-2584",
      "authors": "Pollyea DA et al",
      "elocationId": "doi: 10.1038/s41375-019-0472-2",
      "link": null,
      "reference": "Pollyea DA et al. Leukemia. 2019 Nov;33(11)2575-2584.",
      "abstract": null
    },
    {
      "pmid": "28588020",
      "title": "Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia.",
      "journal": "Blood",
      "pubDate": "2017 Aug 10",
      "volume": "130",
      "issue": "6",
      "pages": "722-731",
      "authors": "Stein EM et al",
      "elocationId": "doi: 10.1182/blood-2017-04-779405",
      "link": null,
      "reference": "Stein EM et al. Blood. 2017 Aug 10;130(6)722-731.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa72"
  },
  "level": "LEVEL_1",
  "gene": "IDH2",
  "alteration": "R172K",
  "alteration_name": "R172K",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Enasidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30967620",
      "title": "Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.",
      "journal": "Leukemia",
      "pubDate": "2019 Nov",
      "volume": "33",
      "issue": "11",
      "pages": "2575-2584",
      "authors": "Pollyea DA et al",
      "elocationId": "doi: 10.1038/s41375-019-0472-2",
      "link": null,
      "reference": "Pollyea DA et al. Leukemia. 2019 Nov;33(11)2575-2584.",
      "abstract": null
    },
    {
      "pmid": "28588020",
      "title": "Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia.",
      "journal": "Blood",
      "pubDate": "2017 Aug 10",
      "volume": "130",
      "issue": "6",
      "pages": "722-731",
      "authors": "Stein EM et al",
      "elocationId": "doi: 10.1182/blood-2017-04-779405",
      "link": null,
      "reference": "Stein EM et al. Blood. 2017 Aug 10;130(6)722-731.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa73"
  },
  "level": "LEVEL_1",
  "gene": "IDH2",
  "alteration": "R172M",
  "alteration_name": "R172M",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Enasidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30967620",
      "title": "Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.",
      "journal": "Leukemia",
      "pubDate": "2019 Nov",
      "volume": "33",
      "issue": "11",
      "pages": "2575-2584",
      "authors": "Pollyea DA et al",
      "elocationId": "doi: 10.1038/s41375-019-0472-2",
      "link": null,
      "reference": "Pollyea DA et al. Leukemia. 2019 Nov;33(11)2575-2584.",
      "abstract": null
    },
    {
      "pmid": "28588020",
      "title": "Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia.",
      "journal": "Blood",
      "pubDate": "2017 Aug 10",
      "volume": "130",
      "issue": "6",
      "pages": "722-731",
      "authors": "Stein EM et al",
      "elocationId": "doi: 10.1182/blood-2017-04-779405",
      "link": null,
      "reference": "Stein EM et al. Blood. 2017 Aug 10;130(6)722-731.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa74"
  },
  "level": "LEVEL_1",
  "gene": "RAD54L",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa75"
  },
  "level": "LEVEL_1",
  "gene": "RAD54L",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa76"
  },
  "level": "LEVEL_1",
  "gene": "RET",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Thyroid Cancer",
  "cancer_sub_type": "Medullary Thyroid Cancer",
  "drug": [
    "Pralsetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/174787/abstract",
      "reference": "null. null. .",
      "abstract": "Taylor et al. Abstract# 6018, ASCO 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/results-from-the-registrational-phase-i-ii-arrow-trial-of-pralsetinib-blu-667-in-patients-pts-with-advanced-ret-mutation-positive-medullary-thy",
      "reference": "null. null. .",
      "abstract": "Hu et al. Abstract# 19130, ESMO 2020"
    },
    {
      "pmid": "29657135",
      "title": "Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers.",
      "journal": "Cancer discovery",
      "pubDate": "2018 Jul",
      "volume": "8",
      "issue": "7",
      "pages": "836-849",
      "authors": "Subbiah V et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0338",
      "link": null,
      "reference": "Subbiah V et al. Cancer discovery. 2018 Jul;8(7)836-849.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa77"
  },
  "level": "LEVEL_1",
  "gene": "RET",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Pralsetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.109",
      "reference": "null. null. .",
      "abstract": "Subbiah et al. Abstract# 109, ASCO 2020"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa78"
  },
  "level": "LEVEL_1",
  "gene": "RAD51D",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa79"
  },
  "level": "LEVEL_1",
  "gene": "RAD51D",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa7a"
  },
  "level": "LEVEL_1",
  "gene": "KIT",
  "alteration": "D816",
  "alteration_name": "D816",
  "cancer_main_type": "Mastocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Avapritinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ashpublications.org/blood/article/136/Supplement%201/37/470030/Pure-Pathologic-Response-Is-Associated-with",
      "reference": "null. null. .",
      "abstract": "Gotlib et al. Abstract# 634, ASH 2020"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.ashclinicalnews.org/on-location/other-meetings/pathfinder-avapritinib-induces-rapid-responses-advanced-systemic-mastocytosis/",
      "reference": "null. null. .",
      "abstract": "DeAngelo et al. Absract# CT023, AACR 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa7b"
  },
  "level": "LEVEL_1",
  "gene": "ATM",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa7c"
  },
  "level": "LEVEL_1",
  "gene": "ATM",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa7d"
  },
  "level": "LEVEL_1",
  "gene": "NTRK1",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Entrectinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28183697",
      "title": "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).",
      "journal": "Cancer discovery",
      "pubDate": "2017 Apr",
      "volume": "7",
      "issue": "4",
      "pages": "400-409",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-16-1237",
      "link": null,
      "reference": "Drilon A et al. Cancer discovery. 2017 Apr;7(4)400-409.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583",
      "reference": "null. null. .",
      "abstract": "Demetri et al. Abstract# LBA17, ESMO 2018 Congress"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407",
      "reference": "null. null. .",
      "abstract": "Rolfo et al. Abstract# 65P, ESMO 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/155954/abstract",
      "reference": "null. null. .",
      "abstract": "Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018"
    },
    {
      "pmid": "31838007",
      "title": "Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Feb",
      "volume": "21",
      "issue": "2",
      "pages": "271-282",
      "authors": "Doebele RC et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30691-6",
      "link": null,
      "reference": "Doebele RC et al. The Lancet. Oncology. 2020 Feb;21(2)271-282.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa7e"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "L858R",
  "alteration_name": "L858R",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erlotinib",
    "Ramucirumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27987585",
      "title": "Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2016 Dec",
      "volume": "102",
      "issue": "",
      "pages": "30-37",
      "authors": "Cicènas S et al",
      "elocationId": "doi: 10.1016/j.lungcan.2016.10.007",
      "link": null,
      "reference": "Cicènas S et al. Lung cancer (Amsterdam, Netherlands). 2016 Dec;102()30-37.",
      "abstract": null
    },
    {
      "pmid": "22285168",
      "title": "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2012 Mar",
      "volume": "13",
      "issue": "3",
      "pages": "239-46",
      "authors": "Rosell R et al",
      "elocationId": "doi: 10.1016/S1470-2045(11)70393-X",
      "link": null,
      "reference": "Rosell R et al. The Lancet. Oncology. 2012 Mar;13(3)239-46.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa7f"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "L858R",
  "alteration_name": "L858R",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erlotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27987585",
      "title": "Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2016 Dec",
      "volume": "102",
      "issue": "",
      "pages": "30-37",
      "authors": "Cicènas S et al",
      "elocationId": "doi: 10.1016/j.lungcan.2016.10.007",
      "link": null,
      "reference": "Cicènas S et al. Lung cancer (Amsterdam, Netherlands). 2016 Dec;102()30-37.",
      "abstract": null
    },
    {
      "pmid": "22285168",
      "title": "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2012 Mar",
      "volume": "13",
      "issue": "3",
      "pages": "239-46",
      "authors": "Rosell R et al",
      "elocationId": "doi: 10.1016/S1470-2045(11)70393-X",
      "link": null,
      "reference": "Rosell R et al. The Lancet. Oncology. 2012 Mar;13(3)239-46.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa80"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "729_761del",
  "alteration_name": "Exon 19 in-frame deletions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erlotinib",
    "Ramucirumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27987585",
      "title": "Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2016 Dec",
      "volume": "102",
      "issue": "",
      "pages": "30-37",
      "authors": "Cicènas S et al",
      "elocationId": "doi: 10.1016/j.lungcan.2016.10.007",
      "link": null,
      "reference": "Cicènas S et al. Lung cancer (Amsterdam, Netherlands). 2016 Dec;102()30-37.",
      "abstract": null
    },
    {
      "pmid": "22285168",
      "title": "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2012 Mar",
      "volume": "13",
      "issue": "3",
      "pages": "239-46",
      "authors": "Rosell R et al",
      "elocationId": "doi: 10.1016/S1470-2045(11)70393-X",
      "link": null,
      "reference": "Rosell R et al. The Lancet. Oncology. 2012 Mar;13(3)239-46.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa81"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "729_761del",
  "alteration_name": "Exon 19 in-frame deletions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erlotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27987585",
      "title": "Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2016 Dec",
      "volume": "102",
      "issue": "",
      "pages": "30-37",
      "authors": "Cicènas S et al",
      "elocationId": "doi: 10.1016/j.lungcan.2016.10.007",
      "link": null,
      "reference": "Cicènas S et al. Lung cancer (Amsterdam, Netherlands). 2016 Dec;102()30-37.",
      "abstract": null
    },
    {
      "pmid": "22285168",
      "title": "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2012 Mar",
      "volume": "13",
      "issue": "3",
      "pages": "239-46",
      "authors": "Rosell R et al",
      "elocationId": "doi: 10.1016/S1470-2045(11)70393-X",
      "link": null,
      "reference": "Rosell R et al. The Lancet. Oncology. 2012 Mar;13(3)239-46.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa82"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Niraparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30948273",
      "title": "Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 May",
      "volume": "20",
      "issue": "5",
      "pages": "636-648",
      "authors": "Moore KN et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30029-4",
      "link": null,
      "reference": "Moore KN et al. The Lancet. Oncology. 2019 May;20(5)636-648.",
      "abstract": null
    },
    {
      "pmid": "27717299",
      "title": "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2016 Dec 1",
      "volume": "375",
      "issue": "22",
      "pages": "2154-2164",
      "authors": "Mirza MR et al",
      "elocationId": "",
      "link": null,
      "reference": "Mirza MR et al. The New England journal of medicine. 2016 Dec 1;375(22)2154-2164.",
      "abstract": null
    },
    {
      "pmid": "31562799",
      "title": "Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Dec 19",
      "volume": "381",
      "issue": "25",
      "pages": "2391-2402",
      "authors": "González-Martín A et al",
      "elocationId": "doi: 10.1056/NEJMoa1910962",
      "link": null,
      "reference": "González-Martín A et al. The New England journal of medicine. 2019 Dec 19;381(25)2391-2402.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa83"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian/Fallopian Tube Cancer, NOS",
  "cancer_sub_type": "Ovary/Fallopian Tube",
  "drug": [
    "Niraparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30948273",
      "title": "Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 May",
      "volume": "20",
      "issue": "5",
      "pages": "636-648",
      "authors": "Moore KN et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30029-4",
      "link": null,
      "reference": "Moore KN et al. The Lancet. Oncology. 2019 May;20(5)636-648.",
      "abstract": null
    },
    {
      "pmid": "27717299",
      "title": "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2016 Dec 1",
      "volume": "375",
      "issue": "22",
      "pages": "2154-2164",
      "authors": "Mirza MR et al",
      "elocationId": "",
      "link": null,
      "reference": "Mirza MR et al. The New England journal of medicine. 2016 Dec 1;375(22)2154-2164.",
      "abstract": null
    },
    {
      "pmid": "31562799",
      "title": "Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Dec 19",
      "volume": "381",
      "issue": "25",
      "pages": "2391-2402",
      "authors": "González-Martín A et al",
      "elocationId": "doi: 10.1056/NEJMoa1910962",
      "link": null,
      "reference": "González-Martín A et al. The New England journal of medicine. 2019 Dec 19;381(25)2391-2402.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa84"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Peritoneal Cancer, NOS",
  "cancer_sub_type": "Peritoneal Serous Carcinoma",
  "drug": [
    "Niraparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30948273",
      "title": "Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 May",
      "volume": "20",
      "issue": "5",
      "pages": "636-648",
      "authors": "Moore KN et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30029-4",
      "link": null,
      "reference": "Moore KN et al. The Lancet. Oncology. 2019 May;20(5)636-648.",
      "abstract": null
    },
    {
      "pmid": "27717299",
      "title": "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2016 Dec 1",
      "volume": "375",
      "issue": "22",
      "pages": "2154-2164",
      "authors": "Mirza MR et al",
      "elocationId": "",
      "link": null,
      "reference": "Mirza MR et al. The New England journal of medicine. 2016 Dec 1;375(22)2154-2164.",
      "abstract": null
    },
    {
      "pmid": "31562799",
      "title": "Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Dec 19",
      "volume": "381",
      "issue": "25",
      "pages": "2391-2402",
      "authors": "González-Martín A et al",
      "elocationId": "doi: 10.1056/NEJMoa1910962",
      "link": null,
      "reference": "González-Martín A et al. The New England journal of medicine. 2019 Dec 19;381(25)2391-2402.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa85"
  },
  "level": "LEVEL_1",
  "gene": "ALK",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Soft Tissue Sarcoma",
  "cancer_sub_type": "Inflammatory Myofibroblastic Tumor",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/full/10.1200/PO.18.00297",
      "reference": "null. null. .",
      "abstract": "Trahair et al. JCO PO, 2018"
    },
    {
      "pmid": "29352732",
      "title": "Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.",
      "journal": "American journal of hematology",
      "pubDate": "2018 May",
      "volume": "93",
      "issue": "5",
      "pages": "607-614",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.25043",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2018 May;93(5)607-614.",
      "abstract": null
    },
    {
      "pmid": "28787259",
      "title": "Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Oct 1",
      "volume": "35",
      "issue": "28",
      "pages": "3215-3221",
      "authors": "Mossé YP et al",
      "elocationId": "doi: 10.1200/JCO.2017.73.4830",
      "link": null,
      "reference": "Mossé YP et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Oct 1;35(28)3215-3221.",
      "abstract": null
    },
    {
      "pmid": "23598171",
      "title": "Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2013 May",
      "volume": "14",
      "issue": "6",
      "pages": "472-80",
      "authors": "Mossé YP et al",
      "elocationId": "doi: 10.1016/S1470-2045(13)70095-0",
      "link": null,
      "reference": "Mossé YP et al. The Lancet. Oncology. 2013 May;14(6)472-80.",
      "abstract": null
    },
    {
      "pmid": "20979472",
      "title": "Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.",
      "journal": "The New England journal of medicine",
      "pubDate": "2010 Oct 28",
      "volume": "363",
      "issue": "18",
      "pages": "1727-33",
      "authors": "Butrynski JE et al",
      "elocationId": "doi: 10.1056/NEJMoa1007056",
      "link": null,
      "reference": "Butrynski JE et al. The New England journal of medicine. 2010 Oct 28;363(18)1727-33.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa86"
  },
  "level": "LEVEL_1",
  "gene": "KRAS",
  "alteration": "Wildtype",
  "alteration_name": "Wildtype",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Cetuximab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "15677699",
      "title": "Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2005 Mar 20",
      "volume": "23",
      "issue": "9",
      "pages": "1803-10",
      "authors": "Chung KY et al",
      "elocationId": "",
      "link": null,
      "reference": "Chung KY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Mar 20;23(9)1803-10.",
      "abstract": null
    },
    {
      "pmid": "19339720",
      "title": "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2009 Apr 2",
      "volume": "360",
      "issue": "14",
      "pages": "1408-17",
      "authors": "Van Cutsem E et al",
      "elocationId": "doi: 10.1056/NEJMoa0805019",
      "link": null,
      "reference": "Van Cutsem E et al. The New England journal of medicine. 2009 Apr 2;360(14)1408-17.",
      "abstract": null
    },
    {
      "pmid": "24739896",
      "title": "Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 May",
      "volume": "15",
      "issue": "6",
      "pages": "569-79",
      "authors": "Price TJ et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70118-4",
      "link": null,
      "reference": "Price TJ et al. The Lancet. Oncology. 2014 May;15(6)569-79.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa87"
  },
  "level": "LEVEL_1",
  "gene": "KRAS",
  "alteration": "Wildtype",
  "alteration_name": "Wildtype",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Cetuximab",
    "Chemotherapy"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "15677699",
      "title": "Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2005 Mar 20",
      "volume": "23",
      "issue": "9",
      "pages": "1803-10",
      "authors": "Chung KY et al",
      "elocationId": "",
      "link": null,
      "reference": "Chung KY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Mar 20;23(9)1803-10.",
      "abstract": null
    },
    {
      "pmid": "19339720",
      "title": "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2009 Apr 2",
      "volume": "360",
      "issue": "14",
      "pages": "1408-17",
      "authors": "Van Cutsem E et al",
      "elocationId": "doi: 10.1056/NEJMoa0805019",
      "link": null,
      "reference": "Van Cutsem E et al. The New England journal of medicine. 2009 Apr 2;360(14)1408-17.",
      "abstract": null
    },
    {
      "pmid": "24739896",
      "title": "Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 May",
      "volume": "15",
      "issue": "6",
      "pages": "569-79",
      "authors": "Price TJ et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70118-4",
      "link": null,
      "reference": "Price TJ et al. The Lancet. Oncology. 2014 May;15(6)569-79.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa88"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.sciencedirect.com/science/article/pii/S0923753419590627",
      "reference": "null. null. .",
      "abstract": "Abida et al. Abstract# 846PD, ESMO 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/full/10.1200/JCO.20.01035",
      "reference": "null. null. .",
      "abstract": "Abida et al. JCO, Aug 2020"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa89"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.sciencedirect.com/science/article/pii/S0923753419590627",
      "reference": "null. null. .",
      "abstract": "Abida et al. Abstract# 846PD, ESMO 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/full/10.1200/JCO.20.01035",
      "reference": "null. null. .",
      "abstract": "Abida et al. JCO, Aug 2020"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa8a"
  },
  "level": "LEVEL_1",
  "gene": "ABL1",
  "alteration": "BCR-ABL1 Fusion",
  "alteration_name": "BCR-ABL1 Fusion",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "12637609",
      "title": "Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.",
      "journal": "The New England journal of medicine",
      "pubDate": "2003 Mar 13",
      "volume": "348",
      "issue": "11",
      "pages": "994-1004",
      "authors": "O'Brien SG et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Brien SG et al. The New England journal of medicine. 2003 Mar 13;348(11)994-1004.",
      "abstract": null
    },
    {
      "pmid": "11287972",
      "title": "Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.",
      "journal": "The New England journal of medicine",
      "pubDate": "2001 Apr 5",
      "volume": "344",
      "issue": "14",
      "pages": "1031-7",
      "authors": "Druker BJ et al",
      "elocationId": "",
      "link": null,
      "reference": "Druker BJ et al. The New England journal of medicine. 2001 Apr 5;344(14)1031-7.",
      "abstract": null
    },
    {
      "pmid": "11287973",
      "title": "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.",
      "journal": "The New England journal of medicine",
      "pubDate": "2001 Apr 5",
      "volume": "344",
      "issue": "14",
      "pages": "1038-42",
      "authors": "Druker BJ et al",
      "elocationId": "",
      "link": null,
      "reference": "Druker BJ et al. The New England journal of medicine. 2001 Apr 5;344(14)1038-42.",
      "abstract": null
    },
    {
      "pmid": "28095277",
      "title": "Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 20",
      "volume": "35",
      "issue": "3",
      "pages": "298-305",
      "authors": "Etienne G et al",
      "elocationId": "doi: 10.1200/JCO.2016.68.2914",
      "link": null,
      "reference": "Etienne G et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 20;35(3)298-305.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa8b"
  },
  "level": "LEVEL_1",
  "gene": "KRAS",
  "alteration": "G12C",
  "alteration_name": "G12C",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Adagrasib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetings.asco.org/abstracts-presentations/208088",
      "reference": "null. null. .",
      "abstract": "Spira et al. Abstract# 9002, ASCO 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa8c"
  },
  "level": "LEVEL_1",
  "gene": "PDGFRB",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Myelodysplastic/Myeloproliferative Neoplasms",
  "cancer_sub_type": "Myelodysplastic/Myeloproliferative Neoplasms",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "12676775",
      "title": "Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.",
      "journal": "Blood",
      "pubDate": "2003 Jun 15",
      "volume": "101",
      "issue": "12",
      "pages": "4660-6",
      "authors": "Klion AD et al",
      "elocationId": "",
      "link": null,
      "reference": "Klion AD et al. Blood. 2003 Jun 15;101(12)4660-6.",
      "abstract": null
    },
    {
      "pmid": "14504092",
      "title": "Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.",
      "journal": "Blood",
      "pubDate": "2004 Jan 15",
      "volume": "103",
      "issue": "2",
      "pages": "473-8",
      "authors": "Klion AD et al",
      "elocationId": "",
      "link": null,
      "reference": "Klion AD et al. Blood. 2004 Jan 15;103(2)473-8.",
      "abstract": null
    },
    {
      "pmid": "22897847",
      "title": "Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.",
      "journal": "Cancer cell",
      "pubDate": "2012 Aug 14",
      "volume": "22",
      "issue": "2",
      "pages": "153-66",
      "authors": "Roberts KG et al",
      "elocationId": "doi: 10.1016/j.ccr.2012.06.005",
      "link": null,
      "reference": "Roberts KG et al. Cancer cell. 2012 Aug 14;22(2)153-66.",
      "abstract": null
    },
    {
      "pmid": "26355392",
      "title": "Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.",
      "journal": "Genes, chromosomes & cancer",
      "pubDate": "2015 Dec",
      "volume": "54",
      "issue": "12",
      "pages": "762-70",
      "authors": "Naumann N et al",
      "elocationId": "doi: 10.1002/gcc.22287",
      "link": null,
      "reference": "Naumann N et al. Genes, chromosomes & cancer. 2015 Dec;54(12)762-70.",
      "abstract": null
    },
    {
      "pmid": "18950453",
      "title": "Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.",
      "journal": "British journal of haematology",
      "pubDate": "2008 Dec",
      "volume": "143",
      "issue": "5",
      "pages": "707-15",
      "authors": "Metzgeroth G et al",
      "elocationId": "doi: 10.1111/j.1365-2141.2008.07294.x",
      "link": null,
      "reference": "Metzgeroth G et al. British journal of haematology. 2008 Dec;143(5)707-15.",
      "abstract": null
    },
    {
      "pmid": "12181402",
      "title": "Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.",
      "journal": "The New England journal of medicine",
      "pubDate": "2002 Aug 15",
      "volume": "347",
      "issue": "7",
      "pages": "481-7",
      "authors": "Apperley JF et al",
      "elocationId": "",
      "link": null,
      "reference": "Apperley JF et al. The New England journal of medicine. 2002 Aug 15;347(7)481-7.",
      "abstract": null
    },
    {
      "pmid": "16960151",
      "title": "Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.",
      "journal": "Blood",
      "pubDate": "2007 Jan 1",
      "volume": "109",
      "issue": "1",
      "pages": "61-4",
      "authors": "David M et al",
      "elocationId": "",
      "link": null,
      "reference": "David M et al. Blood. 2007 Jan 1;109(1)61-4.",
      "abstract": null
    },
    {
      "pmid": "1516603",
      "title": "Adverse events in phase one studies: a study in 430 healthy volunteers.",
      "journal": "European journal of clinical pharmacology",
      "pubDate": "1992",
      "volume": "42",
      "issue": "4",
      "pages": "389-93",
      "authors": "Sibille M et al",
      "elocationId": "",
      "link": null,
      "reference": "Sibille M et al. European journal of clinical pharmacology. 1992;42(4)389-93.",
      "abstract": null
    },
    {
      "pmid": "24687085",
      "title": "Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.",
      "journal": "Blood",
      "pubDate": "2014 Jun 5",
      "volume": "123",
      "issue": "23",
      "pages": "3574-7",
      "authors": "Cheah CY et al",
      "elocationId": "doi: 10.1182/blood-2014-02-555607",
      "link": null,
      "reference": "Cheah CY et al. Blood. 2014 Jun 5;123(23)3574-7.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa8d"
  },
  "level": "LEVEL_1",
  "gene": "NTRK2",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Entrectinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28183697",
      "title": "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).",
      "journal": "Cancer discovery",
      "pubDate": "2017 Apr",
      "volume": "7",
      "issue": "4",
      "pages": "400-409",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-16-1237",
      "link": null,
      "reference": "Drilon A et al. Cancer discovery. 2017 Apr;7(4)400-409.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://academic.oup.com/annonc/article/29/suppl_8/mdy424.017/5141583",
      "reference": "null. null. .",
      "abstract": "Demetri et al. Abstract# LBA17, ESMO 2018 Congress"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.004/5638407",
      "reference": "null. null. .",
      "abstract": "Rolfo et al. Abstract# 65P, ESMO 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/155954/abstract",
      "reference": "null. null. .",
      "abstract": "Pishvaian et al. Abstract# 521, Gastrointestinal Cancer Symposium, 2018"
    },
    {
      "pmid": "31838007",
      "title": "Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Feb",
      "volume": "21",
      "issue": "2",
      "pages": "271-282",
      "authors": "Doebele RC et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30691-6",
      "link": null,
      "reference": "Doebele RC et al. The Lancet. Oncology. 2020 Feb;21(2)271-282.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa8e"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26510020",
      "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Oct 29",
      "volume": "373",
      "issue": "18",
      "pages": "1697-708",
      "authors": "Mateo J et al",
      "elocationId": "doi: 10.1056/NEJMoa1506859",
      "link": null,
      "reference": "Mateo J et al. The New England journal of medicine. 2015 Oct 29;373(18)1697-708.",
      "abstract": null
    },
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa8f"
  },
  "level": "LEVEL_1",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26510020",
      "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Oct 29",
      "volume": "373",
      "issue": "18",
      "pages": "1697-708",
      "authors": "Mateo J et al",
      "elocationId": "doi: 10.1056/NEJMoa1506859",
      "link": null,
      "reference": "Mateo J et al. The New England journal of medicine. 2015 Oct 29;373(18)1697-708.",
      "abstract": null
    },
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa90"
  },
  "level": "LEVEL_1",
  "gene": "TSC2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Glioma",
  "cancer_sub_type": "Encapsulated Glioma",
  "drug": [
    "Everolimus"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23158522",
      "title": "Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2013 Jan 12",
      "volume": "381",
      "issue": "9861",
      "pages": "125-32",
      "authors": "Franz DN et al",
      "elocationId": "doi: 10.1016/S0140-6736(12)61134-9",
      "link": null,
      "reference": "Franz DN et al. Lancet (London, England). 2013 Jan 12;381(9861)125-32.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa91"
  },
  "level": "LEVEL_1",
  "gene": "FGFR1",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2",
  "drug": [
    "Pemigatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.sciencedirect.com/science/article/pii/S0006497121023806#!",
      "reference": "null. null. .",
      "abstract": "Gotlib et al. Abstract# 634, ASH 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa92"
  },
  "level": "LEVEL_1",
  "gene": "BRIP1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa93"
  },
  "level": "LEVEL_1",
  "gene": "BRIP1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa94"
  },
  "level": "LEVEL_1",
  "gene": "FLT3",
  "alteration": "572_630ins",
  "alteration_name": "Internal tandem duplication",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "High Dose Chemotherapy",
    "Midostaurin"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28644114",
      "title": "Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Aug 3",
      "volume": "377",
      "issue": "5",
      "pages": "454-464",
      "authors": "Stone RM et al",
      "elocationId": "doi: 10.1056/NEJMoa1614359",
      "link": null,
      "reference": "Stone RM et al. The New England journal of medicine. 2017 Aug 3;377(5)454-464.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa95"
  },
  "level": "LEVEL_1",
  "gene": "FLT3",
  "alteration": "D835",
  "alteration_name": "D835",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "High Dose Chemotherapy",
    "Midostaurin"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28644114",
      "title": "Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Aug 3",
      "volume": "377",
      "issue": "5",
      "pages": "454-464",
      "authors": "Stone RM et al",
      "elocationId": "doi: 10.1056/NEJMoa1614359",
      "link": null,
      "reference": "Stone RM et al. The New England journal of medicine. 2017 Aug 3;377(5)454-464.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa96"
  },
  "level": "LEVEL_1",
  "gene": "FLT3",
  "alteration": "I836",
  "alteration_name": "I836",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "High Dose Chemotherapy",
    "Midostaurin"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28644114",
      "title": "Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Aug 3",
      "volume": "377",
      "issue": "5",
      "pages": "454-464",
      "authors": "Stone RM et al",
      "elocationId": "doi: 10.1056/NEJMoa1614359",
      "link": null,
      "reference": "Stone RM et al. The New England journal of medicine. 2017 Aug 3;377(5)454-464.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa97"
  },
  "level": "LEVEL_1",
  "gene": "FGFR2",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Hepatobiliary Cancer",
  "cancer_sub_type": "Cholangiocarcinoma",
  "drug": [
    "Futibatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "36652354",
      "title": "Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2023 Jan 19",
      "volume": "388",
      "issue": "3",
      "pages": "228-239",
      "authors": "Goyal L et al",
      "elocationId": "doi: 10.1056/NEJMoa2206834",
      "link": null,
      "reference": "Goyal L et al. The New England journal of medicine. 2023 Jan 19;388(3)228-239.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa98"
  },
  "level": "LEVEL_1",
  "gene": "ALK",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Mature T and NK Neoplasms",
  "cancer_sub_type": "Anaplastic Large-Cell Lymphoma ALK Positive",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28032129",
      "title": "First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium.",
      "journal": "Cancer chemotherapy and pharmacology",
      "pubDate": "2017 Jan",
      "volume": "79",
      "issue": "1",
      "pages": "181-187",
      "authors": "Balis FM et al",
      "elocationId": "doi: 10.1007/s00280-016-3220-6",
      "link": null,
      "reference": "Balis FM et al. Cancer chemotherapy and pharmacology. 2017 Jan;79(1)181-187.",
      "abstract": null
    },
    {
      "pmid": "29352732",
      "title": "Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.",
      "journal": "American journal of hematology",
      "pubDate": "2018 May",
      "volume": "93",
      "issue": "5",
      "pages": "607-614",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.25043",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2018 May;93(5)607-614.",
      "abstract": null
    },
    {
      "pmid": "23598171",
      "title": "Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2013 May",
      "volume": "14",
      "issue": "6",
      "pages": "472-80",
      "authors": "Mossé YP et al",
      "elocationId": "doi: 10.1016/S1470-2045(13)70095-0",
      "link": null,
      "reference": "Mossé YP et al. The Lancet. Oncology. 2013 May;14(6)472-80.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa99"
  },
  "level": "LEVEL_1",
  "gene": "NTRK1",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Larotrectinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26216294",
      "title": "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.",
      "journal": "Cancer discovery",
      "pubDate": "2015 Oct",
      "volume": "5",
      "issue": "10",
      "pages": "1049-57",
      "authors": "Doebele RC et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0443",
      "link": null,
      "reference": "Doebele RC et al. Cancer discovery. 2015 Oct;5(10)1049-57.",
      "abstract": null
    },
    {
      "pmid": "29466156",
      "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Feb 22",
      "volume": "378",
      "issue": "8",
      "pages": "731-739",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1056/NEJMoa1714448",
      "link": null,
      "reference": "Drilon A et al. The New England journal of medicine. 2018 Feb 22;378(8)731-739.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa9a"
  },
  "level": "LEVEL_1",
  "gene": "NRAS",
  "alteration": "Wildtype",
  "alteration_name": "Wildtype",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Chemotherapy",
    "Panitumumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27736842",
      "title": "A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.",
      "journal": "British journal of cancer",
      "pubDate": "2016 Nov 8",
      "volume": "115",
      "issue": "10",
      "pages": "1206-1214",
      "authors": "Kim TW et al",
      "elocationId": "doi: 10.1038/bjc.2016.309",
      "link": null,
      "reference": "Kim TW et al. British journal of cancer. 2016 Nov 8;115(10)1206-1214.",
      "abstract": null
    },
    {
      "pmid": "18316791",
      "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Apr 1",
      "volume": "26",
      "issue": "10",
      "pages": "1626-34",
      "authors": "Amado RG et al",
      "elocationId": "doi: 10.1200/JCO.2007.14.7116",
      "link": null,
      "reference": "Amado RG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Apr 1;26(10)1626-34.",
      "abstract": null
    },
    {
      "pmid": "24739896",
      "title": "Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 May",
      "volume": "15",
      "issue": "6",
      "pages": "569-79",
      "authors": "Price TJ et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70118-4",
      "link": null,
      "reference": "Price TJ et al. The Lancet. Oncology. 2014 May;15(6)569-79.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa9b"
  },
  "level": "LEVEL_1",
  "gene": "NRAS",
  "alteration": "Wildtype",
  "alteration_name": "Wildtype",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Panitumumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27736842",
      "title": "A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.",
      "journal": "British journal of cancer",
      "pubDate": "2016 Nov 8",
      "volume": "115",
      "issue": "10",
      "pages": "1206-1214",
      "authors": "Kim TW et al",
      "elocationId": "doi: 10.1038/bjc.2016.309",
      "link": null,
      "reference": "Kim TW et al. British journal of cancer. 2016 Nov 8;115(10)1206-1214.",
      "abstract": null
    },
    {
      "pmid": "18316791",
      "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Apr 1",
      "volume": "26",
      "issue": "10",
      "pages": "1626-34",
      "authors": "Amado RG et al",
      "elocationId": "doi: 10.1200/JCO.2007.14.7116",
      "link": null,
      "reference": "Amado RG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Apr 1;26(10)1626-34.",
      "abstract": null
    },
    {
      "pmid": "24739896",
      "title": "Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 May",
      "volume": "15",
      "issue": "6",
      "pages": "569-79",
      "authors": "Price TJ et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70118-4",
      "link": null,
      "reference": "Price TJ et al. The Lancet. Oncology. 2014 May;15(6)569-79.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa9c"
  },
  "level": "LEVEL_1",
  "gene": "ALK",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Lorlatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "35605188",
      "title": "Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2022 Nov 1",
      "volume": "40",
      "issue": "31",
      "pages": "3593-3602",
      "authors": "Solomon BJ et al",
      "elocationId": "doi: 10.1200/JCO.21.02278",
      "link": null,
      "reference": "Solomon BJ et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Nov 1;40(31)3593-3602.",
      "abstract": null
    },
    {
      "pmid": "30892989",
      "title": "<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2019 Jun 1",
      "volume": "37",
      "issue": "16",
      "pages": "1370-1379",
      "authors": "Shaw AT et al",
      "elocationId": "doi: 10.1200/JCO.18.02236",
      "link": null,
      "reference": "Shaw AT et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Jun 1;37(16)1370-1379.",
      "abstract": null
    },
    {
      "pmid": "29074098",
      "title": "Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2017 Dec",
      "volume": "18",
      "issue": "12",
      "pages": "1590-1599",
      "authors": "Shaw AT et al",
      "elocationId": "doi: 10.1016/S1470-2045(17)30680-0",
      "link": null,
      "reference": "Shaw AT et al. The Lancet. Oncology. 2017 Dec;18(12)1590-1599.",
      "abstract": null
    },
    {
      "pmid": "30413378",
      "title": "Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2018 Dec",
      "volume": "19",
      "issue": "12",
      "pages": "1654-1667",
      "authors": "Solomon BJ et al",
      "elocationId": "doi: 10.1016/S1470-2045(18)30649-1",
      "link": null,
      "reference": "Solomon BJ et al. The Lancet. Oncology. 2018 Dec;19(12)1654-1667.",
      "abstract": null
    },
    {
      "pmid": "27432227",
      "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2016 Oct",
      "volume": "6",
      "issue": "10",
      "pages": "1118-1133",
      "authors": "Gainor JF et al",
      "elocationId": "",
      "link": null,
      "reference": "Gainor JF et al. Cancer discovery. 2016 Oct;6(10)1118-1133.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa9d"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600K",
  "alteration_name": "V600K",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Cobimetinib",
    "Vemurafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27480103",
      "title": "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2016 Sep",
      "volume": "17",
      "issue": "9",
      "pages": "1248-60",
      "authors": "Ascierto PA et al",
      "elocationId": "doi: 10.1016/S1470-2045(16)30122-X",
      "link": null,
      "reference": "Ascierto PA et al. The Lancet. Oncology. 2016 Sep;17(9)1248-60.",
      "abstract": null
    },
    {
      "pmid": "31732523",
      "title": "Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant Melanoma.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2020 Jan 1",
      "volume": "26",
      "issue": "1",
      "pages": "46-53",
      "authors": "Ribas A et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-4180",
      "link": null,
      "reference": "Ribas A et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Jan 1;26(1)46-53.",
      "abstract": null
    },
    {
      "pmid": "25265494",
      "title": "Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2014 Nov 13",
      "volume": "371",
      "issue": "20",
      "pages": "1867-76",
      "authors": "Larkin J et al",
      "elocationId": "doi: 10.1056/NEJMoa1408868",
      "link": null,
      "reference": "Larkin J et al. The New England journal of medicine. 2014 Nov 13;371(20)1867-76.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa9e"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Cobimetinib",
    "Vemurafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27480103",
      "title": "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2016 Sep",
      "volume": "17",
      "issue": "9",
      "pages": "1248-60",
      "authors": "Ascierto PA et al",
      "elocationId": "doi: 10.1016/S1470-2045(16)30122-X",
      "link": null,
      "reference": "Ascierto PA et al. The Lancet. Oncology. 2016 Sep;17(9)1248-60.",
      "abstract": null
    },
    {
      "pmid": "31732523",
      "title": "Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in <i>BRAF</i>-Mutant Melanoma.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2020 Jan 1",
      "volume": "26",
      "issue": "1",
      "pages": "46-53",
      "authors": "Ribas A et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-4180",
      "link": null,
      "reference": "Ribas A et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Jan 1;26(1)46-53.",
      "abstract": null
    },
    {
      "pmid": "25265494",
      "title": "Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2014 Nov 13",
      "volume": "371",
      "issue": "20",
      "pages": "1867-76",
      "authors": "Larkin J et al",
      "elocationId": "doi: 10.1056/NEJMoa1408868",
      "link": null,
      "reference": "Larkin J et al. The New England journal of medicine. 2014 Nov 13;371(20)1867-76.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faa9f"
  },
  "level": "LEVEL_1",
  "gene": "FANCL",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaa0"
  },
  "level": "LEVEL_1",
  "gene": "FANCL",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaa1"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26510020",
      "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Oct 29",
      "volume": "373",
      "issue": "18",
      "pages": "1697-708",
      "authors": "Mateo J et al",
      "elocationId": "doi: 10.1056/NEJMoa1506859",
      "link": null,
      "reference": "Mateo J et al. The New England journal of medicine. 2015 Oct 29;373(18)1697-708.",
      "abstract": null
    },
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaa2"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26510020",
      "title": "DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Oct 29",
      "volume": "373",
      "issue": "18",
      "pages": "1697-708",
      "authors": "Mateo J et al",
      "elocationId": "doi: 10.1056/NEJMoa1506859",
      "link": null,
      "reference": "Mateo J et al. The New England journal of medicine. 2015 Oct 29;373(18)1697-708.",
      "abstract": null
    },
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaa3"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Dabrafenib",
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28919011",
      "title": "Dabrafenib plus trametinib in patients with previously untreated BRAF<sup>V600E</sup>-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2017 Oct",
      "volume": "18",
      "issue": "10",
      "pages": "1307-1316",
      "authors": "Planchard D et al",
      "elocationId": "doi: 10.1016/S1470-2045(17)30679-4",
      "link": null,
      "reference": "Planchard D et al. The Lancet. Oncology. 2017 Oct;18(10)1307-1316.",
      "abstract": null
    },
    {
      "pmid": "27283860",
      "title": "Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2016 Jul",
      "volume": "17",
      "issue": "7",
      "pages": "984-993",
      "authors": "Planchard D et al",
      "elocationId": "doi: 10.1016/S1470-2045(16)30146-2",
      "link": null,
      "reference": "Planchard D et al. The Lancet. Oncology. 2016 Jul;17(7)984-993.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaa4"
  },
  "level": "LEVEL_1",
  "gene": "KRAS",
  "alteration": "G12C",
  "alteration_name": "G12C",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Sotorasib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "34096690",
      "title": "Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation.",
      "journal": "The New England journal of medicine",
      "pubDate": "2021 Jun 4",
      "volume": "",
      "issue": "",
      "pages": "",
      "authors": "Skoulidis F et al",
      "elocationId": "doi: 10.1056/NEJMoa2103695",
      "link": null,
      "reference": "Skoulidis F et al. The New England journal of medicine. 2021 Jun 4;().",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://oncologypro.esmo.org/meeting-resources/esmo-congress/sotorasib-versus-docetaxel-for-previously-treated-non-small-cell-lung-cancer-with-kras-g12c-mutation-codebreak-200-phase-iii-study",
      "reference": "null. null. .",
      "abstract": "Johnson et al. Abstract# LBA10, ESMO 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaa5"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "762_823ins",
  "alteration_name": "Exon 20 in-frame insertions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Mobocertinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33632775",
      "title": "Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial.",
      "journal": "Cancer discovery",
      "pubDate": "2021 Feb 25",
      "volume": "",
      "issue": "",
      "pages": "",
      "authors": "Riely GJ et al",
      "elocationId": "pii: candisc.1598.2020. doi: 10.1158/2159-8290.CD-20-1598",
      "link": null,
      "reference": "Riely GJ et al. Cancer discovery. 2021 Feb 25;().",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.9014",
      "reference": "null. null. .",
      "abstract": "Ramalingham et al. Abstract # 9014, ASCO 2021"
    },
    {
      "pmid": "33632773",
      "title": "Mobocertinib (TAK-788): A Targeted Inhibitor of <i>EGFR</i> Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2021 Jul",
      "volume": "11",
      "issue": "7",
      "pages": "1672-1687",
      "authors": "Gonzalvez F et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-20-1683",
      "link": null,
      "reference": "Gonzalvez F et al. Cancer discovery. 2021 Jul;11(7)1672-1687.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaa6"
  },
  "level": "LEVEL_1",
  "gene": "RET",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Selpercatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.jto.org/article/S1556-0864(19",
      "reference": "null. null. .",
      "abstract": "Drilon et al. Abstract# PL02.08, IASCL 2019"
    },
    {
      "pmid": "32846060",
      "title": "Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 Aug 27",
      "volume": "383",
      "issue": "9",
      "pages": "813-824",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1056/NEJMoa2005653",
      "link": null,
      "reference": "Drilon A et al. The New England journal of medicine. 2020 Aug 27;383(9)813-824.",
      "abstract": null
    },
    {
      "pmid": "36122315",
      "title": "Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2023 Jan 10",
      "volume": "41",
      "issue": "2",
      "pages": "385-394",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1200/JCO.22.00393",
      "link": null,
      "reference": "Drilon A et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023 Jan 10;41(2)385-394.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaa7"
  },
  "level": "LEVEL_1",
  "gene": "FGFR2",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Hepatobiliary Cancer",
  "cancer_sub_type": "Cholangiocarcinoma",
  "drug": [
    "Pemigatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32203698",
      "title": "Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 May",
      "volume": "21",
      "issue": "5",
      "pages": "671-684",
      "authors": "Abou-Alfa GK et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30109-1",
      "link": null,
      "reference": "Abou-Alfa GK et al. The Lancet. Oncology. 2020 May;21(5)671-684.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaa8"
  },
  "level": "LEVEL_1",
  "gene": "IDH1",
  "alteration": "R132",
  "alteration_name": "R132",
  "cancer_main_type": "Hepatobiliary Cancer",
  "cancer_sub_type": "Intrahepatic Cholangiocarcinoma",
  "drug": [
    "Ivosidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "34554208",
      "title": "Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2021 Sep 23",
      "volume": "",
      "issue": "",
      "pages": "",
      "authors": "Zhu AX et al",
      "elocationId": "doi: 10.1001/jamaoncol.2021.3836",
      "link": null,
      "reference": "Zhu AX et al. JAMA oncology. 2021 Sep 23;().",
      "abstract": null
    },
    {
      "pmid": "32416072",
      "title": "Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Jun",
      "volume": "21",
      "issue": "6",
      "pages": "796-807",
      "authors": "Abou-Alfa GK et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30157-1",
      "link": null,
      "reference": "Abou-Alfa GK et al. The Lancet. Oncology. 2020 Jun;21(6)796-807.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaa9"
  },
  "level": "LEVEL_1",
  "gene": "IDH1",
  "alteration": "R132",
  "alteration_name": "R132",
  "cancer_main_type": "Hepatobiliary Cancer",
  "cancer_sub_type": "Cholangiocarcinoma",
  "drug": [
    "Ivosidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "34554208",
      "title": "Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2021 Sep 23",
      "volume": "",
      "issue": "",
      "pages": "",
      "authors": "Zhu AX et al",
      "elocationId": "doi: 10.1001/jamaoncol.2021.3836",
      "link": null,
      "reference": "Zhu AX et al. JAMA oncology. 2021 Sep 23;().",
      "abstract": null
    },
    {
      "pmid": "32416072",
      "title": "Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Jun",
      "volume": "21",
      "issue": "6",
      "pages": "796-807",
      "authors": "Abou-Alfa GK et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30157-1",
      "link": null,
      "reference": "Abou-Alfa GK et al. The Lancet. Oncology. 2020 Jun;21(6)796-807.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaaa"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Trastuzumab Deruxtecan"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31825192",
      "title": "Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 Feb 13",
      "volume": "382",
      "issue": "7",
      "pages": "610-621",
      "authors": "Modi S et al",
      "elocationId": "doi: 10.1056/NEJMoa1914510",
      "link": null,
      "reference": "Modi S et al. The New England journal of medicine. 2020 Feb 13;382(7)610-621.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.sabcs.org/Portals/SABCS2016/2022%20SABCS/SABCS%202022%20Abstract%20Report.pdf?ver=2022-12-08-111637-860.",
      "reference": "null. null. .",
      "abstract": "Krop I et al. Abstract# GS2-01, SABCS 2022"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.annalsofoncology.org/article/S0923-7534(21",
      "reference": "null. null. .",
      "abstract": "Cortés et al. Abstract# LBA1, Annals of Oncology 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaab"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Vemurafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24508103",
      "title": "Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2014 Mar",
      "volume": "15",
      "issue": "3",
      "pages": "323-32",
      "authors": "McArthur GA et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)70012-9",
      "link": null,
      "reference": "McArthur GA et al. The Lancet. Oncology. 2014 Mar;15(3)323-32.",
      "abstract": null
    },
    {
      "pmid": "25399551",
      "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Jan 1",
      "volume": "372",
      "issue": "1",
      "pages": "30-9",
      "authors": "Robert C et al",
      "elocationId": "doi: 10.1056/NEJMoa1412690",
      "link": null,
      "reference": "Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.",
      "abstract": null
    },
    {
      "pmid": "28961848",
      "title": "Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2017 Oct 1",
      "volume": "28",
      "issue": "10",
      "pages": "2581-2587",
      "authors": "Chapman PB et al",
      "elocationId": "doi: 10.1093/annonc/mdx339",
      "link": null,
      "reference": "Chapman PB et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Oct 1;28(10)2581-2587.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaac"
  },
  "level": "LEVEL_1",
  "gene": "MET",
  "alteration": "963_1010del",
  "alteration_name": "Exon 14 in-frame deletions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Capmatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9004",
      "reference": "null. null. .",
      "abstract": "Wolf et al. Abstract# 9004, ASCO 2019"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaad"
  },
  "level": "LEVEL_1",
  "gene": "MET",
  "alteration": "Exon 14 Deletion",
  "alteration_name": "Exon 14 Deletion",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Capmatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9004",
      "reference": "null. null. .",
      "abstract": "Wolf et al. Abstract# 9004, ASCO 2019"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaae"
  },
  "level": "LEVEL_1",
  "gene": "MET",
  "alteration": "D1010",
  "alteration_name": "D1010",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Capmatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9004",
      "reference": "null. null. .",
      "abstract": "Wolf et al. Abstract# 9004, ASCO 2019"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaaf"
  },
  "level": "LEVEL_1",
  "gene": "MET",
  "alteration": "963_1010splice",
  "alteration_name": "Exon 14 splice mutations",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Capmatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9004",
      "reference": "null. null. .",
      "abstract": "Wolf et al. Abstract# 9004, ASCO 2019"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faab0"
  },
  "level": "LEVEL_1",
  "gene": "BARD1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faab1"
  },
  "level": "LEVEL_1",
  "gene": "BARD1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faab2"
  },
  "level": "LEVEL_1",
  "gene": "KIT",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "Gastrointestinal Stromal Tumor",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28196207",
      "title": "Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.",
      "journal": "JAMA oncology",
      "pubDate": "2017 Jul 1",
      "volume": "3",
      "issue": "7",
      "pages": "944-952",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1001/jamaoncol.2016.6728",
      "link": null,
      "reference": "Heinrich MC et al. JAMA oncology. 2017 Jul 1;3(7)944-952.",
      "abstract": null
    },
    {
      "pmid": "18235122",
      "title": "Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Feb 1",
      "volume": "26",
      "issue": "4",
      "pages": "626-32",
      "authors": "Blanke CD et al",
      "elocationId": "doi: 10.1200/JCO.2007.13.4452",
      "link": null,
      "reference": "Blanke CD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Feb 1;26(4)626-32.",
      "abstract": null
    },
    {
      "pmid": "12181401",
      "title": "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.",
      "journal": "The New England journal of medicine",
      "pubDate": "2002 Aug 15",
      "volume": "347",
      "issue": "7",
      "pages": "472-80",
      "authors": "Demetri GD et al",
      "elocationId": "",
      "link": null,
      "reference": "Demetri GD et al. The New England journal of medicine. 2002 Aug 15;347(7)472-80.",
      "abstract": null
    },
    {
      "pmid": "18955451",
      "title": "Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Nov 20",
      "volume": "26",
      "issue": "33",
      "pages": "5360-7",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1200/JCO.2008.17.4284",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5360-7.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faab3"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "L858R",
  "alteration_name": "L858R",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Osimertinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://academic.oup.com/annonc/article/30/Supplement_5/mdz394.076/55783630",
      "reference": "null. null. .",
      "abstract": "Ramalingam et al. Abstract# LBA5_PR, ESMO 2019"
    },
    {
      "pmid": "30659024",
      "title": "Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Apr 1",
      "volume": "25",
      "issue": "7",
      "pages": "2058-2063",
      "authors": "Planchard D et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3325",
      "link": null,
      "reference": "Planchard D et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Apr 1;25(7)2058-2063.",
      "abstract": null
    },
    {
      "pmid": "29151359",
      "title": "Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Jan 11",
      "volume": "378",
      "issue": "2",
      "pages": "113-125",
      "authors": "Soria JC et al",
      "elocationId": "doi: 10.1056/NEJMoa1713137",
      "link": null,
      "reference": "Soria JC et al. The New England journal of medicine. 2018 Jan 11;378(2)113-125.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faab4"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "729_761del",
  "alteration_name": "Exon 19 in-frame deletions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Osimertinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://academic.oup.com/annonc/article/30/Supplement_5/mdz394.076/55783630",
      "reference": "null. null. .",
      "abstract": "Ramalingam et al. Abstract# LBA5_PR, ESMO 2019"
    },
    {
      "pmid": "30659024",
      "title": "Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Apr 1",
      "volume": "25",
      "issue": "7",
      "pages": "2058-2063",
      "authors": "Planchard D et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3325",
      "link": null,
      "reference": "Planchard D et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Apr 1;25(7)2058-2063.",
      "abstract": null
    },
    {
      "pmid": "29151359",
      "title": "Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Jan 11",
      "volume": "378",
      "issue": "2",
      "pages": "113-125",
      "authors": "Soria JC et al",
      "elocationId": "doi: 10.1056/NEJMoa1713137",
      "link": null,
      "reference": "Soria JC et al. The New England journal of medicine. 2018 Jan 11;378(2)113-125.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faab5"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600",
  "alteration_name": "V600",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Atezolizumab",
    "Cobimetinib",
    "Vemurafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32534646",
      "title": "Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF<sup>V600</sup> mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2020 Jun 13",
      "volume": "395",
      "issue": "10240",
      "pages": "1835-1844",
      "authors": "Gutzmer R et al",
      "elocationId": "doi: 10.1016/S0140-6736(20)30934-X",
      "link": null,
      "reference": "Gutzmer R et al. Lancet (London, England). 2020 Jun 13;395(10240)1835-1844.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faab6"
  },
  "level": "LEVEL_1",
  "gene": "PDGFRA",
  "alteration": "FIP1L1-PDGFRA Fusion",
  "alteration_name": "FIP1L1-PDGFRA Fusion",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Eosinophilic Leukemia, NOS",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "18950453",
      "title": "Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.",
      "journal": "British journal of haematology",
      "pubDate": "2008 Dec",
      "volume": "143",
      "issue": "5",
      "pages": "707-15",
      "authors": "Metzgeroth G et al",
      "elocationId": "doi: 10.1111/j.1365-2141.2008.07294.x",
      "link": null,
      "reference": "Metzgeroth G et al. British journal of haematology. 2008 Dec;143(5)707-15.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faab7"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600K",
  "alteration_name": "V600K",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29361468",
      "title": "Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2018 Feb",
      "volume": "19",
      "issue": "2",
      "pages": "181-193",
      "authors": "Amaria RN et al",
      "elocationId": "doi: 10.1016/S1470-2045(18)30015-9",
      "link": null,
      "reference": "Amaria RN et al. The Lancet. Oncology. 2018 Feb;19(2)181-193.",
      "abstract": null
    },
    {
      "pmid": "22663011",
      "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2012 Jul 12",
      "volume": "367",
      "issue": "2",
      "pages": "107-14",
      "authors": "Flaherty KT et al",
      "elocationId": "doi: 10.1056/NEJMoa1203421",
      "link": null,
      "reference": "Flaherty KT et al. The New England journal of medicine. 2012 Jul 12;367(2)107-14.",
      "abstract": null
    },
    {
      "pmid": "25399551",
      "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Jan 1",
      "volume": "372",
      "issue": "1",
      "pages": "30-9",
      "authors": "Robert C et al",
      "elocationId": "doi: 10.1056/NEJMoa1412690",
      "link": null,
      "reference": "Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.",
      "abstract": null
    },
    {
      "pmid": "25265492",
      "title": "Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2014 Nov 13",
      "volume": "371",
      "issue": "20",
      "pages": "1877-88",
      "authors": "Long GV et al",
      "elocationId": "doi: 10.1056/NEJMoa1406037",
      "link": null,
      "reference": "Long GV et al. The New England journal of medicine. 2014 Nov 13;371(20)1877-88.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faab8"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29361468",
      "title": "Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2018 Feb",
      "volume": "19",
      "issue": "2",
      "pages": "181-193",
      "authors": "Amaria RN et al",
      "elocationId": "doi: 10.1016/S1470-2045(18)30015-9",
      "link": null,
      "reference": "Amaria RN et al. The Lancet. Oncology. 2018 Feb;19(2)181-193.",
      "abstract": null
    },
    {
      "pmid": "22663011",
      "title": "Improved survival with MEK inhibition in BRAF-mutated melanoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2012 Jul 12",
      "volume": "367",
      "issue": "2",
      "pages": "107-14",
      "authors": "Flaherty KT et al",
      "elocationId": "doi: 10.1056/NEJMoa1203421",
      "link": null,
      "reference": "Flaherty KT et al. The New England journal of medicine. 2012 Jul 12;367(2)107-14.",
      "abstract": null
    },
    {
      "pmid": "25399551",
      "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Jan 1",
      "volume": "372",
      "issue": "1",
      "pages": "30-9",
      "authors": "Robert C et al",
      "elocationId": "doi: 10.1056/NEJMoa1412690",
      "link": null,
      "reference": "Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.",
      "abstract": null
    },
    {
      "pmid": "25265492",
      "title": "Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2014 Nov 13",
      "volume": "371",
      "issue": "20",
      "pages": "1877-88",
      "authors": "Long GV et al",
      "elocationId": "doi: 10.1056/NEJMoa1406037",
      "link": null,
      "reference": "Long GV et al. The New England journal of medicine. 2014 Nov 13;371(20)1877-88.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faab9"
  },
  "level": "LEVEL_1",
  "gene": "PALB2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaba"
  },
  "level": "LEVEL_1",
  "gene": "PALB2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32343890",
      "title": "Olaparib for Metastatic Castration-Resistant Prostate Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 May 28",
      "volume": "382",
      "issue": "22",
      "pages": "2091-2102",
      "authors": "de Bono J et al",
      "elocationId": "doi: 10.1056/NEJMoa1911440",
      "link": null,
      "reference": "de Bono J et al. The New England journal of medicine. 2020 May 28;382(22)2091-2102.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faabb"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Dabrafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23051966",
      "title": "Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2012 Nov",
      "volume": "13",
      "issue": "11",
      "pages": "1087-95",
      "authors": "Long GV et al",
      "elocationId": "doi: 10.1016/S1470-2045(12)70431-X",
      "link": null,
      "reference": "Long GV et al. The Lancet. Oncology. 2012 Nov;13(11)1087-95.",
      "abstract": null
    },
    {
      "pmid": "22608338",
      "title": "Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2012 May 19",
      "volume": "379",
      "issue": "9829",
      "pages": "1893-901",
      "authors": "Falchook GS et al",
      "elocationId": "doi: 10.1016/S0140-6736(12)60398-5",
      "link": null,
      "reference": "Falchook GS et al. Lancet (London, England). 2012 May 19;379(9829)1893-901.",
      "abstract": null
    },
    {
      "pmid": "22735384",
      "title": "Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2012 Jul 28",
      "volume": "380",
      "issue": "9839",
      "pages": "358-65",
      "authors": "Hauschild A et al",
      "elocationId": "doi: 10.1016/S0140-6736(12)60868-X",
      "link": null,
      "reference": "Hauschild A et al. Lancet (London, England). 2012 Jul 28;380(9839)358-65.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faabc"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Trastuzumab Deruxtecan"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "34534430",
      "title": "Trastuzumab Deruxtecan in <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2022 Jan 20",
      "volume": "386",
      "issue": "3",
      "pages": "241-251",
      "authors": "Li BT et al",
      "elocationId": "doi: 10.1056/NEJMoa2112431",
      "link": null,
      "reference": "Li BT et al. The New England journal of medicine. 2022 Jan 20;386(3)241-251.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faabd"
  },
  "level": "LEVEL_1",
  "gene": "KIT",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "Gastrointestinal Stromal Tumor",
  "drug": [
    "Ripretinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32511981",
      "title": "Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Jul",
      "volume": "21",
      "issue": "7",
      "pages": "923-934",
      "authors": "Blay JY et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30168-6",
      "link": null,
      "reference": "Blay JY et al. The Lancet. Oncology. 2020 Jul;21(7)923-934.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faabe"
  },
  "level": "LEVEL_1",
  "gene": "RET",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Selpercatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3094",
      "reference": "null. null. .",
      "abstract": "Subbiah et al. Abstract# 3094, ASCO 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faabf"
  },
  "level": "LEVEL_1",
  "gene": "NTRK3",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Larotrectinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26216294",
      "title": "An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101.",
      "journal": "Cancer discovery",
      "pubDate": "2015 Oct",
      "volume": "5",
      "issue": "10",
      "pages": "1049-57",
      "authors": "Doebele RC et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0443",
      "link": null,
      "reference": "Doebele RC et al. Cancer discovery. 2015 Oct;5(10)1049-57.",
      "abstract": null
    },
    {
      "pmid": "29466156",
      "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Feb 22",
      "volume": "378",
      "issue": "8",
      "pages": "731-739",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1056/NEJMoa1714448",
      "link": null,
      "reference": "Drilon A et al. The New England journal of medicine. 2018 Feb 22;378(8)731-739.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faac0"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "G719",
  "alteration_name": "G719",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Afatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22452895",
      "title": "Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2012 May",
      "volume": "13",
      "issue": "5",
      "pages": "539-48",
      "authors": "Yang JC et al",
      "elocationId": "doi: 10.1016/S1470-2045(12)70086-4",
      "link": null,
      "reference": "Yang JC et al. The Lancet. Oncology. 2012 May;13(5)539-48.",
      "abstract": null
    },
    {
      "pmid": "25589191",
      "title": "Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2015 Feb",
      "volume": "16",
      "issue": "2",
      "pages": "141-51",
      "authors": "Yang JC et al",
      "elocationId": "doi: 10.1016/S1470-2045(14)71173-8",
      "link": null,
      "reference": "Yang JC et al. The Lancet. Oncology. 2015 Feb;16(2)141-51.",
      "abstract": null
    },
    {
      "pmid": "23816960",
      "title": "Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 20",
      "volume": "31",
      "issue": "27",
      "pages": "3327-34",
      "authors": "Sequist LV et al",
      "elocationId": "doi: 10.1200/JCO.2012.44.2806",
      "link": null,
      "reference": "Sequist LV et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 20;31(27)3327-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faac1"
  },
  "level": "LEVEL_1",
  "gene": "RET",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Thyroid Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Selpercatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.sciencedirect.com/science/article/pii/S0923753419604539",
      "reference": "null. null. .",
      "abstract": "Wirth et al. Abstract# LBA93, ESMO 2019"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faac2"
  },
  "level": "LEVEL_1",
  "gene": "ABL1",
  "alteration": "BCR-ABL1 Fusion",
  "alteration_name": "BCR-ABL1 Fusion",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "28218239",
      "title": "Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.",
      "journal": "Leukemia",
      "pubDate": "2017 Jul",
      "volume": "31",
      "issue": "7",
      "pages": "1525-1531",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1038/leu.2017.63",
      "link": null,
      "reference": "Hochhaus A et al. Leukemia. 2017 Jul;31(7)1525-1531.",
      "abstract": null
    },
    {
      "pmid": "20525993",
      "title": "Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.",
      "journal": "The New England journal of medicine",
      "pubDate": "2010 Jun 17",
      "volume": "362",
      "issue": "24",
      "pages": "2251-9",
      "authors": "Saglio G et al",
      "elocationId": "doi: 10.1056/NEJMoa0912614",
      "link": null,
      "reference": "Saglio G et al. The New England journal of medicine. 2010 Jun 17;362(24)2251-9.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faac3"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Trastuzumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "16236738",
      "title": "Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2005 Oct 20",
      "volume": "353",
      "issue": "16",
      "pages": "1673-84",
      "authors": "Romond EH et al",
      "elocationId": "",
      "link": null,
      "reference": "Romond EH et al. The New England journal of medicine. 2005 Oct 20;353(16)1673-84.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faac4"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Chemotherapy",
    "Trastuzumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "16236738",
      "title": "Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2005 Oct 20",
      "volume": "353",
      "issue": "16",
      "pages": "1673-84",
      "authors": "Romond EH et al",
      "elocationId": "",
      "link": null,
      "reference": "Romond EH et al. The New England journal of medicine. 2005 Oct 20;353(16)1673-84.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faac5"
  },
  "level": "LEVEL_1",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Thyroid Cancer",
  "cancer_sub_type": "Anaplastic Thyroid Cancer",
  "drug": [
    "Dabrafenib",
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29072975",
      "title": "Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Jan 1",
      "volume": "36",
      "issue": "1",
      "pages": "7-13",
      "authors": "Subbiah V et al",
      "elocationId": "doi: 10.1200/JCO.2017.73.6785",
      "link": null,
      "reference": "Subbiah V et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Jan 1;36(1)7-13.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faac6"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "L858R",
  "alteration_name": "L858R",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Dacomitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29864379",
      "title": "Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Aug 1",
      "volume": "36",
      "issue": "22",
      "pages": "2244-2250",
      "authors": "Mok TS et al",
      "elocationId": "doi: 10.1200/JCO.2018.78.7994",
      "link": null,
      "reference": "Mok TS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Aug 1;36(22)2244-2250.",
      "abstract": null
    },
    {
      "pmid": "28958502",
      "title": "Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2017 Nov",
      "volume": "18",
      "issue": "11",
      "pages": "1454-1466",
      "authors": "Wu YL et al",
      "elocationId": "doi: 10.1016/S1470-2045(17)30608-3",
      "link": null,
      "reference": "Wu YL et al. The Lancet. Oncology. 2017 Nov;18(11)1454-1466.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faac7"
  },
  "level": "LEVEL_1",
  "gene": "EGFR",
  "alteration": "729_761del",
  "alteration_name": "Exon 19 in-frame deletions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Dacomitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29864379",
      "title": "Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Aug 1",
      "volume": "36",
      "issue": "22",
      "pages": "2244-2250",
      "authors": "Mok TS et al",
      "elocationId": "doi: 10.1200/JCO.2018.78.7994",
      "link": null,
      "reference": "Mok TS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Aug 1;36(22)2244-2250.",
      "abstract": null
    },
    {
      "pmid": "28958502",
      "title": "Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2017 Nov",
      "volume": "18",
      "issue": "11",
      "pages": "1454-1466",
      "authors": "Wu YL et al",
      "elocationId": "doi: 10.1016/S1470-2045(17)30608-3",
      "link": null,
      "reference": "Wu YL et al. The Lancet. Oncology. 2017 Nov;18(11)1454-1466.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faac8"
  },
  "level": "LEVEL_1",
  "gene": "SMARCB1",
  "alteration": "Deletion",
  "alteration_name": "Deletion",
  "cancer_main_type": "Soft Tissue Sarcoma",
  "cancer_sub_type": "Epithelioid Sarcoma",
  "drug": [
    "Tazemetostat"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33035459",
      "title": "Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Nov",
      "volume": "21",
      "issue": "11",
      "pages": "1423-1432",
      "authors": "Gounder M et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30451-4",
      "link": null,
      "reference": "Gounder M et al. The Lancet. Oncology. 2020 Nov;21(11)1423-1432.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faac9"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Trastuzumab",
    "Tucatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://oncologypro.esmo.org/meeting-resources/esmo-congress/additional-analyses-of-mountaineer-a-phase-ii-study-of-tucatinib-and-trastuzumab-for-her2-positive-mcrc",
      "reference": "null. null. .",
      "abstract": "Strickler et al. Abstract# LBA27, ESMO 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaca"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Capecitabine",
    "Trastuzumab",
    "Tucatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1043",
      "reference": "null. null. .",
      "abstract": "Curigliano et al. Abstract# 1043, ASCO 2021"
    },
    {
      "pmid": "31825569",
      "title": "Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 Feb 13",
      "volume": "382",
      "issue": "7",
      "pages": "597-609",
      "authors": "Murthy RK et al",
      "elocationId": "doi: 10.1056/NEJMoa1914609",
      "link": null,
      "reference": "Murthy RK et al. The New England journal of medicine. 2020 Feb 13;382(7)597-609.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faacb"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Esophagogastric Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Chemotherapy",
    "Pembrolizumab",
    "Trastuzumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33167735",
      "title": "First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811.",
      "journal": "Future oncology (London, England)",
      "pubDate": "2021 Feb",
      "volume": "17",
      "issue": "5",
      "pages": "491-501",
      "authors": "Chung HC et al",
      "elocationId": "doi: 10.2217/fon-2020-0737",
      "link": null,
      "reference": "Chung HC et al. Future oncology (London, England). 2021 Feb;17(5)491-501.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faacc"
  },
  "level": "LEVEL_1",
  "gene": "ALK",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23724913",
      "title": "Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2013 Jun 20",
      "volume": "368",
      "issue": "25",
      "pages": "2385-94",
      "authors": "Shaw AT et al",
      "elocationId": "doi: 10.1056/NEJMoa1214886",
      "link": null,
      "reference": "Shaw AT et al. The New England journal of medicine. 2013 Jun 20;368(25)2385-94.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faacd"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer, NOS",
  "cancer_sub_type": "",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.sciencedirect.com/science/article/pii/S0923753419590627",
      "reference": "null. null. .",
      "abstract": "Abida et al. Abstract# 846PD, ESMO 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/full/10.1200/JCO.20.01035",
      "reference": "null. null. .",
      "abstract": "Abida et al. JCO, Aug 2020"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faace"
  },
  "level": "LEVEL_1",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Prostate Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.sciencedirect.com/science/article/pii/S0923753419590627",
      "reference": "null. null. .",
      "abstract": "Abida et al. Abstract# 846PD, ESMO 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/full/10.1200/JCO.20.01035",
      "reference": "null. null. .",
      "abstract": "Abida et al. JCO, Aug 2020"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faacf"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Lapatinib",
    "Letrozole"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "17192538",
      "title": "Lapatinib plus capecitabine for HER2-positive advanced breast cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Dec 28",
      "volume": "355",
      "issue": "26",
      "pages": "2733-43",
      "authors": "Geyer CE et al",
      "elocationId": "",
      "link": null,
      "reference": "Geyer CE et al. The New England journal of medicine. 2006 Dec 28;355(26)2733-43.",
      "abstract": null
    },
    {
      "pmid": "19786658",
      "title": "Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Nov 20",
      "volume": "27",
      "issue": "33",
      "pages": "5538-46",
      "authors": "Johnston S et al",
      "elocationId": "doi: 10.1200/JCO.2009.23.3734",
      "link": null,
      "reference": "Johnston S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Nov 20;27(33)5538-46.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faad0"
  },
  "level": "LEVEL_1",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Capecitabine",
    "Lapatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "17192538",
      "title": "Lapatinib plus capecitabine for HER2-positive advanced breast cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Dec 28",
      "volume": "355",
      "issue": "26",
      "pages": "2733-43",
      "authors": "Geyer CE et al",
      "elocationId": "",
      "link": null,
      "reference": "Geyer CE et al. The New England journal of medicine. 2006 Dec 28;355(26)2733-43.",
      "abstract": null
    },
    {
      "pmid": "19786658",
      "title": "Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Nov 20",
      "volume": "27",
      "issue": "33",
      "pages": "5538-46",
      "authors": "Johnston S et al",
      "elocationId": "doi: 10.1200/JCO.2009.23.3734",
      "link": null,
      "reference": "Johnston S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Nov 20;27(33)5538-46.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faad1"
  },
  "level": "LEVEL_1",
  "gene": "ALK",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Brigatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30280657",
      "title": "Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Nov 22",
      "volume": "379",
      "issue": "21",
      "pages": "2027-2039",
      "authors": "Camidge DR et al",
      "elocationId": "doi: 10.1056/NEJMoa1810171",
      "link": null,
      "reference": "Camidge DR et al. The New England journal of medicine. 2018 Nov 22;379(21)2027-2039.",
      "abstract": null
    },
    {
      "pmid": "28475456",
      "title": "Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Aug 1",
      "volume": "35",
      "issue": "22",
      "pages": "2490-2498",
      "authors": "Kim DW et al",
      "elocationId": "doi: 10.1200/JCO.2016.71.5904",
      "link": null,
      "reference": "Kim DW et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Aug 1;35(22)2490-2498.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faad2"
  },
  "level": "LEVEL_1",
  "gene": "PDGFRA",
  "alteration": "814_852mis",
  "alteration_name": "Exon 18 missense mutations",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Avapritinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.11022",
      "reference": "null. null. .",
      "abstract": "Heinrich et al. Abstract# 11022, ASCO 2019"
    },
    {
      "pmid": "32615108",
      "title": "Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Jul",
      "volume": "21",
      "issue": "7",
      "pages": "935-946",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30269-2",
      "link": null,
      "reference": "Heinrich MC et al. The Lancet. Oncology. 2020 Jul;21(7)935-946.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faad3"
  },
  "level": "LEVEL_1",
  "gene": "PDGFRA",
  "alteration": "814_852del",
  "alteration_name": "Exon 18 in-frame deletions",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Avapritinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.11022",
      "reference": "null. null. .",
      "abstract": "Heinrich et al. Abstract# 11022, ASCO 2019"
    },
    {
      "pmid": "32615108",
      "title": "Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Jul",
      "volume": "21",
      "issue": "7",
      "pages": "935-946",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30269-2",
      "link": null,
      "reference": "Heinrich MC et al. The Lancet. Oncology. 2020 Jul;21(7)935-946.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faad4"
  },
  "level": "LEVEL_1",
  "gene": "PDGFRA",
  "alteration": "814_852ins",
  "alteration_name": "Exon 18 in-frame insertions",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Avapritinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.11022",
      "reference": "null. null. .",
      "abstract": "Heinrich et al. Abstract# 11022, ASCO 2019"
    },
    {
      "pmid": "32615108",
      "title": "Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Jul",
      "volume": "21",
      "issue": "7",
      "pages": "935-946",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30269-2",
      "link": null,
      "reference": "Heinrich MC et al. The Lancet. Oncology. 2020 Jul;21(7)935-946.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faad5"
  },
  "level": "LEVEL_1",
  "gene": "ABL1",
  "alteration": "T315I",
  "alteration_name": "T315I",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Ponatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23190221",
      "title": "Ponatinib in refractory Philadelphia chromosome-positive leukemias.",
      "journal": "The New England journal of medicine",
      "pubDate": "2012 Nov 29",
      "volume": "367",
      "issue": "22",
      "pages": "2075-88",
      "authors": "Cortes JE et al",
      "elocationId": "doi: 10.1056/NEJMoa1205127",
      "link": null,
      "reference": "Cortes JE et al. The New England journal of medicine. 2012 Nov 29;367(22)2075-88.",
      "abstract": null
    },
    {
      "pmid": "24180494",
      "title": "A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.",
      "journal": "The New England journal of medicine",
      "pubDate": "2013 Nov 7",
      "volume": "369",
      "issue": "19",
      "pages": "1783-96",
      "authors": "Cortes JE et al",
      "elocationId": "doi: 10.1056/NEJMoa1306494",
      "link": null,
      "reference": "Cortes JE et al. The New England journal of medicine. 2013 Nov 7;369(19)1783-96.",
      "abstract": null
    },
    {
      "pmid": "29567798",
      "title": "Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.",
      "journal": "Blood",
      "pubDate": "2018 Jul 26",
      "volume": "132",
      "issue": "4",
      "pages": "393-404",
      "authors": "Cortes JE et al",
      "elocationId": "doi: 10.1182/blood-2016-09-739086",
      "link": null,
      "reference": "Cortes JE et al. Blood. 2018 Jul 26;132(4)393-404.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faad6"
  },
  "level": "LEVEL_1",
  "gene": "ABL1",
  "alteration": "BCR-ABL1 Fusion",
  "alteration_name": "BCR-ABL1 Fusion",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "20525995",
      "title": "Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.",
      "journal": "The New England journal of medicine",
      "pubDate": "2010 Jun 17",
      "volume": "362",
      "issue": "24",
      "pages": "2260-70",
      "authors": "Kantarjian H et al",
      "elocationId": "doi: 10.1056/NEJMoa1002315",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2010 Jun 17;362(24)2260-70.",
      "abstract": null
    },
    {
      "pmid": "27217448",
      "title": "Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2016 Jul 10",
      "volume": "34",
      "issue": "20",
      "pages": "2333-40",
      "authors": "Cortes JE et al",
      "elocationId": "doi: 10.1200/JCO.2015.64.8899",
      "link": null,
      "reference": "Cortes JE et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Jul 10;34(20)2333-40.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faad7"
  },
  "level": "LEVEL_1",
  "gene": "ABL1",
  "alteration": "BCR-ABL1 Fusion",
  "alteration_name": "BCR-ABL1 Fusion",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Asciminib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "34407542",
      "title": "A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs.",
      "journal": "Blood",
      "pubDate": "2021 Aug 18",
      "volume": "",
      "issue": "",
      "pages": "",
      "authors": "Rea D et al",
      "elocationId": "pii: blood.2020009984. doi: 10.1182/blood.2020009984",
      "link": null,
      "reference": "Rea D et al. Blood. 2021 Aug 18;().",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faad8"
  },
  "level": "LEVEL_1",
  "gene": "NF1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Nerve Sheath Tumor",
  "cancer_sub_type": "Neurofibroma",
  "drug": [
    "Selumetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32187457",
      "title": "Selumetinib in Children with Inoperable Plexiform Neurofibromas.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 Apr 9",
      "volume": "382",
      "issue": "15",
      "pages": "1430-1442",
      "authors": "Gross AM et al",
      "elocationId": "doi: 10.1056/NEJMoa1912735",
      "link": null,
      "reference": "Gross AM et al. The New England journal of medicine. 2020 Apr 9;382(15)1430-1442.",
      "abstract": null
    },
    {
      "pmid": "28029918",
      "title": "Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.",
      "journal": "The New England journal of medicine",
      "pubDate": "2016 Dec 29",
      "volume": "375",
      "issue": "26",
      "pages": "2550-2560",
      "authors": "Dombi E et al",
      "elocationId": "doi: 10.1056/NEJMoa1605943",
      "link": null,
      "reference": "Dombi E et al. The New England journal of medicine. 2016 Dec 29;375(26)2550-2560.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faad9"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F359I",
  "alteration_name": "F359I",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "17496201",
      "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.",
      "journal": "Blood",
      "pubDate": "2007 Oct 1",
      "volume": "110",
      "issue": "7",
      "pages": "2309-15",
      "authors": "Ottmann O et al",
      "elocationId": "",
      "link": null,
      "reference": "Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faada"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "E255K",
  "alteration_name": "E255K",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "17496201",
      "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.",
      "journal": "Blood",
      "pubDate": "2007 Oct 1",
      "volume": "110",
      "issue": "7",
      "pages": "2309-15",
      "authors": "Ottmann O et al",
      "elocationId": "",
      "link": null,
      "reference": "Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faadb"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "E255V",
  "alteration_name": "E255V",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "17496201",
      "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.",
      "journal": "Blood",
      "pubDate": "2007 Oct 1",
      "volume": "110",
      "issue": "7",
      "pages": "2309-15",
      "authors": "Ottmann O et al",
      "elocationId": "",
      "link": null,
      "reference": "Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faadc"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "Y253H",
  "alteration_name": "Y253H",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "17496201",
      "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.",
      "journal": "Blood",
      "pubDate": "2007 Oct 1",
      "volume": "110",
      "issue": "7",
      "pages": "2309-15",
      "authors": "Ottmann O et al",
      "elocationId": "",
      "link": null,
      "reference": "Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faadd"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F359V",
  "alteration_name": "F359V",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "17496201",
      "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.",
      "journal": "Blood",
      "pubDate": "2007 Oct 1",
      "volume": "110",
      "issue": "7",
      "pages": "2309-15",
      "authors": "Ottmann O et al",
      "elocationId": "",
      "link": null,
      "reference": "Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faade"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F359C",
  "alteration_name": "F359C",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "17496201",
      "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.",
      "journal": "Blood",
      "pubDate": "2007 Oct 1",
      "volume": "110",
      "issue": "7",
      "pages": "2309-15",
      "authors": "Ottmann O et al",
      "elocationId": "",
      "link": null,
      "reference": "Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faadf"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F317I",
  "alteration_name": "F317I",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    },
    {
      "pmid": "23086624",
      "title": "Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2012 Oct 18",
      "volume": "120",
      "issue": "16",
      "pages": "3382-3",
      "authors": "Jabbour E et al",
      "elocationId": "doi: 10.1182/blood-2012-04-424192",
      "link": null,
      "reference": "Jabbour E et al. Blood. 2012 Oct 18;120(16)3382-3.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faae0"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F317C",
  "alteration_name": "F317C",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    },
    {
      "pmid": "23086624",
      "title": "Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2012 Oct 18",
      "volume": "120",
      "issue": "16",
      "pages": "3382-3",
      "authors": "Jabbour E et al",
      "elocationId": "doi: 10.1182/blood-2012-04-424192",
      "link": null,
      "reference": "Jabbour E et al. Blood. 2012 Oct 18;120(16)3382-3.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faae1"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "T315A",
  "alteration_name": "T315A",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    },
    {
      "pmid": "23086624",
      "title": "Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2012 Oct 18",
      "volume": "120",
      "issue": "16",
      "pages": "3382-3",
      "authors": "Jabbour E et al",
      "elocationId": "doi: 10.1182/blood-2012-04-424192",
      "link": null,
      "reference": "Jabbour E et al. Blood. 2012 Oct 18;120(16)3382-3.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faae2"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F317V",
  "alteration_name": "F317V",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    },
    {
      "pmid": "23086624",
      "title": "Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2012 Oct 18",
      "volume": "120",
      "issue": "16",
      "pages": "3382-3",
      "authors": "Jabbour E et al",
      "elocationId": "doi: 10.1182/blood-2012-04-424192",
      "link": null,
      "reference": "Jabbour E et al. Blood. 2012 Oct 18;120(16)3382-3.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faae3"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "V299L",
  "alteration_name": "V299L",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    },
    {
      "pmid": "23086624",
      "title": "Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2012 Oct 18",
      "volume": "120",
      "issue": "16",
      "pages": "3382-3",
      "authors": "Jabbour E et al",
      "elocationId": "doi: 10.1182/blood-2012-04-424192",
      "link": null,
      "reference": "Jabbour E et al. Blood. 2012 Oct 18;120(16)3382-3.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faae4"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F317L",
  "alteration_name": "F317L",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    },
    {
      "pmid": "23086624",
      "title": "Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2012 Oct 18",
      "volume": "120",
      "issue": "16",
      "pages": "3382-3",
      "authors": "Jabbour E et al",
      "elocationId": "doi: 10.1182/blood-2012-04-424192",
      "link": null,
      "reference": "Jabbour E et al. Blood. 2012 Oct 18;120(16)3382-3.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faae5"
  },
  "level": "LEVEL_2",
  "gene": "EZH2",
  "alteration": "Oncogenic Mutations {excluding Y646S; Y646H; Y646C; Y646F; Y646N; A682G; A692V}",
  "alteration_name": "Oncogenic Mutations (excluding Y646S, Y646H, Y646C, Y646F, Y646N, A682G and A692V)",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Follicular Lymphoma",
  "drug": [
    "Tazemetostat"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33035457",
      "title": "Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Nov",
      "volume": "21",
      "issue": "11",
      "pages": "1433-1442",
      "authors": "Morschhauser F et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30441-1",
      "link": null,
      "reference": "Morschhauser F et al. The Lancet. Oncology. 2020 Nov;21(11)1433-1442.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faae6"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "BCR-ABL1 Fusion",
  "alteration_name": "BCR-ABL1 Fusion",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "25132497",
      "title": "BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.",
      "journal": "Cancer cell",
      "pubDate": "2014 Sep 8",
      "volume": "26",
      "issue": "3",
      "pages": "428-442",
      "authors": "Zabriskie MS et al",
      "elocationId": "doi: 10.1016/j.ccr.2014.07.006",
      "link": null,
      "reference": "Zabriskie MS et al. Cancer cell. 2014 Sep 8;26(3)428-442.",
      "abstract": null
    },
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    },
    {
      "pmid": "24345751",
      "title": "Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2014 Feb 27",
      "volume": "123",
      "issue": "9",
      "pages": "1309-18",
      "authors": "Kantarjian HM et al",
      "elocationId": "doi: 10.1182/blood-2013-07-513937",
      "link": null,
      "reference": "Kantarjian HM et al. Blood. 2014 Feb 27;123(9)1309-18.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faae7"
  },
  "level": "LEVEL_2",
  "gene": "ALK",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Soft Tissue Sarcoma",
  "cancer_sub_type": "Inflammatory Myofibroblastic Tumor",
  "drug": [
    "Ceritinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26020125",
      "title": "Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2015 Jul",
      "volume": "10",
      "issue": "7",
      "pages": "1058-66",
      "authors": "Nishio M et al",
      "elocationId": "doi: 10.1097/JTO.0000000000000566",
      "link": null,
      "reference": "Nishio M et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Jul;10(7)1058-66.",
      "abstract": null
    },
    {
      "pmid": "24670165",
      "title": "Ceritinib in ALK-rearranged non-small-cell lung cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2014 Mar 27",
      "volume": "370",
      "issue": "13",
      "pages": "1189-97",
      "authors": "Shaw AT et al",
      "elocationId": "doi: 10.1056/NEJMoa1311107",
      "link": null,
      "reference": "Shaw AT et al. The New England journal of medicine. 2014 Mar 27;370(13)1189-97.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faae8"
  },
  "level": "LEVEL_2",
  "gene": "MAP2K1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32991018",
      "title": "Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2020 Dec",
      "volume": "67",
      "issue": "12",
      "pages": "e28712",
      "authors": "Messinger YH et al",
      "elocationId": "doi: 10.1002/pbc.28712",
      "link": null,
      "reference": "Messinger YH et al. Pediatric blood & cancer. 2020 Dec;67(12)e28712.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faae9"
  },
  "level": "LEVEL_2",
  "gene": "MAP2K1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32991018",
      "title": "Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2020 Dec",
      "volume": "67",
      "issue": "12",
      "pages": "e28712",
      "authors": "Messinger YH et al",
      "elocationId": "doi: 10.1002/pbc.28712",
      "link": null,
      "reference": "Messinger YH et al. Pediatric blood & cancer. 2020 Dec;67(12)e28712.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaea"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "V600 {excluding V600E ; V600K}",
  "alteration_name": "V600 (excluding V600E and V600K)",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Binimetinib",
    "Encorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29573941",
      "title": "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2018 May",
      "volume": "19",
      "issue": "5",
      "pages": "603-615",
      "authors": "Dummer R et al",
      "elocationId": "doi: 10.1016/S1470-2045(18)30142-6",
      "link": null,
      "reference": "Dummer R et al. The Lancet. Oncology. 2018 May;19(5)603-615.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaeb"
  },
  "level": "LEVEL_2",
  "gene": "NRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Rosai-Dorfman Disease",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaec"
  },
  "level": "LEVEL_2",
  "gene": "NRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Rosai-Dorfman Disease",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaed"
  },
  "level": "LEVEL_2",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Pancreatic Cancer",
  "cancer_sub_type": "Pancreatic Adenocarcinoma",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33970687",
      "title": "Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2021 Aug 1",
      "volume": "39",
      "issue": "22",
      "pages": "2497-2505",
      "authors": "Reiss KA et al",
      "elocationId": "doi: 10.1200/JCO.21.00003",
      "link": null,
      "reference": "Reiss KA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 1;39(22)2497-2505.",
      "abstract": null
    },
    {
      "pmid": "30051098",
      "title": "Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation.",
      "journal": "JCO precision oncology",
      "pubDate": "2018",
      "volume": "2018",
      "issue": "",
      "pages": "",
      "authors": "Shroff RT et al",
      "elocationId": "doi: 10.1200/PO.17.00316",
      "link": null,
      "reference": "Shroff RT et al. JCO precision oncology. 2018;2018().",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.4_suppl.734",
      "reference": "null. null. .",
      "abstract": "Brown et al. Abstract# 734, ASCO 2023"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaee"
  },
  "level": "LEVEL_2",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Pancreatic Cancer",
  "cancer_sub_type": "Acinar Cell Carcinoma of the Pancreas",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33970687",
      "title": "Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2021 Aug 1",
      "volume": "39",
      "issue": "22",
      "pages": "2497-2505",
      "authors": "Reiss KA et al",
      "elocationId": "doi: 10.1200/JCO.21.00003",
      "link": null,
      "reference": "Reiss KA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 1;39(22)2497-2505.",
      "abstract": null
    },
    {
      "pmid": "30051098",
      "title": "Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation.",
      "journal": "JCO precision oncology",
      "pubDate": "2018",
      "volume": "2018",
      "issue": "",
      "pages": "",
      "authors": "Shroff RT et al",
      "elocationId": "doi: 10.1200/PO.17.00316",
      "link": null,
      "reference": "Shroff RT et al. JCO precision oncology. 2018;2018().",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.4_suppl.734",
      "reference": "null. null. .",
      "abstract": "Brown et al. Abstract# 734, ASCO 2023"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaef"
  },
  "level": "LEVEL_2",
  "gene": "MET",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Capmatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32877583",
      "title": "Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2020 Sep 3",
      "volume": "383",
      "issue": "10",
      "pages": "944-957",
      "authors": "Wolf J et al",
      "elocationId": "doi: 10.1056/NEJMoa2002787",
      "link": null,
      "reference": "Wolf J et al. The New England journal of medicine. 2020 Sep 3;383(10)944-957.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaf0"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "L576P",
  "alteration_name": "L576P",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21642685",
      "title": "KIT as a therapeutic target in metastatic melanoma.",
      "journal": "JAMA",
      "pubDate": "2011 Jun 8",
      "volume": "305",
      "issue": "22",
      "pages": "2327-34",
      "authors": "Carvajal RD et al",
      "elocationId": "doi: 10.1001/jama.2011.746",
      "link": null,
      "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.",
      "abstract": null
    },
    {
      "pmid": "23775962",
      "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 10",
      "volume": "31",
      "issue": "26",
      "pages": "3182-90",
      "authors": "Hodi FS et al",
      "elocationId": "doi: 10.1200/JCO.2012.47.7836",
      "link": null,
      "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaf1"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "W557G",
  "alteration_name": "W557G",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21642685",
      "title": "KIT as a therapeutic target in metastatic melanoma.",
      "journal": "JAMA",
      "pubDate": "2011 Jun 8",
      "volume": "305",
      "issue": "22",
      "pages": "2327-34",
      "authors": "Carvajal RD et al",
      "elocationId": "doi: 10.1001/jama.2011.746",
      "link": null,
      "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.",
      "abstract": null
    },
    {
      "pmid": "23775962",
      "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 10",
      "volume": "31",
      "issue": "26",
      "pages": "3182-90",
      "authors": "Hodi FS et al",
      "elocationId": "doi: 10.1200/JCO.2012.47.7836",
      "link": null,
      "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaf2"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "L576del",
  "alteration_name": "L576del",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21642685",
      "title": "KIT as a therapeutic target in metastatic melanoma.",
      "journal": "JAMA",
      "pubDate": "2011 Jun 8",
      "volume": "305",
      "issue": "22",
      "pages": "2327-34",
      "authors": "Carvajal RD et al",
      "elocationId": "doi: 10.1001/jama.2011.746",
      "link": null,
      "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.",
      "abstract": null
    },
    {
      "pmid": "23775962",
      "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 10",
      "volume": "31",
      "issue": "26",
      "pages": "3182-90",
      "authors": "Hodi FS et al",
      "elocationId": "doi: 10.1200/JCO.2012.47.7836",
      "link": null,
      "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaf3"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "W557R",
  "alteration_name": "W557R",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21642685",
      "title": "KIT as a therapeutic target in metastatic melanoma.",
      "journal": "JAMA",
      "pubDate": "2011 Jun 8",
      "volume": "305",
      "issue": "22",
      "pages": "2327-34",
      "authors": "Carvajal RD et al",
      "elocationId": "doi: 10.1001/jama.2011.746",
      "link": null,
      "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.",
      "abstract": null
    },
    {
      "pmid": "23775962",
      "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 10",
      "volume": "31",
      "issue": "26",
      "pages": "3182-90",
      "authors": "Hodi FS et al",
      "elocationId": "doi: 10.1200/JCO.2012.47.7836",
      "link": null,
      "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaf4"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "D579del",
  "alteration_name": "D579del",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21642685",
      "title": "KIT as a therapeutic target in metastatic melanoma.",
      "journal": "JAMA",
      "pubDate": "2011 Jun 8",
      "volume": "305",
      "issue": "22",
      "pages": "2327-34",
      "authors": "Carvajal RD et al",
      "elocationId": "doi: 10.1001/jama.2011.746",
      "link": null,
      "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.",
      "abstract": null
    },
    {
      "pmid": "23775962",
      "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 10",
      "volume": "31",
      "issue": "26",
      "pages": "3182-90",
      "authors": "Hodi FS et al",
      "elocationId": "doi: 10.1200/JCO.2012.47.7836",
      "link": null,
      "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaf5"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "V559A",
  "alteration_name": "V559A",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21642685",
      "title": "KIT as a therapeutic target in metastatic melanoma.",
      "journal": "JAMA",
      "pubDate": "2011 Jun 8",
      "volume": "305",
      "issue": "22",
      "pages": "2327-34",
      "authors": "Carvajal RD et al",
      "elocationId": "doi: 10.1001/jama.2011.746",
      "link": null,
      "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.",
      "abstract": null
    },
    {
      "pmid": "23775962",
      "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 10",
      "volume": "31",
      "issue": "26",
      "pages": "3182-90",
      "authors": "Hodi FS et al",
      "elocationId": "doi: 10.1200/JCO.2012.47.7836",
      "link": null,
      "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaf6"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "V654A",
  "alteration_name": "V654A",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21642685",
      "title": "KIT as a therapeutic target in metastatic melanoma.",
      "journal": "JAMA",
      "pubDate": "2011 Jun 8",
      "volume": "305",
      "issue": "22",
      "pages": "2327-34",
      "authors": "Carvajal RD et al",
      "elocationId": "doi: 10.1001/jama.2011.746",
      "link": null,
      "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.",
      "abstract": null
    },
    {
      "pmid": "23775962",
      "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 10",
      "volume": "31",
      "issue": "26",
      "pages": "3182-90",
      "authors": "Hodi FS et al",
      "elocationId": "doi: 10.1200/JCO.2012.47.7836",
      "link": null,
      "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaf7"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "K642E",
  "alteration_name": "K642E",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21642685",
      "title": "KIT as a therapeutic target in metastatic melanoma.",
      "journal": "JAMA",
      "pubDate": "2011 Jun 8",
      "volume": "305",
      "issue": "22",
      "pages": "2327-34",
      "authors": "Carvajal RD et al",
      "elocationId": "doi: 10.1001/jama.2011.746",
      "link": null,
      "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.",
      "abstract": null
    },
    {
      "pmid": "23775962",
      "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 10",
      "volume": "31",
      "issue": "26",
      "pages": "3182-90",
      "authors": "Hodi FS et al",
      "elocationId": "doi: 10.1200/JCO.2012.47.7836",
      "link": null,
      "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaf8"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "V560D",
  "alteration_name": "V560D",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21642685",
      "title": "KIT as a therapeutic target in metastatic melanoma.",
      "journal": "JAMA",
      "pubDate": "2011 Jun 8",
      "volume": "305",
      "issue": "22",
      "pages": "2327-34",
      "authors": "Carvajal RD et al",
      "elocationId": "doi: 10.1001/jama.2011.746",
      "link": null,
      "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.",
      "abstract": null
    },
    {
      "pmid": "23775962",
      "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 10",
      "volume": "31",
      "issue": "26",
      "pages": "3182-90",
      "authors": "Hodi FS et al",
      "elocationId": "doi: 10.1200/JCO.2012.47.7836",
      "link": null,
      "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaf9"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "V560G",
  "alteration_name": "V560G",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21642685",
      "title": "KIT as a therapeutic target in metastatic melanoma.",
      "journal": "JAMA",
      "pubDate": "2011 Jun 8",
      "volume": "305",
      "issue": "22",
      "pages": "2327-34",
      "authors": "Carvajal RD et al",
      "elocationId": "doi: 10.1001/jama.2011.746",
      "link": null,
      "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.",
      "abstract": null
    },
    {
      "pmid": "23775962",
      "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 10",
      "volume": "31",
      "issue": "26",
      "pages": "3182-90",
      "authors": "Hodi FS et al",
      "elocationId": "doi: 10.1200/JCO.2012.47.7836",
      "link": null,
      "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faafa"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "V560del",
  "alteration_name": "V560del",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21642685",
      "title": "KIT as a therapeutic target in metastatic melanoma.",
      "journal": "JAMA",
      "pubDate": "2011 Jun 8",
      "volume": "305",
      "issue": "22",
      "pages": "2327-34",
      "authors": "Carvajal RD et al",
      "elocationId": "doi: 10.1001/jama.2011.746",
      "link": null,
      "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.",
      "abstract": null
    },
    {
      "pmid": "23775962",
      "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 10",
      "volume": "31",
      "issue": "26",
      "pages": "3182-90",
      "authors": "Hodi FS et al",
      "elocationId": "doi: 10.1200/JCO.2012.47.7836",
      "link": null,
      "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faafb"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "P577del",
  "alteration_name": "P577del",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21642685",
      "title": "KIT as a therapeutic target in metastatic melanoma.",
      "journal": "JAMA",
      "pubDate": "2011 Jun 8",
      "volume": "305",
      "issue": "22",
      "pages": "2327-34",
      "authors": "Carvajal RD et al",
      "elocationId": "doi: 10.1001/jama.2011.746",
      "link": null,
      "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.",
      "abstract": null
    },
    {
      "pmid": "23775962",
      "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 10",
      "volume": "31",
      "issue": "26",
      "pages": "3182-90",
      "authors": "Hodi FS et al",
      "elocationId": "doi: 10.1200/JCO.2012.47.7836",
      "link": null,
      "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faafc"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "Y553_K558del",
  "alteration_name": "Y553_K558del",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21642685",
      "title": "KIT as a therapeutic target in metastatic melanoma.",
      "journal": "JAMA",
      "pubDate": "2011 Jun 8",
      "volume": "305",
      "issue": "22",
      "pages": "2327-34",
      "authors": "Carvajal RD et al",
      "elocationId": "doi: 10.1001/jama.2011.746",
      "link": null,
      "reference": "Carvajal RD et al. JAMA. 2011 Jun 8;305(22)2327-34.",
      "abstract": null
    },
    {
      "pmid": "23775962",
      "title": "Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 10",
      "volume": "31",
      "issue": "26",
      "pages": "3182-90",
      "authors": "Hodi FS et al",
      "elocationId": "doi: 10.1200/JCO.2012.47.7836",
      "link": null,
      "reference": "Hodi FS et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 10;31(26)3182-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faafd"
  },
  "level": "LEVEL_2",
  "gene": "KRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faafe"
  },
  "level": "LEVEL_2",
  "gene": "KRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faaff"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "V600 {excluding V600E ; V600K}",
  "alteration_name": "V600 (excluding V600E and V600K)",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Dabrafenib",
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23020132",
      "title": "Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.",
      "journal": "The New England journal of medicine",
      "pubDate": "2012 Nov 1",
      "volume": "367",
      "issue": "18",
      "pages": "1694-703",
      "authors": "Flaherty KT et al",
      "elocationId": "doi: 10.1056/NEJMoa1210093",
      "link": null,
      "reference": "Flaherty KT et al. The New England journal of medicine. 2012 Nov 1;367(18)1694-703.",
      "abstract": null
    },
    {
      "pmid": "29361468",
      "title": "Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2018 Feb",
      "volume": "19",
      "issue": "2",
      "pages": "181-193",
      "authors": "Amaria RN et al",
      "elocationId": "doi: 10.1016/S1470-2045(18)30015-9",
      "link": null,
      "reference": "Amaria RN et al. The Lancet. Oncology. 2018 Feb;19(2)181-193.",
      "abstract": null
    },
    {
      "pmid": "25287827",
      "title": "Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2014 Nov 20",
      "volume": "32",
      "issue": "33",
      "pages": "3697-704",
      "authors": "Johnson DB et al",
      "elocationId": "doi: 10.1200/JCO.2014.57.3535",
      "link": null,
      "reference": "Johnson DB et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Nov 20;32(33)3697-704.",
      "abstract": null
    },
    {
      "pmid": "28891408",
      "title": "Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Nov 9",
      "volume": "377",
      "issue": "19",
      "pages": "1813-1823",
      "authors": "Long GV et al",
      "elocationId": "doi: 10.1056/NEJMoa1708539",
      "link": null,
      "reference": "Long GV et al. The New England journal of medicine. 2017 Nov 9;377(19)1813-1823.",
      "abstract": null
    },
    {
      "pmid": "31171876",
      "title": "Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.",
      "journal": "Nature medicine",
      "pubDate": "2019 Jun",
      "volume": "25",
      "issue": "6",
      "pages": "929-935",
      "authors": "Sullivan RJ et al",
      "elocationId": "doi: 10.1038/s41591-019-0474-7",
      "link": null,
      "reference": "Sullivan RJ et al. Nature medicine. 2019 Jun;25(6)929-935.",
      "abstract": null
    },
    {
      "pmid": "28991513",
      "title": "Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Mar 1",
      "volume": "36",
      "issue": "7",
      "pages": "667-673",
      "authors": "Long GV et al",
      "elocationId": "doi: 10.1200/JCO.2017.74.1025",
      "link": null,
      "reference": "Long GV et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Mar 1;36(7)667-673.",
      "abstract": null
    },
    {
      "pmid": "31171878",
      "title": "Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.",
      "journal": "Nature medicine",
      "pubDate": "2019 Jun",
      "volume": "25",
      "issue": "6",
      "pages": "941-946",
      "authors": "Ascierto PA et al",
      "elocationId": "doi: 10.1038/s41591-019-0448-9",
      "link": null,
      "reference": "Ascierto PA et al. Nature medicine. 2019 Jun;25(6)941-946.",
      "abstract": null
    },
    {
      "pmid": "31171879",
      "title": "Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.",
      "journal": "Nature medicine",
      "pubDate": "2019 Jun",
      "volume": "25",
      "issue": "6",
      "pages": "936-940",
      "authors": "Ribas A et al",
      "elocationId": "doi: 10.1038/s41591-019-0476-5",
      "link": null,
      "reference": "Ribas A et al. Nature medicine. 2019 Jun;25(6)936-940.",
      "abstract": null
    },
    {
      "pmid": "25399551",
      "title": "Improved overall survival in melanoma with combined dabrafenib and trametinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Jan 1",
      "volume": "372",
      "issue": "1",
      "pages": "30-9",
      "authors": "Robert C et al",
      "elocationId": "doi: 10.1056/NEJMoa1412690",
      "link": null,
      "reference": "Robert C et al. The New England journal of medicine. 2015 Jan 1;372(1)30-9.",
      "abstract": null
    },
    {
      "pmid": "25265492",
      "title": "Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2014 Nov 13",
      "volume": "371",
      "issue": "20",
      "pages": "1877-88",
      "authors": "Long GV et al",
      "elocationId": "doi: 10.1056/NEJMoa1406037",
      "link": null,
      "reference": "Long GV et al. The New England journal of medicine. 2014 Nov 13;371(20)1877-88.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab00"
  },
  "level": "LEVEL_2",
  "gene": "MET",
  "alteration": "963_1010del",
  "alteration_name": "Exon 14 in-frame deletions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31932802",
      "title": "Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.",
      "journal": "Nature medicine",
      "pubDate": "2020 Jan",
      "volume": "26",
      "issue": "1",
      "pages": "47-51",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1038/s41591-019-0716-8",
      "link": null,
      "reference": "Drilon A et al. Nature medicine. 2020 Jan;26(1)47-51.",
      "abstract": null
    },
    {
      "pmid": "25971939",
      "title": "Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.",
      "journal": "Cancer discovery",
      "pubDate": "2015 Aug",
      "volume": "5",
      "issue": "8",
      "pages": "842-9",
      "authors": "Paik PK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-14-1467",
      "link": null,
      "reference": "Paik PK et al. Cancer discovery. 2015 Aug;5(8)842-9.",
      "abstract": null
    },
    {
      "pmid": "21623265",
      "title": "Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2011 May",
      "volume": "6",
      "issue": "5",
      "pages": "942-6",
      "authors": "Ou SH et al",
      "elocationId": "doi: 10.1097/JTO.0b013e31821528d3",
      "link": null,
      "reference": "Ou SH et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 May;6(5)942-6.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://meetinglibrary.asco.org/content/132030-144",
      "reference": "null. null. .",
      "abstract": "Camidge et al. Abstract# 8001, ASCO 2014"
    },
    {
      "pmid": "26729443",
      "title": "MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2016 Mar 1",
      "volume": "34",
      "issue": "7",
      "pages": "721-30",
      "authors": "Awad MM et al",
      "elocationId": "doi: 10.1200/JCO.2015.63.4600",
      "link": null,
      "reference": "Awad MM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Mar 1;34(7)721-30.",
      "abstract": null
    },
    {
      "pmid": "31416808",
      "title": "Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Dec 15",
      "volume": "25",
      "issue": "24",
      "pages": "7312-7319",
      "authors": "Landi L et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-19-0994",
      "link": null,
      "reference": "Landi L et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Dec 15;25(24)7312-7319.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab01"
  },
  "level": "LEVEL_2",
  "gene": "MET",
  "alteration": "Exon 14 Deletion",
  "alteration_name": "Exon 14 Deletion",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31932802",
      "title": "Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.",
      "journal": "Nature medicine",
      "pubDate": "2020 Jan",
      "volume": "26",
      "issue": "1",
      "pages": "47-51",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1038/s41591-019-0716-8",
      "link": null,
      "reference": "Drilon A et al. Nature medicine. 2020 Jan;26(1)47-51.",
      "abstract": null
    },
    {
      "pmid": "25971939",
      "title": "Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.",
      "journal": "Cancer discovery",
      "pubDate": "2015 Aug",
      "volume": "5",
      "issue": "8",
      "pages": "842-9",
      "authors": "Paik PK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-14-1467",
      "link": null,
      "reference": "Paik PK et al. Cancer discovery. 2015 Aug;5(8)842-9.",
      "abstract": null
    },
    {
      "pmid": "21623265",
      "title": "Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2011 May",
      "volume": "6",
      "issue": "5",
      "pages": "942-6",
      "authors": "Ou SH et al",
      "elocationId": "doi: 10.1097/JTO.0b013e31821528d3",
      "link": null,
      "reference": "Ou SH et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 May;6(5)942-6.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://meetinglibrary.asco.org/content/132030-144",
      "reference": "null. null. .",
      "abstract": "Camidge et al. Abstract# 8001, ASCO 2014"
    },
    {
      "pmid": "26729443",
      "title": "MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2016 Mar 1",
      "volume": "34",
      "issue": "7",
      "pages": "721-30",
      "authors": "Awad MM et al",
      "elocationId": "doi: 10.1200/JCO.2015.63.4600",
      "link": null,
      "reference": "Awad MM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Mar 1;34(7)721-30.",
      "abstract": null
    },
    {
      "pmid": "31416808",
      "title": "Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Dec 15",
      "volume": "25",
      "issue": "24",
      "pages": "7312-7319",
      "authors": "Landi L et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-19-0994",
      "link": null,
      "reference": "Landi L et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Dec 15;25(24)7312-7319.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab02"
  },
  "level": "LEVEL_2",
  "gene": "MET",
  "alteration": "D1010",
  "alteration_name": "D1010",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31932802",
      "title": "Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.",
      "journal": "Nature medicine",
      "pubDate": "2020 Jan",
      "volume": "26",
      "issue": "1",
      "pages": "47-51",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1038/s41591-019-0716-8",
      "link": null,
      "reference": "Drilon A et al. Nature medicine. 2020 Jan;26(1)47-51.",
      "abstract": null
    },
    {
      "pmid": "25971939",
      "title": "Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.",
      "journal": "Cancer discovery",
      "pubDate": "2015 Aug",
      "volume": "5",
      "issue": "8",
      "pages": "842-9",
      "authors": "Paik PK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-14-1467",
      "link": null,
      "reference": "Paik PK et al. Cancer discovery. 2015 Aug;5(8)842-9.",
      "abstract": null
    },
    {
      "pmid": "21623265",
      "title": "Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2011 May",
      "volume": "6",
      "issue": "5",
      "pages": "942-6",
      "authors": "Ou SH et al",
      "elocationId": "doi: 10.1097/JTO.0b013e31821528d3",
      "link": null,
      "reference": "Ou SH et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 May;6(5)942-6.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://meetinglibrary.asco.org/content/132030-144",
      "reference": "null. null. .",
      "abstract": "Camidge et al. Abstract# 8001, ASCO 2014"
    },
    {
      "pmid": "26729443",
      "title": "MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2016 Mar 1",
      "volume": "34",
      "issue": "7",
      "pages": "721-30",
      "authors": "Awad MM et al",
      "elocationId": "doi: 10.1200/JCO.2015.63.4600",
      "link": null,
      "reference": "Awad MM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Mar 1;34(7)721-30.",
      "abstract": null
    },
    {
      "pmid": "31416808",
      "title": "Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Dec 15",
      "volume": "25",
      "issue": "24",
      "pages": "7312-7319",
      "authors": "Landi L et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-19-0994",
      "link": null,
      "reference": "Landi L et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Dec 15;25(24)7312-7319.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab03"
  },
  "level": "LEVEL_2",
  "gene": "MET",
  "alteration": "963_1010splice",
  "alteration_name": "Exon 14 splice mutations",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31932802",
      "title": "Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.",
      "journal": "Nature medicine",
      "pubDate": "2020 Jan",
      "volume": "26",
      "issue": "1",
      "pages": "47-51",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1038/s41591-019-0716-8",
      "link": null,
      "reference": "Drilon A et al. Nature medicine. 2020 Jan;26(1)47-51.",
      "abstract": null
    },
    {
      "pmid": "25971939",
      "title": "Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.",
      "journal": "Cancer discovery",
      "pubDate": "2015 Aug",
      "volume": "5",
      "issue": "8",
      "pages": "842-9",
      "authors": "Paik PK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-14-1467",
      "link": null,
      "reference": "Paik PK et al. Cancer discovery. 2015 Aug;5(8)842-9.",
      "abstract": null
    },
    {
      "pmid": "21623265",
      "title": "Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2011 May",
      "volume": "6",
      "issue": "5",
      "pages": "942-6",
      "authors": "Ou SH et al",
      "elocationId": "doi: 10.1097/JTO.0b013e31821528d3",
      "link": null,
      "reference": "Ou SH et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 May;6(5)942-6.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://meetinglibrary.asco.org/content/132030-144",
      "reference": "null. null. .",
      "abstract": "Camidge et al. Abstract# 8001, ASCO 2014"
    },
    {
      "pmid": "26729443",
      "title": "MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2016 Mar 1",
      "volume": "34",
      "issue": "7",
      "pages": "721-30",
      "authors": "Awad MM et al",
      "elocationId": "doi: 10.1200/JCO.2015.63.4600",
      "link": null,
      "reference": "Awad MM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Mar 1;34(7)721-30.",
      "abstract": null
    },
    {
      "pmid": "31416808",
      "title": "Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Dec 15",
      "volume": "25",
      "issue": "24",
      "pages": "7312-7319",
      "authors": "Landi L et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-19-0994",
      "link": null,
      "reference": "Landi L et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Dec 15;25(24)7312-7319.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab04"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "BCR-ABL1 Fusion",
  "alteration_name": "BCR-ABL1 Fusion",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26065651",
      "title": "Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.",
      "journal": "Blood",
      "pubDate": "2015 Aug 6",
      "volume": "126",
      "issue": "6",
      "pages": "746-56",
      "authors": "Kim DY et al",
      "elocationId": "doi: 10.1182/blood-2015-03-636548",
      "link": null,
      "reference": "Kim DY et al. Blood. 2015 Aug 6;126(6)746-56.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab05"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F317I",
  "alteration_name": "F317I",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab06"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F317C",
  "alteration_name": "F317C",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab07"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F359I",
  "alteration_name": "F359I",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab08"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "T315A",
  "alteration_name": "T315A",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab09"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F317V",
  "alteration_name": "F317V",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab0a"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "E255K",
  "alteration_name": "E255K",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab0b"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "E255V",
  "alteration_name": "E255V",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab0c"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "Y253H",
  "alteration_name": "Y253H",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab0d"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F359V",
  "alteration_name": "F359V",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab0e"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F359C",
  "alteration_name": "F359C",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab0f"
  },
  "level": "LEVEL_2",
  "gene": "ALK",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Soft Tissue Sarcoma",
  "cancer_sub_type": "Inflammatory Myofibroblastic Tumor",
  "drug": [
    "Brigatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27836716",
      "title": "Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2016 Dec",
      "volume": "17",
      "issue": "12",
      "pages": "1683-1696",
      "authors": "Gettinger SN et al",
      "elocationId": "doi: 10.1016/S1470-2045(16)30392-8",
      "link": null,
      "reference": "Gettinger SN et al. The Lancet. Oncology. 2016 Dec;17(12)1683-1696.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab10"
  },
  "level": "LEVEL_2",
  "gene": "JAK2",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2",
  "drug": [
    "Ruxolitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32279331",
      "title": "Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.",
      "journal": "American journal of hematology",
      "pubDate": "2020 Jul",
      "volume": "95",
      "issue": "7",
      "pages": "824-833",
      "authors": "Schwaab J et al",
      "elocationId": "doi: 10.1002/ajh.25825",
      "link": null,
      "reference": "Schwaab J et al. American journal of hematology. 2020 Jul;95(7)824-833.",
      "abstract": null
    },
    {
      "pmid": "23630205",
      "title": "Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Jun 10",
      "volume": "31",
      "issue": "17",
      "pages": "e269-71",
      "authors": "Rumi E et al",
      "elocationId": "doi: 10.1200/JCO.2012.46.4370",
      "link": null,
      "reference": "Rumi E et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jun 10;31(17)e269-71.",
      "abstract": null
    },
    {
      "pmid": "26202607",
      "title": "Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.",
      "journal": "Annals of hematology",
      "pubDate": "2015 Nov",
      "volume": "94",
      "issue": "11",
      "pages": "1927-8",
      "authors": "Rumi E et al",
      "elocationId": "doi: 10.1007/s00277-015-2451-7",
      "link": null,
      "reference": "Rumi E et al. Annals of hematology. 2015 Nov;94(11)1927-8.",
      "abstract": null
    },
    {
      "pmid": "25260694",
      "title": "Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.",
      "journal": "Annals of hematology",
      "pubDate": "2015 Feb",
      "volume": "94",
      "issue": "2",
      "pages": "233-8",
      "authors": "Schwaab J et al",
      "elocationId": "doi: 10.1007/s00277-014-2221-y",
      "link": null,
      "reference": "Schwaab J et al. Annals of hematology. 2015 Feb;94(2)233-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab11"
  },
  "level": "LEVEL_2",
  "gene": "JAK2",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of  PDGFRA/PDGFRB or FGFR1 or with PCM1-JAK2",
  "drug": [
    "Fedratinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32279331",
      "title": "Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.",
      "journal": "American journal of hematology",
      "pubDate": "2020 Jul",
      "volume": "95",
      "issue": "7",
      "pages": "824-833",
      "authors": "Schwaab J et al",
      "elocationId": "doi: 10.1002/ajh.25825",
      "link": null,
      "reference": "Schwaab J et al. American journal of hematology. 2020 Jul;95(7)824-833.",
      "abstract": null
    },
    {
      "pmid": "23630205",
      "title": "Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Jun 10",
      "volume": "31",
      "issue": "17",
      "pages": "e269-71",
      "authors": "Rumi E et al",
      "elocationId": "doi: 10.1200/JCO.2012.46.4370",
      "link": null,
      "reference": "Rumi E et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jun 10;31(17)e269-71.",
      "abstract": null
    },
    {
      "pmid": "26202607",
      "title": "Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.",
      "journal": "Annals of hematology",
      "pubDate": "2015 Nov",
      "volume": "94",
      "issue": "11",
      "pages": "1927-8",
      "authors": "Rumi E et al",
      "elocationId": "doi: 10.1007/s00277-015-2451-7",
      "link": null,
      "reference": "Rumi E et al. Annals of hematology. 2015 Nov;94(11)1927-8.",
      "abstract": null
    },
    {
      "pmid": "25260694",
      "title": "Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.",
      "journal": "Annals of hematology",
      "pubDate": "2015 Feb",
      "volume": "94",
      "issue": "2",
      "pages": "233-8",
      "authors": "Schwaab J et al",
      "elocationId": "doi: 10.1007/s00277-014-2221-y",
      "link": null,
      "reference": "Schwaab J et al. Annals of hematology. 2015 Feb;94(2)233-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab12"
  },
  "level": "LEVEL_2",
  "gene": "MAP2K1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab13"
  },
  "level": "LEVEL_2",
  "gene": "MAP2K1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab14"
  },
  "level": "LEVEL_2",
  "gene": "EGFR",
  "alteration": "A763_Y764insFQEA",
  "alteration_name": "A763_Y764insFQEA",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erlotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23969006",
      "title": "EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib--Letter.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2013 Nov",
      "volume": "12",
      "issue": "11",
      "pages": "2614-5",
      "authors": "Voon PJ et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-13-0192",
      "link": null,
      "reference": "Voon PJ et al. Molecular cancer therapeutics. 2013 Nov;12(11)2614-5.",
      "abstract": null
    },
    {
      "pmid": "24353160",
      "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2013 Dec 18",
      "volume": "5",
      "issue": "216",
      "pages": "216ra177",
      "authors": "Yasuda H et al",
      "elocationId": "doi: 10.1126/scitranslmed.3007205",
      "link": null,
      "reference": "Yasuda H et al. Science translational medicine. 2013 Dec 18;5(216)216ra177.",
      "abstract": null
    },
    {
      "pmid": "28089594",
      "title": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer.",
      "journal": "Clinical lung cancer",
      "pubDate": "2017 May",
      "volume": "18",
      "issue": "3",
      "pages": "324-332.e1",
      "authors": "Lin YT et al",
      "elocationId": "doi: 10.1016/j.cllc.2016.12.014",
      "link": null,
      "reference": "Lin YT et al. Clinical lung cancer. 2017 May;18(3)324-332.e1.",
      "abstract": null
    },
    {
      "pmid": "23371856",
      "title": "EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2013 Feb",
      "volume": "12",
      "issue": "2",
      "pages": "220-9",
      "authors": "Arcila ME et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-12-0620",
      "link": null,
      "reference": "Arcila ME et al. Molecular cancer therapeutics. 2013 Feb;12(2)220-9.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab15"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "Oncogenic Mutations {excluding V600}",
  "alteration_name": "Oncogenic Mutations (excluding V600)",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab16"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "Oncogenic Mutations {excluding V600}",
  "alteration_name": "Oncogenic Mutations (excluding V600)",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab17"
  },
  "level": "LEVEL_2",
  "gene": "PDGFRA",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Sunitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "17046465",
      "title": "Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2006 Oct 14",
      "volume": "368",
      "issue": "9544",
      "pages": "1329-38",
      "authors": "Demetri GD et al",
      "elocationId": "",
      "link": null,
      "reference": "Demetri GD et al. Lancet (London, England). 2006 Oct 14;368(9544)1329-38.",
      "abstract": null
    },
    {
      "pmid": "25641662",
      "title": "Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.",
      "journal": "Cancer",
      "pubDate": "2015 May 1",
      "volume": "121",
      "issue": "9",
      "pages": "1405-13",
      "authors": "Reichardt P et al",
      "elocationId": "doi: 10.1002/cncr.29220",
      "link": null,
      "reference": "Reichardt P et al. Cancer. 2015 May 1;121(9)1405-13.",
      "abstract": null
    },
    {
      "pmid": "19282169",
      "title": "Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.",
      "journal": "European journal of cancer (Oxford, England : 1990)",
      "pubDate": "2009 Jul",
      "volume": "45",
      "issue": "11",
      "pages": "1959-68",
      "authors": "George S et al",
      "elocationId": "doi: 10.1016/j.ejca.2009.02.011",
      "link": null,
      "reference": "George S et al. European journal of cancer (Oxford, England : 1990). 2009 Jul;45(11)1959-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab18"
  },
  "level": "LEVEL_2",
  "gene": "PDGFRA",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Regorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27371698",
      "title": "Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2016 Sep",
      "volume": "27",
      "issue": "9",
      "pages": "1794-9",
      "authors": "Ben-Ami E et al",
      "elocationId": "doi: 10.1093/annonc/mdw228",
      "link": null,
      "reference": "Ben-Ami E et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Sep;27(9)1794-9.",
      "abstract": null
    },
    {
      "pmid": "23177515",
      "title": "Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.",
      "journal": "Lancet (London, England)",
      "pubDate": "2013 Jan 26",
      "volume": "381",
      "issue": "9863",
      "pages": "295-302",
      "authors": "Demetri GD et al",
      "elocationId": "doi: 10.1016/S0140-6736(12)61857-1",
      "link": null,
      "reference": "Demetri GD et al. Lancet (London, England). 2013 Jan 26;381(9863)295-302.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab19"
  },
  "level": "LEVEL_2",
  "gene": "EGFR",
  "alteration": "S768I",
  "alteration_name": "S768I",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Osimertinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31825714",
      "title": "Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2020 Feb 10",
      "volume": "38",
      "issue": "5",
      "pages": "488-495",
      "authors": "Cho JH et al",
      "elocationId": "doi: 10.1200/JCO.19.00931",
      "link": null,
      "reference": "Cho JH et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Feb 10;38(5)488-495.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab1a"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Encorafenib",
    "Panitumumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31566309",
      "title": "Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Oct 24",
      "volume": "381",
      "issue": "17",
      "pages": "1632-1643",
      "authors": "Kopetz S et al",
      "elocationId": "doi: 10.1056/NEJMoa1908075",
      "link": null,
      "reference": "Kopetz S et al. The New England journal of medicine. 2019 Oct 24;381(17)1632-1643.",
      "abstract": null
    },
    {
      "pmid": "29431699",
      "title": "Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i><sup>V600E</sup>-Mutant Colorectal Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2018 Apr",
      "volume": "8",
      "issue": "4",
      "pages": "428-443",
      "authors": "Corcoran RB et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-17-1226",
      "link": null,
      "reference": "Corcoran RB et al. Cancer discovery. 2018 Apr;8(4)428-443.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab1b"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "V600",
  "alteration_name": "V600",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Dabrafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29188284",
      "title": "Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.",
      "journal": "JAMA oncology",
      "pubDate": "2018 Mar 1",
      "volume": "4",
      "issue": "3",
      "pages": "384-388",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1001/jamaoncol.2017.5029",
      "link": null,
      "reference": "Diamond EL et al. JAMA oncology. 2018 Mar 1;4(3)384-388.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab1c"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "V600",
  "alteration_name": "V600",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Vemurafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29188284",
      "title": "Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.",
      "journal": "JAMA oncology",
      "pubDate": "2018 Mar 1",
      "volume": "4",
      "issue": "3",
      "pages": "384-388",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1001/jamaoncol.2017.5029",
      "link": null,
      "reference": "Diamond EL et al. JAMA oncology. 2018 Mar 1;4(3)384-388.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab1d"
  },
  "level": "LEVEL_2",
  "gene": "ARAF",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab1e"
  },
  "level": "LEVEL_2",
  "gene": "ARAF",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab1f"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Glioma",
  "cancer_sub_type": "Diffuse Glioma",
  "drug": [
    "Cobimetinib",
    "Vemurafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33117675",
      "title": "Multidisciplinary Therapy Managed Recurrent Glioblastoma in a BRAF-V600E Mutant Pregnant Female: A Case Report and Review of the Literature.",
      "journal": "Frontiers in oncology",
      "pubDate": "2020",
      "volume": "10",
      "issue": "",
      "pages": "522816",
      "authors": "Qin C et al",
      "elocationId": "doi: 10.3389/fonc.2020.522816",
      "link": null,
      "reference": "Qin C et al. Frontiers in oncology. 2020;10()522816.",
      "abstract": null
    },
    {
      "pmid": "24725538",
      "title": "Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy.",
      "journal": "BMC cancer",
      "pubDate": "2014 Apr 12",
      "volume": "14",
      "issue": "",
      "pages": "258",
      "authors": "Robinson GW et al",
      "elocationId": "doi: 10.1186/1471-2407-14-258",
      "link": null,
      "reference": "Robinson GW et al. BMC cancer. 2014 Apr 12;14()258.",
      "abstract": null
    },
    {
      "pmid": "30462564",
      "title": "Successful treatment of a BRAF V600E-mutant extracranial metastatic anaplastic oligoastrocytoma with vemurafenib and everolimus.",
      "journal": "Cancer biology & therapy",
      "pubDate": "2019",
      "volume": "20",
      "issue": "4",
      "pages": "431-434",
      "authors": "Shi L et al",
      "elocationId": "doi: 10.1080/15384047.2018.1529115",
      "link": null,
      "reference": "Shi L et al. Cancer biology & therapy. 2019;20(4)431-434.",
      "abstract": null
    },
    {
      "pmid": "26287849",
      "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Aug 20",
      "volume": "373",
      "issue": "8",
      "pages": "726-36",
      "authors": "Hyman DM et al",
      "elocationId": "doi: 10.1056/NEJMoa1502309",
      "link": null,
      "reference": "Hyman DM et al. The New England journal of medicine. 2015 Aug 20;373(8)726-36.",
      "abstract": null
    },
    {
      "pmid": "29621181",
      "title": "Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation.",
      "journal": "International journal of molecular sciences",
      "pubDate": "2018 Apr 5",
      "volume": "19",
      "issue": "4",
      "pages": "",
      "authors": "Ceccon G et al",
      "elocationId": "pii: E1090. doi: 10.3390/ijms19041090",
      "link": null,
      "reference": "Ceccon G et al. International journal of molecular sciences. 2018 Apr 5;19(4).",
      "abstract": null
    },
    {
      "pmid": "34232949",
      "title": "Effective treatment of a BRAF V600E-mutant epithelioid glioblastoma patient by vemurafenib: a case report.",
      "journal": "Anti-cancer drugs",
      "pubDate": "2021 Jul 4",
      "volume": "",
      "issue": "",
      "pages": "",
      "authors": "Lin Z et al",
      "elocationId": "doi: 10.1097/CAD.0000000000001130",
      "link": null,
      "reference": "Lin Z et al. Anti-cancer drugs. 2021 Jul 4;().",
      "abstract": null
    },
    {
      "pmid": "30351999",
      "title": "BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Dec 10",
      "volume": "36",
      "issue": "35",
      "pages": "3477-3484",
      "authors": "Kaley T et al",
      "elocationId": "doi: 10.1200/JCO.2018.78.9990",
      "link": null,
      "reference": "Kaley T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Dec 10;36(35)3477-3484.",
      "abstract": null
    },
    {
      "pmid": "29039591",
      "title": "Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.",
      "journal": "Oncology reports",
      "pubDate": "2017 Dec",
      "volume": "38",
      "issue": "6",
      "pages": "3291-3296",
      "authors": "Burger MC et al",
      "elocationId": "doi: 10.3892/or.2017.6013",
      "link": null,
      "reference": "Burger MC et al. Oncology reports. 2017 Dec;38(6)3291-3296.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab20"
  },
  "level": "LEVEL_2",
  "gene": "PDGFRA",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Ripretinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32511981",
      "title": "Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2020 Jul",
      "volume": "21",
      "issue": "7",
      "pages": "923-934",
      "authors": "Blay JY et al",
      "elocationId": "doi: 10.1016/S1470-2045(20)30168-6",
      "link": null,
      "reference": "Blay JY et al. The Lancet. Oncology. 2020 Jul;21(7)923-934.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab21"
  },
  "level": "LEVEL_2",
  "gene": "EGFR",
  "alteration": "G719",
  "alteration_name": "G719",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Osimertinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31825714",
      "title": "Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2020 Feb 10",
      "volume": "38",
      "issue": "5",
      "pages": "488-495",
      "authors": "Cho JH et al",
      "elocationId": "doi: 10.1200/JCO.19.00931",
      "link": null,
      "reference": "Cho JH et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Feb 10;38(5)488-495.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab22"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Glioma",
  "cancer_sub_type": "Pilocytic Astrocytoma",
  "drug": [
    "Selumetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31151904",
      "title": "Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 Jul",
      "volume": "20",
      "issue": "7",
      "pages": "1011-1022",
      "authors": "Fangusaro J et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30277-3",
      "link": null,
      "reference": "Fangusaro J et al. The Lancet. Oncology. 2019 Jul;20(7)1011-1022.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab23"
  },
  "level": "LEVEL_2",
  "gene": "EGFR",
  "alteration": "L861Q",
  "alteration_name": "L861Q",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "Non-Small Cell Lung Cancer",
  "drug": [
    "Osimertinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31825714",
      "title": "Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09).",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2020 Feb 10",
      "volume": "38",
      "issue": "5",
      "pages": "488-495",
      "authors": "Cho JH et al",
      "elocationId": "doi: 10.1200/JCO.19.00931",
      "link": null,
      "reference": "Cho JH et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Feb 10;38(5)488-495.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab24"
  },
  "level": "LEVEL_2",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Pertuzumab",
    "Trastuzumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30857956",
      "title": "Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 Apr",
      "volume": "20",
      "issue": "4",
      "pages": "518-530",
      "authors": "Meric-Bernstam F et al",
      "elocationId": "doi: 10.1016/S1470-2045(18)30904-5",
      "link": null,
      "reference": "Meric-Bernstam F et al. The Lancet. Oncology. 2019 Apr;20(4)518-530.",
      "abstract": null
    },
    {
      "pmid": "36315917",
      "title": "Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With &lt;i&gt;ERBB2&lt;/i&gt; Amplification or &lt;i&gt;ERBB2/3&lt;/i&gt; Mutations: Results From the TAPUR Study.",
      "journal": "JCO precision oncology",
      "pubDate": "2022 Oct",
      "volume": "6",
      "issue": "",
      "pages": "e2200306",
      "authors": "Gupta R et al",
      "elocationId": "doi: 10.1200/PO.22.00306",
      "link": null,
      "reference": "Gupta R et al. JCO precision oncology. 2022 Oct;6()e2200306.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab25"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F317I",
  "alteration_name": "F317I",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab26"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F317C",
  "alteration_name": "F317C",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab27"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F359I",
  "alteration_name": "F359I",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab28"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "T315A",
  "alteration_name": "T315A",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab29"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F317V",
  "alteration_name": "F317V",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab2a"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "E255K",
  "alteration_name": "E255K",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab2b"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "E255V",
  "alteration_name": "E255V",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab2c"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "Y253H",
  "alteration_name": "Y253H",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab2d"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F359V",
  "alteration_name": "F359V",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab2e"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F359C",
  "alteration_name": "F359C",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab2f"
  },
  "level": "LEVEL_2",
  "gene": "PALB2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Pancreatic Cancer",
  "cancer_sub_type": "Pancreatic Adenocarcinoma",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33970687",
      "title": "Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2021 Aug 1",
      "volume": "39",
      "issue": "22",
      "pages": "2497-2505",
      "authors": "Reiss KA et al",
      "elocationId": "doi: 10.1200/JCO.21.00003",
      "link": null,
      "reference": "Reiss KA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 1;39(22)2497-2505.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.4_suppl.734",
      "reference": "null. null. .",
      "abstract": "Brown et al. Abstract# 734, ASCO 2023"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab30"
  },
  "level": "LEVEL_2",
  "gene": "PALB2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Pancreatic Cancer",
  "cancer_sub_type": "Acinar Cell Carcinoma of the Pancreas",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33970687",
      "title": "Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2021 Aug 1",
      "volume": "39",
      "issue": "22",
      "pages": "2497-2505",
      "authors": "Reiss KA et al",
      "elocationId": "doi: 10.1200/JCO.21.00003",
      "link": null,
      "reference": "Reiss KA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 1;39(22)2497-2505.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.4_suppl.734",
      "reference": "null. null. .",
      "abstract": "Brown et al. Abstract# 734, ASCO 2023"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab31"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Glioma",
  "cancer_sub_type": "Encapsulated Glioma",
  "drug": [
    "Cobimetinib",
    "Vemurafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27398937",
      "title": "Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2016 Nov",
      "volume": "63",
      "issue": "11",
      "pages": "2038-41",
      "authors": "Lassaletta A et al",
      "elocationId": "doi: 10.1002/pbc.26086",
      "link": null,
      "reference": "Lassaletta A et al. Pediatric blood & cancer. 2016 Nov;63(11)2038-41.",
      "abstract": null
    },
    {
      "pmid": "29380516",
      "title": "Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2018 May",
      "volume": "65",
      "issue": "5",
      "pages": "e26969",
      "authors": "Marks AM et al",
      "elocationId": "doi: 10.1002/pbc.26969",
      "link": null,
      "reference": "Marks AM et al. Pediatric blood & cancer. 2018 May;65(5)e26969.",
      "abstract": null
    },
    {
      "pmid": "29039591",
      "title": "Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.",
      "journal": "Oncology reports",
      "pubDate": "2017 Dec",
      "volume": "38",
      "issue": "6",
      "pages": "3291-3296",
      "authors": "Burger MC et al",
      "elocationId": "doi: 10.3892/or.2017.6013",
      "link": null,
      "reference": "Burger MC et al. Oncology reports. 2017 Dec;38(6)3291-3296.",
      "abstract": null
    },
    {
      "pmid": "28984141",
      "title": "Dabrafenib and trametinib in BRAFV600E mutated glioma.",
      "journal": "CNS oncology",
      "pubDate": "2017 Oct",
      "volume": "6",
      "issue": "4",
      "pages": "291-296",
      "authors": "Brown NF et al",
      "elocationId": "doi: 10.2217/cns-2017-0006",
      "link": null,
      "reference": "Brown NF et al. CNS oncology. 2017 Oct;6(4)291-296.",
      "abstract": null
    },
    {
      "pmid": "25524464",
      "title": "Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent.",
      "journal": "Journal of translational medicine",
      "pubDate": "2014 Dec 19",
      "volume": "12",
      "issue": "",
      "pages": "356",
      "authors": "del Bufalo F et al",
      "elocationId": "doi: 10.1186/s12967-014-0356-1",
      "link": null,
      "reference": "del Bufalo F et al. Journal of translational medicine. 2014 Dec 19;12()356.",
      "abstract": null
    },
    {
      "pmid": "26579623",
      "title": "Successful Retreatment of a Child with a Refractory Brainstem Ganglioglioma with Vemurafenib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2016 Mar",
      "volume": "63",
      "issue": "3",
      "pages": "541-3",
      "authors": "Aguilera D et al",
      "elocationId": "doi: 10.1002/pbc.25787",
      "link": null,
      "reference": "Aguilera D et al. Pediatric blood & cancer. 2016 Mar;63(3)541-3.",
      "abstract": null
    },
    {
      "pmid": "26287849",
      "title": "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Aug 20",
      "volume": "373",
      "issue": "8",
      "pages": "726-36",
      "authors": "Hyman DM et al",
      "elocationId": "doi: 10.1056/NEJMoa1502309",
      "link": null,
      "reference": "Hyman DM et al. The New England journal of medicine. 2015 Aug 20;373(8)726-36.",
      "abstract": null
    },
    {
      "pmid": "25092772",
      "title": "Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2016 Apr 1",
      "volume": "34",
      "issue": "10",
      "pages": "e87-9",
      "authors": "Lee EQ et al",
      "elocationId": "doi: 10.1200/JCO.2013.51.1766",
      "link": null,
      "reference": "Lee EQ et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Apr 1;34(10)e87-9.",
      "abstract": null
    },
    {
      "pmid": "31502039",
      "title": "Efficacy of Dabrafenib for three children with brainstem BRAF<sup>V600E</sup> positive ganglioglioma.",
      "journal": "Journal of neuro-oncology",
      "pubDate": "2019 Oct",
      "volume": "145",
      "issue": "1",
      "pages": "135-141",
      "authors": "Philippe L et al",
      "elocationId": "doi: 10.1007/s11060-019-03280-2",
      "link": null,
      "reference": "Philippe L et al. Journal of neuro-oncology. 2019 Oct;145(1)135-141.",
      "abstract": null
    },
    {
      "pmid": "30351999",
      "title": "BRAF Inhibition in <i>BRAF</i><sup>V600</sup>-Mutant Gliomas: Results From the VE-BASKET Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Dec 10",
      "volume": "36",
      "issue": "35",
      "pages": "3477-3484",
      "authors": "Kaley T et al",
      "elocationId": "doi: 10.1200/JCO.2018.78.9990",
      "link": null,
      "reference": "Kaley T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Dec 10;36(35)3477-3484.",
      "abstract": null
    },
    {
      "pmid": "31985841",
      "title": "Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma.",
      "journal": "Journal of clinical pharmacy and therapeutics",
      "pubDate": "2020 Oct",
      "volume": "45",
      "issue": "5",
      "pages": "1172-1174",
      "authors": "Yau WH et al",
      "elocationId": "doi: 10.1111/jcpt.13112",
      "link": null,
      "reference": "Yau WH et al. Journal of clinical pharmacy and therapeutics. 2020 Oct;45(5)1172-1174.",
      "abstract": null
    },
    {
      "pmid": "24821190",
      "title": "Pilomyxoid astrocytoma treated successfully with vemurafenib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2014 Nov",
      "volume": "61",
      "issue": "11",
      "pages": "2099-100",
      "authors": "Skrypek M et al",
      "elocationId": "doi: 10.1002/pbc.25084",
      "link": null,
      "reference": "Skrypek M et al. Pediatric blood & cancer. 2014 Nov;61(11)2099-100.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab32"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "V600 {excluding V600E ; V600K}",
  "alteration_name": "V600 (excluding V600E and V600K)",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Cobimetinib",
    "Vemurafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27480103",
      "title": "Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2016 Sep",
      "volume": "17",
      "issue": "9",
      "pages": "1248-60",
      "authors": "Ascierto PA et al",
      "elocationId": "doi: 10.1016/S1470-2045(16)30122-X",
      "link": null,
      "reference": "Ascierto PA et al. The Lancet. Oncology. 2016 Sep;17(9)1248-60.",
      "abstract": null
    },
    {
      "pmid": "25265494",
      "title": "Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2014 Nov 13",
      "volume": "371",
      "issue": "20",
      "pages": "1867-76",
      "authors": "Larkin J et al",
      "elocationId": "doi: 10.1056/NEJMoa1408868",
      "link": null,
      "reference": "Larkin J et al. The New England journal of medicine. 2014 Nov 13;371(20)1867-76.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab33"
  },
  "level": "LEVEL_2",
  "gene": "MAP2K2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab34"
  },
  "level": "LEVEL_2",
  "gene": "MAP2K2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab35"
  },
  "level": "LEVEL_2",
  "gene": "ARAF",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32991018",
      "title": "Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2020 Dec",
      "volume": "67",
      "issue": "12",
      "pages": "e28712",
      "authors": "Messinger YH et al",
      "elocationId": "doi: 10.1002/pbc.28712",
      "link": null,
      "reference": "Messinger YH et al. Pediatric blood & cancer. 2020 Dec;67(12)e28712.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab36"
  },
  "level": "LEVEL_2",
  "gene": "ARAF",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32991018",
      "title": "Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2020 Dec",
      "volume": "67",
      "issue": "12",
      "pages": "e28712",
      "authors": "Messinger YH et al",
      "elocationId": "doi: 10.1002/pbc.28712",
      "link": null,
      "reference": "Messinger YH et al. Pediatric blood & cancer. 2020 Dec;67(12)e28712.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab37"
  },
  "level": "LEVEL_2",
  "gene": "RAF1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Rosai-Dorfman Disease",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab38"
  },
  "level": "LEVEL_2",
  "gene": "RAF1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Rosai-Dorfman Disease",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab39"
  },
  "level": "LEVEL_2",
  "gene": "NRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab3a"
  },
  "level": "LEVEL_2",
  "gene": "NRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab3b"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "Oncogenic Mutations {excluding V600}",
  "alteration_name": "Oncogenic Mutations (excluding V600)",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Rosai-Dorfman Disease",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab3c"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "Oncogenic Mutations {excluding V600}",
  "alteration_name": "Oncogenic Mutations (excluding V600)",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Rosai-Dorfman Disease",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab3d"
  },
  "level": "LEVEL_2",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Lapatinib",
    "Trastuzumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27108243",
      "title": "Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2016 Jun",
      "volume": "17",
      "issue": "6",
      "pages": "738-746",
      "authors": "Sartore-Bianchi A et al",
      "elocationId": "doi: 10.1016/S1470-2045(16)00150-9",
      "link": null,
      "reference": "Sartore-Bianchi A et al. The Lancet. Oncology. 2016 Jun;17(6)738-746.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab3e"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Glioma",
  "cancer_sub_type": "Pleomorphic Xanthoastrocytoma",
  "drug": [
    "Cobimetinib",
    "Vemurafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30120137",
      "title": "Vemurafenib and cobimetinib overcome resistance to vemurafenib in <i>BRAF</i>-mutant ganglioglioma.",
      "journal": "Neurology",
      "pubDate": "2018 Sep 11",
      "volume": "91",
      "issue": "11",
      "pages": "523-525",
      "authors": "Touat M et al",
      "elocationId": "doi: 10.1212/WNL.0000000000006171",
      "link": null,
      "reference": "Touat M et al. Neurology. 2018 Sep 11;91(11)523-525.",
      "abstract": null
    },
    {
      "pmid": "29380516",
      "title": "Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2018 May",
      "volume": "65",
      "issue": "5",
      "pages": "e26969",
      "authors": "Marks AM et al",
      "elocationId": "doi: 10.1002/pbc.26969",
      "link": null,
      "reference": "Marks AM et al. Pediatric blood & cancer. 2018 May;65(5)e26969.",
      "abstract": null
    },
    {
      "pmid": "28984141",
      "title": "Dabrafenib and trametinib in BRAFV600E mutated glioma.",
      "journal": "CNS oncology",
      "pubDate": "2017 Oct",
      "volume": "6",
      "issue": "4",
      "pages": "291-296",
      "authors": "Brown NF et al",
      "elocationId": "doi: 10.2217/cns-2017-0006",
      "link": null,
      "reference": "Brown NF et al. CNS oncology. 2017 Oct;6(4)291-296.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab3f"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Glioma",
  "cancer_sub_type": "Pilocytic Astrocytoma",
  "drug": [
    "Cobimetinib",
    "Vemurafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30120137",
      "title": "Vemurafenib and cobimetinib overcome resistance to vemurafenib in <i>BRAF</i>-mutant ganglioglioma.",
      "journal": "Neurology",
      "pubDate": "2018 Sep 11",
      "volume": "91",
      "issue": "11",
      "pages": "523-525",
      "authors": "Touat M et al",
      "elocationId": "doi: 10.1212/WNL.0000000000006171",
      "link": null,
      "reference": "Touat M et al. Neurology. 2018 Sep 11;91(11)523-525.",
      "abstract": null
    },
    {
      "pmid": "29380516",
      "title": "Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2018 May",
      "volume": "65",
      "issue": "5",
      "pages": "e26969",
      "authors": "Marks AM et al",
      "elocationId": "doi: 10.1002/pbc.26969",
      "link": null,
      "reference": "Marks AM et al. Pediatric blood & cancer. 2018 May;65(5)e26969.",
      "abstract": null
    },
    {
      "pmid": "28984141",
      "title": "Dabrafenib and trametinib in BRAFV600E mutated glioma.",
      "journal": "CNS oncology",
      "pubDate": "2017 Oct",
      "volume": "6",
      "issue": "4",
      "pages": "291-296",
      "authors": "Brown NF et al",
      "elocationId": "doi: 10.2217/cns-2017-0006",
      "link": null,
      "reference": "Brown NF et al. CNS oncology. 2017 Oct;6(4)291-296.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab40"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Glioma",
  "cancer_sub_type": "Ganglioglioma",
  "drug": [
    "Cobimetinib",
    "Vemurafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30120137",
      "title": "Vemurafenib and cobimetinib overcome resistance to vemurafenib in <i>BRAF</i>-mutant ganglioglioma.",
      "journal": "Neurology",
      "pubDate": "2018 Sep 11",
      "volume": "91",
      "issue": "11",
      "pages": "523-525",
      "authors": "Touat M et al",
      "elocationId": "doi: 10.1212/WNL.0000000000006171",
      "link": null,
      "reference": "Touat M et al. Neurology. 2018 Sep 11;91(11)523-525.",
      "abstract": null
    },
    {
      "pmid": "29380516",
      "title": "Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2018 May",
      "volume": "65",
      "issue": "5",
      "pages": "e26969",
      "authors": "Marks AM et al",
      "elocationId": "doi: 10.1002/pbc.26969",
      "link": null,
      "reference": "Marks AM et al. Pediatric blood & cancer. 2018 May;65(5)e26969.",
      "abstract": null
    },
    {
      "pmid": "28984141",
      "title": "Dabrafenib and trametinib in BRAFV600E mutated glioma.",
      "journal": "CNS oncology",
      "pubDate": "2017 Oct",
      "volume": "6",
      "issue": "4",
      "pages": "291-296",
      "authors": "Brown NF et al",
      "elocationId": "doi: 10.2217/cns-2017-0006",
      "link": null,
      "reference": "Brown NF et al. CNS oncology. 2017 Oct;6(4)291-296.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab41"
  },
  "level": "LEVEL_2",
  "gene": "KRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Rosai-Dorfman Disease",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab42"
  },
  "level": "LEVEL_2",
  "gene": "KRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Rosai-Dorfman Disease",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab43"
  },
  "level": "LEVEL_2",
  "gene": "NRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32991018",
      "title": "Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2020 Dec",
      "volume": "67",
      "issue": "12",
      "pages": "e28712",
      "authors": "Messinger YH et al",
      "elocationId": "doi: 10.1002/pbc.28712",
      "link": null,
      "reference": "Messinger YH et al. Pediatric blood & cancer. 2020 Dec;67(12)e28712.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab44"
  },
  "level": "LEVEL_2",
  "gene": "NRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32991018",
      "title": "Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2020 Dec",
      "volume": "67",
      "issue": "12",
      "pages": "e28712",
      "authors": "Messinger YH et al",
      "elocationId": "doi: 10.1002/pbc.28712",
      "link": null,
      "reference": "Messinger YH et al. Pediatric blood & cancer. 2020 Dec;67(12)e28712.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab45"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F359I",
  "alteration_name": "F359I",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    },
    {
      "pmid": "19779040",
      "title": "Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.",
      "journal": "Blood",
      "pubDate": "2009 Dec 3",
      "volume": "114",
      "issue": "24",
      "pages": "4944-53",
      "authors": "Müller MC et al",
      "elocationId": "doi: 10.1182/blood-2009-04-214221",
      "link": null,
      "reference": "Müller MC et al. Blood. 2009 Dec 3;114(24)4944-53.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab46"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "E255K",
  "alteration_name": "E255K",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    },
    {
      "pmid": "19779040",
      "title": "Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.",
      "journal": "Blood",
      "pubDate": "2009 Dec 3",
      "volume": "114",
      "issue": "24",
      "pages": "4944-53",
      "authors": "Müller MC et al",
      "elocationId": "doi: 10.1182/blood-2009-04-214221",
      "link": null,
      "reference": "Müller MC et al. Blood. 2009 Dec 3;114(24)4944-53.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab47"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "E255V",
  "alteration_name": "E255V",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    },
    {
      "pmid": "19779040",
      "title": "Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.",
      "journal": "Blood",
      "pubDate": "2009 Dec 3",
      "volume": "114",
      "issue": "24",
      "pages": "4944-53",
      "authors": "Müller MC et al",
      "elocationId": "doi: 10.1182/blood-2009-04-214221",
      "link": null,
      "reference": "Müller MC et al. Blood. 2009 Dec 3;114(24)4944-53.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab48"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "Y253H",
  "alteration_name": "Y253H",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    },
    {
      "pmid": "19779040",
      "title": "Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.",
      "journal": "Blood",
      "pubDate": "2009 Dec 3",
      "volume": "114",
      "issue": "24",
      "pages": "4944-53",
      "authors": "Müller MC et al",
      "elocationId": "doi: 10.1182/blood-2009-04-214221",
      "link": null,
      "reference": "Müller MC et al. Blood. 2009 Dec 3;114(24)4944-53.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab49"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F359V",
  "alteration_name": "F359V",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    },
    {
      "pmid": "19779040",
      "title": "Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.",
      "journal": "Blood",
      "pubDate": "2009 Dec 3",
      "volume": "114",
      "issue": "24",
      "pages": "4944-53",
      "authors": "Müller MC et al",
      "elocationId": "doi: 10.1182/blood-2009-04-214221",
      "link": null,
      "reference": "Müller MC et al. Blood. 2009 Dec 3;114(24)4944-53.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab4a"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F359C",
  "alteration_name": "F359C",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    },
    {
      "pmid": "19779040",
      "title": "Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.",
      "journal": "Blood",
      "pubDate": "2009 Dec 3",
      "volume": "114",
      "issue": "24",
      "pages": "4944-53",
      "authors": "Müller MC et al",
      "elocationId": "doi: 10.1182/blood-2009-04-214221",
      "link": null,
      "reference": "Müller MC et al. Blood. 2009 Dec 3;114(24)4944-53.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab4b"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F317I",
  "alteration_name": "F317I",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab4c"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F317C",
  "alteration_name": "F317C",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab4d"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "T315A",
  "alteration_name": "T315A",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab4e"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F317V",
  "alteration_name": "F317V",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab4f"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "V299L",
  "alteration_name": "V299L",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab50"
  },
  "level": "LEVEL_2",
  "gene": "ABL1",
  "alteration": "F317L",
  "alteration_name": "F317L",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "15930265",
      "title": "In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.",
      "journal": "Cancer research",
      "pubDate": "2005 Jun 1",
      "volume": "65",
      "issue": "11",
      "pages": "4500-5",
      "authors": "O'Hare T et al",
      "elocationId": "",
      "link": null,
      "reference": "O'Hare T et al. Cancer research. 2005 Jun 1;65(11)4500-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab51"
  },
  "level": "LEVEL_2",
  "gene": "IDH1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Bone Cancer",
  "cancer_sub_type": "Chondrosarcoma",
  "drug": [
    "Ivosidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32208957",
      "title": "Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2020 May 20",
      "volume": "38",
      "issue": "15",
      "pages": "1693-1701",
      "authors": "Tap WD et al",
      "elocationId": "doi: 10.1200/JCO.19.02492",
      "link": null,
      "reference": "Tap WD et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 May 20;38(15)1693-1701.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab52"
  },
  "level": "LEVEL_2",
  "gene": "PDGFRA",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22718859",
      "title": "Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Aug 15",
      "volume": "18",
      "issue": "16",
      "pages": "4458-64",
      "authors": "Cassier PA et al",
      "elocationId": "",
      "link": null,
      "reference": "Cassier PA et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Aug 15;18(16)4458-64.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab53"
  },
  "level": "LEVEL_2",
  "gene": "ROS1",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Lorlatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31669155",
      "title": "Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 Dec",
      "volume": "20",
      "issue": "12",
      "pages": "1691-1701",
      "authors": "Shaw AT et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30655-2",
      "link": null,
      "reference": "Shaw AT et al. The Lancet. Oncology. 2019 Dec;20(12)1691-1701.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab54"
  },
  "level": "LEVEL_2",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Pancreatic Cancer",
  "cancer_sub_type": "Pancreatic Adenocarcinoma",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33970687",
      "title": "Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2021 Aug 1",
      "volume": "39",
      "issue": "22",
      "pages": "2497-2505",
      "authors": "Reiss KA et al",
      "elocationId": "doi: 10.1200/JCO.21.00003",
      "link": null,
      "reference": "Reiss KA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 1;39(22)2497-2505.",
      "abstract": null
    },
    {
      "pmid": "30051098",
      "title": "Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation.",
      "journal": "JCO precision oncology",
      "pubDate": "2018",
      "volume": "2018",
      "issue": "",
      "pages": "",
      "authors": "Shroff RT et al",
      "elocationId": "doi: 10.1200/PO.17.00316",
      "link": null,
      "reference": "Shroff RT et al. JCO precision oncology. 2018;2018().",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://cancerres.aacrjournals.org/content/79/13_Supplement/CT234",
      "reference": "null. null. .",
      "abstract": "Reiss Binder et al. Abstract# CT234, AACR 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.4_suppl.734",
      "reference": "null. null. .",
      "abstract": "Brown et al. Abstract# 734, ASCO 2023"
    },
    {
      "pmid": "34351646",
      "title": "Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.",
      "journal": "Cancer",
      "pubDate": "2021 Dec 1",
      "volume": "127",
      "issue": "23",
      "pages": "4393-4402",
      "authors": "Momtaz P et al",
      "elocationId": "doi: 10.1002/cncr.33812",
      "link": null,
      "reference": "Momtaz P et al. Cancer. 2021 Dec 1;127(23)4393-4402.",
      "abstract": null
    },
    {
      "pmid": "17444865",
      "title": "Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.",
      "journal": "Journal of gastroenterology and hepatology",
      "pubDate": "2007 May",
      "volume": "22",
      "issue": "5",
      "pages": "738-48",
      "authors": "Jacob DA et al",
      "elocationId": "",
      "link": null,
      "reference": "Jacob DA et al. Journal of gastroenterology and hepatology. 2007 May;22(5)738-48.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab55"
  },
  "level": "LEVEL_2",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Pancreatic Cancer",
  "cancer_sub_type": "Acinar Cell Carcinoma of the Pancreas",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33970687",
      "title": "Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2021 Aug 1",
      "volume": "39",
      "issue": "22",
      "pages": "2497-2505",
      "authors": "Reiss KA et al",
      "elocationId": "doi: 10.1200/JCO.21.00003",
      "link": null,
      "reference": "Reiss KA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Aug 1;39(22)2497-2505.",
      "abstract": null
    },
    {
      "pmid": "30051098",
      "title": "Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation.",
      "journal": "JCO precision oncology",
      "pubDate": "2018",
      "volume": "2018",
      "issue": "",
      "pages": "",
      "authors": "Shroff RT et al",
      "elocationId": "doi: 10.1200/PO.17.00316",
      "link": null,
      "reference": "Shroff RT et al. JCO precision oncology. 2018;2018().",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://cancerres.aacrjournals.org/content/79/13_Supplement/CT234",
      "reference": "null. null. .",
      "abstract": "Reiss Binder et al. Abstract# CT234, AACR 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.4_suppl.734",
      "reference": "null. null. .",
      "abstract": "Brown et al. Abstract# 734, ASCO 2023"
    },
    {
      "pmid": "34351646",
      "title": "Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.",
      "journal": "Cancer",
      "pubDate": "2021 Dec 1",
      "volume": "127",
      "issue": "23",
      "pages": "4393-4402",
      "authors": "Momtaz P et al",
      "elocationId": "doi: 10.1002/cncr.33812",
      "link": null,
      "reference": "Momtaz P et al. Cancer. 2021 Dec 1;127(23)4393-4402.",
      "abstract": null
    },
    {
      "pmid": "17444865",
      "title": "Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.",
      "journal": "Journal of gastroenterology and hepatology",
      "pubDate": "2007 May",
      "volume": "22",
      "issue": "5",
      "pages": "738-48",
      "authors": "Jacob DA et al",
      "elocationId": "",
      "link": null,
      "reference": "Jacob DA et al. Journal of gastroenterology and hepatology. 2007 May;22(5)738-48.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab56"
  },
  "level": "LEVEL_2",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Endometrial Cancer",
  "cancer_sub_type": "Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma",
  "drug": [
    "Carboplatin-Taxol Regimen",
    "Trastuzumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29584549",
      "title": "Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Jul 10",
      "volume": "36",
      "issue": "20",
      "pages": "2044-2051",
      "authors": "Fader AN et al",
      "elocationId": "doi: 10.1200/JCO.2017.76.5966",
      "link": null,
      "reference": "Fader AN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Jul 10;36(20)2044-2051.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab57"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "Oncogenic Mutations {excluding V600}",
  "alteration_name": "Oncogenic Mutations (excluding V600)",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32991018",
      "title": "Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2020 Dec",
      "volume": "67",
      "issue": "12",
      "pages": "e28712",
      "authors": "Messinger YH et al",
      "elocationId": "doi: 10.1002/pbc.28712",
      "link": null,
      "reference": "Messinger YH et al. Pediatric blood & cancer. 2020 Dec;67(12)e28712.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab58"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "Oncogenic Mutations {excluding V600}",
  "alteration_name": "Oncogenic Mutations (excluding V600)",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32991018",
      "title": "Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2020 Dec",
      "volume": "67",
      "issue": "12",
      "pages": "e28712",
      "authors": "Messinger YH et al",
      "elocationId": "doi: 10.1002/pbc.28712",
      "link": null,
      "reference": "Messinger YH et al. Pediatric blood & cancer. 2020 Dec;67(12)e28712.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab59"
  },
  "level": "LEVEL_2",
  "gene": "PDGFRA",
  "alteration": "D842V",
  "alteration_name": "D842V",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://meetinglibrary.asco.org/content/79120-102",
      "reference": "null. null. .",
      "abstract": "Trent et al. Abstract# 10006, ASCO 2011"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab5a"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Glioma",
  "cancer_sub_type": "Pilocytic Astrocytoma",
  "drug": [
    "Selumetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31151904",
      "title": "Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 Jul",
      "volume": "20",
      "issue": "7",
      "pages": "1011-1022",
      "authors": "Fangusaro J et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30277-3",
      "link": null,
      "reference": "Fangusaro J et al. The Lancet. Oncology. 2019 Jul;20(7)1011-1022.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab5b"
  },
  "level": "LEVEL_2",
  "gene": "ALK",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Soft Tissue Sarcoma",
  "cancer_sub_type": "Inflammatory Myofibroblastic Tumor",
  "drug": [
    "Lorlatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32868646",
      "title": "Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib.",
      "journal": "Anti-cancer drugs",
      "pubDate": "2020 Nov",
      "volume": "31",
      "issue": "10",
      "pages": "1106-1110",
      "authors": "Wong HH et al",
      "elocationId": "doi: 10.1097/CAD.0000000000000994",
      "link": null,
      "reference": "Wong HH et al. Anti-cancer drugs. 2020 Nov;31(10)1106-1110.",
      "abstract": null
    },
    {
      "pmid": "33007314",
      "title": "Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.",
      "journal": "Urology",
      "pubDate": "2020 Dec",
      "volume": "146",
      "issue": "",
      "pages": "32-35",
      "authors": "Reinhart S et al",
      "elocationId": "doi: 10.1016/j.urology.2020.09.026",
      "link": null,
      "reference": "Reinhart S et al. Urology. 2020 Dec;146()32-35.",
      "abstract": null
    },
    {
      "pmid": "28713152",
      "title": "Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report.",
      "journal": "The American journal of case reports",
      "pubDate": "2017 Jul 17",
      "volume": "18",
      "issue": "",
      "pages": "799-804",
      "authors": "Yuan C et al",
      "elocationId": "",
      "link": null,
      "reference": "Yuan C et al. The American journal of case reports. 2017 Jul 17;18()799-804.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab5c"
  },
  "level": "LEVEL_2",
  "gene": "RAF1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32991018",
      "title": "Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2020 Dec",
      "volume": "67",
      "issue": "12",
      "pages": "e28712",
      "authors": "Messinger YH et al",
      "elocationId": "doi: 10.1002/pbc.28712",
      "link": null,
      "reference": "Messinger YH et al. Pediatric blood & cancer. 2020 Dec;67(12)e28712.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab5d"
  },
  "level": "LEVEL_2",
  "gene": "RAF1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32991018",
      "title": "Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2020 Dec",
      "volume": "67",
      "issue": "12",
      "pages": "e28712",
      "authors": "Messinger YH et al",
      "elocationId": "doi: 10.1002/pbc.28712",
      "link": null,
      "reference": "Messinger YH et al. Pediatric blood & cancer. 2020 Dec;67(12)e28712.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab5e"
  },
  "level": "LEVEL_2",
  "gene": "MET",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "25971939",
      "title": "Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.",
      "journal": "Cancer discovery",
      "pubDate": "2015 Aug",
      "volume": "5",
      "issue": "8",
      "pages": "842-9",
      "authors": "Paik PK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-14-1467",
      "link": null,
      "reference": "Paik PK et al. Cancer discovery. 2015 Aug;5(8)842-9.",
      "abstract": null
    },
    {
      "pmid": "21623265",
      "title": "Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2011 May",
      "volume": "6",
      "issue": "5",
      "pages": "942-6",
      "authors": "Ou SH et al",
      "elocationId": "doi: 10.1097/JTO.0b013e31821528d3",
      "link": null,
      "reference": "Ou SH et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 May;6(5)942-6.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://meetinglibrary.asco.org/content/132030-144",
      "reference": "null. null. .",
      "abstract": "Camidge et al. Abstract# 8001, ASCO 2014"
    },
    {
      "pmid": "33676017",
      "title": "Crizotinib in Patients With MET-Amplified NSCLC.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2021 Jun",
      "volume": "16",
      "issue": "6",
      "pages": "1017-1029",
      "authors": "Camidge DR et al",
      "elocationId": "doi: 10.1016/j.jtho.2021.02.010",
      "link": null,
      "reference": "Camidge DR et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2021 Jun;16(6)1017-1029.",
      "abstract": null
    },
    {
      "pmid": "26729443",
      "title": "MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2016 Mar 1",
      "volume": "34",
      "issue": "7",
      "pages": "721-30",
      "authors": "Awad MM et al",
      "elocationId": "doi: 10.1200/JCO.2015.63.4600",
      "link": null,
      "reference": "Awad MM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Mar 1;34(7)721-30.",
      "abstract": null
    },
    {
      "pmid": "31416808",
      "title": "Crizotinib in <i>MET</i>-Deregulated or <i>ROS1</i>-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Dec 15",
      "volume": "25",
      "issue": "24",
      "pages": "7312-7319",
      "authors": "Landi L et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-19-0994",
      "link": null,
      "reference": "Landi L et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Dec 15;25(24)7312-7319.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab5f"
  },
  "level": "LEVEL_2",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Uterine Sarcoma",
  "cancer_sub_type": "",
  "drug": [
    "Niraparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32299819",
      "title": "Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2020 Jul 15",
      "volume": "26",
      "issue": "14",
      "pages": "3881-3888",
      "authors": "Hensley ML et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-19-3959",
      "link": null,
      "reference": "Hensley ML et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Jul 15;26(14)3881-3888.",
      "abstract": null
    },
    {
      "pmid": "33970096",
      "title": "Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report.",
      "journal": "The Permanente journal",
      "pubDate": "2021 May",
      "volume": "25",
      "issue": "",
      "pages": "",
      "authors": "Pan M et al",
      "elocationId": "doi: 10.7812/TPP/20.251",
      "link": null,
      "reference": "Pan M et al. The Permanente journal. 2021 May;25().",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab60"
  },
  "level": "LEVEL_2",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Uterine Sarcoma",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32299819",
      "title": "Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2020 Jul 15",
      "volume": "26",
      "issue": "14",
      "pages": "3881-3888",
      "authors": "Hensley ML et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-19-3959",
      "link": null,
      "reference": "Hensley ML et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Jul 15;26(14)3881-3888.",
      "abstract": null
    },
    {
      "pmid": "33970096",
      "title": "Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report.",
      "journal": "The Permanente journal",
      "pubDate": "2021 May",
      "volume": "25",
      "issue": "",
      "pages": "",
      "authors": "Pan M et al",
      "elocationId": "doi: 10.7812/TPP/20.251",
      "link": null,
      "reference": "Pan M et al. The Permanente journal. 2021 May;25().",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab61"
  },
  "level": "LEVEL_2",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Uterine Sarcoma",
  "cancer_sub_type": "",
  "drug": [
    "Rucaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32299819",
      "title": "Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2020 Jul 15",
      "volume": "26",
      "issue": "14",
      "pages": "3881-3888",
      "authors": "Hensley ML et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-19-3959",
      "link": null,
      "reference": "Hensley ML et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Jul 15;26(14)3881-3888.",
      "abstract": null
    },
    {
      "pmid": "33970096",
      "title": "Rapid Response of a BRCA2/TP53/PTEN-Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report.",
      "journal": "The Permanente journal",
      "pubDate": "2021 May",
      "volume": "25",
      "issue": "",
      "pages": "",
      "authors": "Pan M et al",
      "elocationId": "doi: 10.7812/TPP/20.251",
      "link": null,
      "reference": "Pan M et al. The Permanente journal. 2021 May;25().",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab62"
  },
  "level": "LEVEL_2",
  "gene": "RET",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Cabozantinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23533264",
      "title": "Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.",
      "journal": "Cancer discovery",
      "pubDate": "2013 Jun",
      "volume": "3",
      "issue": "6",
      "pages": "630-5",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-13-0035",
      "link": null,
      "reference": "Drilon A et al. Cancer discovery. 2013 Jun;3(6)630-5.",
      "abstract": null
    },
    {
      "pmid": "27825636",
      "title": "Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2016 Dec",
      "volume": "17",
      "issue": "12",
      "pages": "1653-1660",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1016/S1470-2045(16)30562-9",
      "link": null,
      "reference": "Drilon A et al. The Lancet. Oncology. 2016 Dec;17(12)1653-1660.",
      "abstract": null
    },
    {
      "pmid": "28447912",
      "title": "Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 May 1",
      "volume": "35",
      "issue": "13",
      "pages": "1403-1410",
      "authors": "Gautschi O et al",
      "elocationId": "doi: 10.1200/JCO.2016.70.9352",
      "link": null,
      "reference": "Gautschi O et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 May 1;35(13)1403-1410.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab63"
  },
  "level": "LEVEL_2",
  "gene": "ERBB2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Trastuzumab Deruxtecan"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.4000",
      "reference": "null. null. .",
      "abstract": "Siena et al. Abstract# 4000, ASCO 2020"
    },
    {
      "pmid": "33961795",
      "title": "Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2021 Jun",
      "volume": "22",
      "issue": "6",
      "pages": "779-789",
      "authors": "Siena S et al",
      "elocationId": "doi: 10.1016/S1470-2045(21)00086-3",
      "link": null,
      "reference": "Siena S et al. The Lancet. Oncology. 2021 Jun;22(6)779-789.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab64"
  },
  "level": "LEVEL_2",
  "gene": "MET",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Tepotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.9021",
      "reference": "null. null. .",
      "abstract": "Le et al. Abstract# 9021, ASCO 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab65"
  },
  "level": "LEVEL_2",
  "gene": "KRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32991018",
      "title": "Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2020 Dec",
      "volume": "67",
      "issue": "12",
      "pages": "e28712",
      "authors": "Messinger YH et al",
      "elocationId": "doi: 10.1002/pbc.28712",
      "link": null,
      "reference": "Messinger YH et al. Pediatric blood & cancer. 2020 Dec;67(12)e28712.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab66"
  },
  "level": "LEVEL_2",
  "gene": "KRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32991018",
      "title": "Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2020 Dec",
      "volume": "67",
      "issue": "12",
      "pages": "e28712",
      "authors": "Messinger YH et al",
      "elocationId": "doi: 10.1002/pbc.28712",
      "link": null,
      "reference": "Messinger YH et al. Pediatric blood & cancer. 2020 Dec;67(12)e28712.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab67"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "D816",
  "alteration_name": "D816",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Sorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://meetinglibrary.asco.org/content/80567-102",
      "reference": "null. null. .",
      "abstract": "Kindler et al. Abstract# 10009, ASCO 2011"
    },
    {
      "pmid": "23140824",
      "title": "Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.",
      "journal": "European journal of cancer (Oxford, England : 1990)",
      "pubDate": "2013 Mar",
      "volume": "49",
      "issue": "5",
      "pages": "1027-31",
      "authors": "Montemurro M et al",
      "elocationId": "doi: 10.1016/j.ejca.2012.10.009",
      "link": null,
      "reference": "Montemurro M et al. European journal of cancer (Oxford, England : 1990). 2013 Mar;49(5)1027-31.",
      "abstract": null
    },
    {
      "pmid": "22270258",
      "title": "Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.",
      "journal": "Investigational new drugs",
      "pubDate": "2012 Dec",
      "volume": "30",
      "issue": "6",
      "pages": "2377-83",
      "authors": "Park SH et al",
      "elocationId": "doi: 10.1007/s10637-012-9795-9",
      "link": null,
      "reference": "Park SH et al. Investigational new drugs. 2012 Dec;30(6)2377-83.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab68"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "D820",
  "alteration_name": "D820",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Sorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://meetinglibrary.asco.org/content/80567-102",
      "reference": "null. null. .",
      "abstract": "Kindler et al. Abstract# 10009, ASCO 2011"
    },
    {
      "pmid": "23140824",
      "title": "Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.",
      "journal": "European journal of cancer (Oxford, England : 1990)",
      "pubDate": "2013 Mar",
      "volume": "49",
      "issue": "5",
      "pages": "1027-31",
      "authors": "Montemurro M et al",
      "elocationId": "doi: 10.1016/j.ejca.2012.10.009",
      "link": null,
      "reference": "Montemurro M et al. European journal of cancer (Oxford, England : 1990). 2013 Mar;49(5)1027-31.",
      "abstract": null
    },
    {
      "pmid": "22270258",
      "title": "Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.",
      "journal": "Investigational new drugs",
      "pubDate": "2012 Dec",
      "volume": "30",
      "issue": "6",
      "pages": "2377-83",
      "authors": "Park SH et al",
      "elocationId": "doi: 10.1007/s10637-012-9795-9",
      "link": null,
      "reference": "Park SH et al. Investigational new drugs. 2012 Dec;30(6)2377-83.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab69"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "N822",
  "alteration_name": "N822",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Sorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://meetinglibrary.asco.org/content/80567-102",
      "reference": "null. null. .",
      "abstract": "Kindler et al. Abstract# 10009, ASCO 2011"
    },
    {
      "pmid": "23140824",
      "title": "Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.",
      "journal": "European journal of cancer (Oxford, England : 1990)",
      "pubDate": "2013 Mar",
      "volume": "49",
      "issue": "5",
      "pages": "1027-31",
      "authors": "Montemurro M et al",
      "elocationId": "doi: 10.1016/j.ejca.2012.10.009",
      "link": null,
      "reference": "Montemurro M et al. European journal of cancer (Oxford, England : 1990). 2013 Mar;49(5)1027-31.",
      "abstract": null
    },
    {
      "pmid": "22270258",
      "title": "Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.",
      "journal": "Investigational new drugs",
      "pubDate": "2012 Dec",
      "volume": "30",
      "issue": "6",
      "pages": "2377-83",
      "authors": "Park SH et al",
      "elocationId": "doi: 10.1007/s10637-012-9795-9",
      "link": null,
      "reference": "Park SH et al. Investigational new drugs. 2012 Dec;30(6)2377-83.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab6a"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "Y823D",
  "alteration_name": "Y823D",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Sorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://meetinglibrary.asco.org/content/80567-102",
      "reference": "null. null. .",
      "abstract": "Kindler et al. Abstract# 10009, ASCO 2011"
    },
    {
      "pmid": "23140824",
      "title": "Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.",
      "journal": "European journal of cancer (Oxford, England : 1990)",
      "pubDate": "2013 Mar",
      "volume": "49",
      "issue": "5",
      "pages": "1027-31",
      "authors": "Montemurro M et al",
      "elocationId": "doi: 10.1016/j.ejca.2012.10.009",
      "link": null,
      "reference": "Montemurro M et al. European journal of cancer (Oxford, England : 1990). 2013 Mar;49(5)1027-31.",
      "abstract": null
    },
    {
      "pmid": "22270258",
      "title": "Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.",
      "journal": "Investigational new drugs",
      "pubDate": "2012 Dec",
      "volume": "30",
      "issue": "6",
      "pages": "2377-83",
      "authors": "Park SH et al",
      "elocationId": "doi: 10.1007/s10637-012-9795-9",
      "link": null,
      "reference": "Park SH et al. Investigational new drugs. 2012 Dec;30(6)2377-83.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab6b"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "C809G",
  "alteration_name": "C809G",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Sorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://meetinglibrary.asco.org/content/80567-102",
      "reference": "null. null. .",
      "abstract": "Kindler et al. Abstract# 10009, ASCO 2011"
    },
    {
      "pmid": "23140824",
      "title": "Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.",
      "journal": "European journal of cancer (Oxford, England : 1990)",
      "pubDate": "2013 Mar",
      "volume": "49",
      "issue": "5",
      "pages": "1027-31",
      "authors": "Montemurro M et al",
      "elocationId": "doi: 10.1016/j.ejca.2012.10.009",
      "link": null,
      "reference": "Montemurro M et al. European journal of cancer (Oxford, England : 1990). 2013 Mar;49(5)1027-31.",
      "abstract": null
    },
    {
      "pmid": "22270258",
      "title": "Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.",
      "journal": "Investigational new drugs",
      "pubDate": "2012 Dec",
      "volume": "30",
      "issue": "6",
      "pages": "2377-83",
      "authors": "Park SH et al",
      "elocationId": "doi: 10.1007/s10637-012-9795-9",
      "link": null,
      "reference": "Park SH et al. Investigational new drugs. 2012 Dec;30(6)2377-83.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab6c"
  },
  "level": "LEVEL_2",
  "gene": "KIT",
  "alteration": "A829P",
  "alteration_name": "A829P",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Sorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://meetinglibrary.asco.org/content/80567-102",
      "reference": "null. null. .",
      "abstract": "Kindler et al. Abstract# 10009, ASCO 2011"
    },
    {
      "pmid": "23140824",
      "title": "Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.",
      "journal": "European journal of cancer (Oxford, England : 1990)",
      "pubDate": "2013 Mar",
      "volume": "49",
      "issue": "5",
      "pages": "1027-31",
      "authors": "Montemurro M et al",
      "elocationId": "doi: 10.1016/j.ejca.2012.10.009",
      "link": null,
      "reference": "Montemurro M et al. European journal of cancer (Oxford, England : 1990). 2013 Mar;49(5)1027-31.",
      "abstract": null
    },
    {
      "pmid": "22270258",
      "title": "Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.",
      "journal": "Investigational new drugs",
      "pubDate": "2012 Dec",
      "volume": "30",
      "issue": "6",
      "pages": "2377-83",
      "authors": "Park SH et al",
      "elocationId": "doi: 10.1007/s10637-012-9795-9",
      "link": null,
      "reference": "Park SH et al. Investigational new drugs. 2012 Dec;30(6)2377-83.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab6d"
  },
  "level": "LEVEL_2",
  "gene": "RAF1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab6e"
  },
  "level": "LEVEL_2",
  "gene": "RAF1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Erdheim-Chester Disease",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab6f"
  },
  "level": "LEVEL_2",
  "gene": "MAP2K2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Rosai-Dorfman Disease",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab70"
  },
  "level": "LEVEL_2",
  "gene": "MAP2K2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Rosai-Dorfman Disease",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab71"
  },
  "level": "LEVEL_2",
  "gene": "ERBB2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Ado-Trastuzumab Emtansine"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31588020",
      "title": "Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.",
      "journal": "Cancer cell",
      "pubDate": "2019 Oct 14",
      "volume": "36",
      "issue": "4",
      "pages": "444-457.e7",
      "authors": "Robichaux JP et al",
      "elocationId": "doi: 10.1016/j.ccell.2019.09.001",
      "link": null,
      "reference": "Robichaux JP et al. Cancer cell. 2019 Oct 14;36(4)444-457.e7.",
      "abstract": null
    },
    {
      "pmid": "29989854",
      "title": "Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Aug 20",
      "volume": "36",
      "issue": "24",
      "pages": "2532-2537",
      "authors": "Li BT et al",
      "elocationId": "doi: 10.1200/JCO.2018.77.9777",
      "link": null,
      "reference": "Li BT et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Aug 20;36(24)2532-2537.",
      "abstract": null
    },
    {
      "pmid": "30206164",
      "title": "Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Jan 1",
      "volume": "25",
      "issue": "1",
      "pages": "64-72",
      "authors": "Peters S et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1590",
      "link": null,
      "reference": "Peters S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jan 1;25(1)64-72.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab72"
  },
  "level": "LEVEL_2",
  "gene": "MAP2K2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32991018",
      "title": "Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2020 Dec",
      "volume": "67",
      "issue": "12",
      "pages": "e28712",
      "authors": "Messinger YH et al",
      "elocationId": "doi: 10.1002/pbc.28712",
      "link": null,
      "reference": "Messinger YH et al. Pediatric blood & cancer. 2020 Dec;67(12)e28712.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab73"
  },
  "level": "LEVEL_2",
  "gene": "MAP2K2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Langerhans Cell Histiocytosis",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32991018",
      "title": "Langerhans cell histiocytosis with BRAF p.N486_P490del or MAP2K1 p.K57_G61del treated by the MEK inhibitor trametinib.",
      "journal": "Pediatric blood & cancer",
      "pubDate": "2020 Dec",
      "volume": "67",
      "issue": "12",
      "pages": "e28712",
      "authors": "Messinger YH et al",
      "elocationId": "doi: 10.1002/pbc.28712",
      "link": null,
      "reference": "Messinger YH et al. Pediatric blood & cancer. 2020 Dec;67(12)e28712.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab74"
  },
  "level": "LEVEL_2",
  "gene": "ARAF",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Rosai-Dorfman Disease",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab75"
  },
  "level": "LEVEL_2",
  "gene": "ARAF",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Rosai-Dorfman Disease",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab76"
  },
  "level": "LEVEL_2",
  "gene": "ROS1",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Ceritinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28520527",
      "title": "Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Aug 10",
      "volume": "35",
      "issue": "23",
      "pages": "2613-2618",
      "authors": "Lim SM et al",
      "elocationId": "doi: 10.1200/JCO.2016.71.3701",
      "link": null,
      "reference": "Lim SM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Aug 10;35(23)2613-2618.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab77"
  },
  "level": "LEVEL_2",
  "gene": "PIK3CA",
  "alteration": "Oncogenic Mutations {excluding C420R; E542K; E545A; E545D; E545G; E545K; Q546E; Q546R; H1047L; H1047R; H1047Y}",
  "alteration_name": "Oncogenic Mutations (excluding C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R and H1047Y)",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alpelisib",
    "Fulvestrant"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30543347",
      "title": "Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Feb 1",
      "volume": "5",
      "issue": "2",
      "pages": "e184475",
      "authors": "Juric D et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.4475",
      "link": null,
      "reference": "Juric D et al. JAMA oncology. 2019 Feb 1;5(2)e184475.",
      "abstract": null
    },
    {
      "pmid": "31091374",
      "title": "Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 May 16",
      "volume": "380",
      "issue": "20",
      "pages": "1929-1940",
      "authors": "André F et al",
      "elocationId": "doi: 10.1056/NEJMoa1813904",
      "link": null,
      "reference": "André F et al. The New England journal of medicine. 2019 May 16;380(20)1929-1940.",
      "abstract": null
    },
    {
      "pmid": "25877889",
      "title": "PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2015 Apr 15",
      "volume": "7",
      "issue": "283",
      "pages": "283ra51",
      "authors": "Bosch A et al",
      "elocationId": "doi: 10.1126/scitranslmed.aaa4442",
      "link": null,
      "reference": "Bosch A et al. Science translational medicine. 2015 Apr 15;7(283)283ra51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab78"
  },
  "level": "LEVEL_2",
  "gene": "BRAF",
  "alteration": "V600E",
  "alteration_name": "V600E",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Hairy Cell Leukemia",
  "drug": [
    "Vemurafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26352686",
      "title": "Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.",
      "journal": "The New England journal of medicine",
      "pubDate": "2015 Oct 29",
      "volume": "373",
      "issue": "18",
      "pages": "1733-47",
      "authors": "Tiacci E et al",
      "elocationId": "doi: 10.1056/NEJMoa1506583",
      "link": null,
      "reference": "Tiacci E et al. The New England journal of medicine. 2015 Oct 29;373(18)1733-47.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab79"
  },
  "level": "LEVEL_2",
  "gene": "MAP2K1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Rosai-Dorfman Disease",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab7a"
  },
  "level": "LEVEL_2",
  "gene": "MAP2K1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "Rosai-Dorfman Disease",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab7b"
  },
  "level": "LEVEL_R2",
  "gene": "KIT",
  "alteration": "Y823D",
  "alteration_name": "Y823D",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Sunitinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "22301675",
      "title": "Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.",
      "journal": "Leukemia",
      "pubDate": "2012 Jul",
      "volume": "26",
      "issue": "7",
      "pages": "1693-5",
      "authors": "Lierman E et al",
      "elocationId": "doi: 10.1038/leu.2012.8",
      "link": null,
      "reference": "Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.",
      "abstract": null
    },
    {
      "pmid": "18955458",
      "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Nov 20",
      "volume": "26",
      "issue": "33",
      "pages": "5352-9",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1200/JCO.2007.15.7461",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.",
      "abstract": null
    },
    {
      "pmid": "23840364",
      "title": "Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.",
      "journal": "PloS one",
      "pubDate": "2013",
      "volume": "8",
      "issue": "6",
      "pages": "e65762",
      "authors": "Hsueh YS et al",
      "elocationId": "doi: 10.1371/journal.pone.0065762",
      "link": null,
      "reference": "Hsueh YS et al. PloS one. 2013;8(6)e65762.",
      "abstract": null
    },
    {
      "pmid": "25239608",
      "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Nov 15",
      "volume": "20",
      "issue": "22",
      "pages": "5745-5755",
      "authors": "Garner AP et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-1397",
      "link": null,
      "reference": "Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab7c"
  },
  "level": "LEVEL_R2",
  "gene": "KIT",
  "alteration": "T670I",
  "alteration_name": "T670I",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "1675110",
      "title": "The use of analgesia in medical patients in neonatal intensive care units in Australia: results of a questionnaire.",
      "journal": "Journal of paediatrics and child health",
      "pubDate": "1991 Feb",
      "volume": "27",
      "issue": "1",
      "pages": "64",
      "authors": "Colditz PB",
      "elocationId": "",
      "link": null,
      "reference": "Colditz PB. Journal of paediatrics and child health. 1991 Feb;27(1)64.",
      "abstract": null
    },
    {
      "pmid": "16551858",
      "title": "Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Mar 15",
      "volume": "12",
      "issue": "6",
      "pages": "1743-9",
      "authors": "Wardelmann E et al",
      "elocationId": "",
      "link": null,
      "reference": "Wardelmann E et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Mar 15;12(6)1743-9.",
      "abstract": null
    },
    {
      "pmid": "23840364",
      "title": "Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.",
      "journal": "PloS one",
      "pubDate": "2013",
      "volume": "8",
      "issue": "6",
      "pages": "e65762",
      "authors": "Hsueh YS et al",
      "elocationId": "doi: 10.1371/journal.pone.0065762",
      "link": null,
      "reference": "Hsueh YS et al. PloS one. 2013;8(6)e65762.",
      "abstract": null
    },
    {
      "pmid": "17699867",
      "title": "Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2007 Aug 15",
      "volume": "13",
      "issue": "16",
      "pages": "4874-81",
      "authors": "Guo T et al",
      "elocationId": "",
      "link": null,
      "reference": "Guo T et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Aug 15;13(16)4874-81.",
      "abstract": null
    },
    {
      "pmid": "17545544",
      "title": "Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2007 Jun 1",
      "volume": "13",
      "issue": "11",
      "pages": "3363-9",
      "authors": "Guida T et al",
      "elocationId": "",
      "link": null,
      "reference": "Guida T et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Jun 1;13(11)3363-9.",
      "abstract": null
    },
    {
      "pmid": "16954519",
      "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2006 Oct 10",
      "volume": "24",
      "issue": "29",
      "pages": "4764-74",
      "authors": "Heinrich MC et al",
      "elocationId": "",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Oct 10;24(29)4764-74.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab7d"
  },
  "level": "LEVEL_R2",
  "gene": "KIT",
  "alteration": "Y823D",
  "alteration_name": "Y823D",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "22301675",
      "title": "Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.",
      "journal": "Leukemia",
      "pubDate": "2012 Jul",
      "volume": "26",
      "issue": "7",
      "pages": "1693-5",
      "authors": "Lierman E et al",
      "elocationId": "doi: 10.1038/leu.2012.8",
      "link": null,
      "reference": "Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.",
      "abstract": null
    },
    {
      "pmid": "18955458",
      "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Nov 20",
      "volume": "26",
      "issue": "33",
      "pages": "5352-9",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1200/JCO.2007.15.7461",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.",
      "abstract": null
    },
    {
      "pmid": "23840364",
      "title": "Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.",
      "journal": "PloS one",
      "pubDate": "2013",
      "volume": "8",
      "issue": "6",
      "pages": "e65762",
      "authors": "Hsueh YS et al",
      "elocationId": "doi: 10.1371/journal.pone.0065762",
      "link": null,
      "reference": "Hsueh YS et al. PloS one. 2013;8(6)e65762.",
      "abstract": null
    },
    {
      "pmid": "25239608",
      "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Nov 15",
      "volume": "20",
      "issue": "22",
      "pages": "5745-5755",
      "authors": "Garner AP et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-1397",
      "link": null,
      "reference": "Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab7e"
  },
  "level": "LEVEL_R2",
  "gene": "NTRK1",
  "alteration": "G595R",
  "alteration_name": "G595R",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Entrectinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "26546295",
      "title": "Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2016 Jan",
      "volume": "6",
      "issue": "1",
      "pages": "36-44",
      "authors": "Russo M et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0940",
      "link": null,
      "reference": "Russo M et al. Cancer discovery. 2016 Jan;6(1)36-44.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://tptherapeutics.com/wp-content/uploads/AACR_2019_TRK_Final_S.pdf",
      "reference": "null. null. .",
      "abstract": "Drilon et al. Abstract# 4000, AACR 2019"
    },
    {
      "pmid": "28751539",
      "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2017 Oct",
      "volume": "16",
      "issue": "10",
      "pages": "2130-2143",
      "authors": "Fuse MJ et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-16-0909",
      "link": null,
      "reference": "Fuse MJ et al. Molecular cancer therapeutics. 2017 Oct;16(10)2130-2143.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab7f"
  },
  "level": "LEVEL_R2",
  "gene": "BTK",
  "alteration": "T474S",
  "alteration_name": "T474S",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
  "drug": [
    "Ibrutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "27626698",
      "title": "Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.",
      "journal": "Oncotarget",
      "pubDate": "2016 Oct 18",
      "volume": "7",
      "issue": "42",
      "pages": "68833-68841",
      "authors": "Sharma S et al",
      "elocationId": "doi: 10.18632/oncotarget.11932",
      "link": null,
      "reference": "Sharma S et al. Oncotarget. 2016 Oct 18;7(42)68833-68841.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab80"
  },
  "level": "LEVEL_R2",
  "gene": "EGFR",
  "alteration": "C797G",
  "alteration_name": "C797G",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Osimertinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "27086175",
      "title": "A Novel EGFR(C797) Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2016 Sep",
      "volume": "11",
      "issue": "9",
      "pages": "e105-7",
      "authors": "Menon R et al",
      "elocationId": "doi: 10.1016/j.jtho.2016.04.005",
      "link": null,
      "reference": "Menon R et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Sep;11(9)e105-7.",
      "abstract": null
    },
    {
      "pmid": "29713646",
      "title": "Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients.",
      "journal": "BioMed research international",
      "pubDate": "2018",
      "volume": "2018",
      "issue": "",
      "pages": "9010353",
      "authors": "Nie K et al",
      "elocationId": "doi: 10.1155/2018/9010353",
      "link": null,
      "reference": "Nie K et al. BioMed research international. 2018;2018()9010353.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab81"
  },
  "level": "LEVEL_R2",
  "gene": "KIT",
  "alteration": "C809G",
  "alteration_name": "C809G",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "22301675",
      "title": "Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.",
      "journal": "Leukemia",
      "pubDate": "2012 Jul",
      "volume": "26",
      "issue": "7",
      "pages": "1693-5",
      "authors": "Lierman E et al",
      "elocationId": "doi: 10.1038/leu.2012.8",
      "link": null,
      "reference": "Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.",
      "abstract": null
    },
    {
      "pmid": "18955458",
      "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Nov 20",
      "volume": "26",
      "issue": "33",
      "pages": "5352-9",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1200/JCO.2007.15.7461",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.",
      "abstract": null
    },
    {
      "pmid": "23840364",
      "title": "Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.",
      "journal": "PloS one",
      "pubDate": "2013",
      "volume": "8",
      "issue": "6",
      "pages": "e65762",
      "authors": "Hsueh YS et al",
      "elocationId": "doi: 10.1371/journal.pone.0065762",
      "link": null,
      "reference": "Hsueh YS et al. PloS one. 2013;8(6)e65762.",
      "abstract": null
    },
    {
      "pmid": "25239608",
      "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Nov 15",
      "volume": "20",
      "issue": "22",
      "pages": "5745-5755",
      "authors": "Garner AP et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-1397",
      "link": null,
      "reference": "Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab82"
  },
  "level": "LEVEL_R2",
  "gene": "MET",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Osimertinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "18093943",
      "title": "MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.",
      "journal": "Proceedings of the National Academy of Sciences of the United States of America",
      "pubDate": "2007 Dec 26",
      "volume": "104",
      "issue": "52",
      "pages": "20932-7",
      "authors": "Bean J et al",
      "elocationId": "",
      "link": null,
      "reference": "Bean J et al. Proceedings of the National Academy of Sciences of the United States of America. 2007 Dec 26;104(52)20932-7.",
      "abstract": null
    },
    {
      "pmid": "30676858",
      "title": "Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2019 Apr 10",
      "volume": "37",
      "issue": "11",
      "pages": "876-884",
      "authors": "Lai GGY et al",
      "elocationId": "doi: 10.1200/JCO.18.00177",
      "link": null,
      "reference": "Lai GGY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Apr 10;37(11)876-884.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/full/10.1200/PO.18.00210",
      "reference": "null. null. .",
      "abstract": "Michels et al. JCO PO, 2018"
    },
    {
      "pmid": "17463250",
      "title": "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.",
      "journal": "Science (New York, N.Y.)",
      "pubDate": "2007 May 18",
      "volume": "316",
      "issue": "5827",
      "pages": "1039-43",
      "authors": "Engelman JA et al",
      "elocationId": "",
      "link": null,
      "reference": "Engelman JA et al. Science (New York, N.Y.). 2007 May 18;316(5827)1039-43.",
      "abstract": null
    },
    {
      "pmid": "30073261",
      "title": "Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.",
      "journal": "JAMA oncology",
      "pubDate": "2018 Nov 1",
      "volume": "4",
      "issue": "11",
      "pages": "1527-1534",
      "authors": "Oxnard GR et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.2969",
      "link": null,
      "reference": "Oxnard GR et al. JAMA oncology. 2018 Nov 1;4(11)1527-1534.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab83"
  },
  "level": "LEVEL_R2",
  "gene": "MET",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erlotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "18093943",
      "title": "MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.",
      "journal": "Proceedings of the National Academy of Sciences of the United States of America",
      "pubDate": "2007 Dec 26",
      "volume": "104",
      "issue": "52",
      "pages": "20932-7",
      "authors": "Bean J et al",
      "elocationId": "",
      "link": null,
      "reference": "Bean J et al. Proceedings of the National Academy of Sciences of the United States of America. 2007 Dec 26;104(52)20932-7.",
      "abstract": null
    },
    {
      "pmid": "30676858",
      "title": "Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2019 Apr 10",
      "volume": "37",
      "issue": "11",
      "pages": "876-884",
      "authors": "Lai GGY et al",
      "elocationId": "doi: 10.1200/JCO.18.00177",
      "link": null,
      "reference": "Lai GGY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Apr 10;37(11)876-884.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/full/10.1200/PO.18.00210",
      "reference": "null. null. .",
      "abstract": "Michels et al. JCO PO, 2018"
    },
    {
      "pmid": "17463250",
      "title": "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.",
      "journal": "Science (New York, N.Y.)",
      "pubDate": "2007 May 18",
      "volume": "316",
      "issue": "5827",
      "pages": "1039-43",
      "authors": "Engelman JA et al",
      "elocationId": "",
      "link": null,
      "reference": "Engelman JA et al. Science (New York, N.Y.). 2007 May 18;316(5827)1039-43.",
      "abstract": null
    },
    {
      "pmid": "30073261",
      "title": "Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.",
      "journal": "JAMA oncology",
      "pubDate": "2018 Nov 1",
      "volume": "4",
      "issue": "11",
      "pages": "1527-1534",
      "authors": "Oxnard GR et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.2969",
      "link": null,
      "reference": "Oxnard GR et al. JAMA oncology. 2018 Nov 1;4(11)1527-1534.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab84"
  },
  "level": "LEVEL_R2",
  "gene": "MET",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Gefitinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "18093943",
      "title": "MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.",
      "journal": "Proceedings of the National Academy of Sciences of the United States of America",
      "pubDate": "2007 Dec 26",
      "volume": "104",
      "issue": "52",
      "pages": "20932-7",
      "authors": "Bean J et al",
      "elocationId": "",
      "link": null,
      "reference": "Bean J et al. Proceedings of the National Academy of Sciences of the United States of America. 2007 Dec 26;104(52)20932-7.",
      "abstract": null
    },
    {
      "pmid": "30676858",
      "title": "Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2019 Apr 10",
      "volume": "37",
      "issue": "11",
      "pages": "876-884",
      "authors": "Lai GGY et al",
      "elocationId": "doi: 10.1200/JCO.18.00177",
      "link": null,
      "reference": "Lai GGY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Apr 10;37(11)876-884.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/full/10.1200/PO.18.00210",
      "reference": "null. null. .",
      "abstract": "Michels et al. JCO PO, 2018"
    },
    {
      "pmid": "17463250",
      "title": "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.",
      "journal": "Science (New York, N.Y.)",
      "pubDate": "2007 May 18",
      "volume": "316",
      "issue": "5827",
      "pages": "1039-43",
      "authors": "Engelman JA et al",
      "elocationId": "",
      "link": null,
      "reference": "Engelman JA et al. Science (New York, N.Y.). 2007 May 18;316(5827)1039-43.",
      "abstract": null
    },
    {
      "pmid": "30073261",
      "title": "Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.",
      "journal": "JAMA oncology",
      "pubDate": "2018 Nov 1",
      "volume": "4",
      "issue": "11",
      "pages": "1527-1534",
      "authors": "Oxnard GR et al",
      "elocationId": "doi: 10.1001/jamaoncol.2018.2969",
      "link": null,
      "reference": "Oxnard GR et al. JAMA oncology. 2018 Nov 1;4(11)1527-1534.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab85"
  },
  "level": "LEVEL_R2",
  "gene": "ALK",
  "alteration": "C1156Y",
  "alteration_name": "C1156Y",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "26144315",
      "title": "PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.",
      "journal": "Cancer cell",
      "pubDate": "2015 Jul 13",
      "volume": "28",
      "issue": "1",
      "pages": "70-81",
      "authors": "Zou HY et al",
      "elocationId": "doi: 10.1016/j.ccell.2015.05.010",
      "link": null,
      "reference": "Zou HY et al. Cancer cell. 2015 Jul 13;28(1)70-81.",
      "abstract": null
    },
    {
      "pmid": "26698910",
      "title": "Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.",
      "journal": "The New England journal of medicine",
      "pubDate": "2016 Jan 7",
      "volume": "374",
      "issue": "1",
      "pages": "54-61",
      "authors": "Shaw AT et al",
      "elocationId": "doi: 10.1056/NEJMoa1508887",
      "link": null,
      "reference": "Shaw AT et al. The New England journal of medicine. 2016 Jan 7;374(1)54-61.",
      "abstract": null
    },
    {
      "pmid": "20979473",
      "title": "EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.",
      "journal": "The New England journal of medicine",
      "pubDate": "2010 Oct 28",
      "volume": "363",
      "issue": "18",
      "pages": "1734-9",
      "authors": "Choi YL et al",
      "elocationId": "doi: 10.1056/NEJMoa1007478",
      "link": null,
      "reference": "Choi YL et al. The New England journal of medicine. 2010 Oct 28;363(18)1734-9.",
      "abstract": null
    },
    {
      "pmid": "24675041",
      "title": "The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2014 Jun",
      "volume": "4",
      "issue": "6",
      "pages": "662-673",
      "authors": "Friboulet L et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-13-0846",
      "link": null,
      "reference": "Friboulet L et al. Cancer discovery. 2014 Jun;4(6)662-673.",
      "abstract": null
    },
    {
      "pmid": "23434628",
      "title": "Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.",
      "journal": "Genomics",
      "pubDate": "2013 Sep",
      "volume": "102",
      "issue": "3",
      "pages": "157-62",
      "authors": "Huang D et al",
      "elocationId": "doi: 10.1016/j.ygeno.2013.02.006",
      "link": null,
      "reference": "Huang D et al. Genomics. 2013 Sep;102(3)157-62.",
      "abstract": null
    },
    {
      "pmid": "22235099",
      "title": "Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Mar 1",
      "volume": "18",
      "issue": "5",
      "pages": "1472-82",
      "authors": "Doebele RC et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-11-2906",
      "link": null,
      "reference": "Doebele RC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Mar 1;18(5)1472-82.",
      "abstract": null
    },
    {
      "pmid": "27045755",
      "title": "Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.",
      "journal": "PloS one",
      "pubDate": "2016",
      "volume": "11",
      "issue": "4",
      "pages": "e0153065",
      "authors": "Saber A et al",
      "elocationId": "doi: 10.1371/journal.pone.0153065",
      "link": null,
      "reference": "Saber A et al. PloS one. 2016;11(4)e0153065.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab86"
  },
  "level": "LEVEL_R2",
  "gene": "ALK",
  "alteration": "I1171N",
  "alteration_name": "I1171N",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alectinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "23239810",
      "title": "Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.",
      "journal": "Molecular cancer research : MCR",
      "pubDate": "2013 Feb",
      "volume": "11",
      "issue": "2",
      "pages": "122-32",
      "authors": "Ceccon M et al",
      "elocationId": "doi: 10.1158/1541-7786.MCR-12-0569",
      "link": null,
      "reference": "Ceccon M et al. Molecular cancer research : MCR. 2013 Feb;11(2)122-32.",
      "abstract": null
    },
    {
      "pmid": "29650534",
      "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2018 Jun",
      "volume": "8",
      "issue": "6",
      "pages": "714-729",
      "authors": "Yoda S et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-17-1256",
      "link": null,
      "reference": "Yoda S et al. Cancer discovery. 2018 Jun;8(6)714-729.",
      "abstract": null
    },
    {
      "pmid": "25393798",
      "title": "Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2014 Dec",
      "volume": "9",
      "issue": "12",
      "pages": "e86-7",
      "authors": "Toyokawa G et al",
      "elocationId": "doi: 10.1097/JTO.0000000000000358",
      "link": null,
      "reference": "Toyokawa G et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Dec;9(12)e86-7.",
      "abstract": null
    },
    {
      "pmid": "25393796",
      "title": "Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2014 Dec",
      "volume": "9",
      "issue": "12",
      "pages": "1821-5",
      "authors": "Ou SH et al",
      "elocationId": "doi: 10.1097/JTO.0000000000000368",
      "link": null,
      "reference": "Ou SH et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Dec;9(12)1821-5.",
      "abstract": null
    },
    {
      "pmid": "25736571",
      "title": "I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2015 May",
      "volume": "88",
      "issue": "2",
      "pages": "231-4",
      "authors": "Ou SH et al",
      "elocationId": "doi: 10.1016/j.lungcan.2015.02.005",
      "link": null,
      "reference": "Ou SH et al. Lung cancer (Amsterdam, Netherlands). 2015 May;88(2)231-4.",
      "abstract": null
    },
    {
      "pmid": "27565911",
      "title": "Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2016 Sep",
      "volume": "99",
      "issue": "",
      "pages": "38-40",
      "authors": "Johnson AC et al",
      "elocationId": "doi: 10.1016/j.lungcan.2016.06.010",
      "link": null,
      "reference": "Johnson AC et al. Lung cancer (Amsterdam, Netherlands). 2016 Sep;99()38-40.",
      "abstract": null
    },
    {
      "pmid": "29376144",
      "title": "Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.",
      "journal": "JCO precision oncology",
      "pubDate": "2018",
      "volume": "2018",
      "issue": "",
      "pages": "",
      "authors": "Dagogo-Jack I et al",
      "elocationId": "doi: 10.1200/PO.17.00160",
      "link": null,
      "reference": "Dagogo-Jack I et al. JCO precision oncology. 2018;2018().",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab87"
  },
  "level": "LEVEL_R2",
  "gene": "ALK",
  "alteration": "L1196M",
  "alteration_name": "L1196M",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "22277784",
      "title": "Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.",
      "journal": "Science translational medicine",
      "pubDate": "2012 Feb 8",
      "volume": "4",
      "issue": "120",
      "pages": "120ra17",
      "authors": "Katayama R et al",
      "elocationId": "doi: 10.1126/scitranslmed.3003316",
      "link": null,
      "reference": "Katayama R et al. Science translational medicine. 2012 Feb 8;4(120)120ra17.",
      "abstract": null
    },
    {
      "pmid": "24675041",
      "title": "The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2014 Jun",
      "volume": "4",
      "issue": "6",
      "pages": "662-673",
      "authors": "Friboulet L et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-13-0846",
      "link": null,
      "reference": "Friboulet L et al. Cancer discovery. 2014 Jun;4(6)662-673.",
      "abstract": null
    },
    {
      "pmid": "28434515",
      "title": "Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2017 May",
      "volume": "12",
      "issue": "5",
      "pages": "e49-e51",
      "authors": "Wang HY et al",
      "elocationId": "doi: 10.1016/j.jtho.2017.01.009",
      "link": null,
      "reference": "Wang HY et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 May;12(5)e49-e51.",
      "abstract": null
    },
    {
      "pmid": "23434628",
      "title": "Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.",
      "journal": "Genomics",
      "pubDate": "2013 Sep",
      "volume": "102",
      "issue": "3",
      "pages": "157-62",
      "authors": "Huang D et al",
      "elocationId": "doi: 10.1016/j.ygeno.2013.02.006",
      "link": null,
      "reference": "Huang D et al. Genomics. 2013 Sep;102(3)157-62.",
      "abstract": null
    },
    {
      "pmid": "23344087",
      "title": "Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2013 Apr",
      "volume": "8",
      "issue": "4",
      "pages": "415-22",
      "authors": "Kim S et al",
      "elocationId": "doi: 10.1097/JTO.0b013e318283dcc0",
      "link": null,
      "reference": "Kim S et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Apr;8(4)415-22.",
      "abstract": null
    },
    {
      "pmid": "22235099",
      "title": "Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Mar 1",
      "volume": "18",
      "issue": "5",
      "pages": "1472-82",
      "authors": "Doebele RC et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-11-2906",
      "link": null,
      "reference": "Doebele RC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Mar 1;18(5)1472-82.",
      "abstract": null
    },
    {
      "pmid": "27432227",
      "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2016 Oct",
      "volume": "6",
      "issue": "10",
      "pages": "1118-1133",
      "authors": "Gainor JF et al",
      "elocationId": "",
      "link": null,
      "reference": "Gainor JF et al. Cancer discovery. 2016 Oct;6(10)1118-1133.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab88"
  },
  "level": "LEVEL_R2",
  "gene": "KIT",
  "alteration": "N822",
  "alteration_name": "N822",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "22301675",
      "title": "Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.",
      "journal": "Leukemia",
      "pubDate": "2012 Jul",
      "volume": "26",
      "issue": "7",
      "pages": "1693-5",
      "authors": "Lierman E et al",
      "elocationId": "doi: 10.1038/leu.2012.8",
      "link": null,
      "reference": "Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.",
      "abstract": null
    },
    {
      "pmid": "18955458",
      "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Nov 20",
      "volume": "26",
      "issue": "33",
      "pages": "5352-9",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1200/JCO.2007.15.7461",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.",
      "abstract": null
    },
    {
      "pmid": "23840364",
      "title": "Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.",
      "journal": "PloS one",
      "pubDate": "2013",
      "volume": "8",
      "issue": "6",
      "pages": "e65762",
      "authors": "Hsueh YS et al",
      "elocationId": "doi: 10.1371/journal.pone.0065762",
      "link": null,
      "reference": "Hsueh YS et al. PloS one. 2013;8(6)e65762.",
      "abstract": null
    },
    {
      "pmid": "25239608",
      "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Nov 15",
      "volume": "20",
      "issue": "22",
      "pages": "5745-5755",
      "authors": "Garner AP et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-1397",
      "link": null,
      "reference": "Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab89"
  },
  "level": "LEVEL_R2",
  "gene": "KIT",
  "alteration": "C809G",
  "alteration_name": "C809G",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Sunitinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "22301675",
      "title": "Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.",
      "journal": "Leukemia",
      "pubDate": "2012 Jul",
      "volume": "26",
      "issue": "7",
      "pages": "1693-5",
      "authors": "Lierman E et al",
      "elocationId": "doi: 10.1038/leu.2012.8",
      "link": null,
      "reference": "Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.",
      "abstract": null
    },
    {
      "pmid": "18955458",
      "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Nov 20",
      "volume": "26",
      "issue": "33",
      "pages": "5352-9",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1200/JCO.2007.15.7461",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.",
      "abstract": null
    },
    {
      "pmid": "23840364",
      "title": "Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.",
      "journal": "PloS one",
      "pubDate": "2013",
      "volume": "8",
      "issue": "6",
      "pages": "e65762",
      "authors": "Hsueh YS et al",
      "elocationId": "doi: 10.1371/journal.pone.0065762",
      "link": null,
      "reference": "Hsueh YS et al. PloS one. 2013;8(6)e65762.",
      "abstract": null
    },
    {
      "pmid": "25239608",
      "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Nov 15",
      "volume": "20",
      "issue": "22",
      "pages": "5745-5755",
      "authors": "Garner AP et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-1397",
      "link": null,
      "reference": "Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab8a"
  },
  "level": "LEVEL_R2",
  "gene": "KIT",
  "alteration": "D820",
  "alteration_name": "D820",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Sunitinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "22301675",
      "title": "Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.",
      "journal": "Leukemia",
      "pubDate": "2012 Jul",
      "volume": "26",
      "issue": "7",
      "pages": "1693-5",
      "authors": "Lierman E et al",
      "elocationId": "doi: 10.1038/leu.2012.8",
      "link": null,
      "reference": "Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.",
      "abstract": null
    },
    {
      "pmid": "18955458",
      "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Nov 20",
      "volume": "26",
      "issue": "33",
      "pages": "5352-9",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1200/JCO.2007.15.7461",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.",
      "abstract": null
    },
    {
      "pmid": "23840364",
      "title": "Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.",
      "journal": "PloS one",
      "pubDate": "2013",
      "volume": "8",
      "issue": "6",
      "pages": "e65762",
      "authors": "Hsueh YS et al",
      "elocationId": "doi: 10.1371/journal.pone.0065762",
      "link": null,
      "reference": "Hsueh YS et al. PloS one. 2013;8(6)e65762.",
      "abstract": null
    },
    {
      "pmid": "25239608",
      "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Nov 15",
      "volume": "20",
      "issue": "22",
      "pages": "5745-5755",
      "authors": "Garner AP et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-1397",
      "link": null,
      "reference": "Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab8b"
  },
  "level": "LEVEL_R2",
  "gene": "BTK",
  "alteration": "T316A",
  "alteration_name": "T316A",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
  "drug": [
    "Ibrutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "27626698",
      "title": "Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.",
      "journal": "Oncotarget",
      "pubDate": "2016 Oct 18",
      "volume": "7",
      "issue": "42",
      "pages": "68833-68841",
      "authors": "Sharma S et al",
      "elocationId": "doi: 10.18632/oncotarget.11932",
      "link": null,
      "reference": "Sharma S et al. Oncotarget. 2016 Oct 18;7(42)68833-68841.",
      "abstract": null
    },
    {
      "pmid": "29296715",
      "title": "Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.",
      "journal": "Blood advances",
      "pubDate": "2017 May 9",
      "volume": "1",
      "issue": "12",
      "pages": "715-727",
      "authors": "Kadri S et al",
      "elocationId": "doi: 10.1182/bloodadvances.2016003632",
      "link": null,
      "reference": "Kadri S et al. Blood advances. 2017 May 9;1(12)715-727.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab8c"
  },
  "level": "LEVEL_R2",
  "gene": "KIT",
  "alteration": "A829P",
  "alteration_name": "A829P",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "Gastrointestinal Stromal Tumor",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "18955458",
      "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Nov 20",
      "volume": "26",
      "issue": "33",
      "pages": "5352-9",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1200/JCO.2007.15.7461",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.",
      "abstract": null
    },
    {
      "pmid": "31085175",
      "title": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
      "journal": "Cancer cell",
      "pubDate": "2019 May 13",
      "volume": "35",
      "issue": "5",
      "pages": "738-751.e9",
      "authors": "Smith BD et al",
      "elocationId": "doi: 10.1016/j.ccell.2019.04.006",
      "link": null,
      "reference": "Smith BD et al. Cancer cell. 2019 May 13;35(5)738-751.e9.",
      "abstract": null
    },
    {
      "pmid": "25239608",
      "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Nov 15",
      "volume": "20",
      "issue": "22",
      "pages": "5745-5755",
      "authors": "Garner AP et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-1397",
      "link": null,
      "reference": "Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab8d"
  },
  "level": "LEVEL_R2",
  "gene": "KIT",
  "alteration": "A829P",
  "alteration_name": "A829P",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "Gastrointestinal Stromal Tumor",
  "drug": [
    "Sunitinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "31085175",
      "title": "Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.",
      "journal": "Cancer cell",
      "pubDate": "2019 May 13",
      "volume": "35",
      "issue": "5",
      "pages": "738-751.e9",
      "authors": "Smith BD et al",
      "elocationId": "doi: 10.1016/j.ccell.2019.04.006",
      "link": null,
      "reference": "Smith BD et al. Cancer cell. 2019 May 13;35(5)738-751.e9.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab8e"
  },
  "level": "LEVEL_R2",
  "gene": "BTK",
  "alteration": "C481Y",
  "alteration_name": "C481Y",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
  "drug": [
    "Ibrutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "27282255",
      "title": "Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.",
      "journal": "Leukemia",
      "pubDate": "2017 Jan",
      "volume": "31",
      "issue": "1",
      "pages": "177-185",
      "authors": "Hamasy A et al",
      "elocationId": "doi: 10.1038/leu.2016.153",
      "link": null,
      "reference": "Hamasy A et al. Leukemia. 2017 Jan;31(1)177-185.",
      "abstract": null
    },
    {
      "pmid": "29296715",
      "title": "Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.",
      "journal": "Blood advances",
      "pubDate": "2017 May 9",
      "volume": "1",
      "issue": "12",
      "pages": "715-727",
      "authors": "Kadri S et al",
      "elocationId": "doi: 10.1182/bloodadvances.2016003632",
      "link": null,
      "reference": "Kadri S et al. Blood advances. 2017 May 9;1(12)715-727.",
      "abstract": null
    },
    {
      "pmid": "26182309",
      "title": "Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.",
      "journal": "JAMA oncology",
      "pubDate": "2015 Apr",
      "volume": "1",
      "issue": "1",
      "pages": "80-7",
      "authors": "Maddocks KJ et al",
      "elocationId": "doi: 10.1001/jamaoncol.2014.218",
      "link": null,
      "reference": "Maddocks KJ et al. JAMA oncology. 2015 Apr;1(1)80-7.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab8f"
  },
  "level": "LEVEL_R2",
  "gene": "BTK",
  "alteration": "T474I",
  "alteration_name": "T474I",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
  "drug": [
    "Ibrutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "27571029",
      "title": "Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.",
      "journal": "ACS chemical biology",
      "pubDate": "2016 Oct 21",
      "volume": "11",
      "issue": "10",
      "pages": "2897-2907",
      "authors": "Johnson AR et al",
      "elocationId": "",
      "link": null,
      "reference": "Johnson AR et al. ACS chemical biology. 2016 Oct 21;11(10)2897-2907.",
      "abstract": null
    },
    {
      "pmid": "27626698",
      "title": "Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.",
      "journal": "Oncotarget",
      "pubDate": "2016 Oct 18",
      "volume": "7",
      "issue": "42",
      "pages": "68833-68841",
      "authors": "Sharma S et al",
      "elocationId": "doi: 10.18632/oncotarget.11932",
      "link": null,
      "reference": "Sharma S et al. Oncotarget. 2016 Oct 18;7(42)68833-68841.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab90"
  },
  "level": "LEVEL_R2",
  "gene": "ALK",
  "alteration": "G1202R",
  "alteration_name": "G1202R",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Alectinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "29650534",
      "title": "Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2018 Jun",
      "volume": "8",
      "issue": "6",
      "pages": "714-729",
      "authors": "Yoda S et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-17-1256",
      "link": null,
      "reference": "Yoda S et al. Cancer discovery. 2018 Jun;8(6)714-729.",
      "abstract": null
    },
    {
      "pmid": "27130468",
      "title": "Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.",
      "journal": "Clinical lung cancer",
      "pubDate": "2016 Sep",
      "volume": "17",
      "issue": "5",
      "pages": "e77-e94",
      "authors": "Lin YT et al",
      "elocationId": "doi: 10.1016/j.cllc.2016.03.005",
      "link": null,
      "reference": "Lin YT et al. Clinical lung cancer. 2016 Sep;17(5)e77-e94.",
      "abstract": null
    },
    {
      "pmid": "29373100",
      "title": "Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2018 Apr 20",
      "volume": "36",
      "issue": "12",
      "pages": "1199-1206",
      "authors": "Lin JJ et al",
      "elocationId": "doi: 10.1200/JCO.2017.76.2294",
      "link": null,
      "reference": "Lin JJ et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Apr 20;36(12)1199-1206.",
      "abstract": null
    },
    {
      "pmid": "27432227",
      "title": "Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2016 Oct",
      "volume": "6",
      "issue": "10",
      "pages": "1118-1133",
      "authors": "Gainor JF et al",
      "elocationId": "",
      "link": null,
      "reference": "Gainor JF et al. Cancer discovery. 2016 Oct;6(10)1118-1133.",
      "abstract": null
    },
    {
      "pmid": "29376144",
      "title": "Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.",
      "journal": "JCO precision oncology",
      "pubDate": "2018",
      "volume": "2018",
      "issue": "",
      "pages": "",
      "authors": "Dagogo-Jack I et al",
      "elocationId": "doi: 10.1200/PO.17.00160",
      "link": null,
      "reference": "Dagogo-Jack I et al. JCO precision oncology. 2018;2018().",
      "abstract": null
    },
    {
      "pmid": "24736079",
      "title": "Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2014 Apr",
      "volume": "9",
      "issue": "4",
      "pages": "549-53",
      "authors": "Ignatius Ou SH et al",
      "elocationId": "doi: 10.1097/JTO.0000000000000094",
      "link": null,
      "reference": "Ignatius Ou SH et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Apr;9(4)549-53.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab91"
  },
  "level": "LEVEL_R2",
  "gene": "BTK",
  "alteration": "C481R",
  "alteration_name": "C481R",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
  "drug": [
    "Ibrutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "27282255",
      "title": "Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.",
      "journal": "Leukemia",
      "pubDate": "2017 Jan",
      "volume": "31",
      "issue": "1",
      "pages": "177-185",
      "authors": "Hamasy A et al",
      "elocationId": "doi: 10.1038/leu.2016.153",
      "link": null,
      "reference": "Hamasy A et al. Leukemia. 2017 Jan;31(1)177-185.",
      "abstract": null
    },
    {
      "pmid": "27571029",
      "title": "Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.",
      "journal": "ACS chemical biology",
      "pubDate": "2016 Oct 21",
      "volume": "11",
      "issue": "10",
      "pages": "2897-2907",
      "authors": "Johnson AR et al",
      "elocationId": "",
      "link": null,
      "reference": "Johnson AR et al. ACS chemical biology. 2016 Oct 21;11(10)2897-2907.",
      "abstract": null
    },
    {
      "pmid": "28049639",
      "title": "Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.",
      "journal": "Blood",
      "pubDate": "2017 Mar 16",
      "volume": "129",
      "issue": "11",
      "pages": "1469-1479",
      "authors": "Ahn IE et al",
      "elocationId": "doi: 10.1182/blood-2016-06-719294",
      "link": null,
      "reference": "Ahn IE et al. Blood. 2017 Mar 16;129(11)1469-1479.",
      "abstract": null
    },
    {
      "pmid": "28235842",
      "title": "Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.",
      "journal": "Blood",
      "pubDate": "2017 May 4",
      "volume": "129",
      "issue": "18",
      "pages": "2519-2525",
      "authors": "Xu L et al",
      "elocationId": "doi: 10.1182/blood-2017-01-761726",
      "link": null,
      "reference": "Xu L et al. Blood. 2017 May 4;129(18)2519-2525.",
      "abstract": null
    },
    {
      "pmid": "29381098",
      "title": "Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?",
      "journal": "Expert review of hematology",
      "pubDate": "2018 Mar",
      "volume": "11",
      "issue": "3",
      "pages": "185-194",
      "authors": "Lampson BL et al",
      "elocationId": "doi: 10.1080/17474086.2018.1435268",
      "link": null,
      "reference": "Lampson BL et al. Expert review of hematology. 2018 Mar;11(3)185-194.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab92"
  },
  "level": "LEVEL_R2",
  "gene": "EGFR",
  "alteration": "G724S",
  "alteration_name": "G724S",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Osimertinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "30796031",
      "title": "On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Jun 1",
      "volume": "25",
      "issue": "11",
      "pages": "3341-3351",
      "authors": "Brown BP et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3829",
      "link": null,
      "reference": "Brown BP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jun 1;25(11)3341-3351.",
      "abstract": null
    },
    {
      "pmid": "28838405",
      "title": "Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2017 Sep",
      "volume": "111",
      "issue": "",
      "pages": "84-87",
      "authors": "Oztan A et al",
      "elocationId": "doi: 10.1016/j.lungcan.2017.07.002",
      "link": null,
      "reference": "Oztan A et al. Lung cancer (Amsterdam, Netherlands). 2017 Sep;111()84-87.",
      "abstract": null
    },
    {
      "pmid": "30405134",
      "title": "Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.",
      "journal": "Nature communications",
      "pubDate": "2018 Nov 7",
      "volume": "9",
      "issue": "1",
      "pages": "4655",
      "authors": "Fassunke J et al",
      "elocationId": "doi: 10.1038/s41467-018-07078-0",
      "link": null,
      "reference": "Fassunke J et al. Nature communications. 2018 Nov 7;9(1)4655.",
      "abstract": null
    },
    {
      "pmid": "30228210",
      "title": "Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in <i>EGFR</i>-Mutant NSCLC.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2018 Dec 15",
      "volume": "24",
      "issue": "24",
      "pages": "6195-6203",
      "authors": "Le X et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1542",
      "link": null,
      "reference": "Le X et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Dec 15;24(24)6195-6203.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab93"
  },
  "level": "LEVEL_R2",
  "gene": "EGFR",
  "alteration": "L718V",
  "alteration_name": "L718V",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "Non-Small Cell Lung Cancer",
  "drug": [
    "Osimertinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "31757379",
      "title": "Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2019 Dec",
      "volume": "14",
      "issue": "12",
      "pages": "e274-e275",
      "authors": "Fang W et al",
      "elocationId": "doi: 10.1016/j.jtho.2019.07.018",
      "link": null,
      "reference": "Fang W et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Dec;14(12)e274-e275.",
      "abstract": null
    },
    {
      "pmid": "29568384",
      "title": "Structural insights into drug development strategy targeting EGFR T790M/C797S.",
      "journal": "Oncotarget",
      "pubDate": "2018 Mar 2",
      "volume": "9",
      "issue": "17",
      "pages": "13652-13665",
      "authors": "Zhu SJ et al",
      "elocationId": "doi: 10.18632/oncotarget.24113",
      "link": null,
      "reference": "Zhu SJ et al. Oncotarget. 2018 Mar 2;9(17)13652-13665.",
      "abstract": null
    },
    {
      "pmid": "29571986",
      "title": "Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2018 Apr",
      "volume": "118",
      "issue": "",
      "pages": "1-5",
      "authors": "Liu Y et al",
      "elocationId": "doi: 10.1016/j.lungcan.2018.01.015",
      "link": null,
      "reference": "Liu Y et al. Lung cancer (Amsterdam, Netherlands). 2018 Apr;118()1-5.",
      "abstract": null
    },
    {
      "pmid": "31301016",
      "title": "Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient.",
      "journal": "Targeted oncology",
      "pubDate": "2019 Aug",
      "volume": "14",
      "issue": "4",
      "pages": "369-374",
      "authors": "Yang Z et al",
      "elocationId": "doi: 10.1007/s11523-019-00652-6",
      "link": null,
      "reference": "Yang Z et al. Targeted oncology. 2019 Aug;14(4)369-374.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab94"
  },
  "level": "LEVEL_R2",
  "gene": "MET",
  "alteration": "D1228N",
  "alteration_name": "D1228N",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Cabozantinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "27343442",
      "title": "Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2016 Aug",
      "volume": "11",
      "issue": "8",
      "pages": "1242-1245",
      "authors": "Heist RS et al",
      "elocationId": "doi: 10.1016/j.jtho.2016.06.013",
      "link": null,
      "reference": "Heist RS et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Aug;11(8)1242-1245.",
      "abstract": null
    },
    {
      "pmid": "29128427",
      "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2018 Apr",
      "volume": "13",
      "issue": "4",
      "pages": "e49-e53",
      "authors": "Kang J et al",
      "elocationId": "doi: 10.1016/j.jtho.2017.10.028",
      "link": null,
      "reference": "Kang J et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Apr;13(4)e49-e53.",
      "abstract": null
    },
    {
      "pmid": "28396313",
      "title": "Acquired <i>MET</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2017 Aug 15",
      "volume": "23",
      "issue": "16",
      "pages": "4929-4937",
      "authors": "Li A et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-16-3273",
      "link": null,
      "reference": "Li A et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Aug 15;23(16)4929-4937.",
      "abstract": null
    },
    {
      "pmid": "28522754",
      "title": "<i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.",
      "journal": "Cancer research",
      "pubDate": "2017 Aug 15",
      "volume": "77",
      "issue": "16",
      "pages": "4498-4505",
      "authors": "Lu X et al",
      "elocationId": "doi: 10.1158/0008-5472.CAN-16-1944",
      "link": null,
      "reference": "Lu X et al. Cancer research. 2017 Aug 15;77(16)4498-4505.",
      "abstract": null
    },
    {
      "pmid": "27987579",
      "title": "Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2016 Dec",
      "volume": "102",
      "issue": "",
      "pages": "118-121",
      "authors": "Dong HJ et al",
      "elocationId": "doi: 10.1016/j.lungcan.2016.11.006",
      "link": null,
      "reference": "Dong HJ et al. Lung cancer (Amsterdam, Netherlands). 2016 Dec;102()118-121.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab95"
  },
  "level": "LEVEL_R2",
  "gene": "MET",
  "alteration": "D1228N",
  "alteration_name": "D1228N",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Capmatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "27343442",
      "title": "Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2016 Aug",
      "volume": "11",
      "issue": "8",
      "pages": "1242-1245",
      "authors": "Heist RS et al",
      "elocationId": "doi: 10.1016/j.jtho.2016.06.013",
      "link": null,
      "reference": "Heist RS et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Aug;11(8)1242-1245.",
      "abstract": null
    },
    {
      "pmid": "29128427",
      "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2018 Apr",
      "volume": "13",
      "issue": "4",
      "pages": "e49-e53",
      "authors": "Kang J et al",
      "elocationId": "doi: 10.1016/j.jtho.2017.10.028",
      "link": null,
      "reference": "Kang J et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Apr;13(4)e49-e53.",
      "abstract": null
    },
    {
      "pmid": "28396313",
      "title": "Acquired <i>MET</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2017 Aug 15",
      "volume": "23",
      "issue": "16",
      "pages": "4929-4937",
      "authors": "Li A et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-16-3273",
      "link": null,
      "reference": "Li A et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Aug 15;23(16)4929-4937.",
      "abstract": null
    },
    {
      "pmid": "28522754",
      "title": "<i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.",
      "journal": "Cancer research",
      "pubDate": "2017 Aug 15",
      "volume": "77",
      "issue": "16",
      "pages": "4498-4505",
      "authors": "Lu X et al",
      "elocationId": "doi: 10.1158/0008-5472.CAN-16-1944",
      "link": null,
      "reference": "Lu X et al. Cancer research. 2017 Aug 15;77(16)4498-4505.",
      "abstract": null
    },
    {
      "pmid": "27987579",
      "title": "Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2016 Dec",
      "volume": "102",
      "issue": "",
      "pages": "118-121",
      "authors": "Dong HJ et al",
      "elocationId": "doi: 10.1016/j.lungcan.2016.11.006",
      "link": null,
      "reference": "Dong HJ et al. Lung cancer (Amsterdam, Netherlands). 2016 Dec;102()118-121.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab96"
  },
  "level": "LEVEL_R2",
  "gene": "MET",
  "alteration": "D1228N",
  "alteration_name": "D1228N",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "27343442",
      "title": "Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2016 Aug",
      "volume": "11",
      "issue": "8",
      "pages": "1242-1245",
      "authors": "Heist RS et al",
      "elocationId": "doi: 10.1016/j.jtho.2016.06.013",
      "link": null,
      "reference": "Heist RS et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Aug;11(8)1242-1245.",
      "abstract": null
    },
    {
      "pmid": "29128427",
      "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2018 Apr",
      "volume": "13",
      "issue": "4",
      "pages": "e49-e53",
      "authors": "Kang J et al",
      "elocationId": "doi: 10.1016/j.jtho.2017.10.028",
      "link": null,
      "reference": "Kang J et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Apr;13(4)e49-e53.",
      "abstract": null
    },
    {
      "pmid": "28396313",
      "title": "Acquired <i>MET</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2017 Aug 15",
      "volume": "23",
      "issue": "16",
      "pages": "4929-4937",
      "authors": "Li A et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-16-3273",
      "link": null,
      "reference": "Li A et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Aug 15;23(16)4929-4937.",
      "abstract": null
    },
    {
      "pmid": "28522754",
      "title": "<i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.",
      "journal": "Cancer research",
      "pubDate": "2017 Aug 15",
      "volume": "77",
      "issue": "16",
      "pages": "4498-4505",
      "authors": "Lu X et al",
      "elocationId": "doi: 10.1158/0008-5472.CAN-16-1944",
      "link": null,
      "reference": "Lu X et al. Cancer research. 2017 Aug 15;77(16)4498-4505.",
      "abstract": null
    },
    {
      "pmid": "27987579",
      "title": "Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2016 Dec",
      "volume": "102",
      "issue": "",
      "pages": "118-121",
      "authors": "Dong HJ et al",
      "elocationId": "doi: 10.1016/j.lungcan.2016.11.006",
      "link": null,
      "reference": "Dong HJ et al. Lung cancer (Amsterdam, Netherlands). 2016 Dec;102()118-121.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab97"
  },
  "level": "LEVEL_R2",
  "gene": "KIT",
  "alteration": "V654A",
  "alteration_name": "V654A",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "18955458",
      "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Nov 20",
      "volume": "26",
      "issue": "33",
      "pages": "5352-9",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1200/JCO.2007.15.7461",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.",
      "abstract": null
    },
    {
      "pmid": "16551858",
      "title": "Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Mar 15",
      "volume": "12",
      "issue": "6",
      "pages": "1743-9",
      "authors": "Wardelmann E et al",
      "elocationId": "",
      "link": null,
      "reference": "Wardelmann E et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Mar 15;12(6)1743-9.",
      "abstract": null
    },
    {
      "pmid": "23840364",
      "title": "Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.",
      "journal": "PloS one",
      "pubDate": "2013",
      "volume": "8",
      "issue": "6",
      "pages": "e65762",
      "authors": "Hsueh YS et al",
      "elocationId": "doi: 10.1371/journal.pone.0065762",
      "link": null,
      "reference": "Hsueh YS et al. PloS one. 2013;8(6)e65762.",
      "abstract": null
    },
    {
      "pmid": "16954519",
      "title": "Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2006 Oct 10",
      "volume": "24",
      "issue": "29",
      "pages": "4764-74",
      "authors": "Heinrich MC et al",
      "elocationId": "",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Oct 10;24(29)4764-74.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab98"
  },
  "level": "LEVEL_R2",
  "gene": "KIT",
  "alteration": "D816",
  "alteration_name": "D816",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "22301675",
      "title": "Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.",
      "journal": "Leukemia",
      "pubDate": "2012 Jul",
      "volume": "26",
      "issue": "7",
      "pages": "1693-5",
      "authors": "Lierman E et al",
      "elocationId": "doi: 10.1038/leu.2012.8",
      "link": null,
      "reference": "Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.",
      "abstract": null
    },
    {
      "pmid": "18955458",
      "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Nov 20",
      "volume": "26",
      "issue": "33",
      "pages": "5352-9",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1200/JCO.2007.15.7461",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.",
      "abstract": null
    },
    {
      "pmid": "23840364",
      "title": "Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.",
      "journal": "PloS one",
      "pubDate": "2013",
      "volume": "8",
      "issue": "6",
      "pages": "e65762",
      "authors": "Hsueh YS et al",
      "elocationId": "doi: 10.1371/journal.pone.0065762",
      "link": null,
      "reference": "Hsueh YS et al. PloS one. 2013;8(6)e65762.",
      "abstract": null
    },
    {
      "pmid": "25239608",
      "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Nov 15",
      "volume": "20",
      "issue": "22",
      "pages": "5745-5755",
      "authors": "Garner AP et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-1397",
      "link": null,
      "reference": "Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab99"
  },
  "level": "LEVEL_R2",
  "gene": "KIT",
  "alteration": "N822",
  "alteration_name": "N822",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Sunitinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "22301675",
      "title": "Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.",
      "journal": "Leukemia",
      "pubDate": "2012 Jul",
      "volume": "26",
      "issue": "7",
      "pages": "1693-5",
      "authors": "Lierman E et al",
      "elocationId": "doi: 10.1038/leu.2012.8",
      "link": null,
      "reference": "Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.",
      "abstract": null
    },
    {
      "pmid": "18955458",
      "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Nov 20",
      "volume": "26",
      "issue": "33",
      "pages": "5352-9",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1200/JCO.2007.15.7461",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.",
      "abstract": null
    },
    {
      "pmid": "23840364",
      "title": "Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.",
      "journal": "PloS one",
      "pubDate": "2013",
      "volume": "8",
      "issue": "6",
      "pages": "e65762",
      "authors": "Hsueh YS et al",
      "elocationId": "doi: 10.1371/journal.pone.0065762",
      "link": null,
      "reference": "Hsueh YS et al. PloS one. 2013;8(6)e65762.",
      "abstract": null
    },
    {
      "pmid": "25239608",
      "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Nov 15",
      "volume": "20",
      "issue": "22",
      "pages": "5745-5755",
      "authors": "Garner AP et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-1397",
      "link": null,
      "reference": "Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab9a"
  },
  "level": "LEVEL_R2",
  "gene": "MET",
  "alteration": "Y1230H",
  "alteration_name": "Y1230H",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "27666659",
      "title": "Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2017 Jan",
      "volume": "12",
      "issue": "1",
      "pages": "137-140",
      "authors": "Ou SI et al",
      "elocationId": "doi: 10.1016/j.jtho.2016.09.119",
      "link": null,
      "reference": "Ou SI et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 Jan;12(1)137-140.",
      "abstract": null
    },
    {
      "pmid": "29128427",
      "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2018 Apr",
      "volume": "13",
      "issue": "4",
      "pages": "e49-e53",
      "authors": "Kang J et al",
      "elocationId": "doi: 10.1016/j.jtho.2017.10.028",
      "link": null,
      "reference": "Kang J et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Apr;13(4)e49-e53.",
      "abstract": null
    },
    {
      "pmid": "28396313",
      "title": "Acquired <i>MET</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2017 Aug 15",
      "volume": "23",
      "issue": "16",
      "pages": "4929-4937",
      "authors": "Li A et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-16-3273",
      "link": null,
      "reference": "Li A et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Aug 15;23(16)4929-4937.",
      "abstract": null
    },
    {
      "pmid": "28522754",
      "title": "<i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.",
      "journal": "Cancer research",
      "pubDate": "2017 Aug 15",
      "volume": "77",
      "issue": "16",
      "pages": "4498-4505",
      "authors": "Lu X et al",
      "elocationId": "doi: 10.1158/0008-5472.CAN-16-1944",
      "link": null,
      "reference": "Lu X et al. Cancer research. 2017 Aug 15;77(16)4498-4505.",
      "abstract": null
    },
    {
      "pmid": "27987579",
      "title": "Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2016 Dec",
      "volume": "102",
      "issue": "",
      "pages": "118-121",
      "authors": "Dong HJ et al",
      "elocationId": "doi: 10.1016/j.lungcan.2016.11.006",
      "link": null,
      "reference": "Dong HJ et al. Lung cancer (Amsterdam, Netherlands). 2016 Dec;102()118-121.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab9b"
  },
  "level": "LEVEL_R2",
  "gene": "MET",
  "alteration": "Y1230H",
  "alteration_name": "Y1230H",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Capmatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "27666659",
      "title": "Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2017 Jan",
      "volume": "12",
      "issue": "1",
      "pages": "137-140",
      "authors": "Ou SI et al",
      "elocationId": "doi: 10.1016/j.jtho.2016.09.119",
      "link": null,
      "reference": "Ou SI et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 Jan;12(1)137-140.",
      "abstract": null
    },
    {
      "pmid": "29128427",
      "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2018 Apr",
      "volume": "13",
      "issue": "4",
      "pages": "e49-e53",
      "authors": "Kang J et al",
      "elocationId": "doi: 10.1016/j.jtho.2017.10.028",
      "link": null,
      "reference": "Kang J et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Apr;13(4)e49-e53.",
      "abstract": null
    },
    {
      "pmid": "28396313",
      "title": "Acquired <i>MET</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2017 Aug 15",
      "volume": "23",
      "issue": "16",
      "pages": "4929-4937",
      "authors": "Li A et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-16-3273",
      "link": null,
      "reference": "Li A et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Aug 15;23(16)4929-4937.",
      "abstract": null
    },
    {
      "pmid": "28522754",
      "title": "<i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.",
      "journal": "Cancer research",
      "pubDate": "2017 Aug 15",
      "volume": "77",
      "issue": "16",
      "pages": "4498-4505",
      "authors": "Lu X et al",
      "elocationId": "doi: 10.1158/0008-5472.CAN-16-1944",
      "link": null,
      "reference": "Lu X et al. Cancer research. 2017 Aug 15;77(16)4498-4505.",
      "abstract": null
    },
    {
      "pmid": "27987579",
      "title": "Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2016 Dec",
      "volume": "102",
      "issue": "",
      "pages": "118-121",
      "authors": "Dong HJ et al",
      "elocationId": "doi: 10.1016/j.lungcan.2016.11.006",
      "link": null,
      "reference": "Dong HJ et al. Lung cancer (Amsterdam, Netherlands). 2016 Dec;102()118-121.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab9c"
  },
  "level": "LEVEL_R2",
  "gene": "ALK",
  "alteration": "G1269A",
  "alteration_name": "G1269A",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "24675041",
      "title": "The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2014 Jun",
      "volume": "4",
      "issue": "6",
      "pages": "662-673",
      "authors": "Friboulet L et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-13-0846",
      "link": null,
      "reference": "Friboulet L et al. Cancer discovery. 2014 Jun;4(6)662-673.",
      "abstract": null
    },
    {
      "pmid": "28434515",
      "title": "Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2017 May",
      "volume": "12",
      "issue": "5",
      "pages": "e49-e51",
      "authors": "Wang HY et al",
      "elocationId": "doi: 10.1016/j.jtho.2017.01.009",
      "link": null,
      "reference": "Wang HY et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017 May;12(5)e49-e51.",
      "abstract": null
    },
    {
      "pmid": "23434628",
      "title": "Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.",
      "journal": "Genomics",
      "pubDate": "2013 Sep",
      "volume": "102",
      "issue": "3",
      "pages": "157-62",
      "authors": "Huang D et al",
      "elocationId": "doi: 10.1016/j.ygeno.2013.02.006",
      "link": null,
      "reference": "Huang D et al. Genomics. 2013 Sep;102(3)157-62.",
      "abstract": null
    },
    {
      "pmid": "23344087",
      "title": "Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2013 Apr",
      "volume": "8",
      "issue": "4",
      "pages": "415-22",
      "authors": "Kim S et al",
      "elocationId": "doi: 10.1097/JTO.0b013e318283dcc0",
      "link": null,
      "reference": "Kim S et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Apr;8(4)415-22.",
      "abstract": null
    },
    {
      "pmid": "22235099",
      "title": "Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Mar 1",
      "volume": "18",
      "issue": "5",
      "pages": "1472-82",
      "authors": "Doebele RC et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-11-2906",
      "link": null,
      "reference": "Doebele RC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Mar 1;18(5)1472-82.",
      "abstract": null
    },
    {
      "pmid": "27045755",
      "title": "Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.",
      "journal": "PloS one",
      "pubDate": "2016",
      "volume": "11",
      "issue": "4",
      "pages": "e0153065",
      "authors": "Saber A et al",
      "elocationId": "doi: 10.1371/journal.pone.0153065",
      "link": null,
      "reference": "Saber A et al. PloS one. 2016;11(4)e0153065.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab9d"
  },
  "level": "LEVEL_R2",
  "gene": "BTK",
  "alteration": "C481F",
  "alteration_name": "C481F",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
  "drug": [
    "Ibrutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "27282255",
      "title": "Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.",
      "journal": "Leukemia",
      "pubDate": "2017 Jan",
      "volume": "31",
      "issue": "1",
      "pages": "177-185",
      "authors": "Hamasy A et al",
      "elocationId": "doi: 10.1038/leu.2016.153",
      "link": null,
      "reference": "Hamasy A et al. Leukemia. 2017 Jan;31(1)177-185.",
      "abstract": null
    },
    {
      "pmid": "26182309",
      "title": "Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.",
      "journal": "JAMA oncology",
      "pubDate": "2015 Apr",
      "volume": "1",
      "issue": "1",
      "pages": "80-7",
      "authors": "Maddocks KJ et al",
      "elocationId": "doi: 10.1001/jamaoncol.2014.218",
      "link": null,
      "reference": "Maddocks KJ et al. JAMA oncology. 2015 Apr;1(1)80-7.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab9e"
  },
  "level": "LEVEL_R2",
  "gene": "EGFR",
  "alteration": "C797S",
  "alteration_name": "C797S",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Osimertinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "28625641",
      "title": "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2017 Jun",
      "volume": "108",
      "issue": "",
      "pages": "228-231",
      "authors": "Ou SI et al",
      "elocationId": "doi: 10.1016/j.lungcan.2017.04.003",
      "link": null,
      "reference": "Ou SI et al. Lung cancer (Amsterdam, Netherlands). 2017 Jun;108()228-231.",
      "abstract": null
    },
    {
      "pmid": "26181354",
      "title": "Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.",
      "journal": "JAMA oncology",
      "pubDate": "2015 Oct",
      "volume": "1",
      "issue": "7",
      "pages": "982-4",
      "authors": "Yu HA et al",
      "elocationId": "doi: 10.1001/jamaoncol.2015.1066",
      "link": null,
      "reference": "Yu HA et al. JAMA oncology. 2015 Oct;1(7)982-4.",
      "abstract": null
    },
    {
      "pmid": "25939061",
      "title": "Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.",
      "journal": "Nature medicine",
      "pubDate": "2015 Jun",
      "volume": "21",
      "issue": "6",
      "pages": "560-2",
      "authors": "Thress KS et al",
      "elocationId": "doi: 10.1038/nm.3854",
      "link": null,
      "reference": "Thress KS et al. Nature medicine. 2015 Jun;21(6)560-2.",
      "abstract": null
    },
    {
      "pmid": "26749488",
      "title": "Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2016 Apr",
      "volume": "11",
      "issue": "4",
      "pages": "e45-7",
      "authors": "Song HN et al",
      "elocationId": "doi: 10.1016/j.jtho.2015.12.093",
      "link": null,
      "reference": "Song HN et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Apr;11(4)e45-7.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fab9f"
  },
  "level": "LEVEL_R2",
  "gene": "KIT",
  "alteration": "D816",
  "alteration_name": "D816",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Sunitinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "22301675",
      "title": "Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.",
      "journal": "Leukemia",
      "pubDate": "2012 Jul",
      "volume": "26",
      "issue": "7",
      "pages": "1693-5",
      "authors": "Lierman E et al",
      "elocationId": "doi: 10.1038/leu.2012.8",
      "link": null,
      "reference": "Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.",
      "abstract": null
    },
    {
      "pmid": "18955458",
      "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Nov 20",
      "volume": "26",
      "issue": "33",
      "pages": "5352-9",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1200/JCO.2007.15.7461",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.",
      "abstract": null
    },
    {
      "pmid": "23840364",
      "title": "Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.",
      "journal": "PloS one",
      "pubDate": "2013",
      "volume": "8",
      "issue": "6",
      "pages": "e65762",
      "authors": "Hsueh YS et al",
      "elocationId": "doi: 10.1371/journal.pone.0065762",
      "link": null,
      "reference": "Hsueh YS et al. PloS one. 2013;8(6)e65762.",
      "abstract": null
    },
    {
      "pmid": "25239608",
      "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Nov 15",
      "volume": "20",
      "issue": "22",
      "pages": "5745-5755",
      "authors": "Garner AP et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-1397",
      "link": null,
      "reference": "Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faba0"
  },
  "level": "LEVEL_R2",
  "gene": "KIT",
  "alteration": "D820",
  "alteration_name": "D820",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "22301675",
      "title": "Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.",
      "journal": "Leukemia",
      "pubDate": "2012 Jul",
      "volume": "26",
      "issue": "7",
      "pages": "1693-5",
      "authors": "Lierman E et al",
      "elocationId": "doi: 10.1038/leu.2012.8",
      "link": null,
      "reference": "Lierman E et al. Leukemia. 2012 Jul;26(7)1693-5.",
      "abstract": null
    },
    {
      "pmid": "18955458",
      "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Nov 20",
      "volume": "26",
      "issue": "33",
      "pages": "5352-9",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1200/JCO.2007.15.7461",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.",
      "abstract": null
    },
    {
      "pmid": "23840364",
      "title": "Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.",
      "journal": "PloS one",
      "pubDate": "2013",
      "volume": "8",
      "issue": "6",
      "pages": "e65762",
      "authors": "Hsueh YS et al",
      "elocationId": "doi: 10.1371/journal.pone.0065762",
      "link": null,
      "reference": "Hsueh YS et al. PloS one. 2013;8(6)e65762.",
      "abstract": null
    },
    {
      "pmid": "25239608",
      "title": "Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Nov 15",
      "volume": "20",
      "issue": "22",
      "pages": "5745-5755",
      "authors": "Garner AP et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-1397",
      "link": null,
      "reference": "Garner AP et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Nov 15;20(22)5745-5755.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faba1"
  },
  "level": "LEVEL_R2",
  "gene": "EGFR",
  "alteration": "D761Y",
  "alteration_name": "D761Y",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Gefitinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17192902",
      "title": "The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.",
      "journal": "International journal of cancer",
      "pubDate": "2007 Mar 15",
      "volume": "120",
      "issue": "6",
      "pages": "1239-47",
      "authors": "Ichihara S et al",
      "elocationId": "",
      "link": null,
      "reference": "Ichihara S et al. International journal of cancer. 2007 Mar 15;120(6)1239-47.",
      "abstract": null
    },
    {
      "pmid": "17085664",
      "title": "Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Nov 1",
      "volume": "12",
      "issue": "21",
      "pages": "6494-501",
      "authors": "Balak MN et al",
      "elocationId": "",
      "link": null,
      "reference": "Balak MN et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Nov 1;12(21)6494-501.",
      "abstract": null
    },
    {
      "pmid": "28424065",
      "title": "Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.",
      "journal": "BMC cancer",
      "pubDate": "2017 Apr 19",
      "volume": "17",
      "issue": "1",
      "pages": "281",
      "authors": "Chiba M et al",
      "elocationId": "doi: 10.1186/s12885-017-3263-z",
      "link": null,
      "reference": "Chiba M et al. BMC cancer. 2017 Apr 19;17(1)281.",
      "abstract": null
    },
    {
      "pmid": "22052230",
      "title": "Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2011 Dec",
      "volume": "6",
      "issue": "12",
      "pages": "2011-7",
      "authors": "Yano S et al",
      "elocationId": "doi: 10.1097/JTO.0b013e31823ab0dd",
      "link": null,
      "reference": "Yano S et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Dec;6(12)2011-7.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faba2"
  },
  "level": "LEVEL_3A",
  "gene": "NTRK3",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Repotrectinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/mct/article/20/12_Supplement/P02-01/675917/Abstract-P02-01-Repotrectinib-in-patients-with",
      "reference": "null. null. .",
      "abstract": "Besse et al. Abstract# P02-01, AACR-NCI-EORTC MTCT 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faba3"
  },
  "level": "LEVEL_3A",
  "gene": "NPM1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "SNDX-5613"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ash.confex.com/ash/2021/webprogram/Paper146944.html",
      "reference": "null. null. .",
      "abstract": "Stein et al. Abstract# 699, ASH 2021"
    },
    {
      "pmid": "31855575",
      "title": "Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2020 Feb 3",
      "volume": "130",
      "issue": "2",
      "pages": "981-997",
      "authors": "Klossowski S et al",
      "elocationId": "doi: 10.1172/JCI129126",
      "link": null,
      "reference": "Klossowski S et al. The Journal of clinical investigation. 2020 Feb 3;130(2)981-997.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faba4"
  },
  "level": "LEVEL_3A",
  "gene": "BRAF",
  "alteration": "L597",
  "alteration_name": "L597",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24933606",
      "title": "Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.",
      "journal": "Melanoma research",
      "pubDate": "2014 Oct",
      "volume": "24",
      "issue": "5",
      "pages": "504-8",
      "authors": "Bowyer SE et al",
      "elocationId": "doi: 10.1097/CMR.0000000000000099",
      "link": null,
      "reference": "Bowyer SE et al. Melanoma research. 2014 Oct;24(5)504-8.",
      "abstract": null
    },
    {
      "pmid": "22798288",
      "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
      "journal": "Cancer discovery",
      "pubDate": "2012 Sep",
      "volume": "2",
      "issue": "9",
      "pages": "791-7",
      "authors": "Dahlman KB et al",
      "elocationId": "",
      "link": null,
      "reference": "Dahlman KB et al. Cancer discovery. 2012 Sep;2(9)791-7.",
      "abstract": null
    },
    {
      "pmid": "29903896",
      "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2018 Dec 15",
      "volume": "24",
      "issue": "24",
      "pages": "6483-6494",
      "authors": "Dankner M et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-17-3384",
      "link": null,
      "reference": "Dankner M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Dec 15;24(24)6483-6494.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faba5"
  },
  "level": "LEVEL_3A",
  "gene": "EGFR",
  "alteration": "Kinase Domain Duplication",
  "alteration_name": "Kinase Domain Duplication",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Afatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28336552",
      "title": "Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.",
      "journal": "Cancer discovery",
      "pubDate": "2017 Jun",
      "volume": "7",
      "issue": "6",
      "pages": "596-609",
      "authors": "Jordan EJ et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-16-1337",
      "link": null,
      "reference": "Jordan EJ et al. Cancer discovery. 2017 Jun;7(6)596-609.",
      "abstract": null
    },
    {
      "pmid": "26286086",
      "title": "EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.",
      "journal": "Cancer discovery",
      "pubDate": "2015 Nov",
      "volume": "5",
      "issue": "11",
      "pages": "1155-63",
      "authors": "Gallant JN et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0654",
      "link": null,
      "reference": "Gallant JN et al. Cancer discovery. 2015 Nov;5(11)1155-63.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faba6"
  },
  "level": "LEVEL_3A",
  "gene": "BRAF",
  "alteration": "K601",
  "alteration_name": "K601",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24933606",
      "title": "Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.",
      "journal": "Melanoma research",
      "pubDate": "2014 Oct",
      "volume": "24",
      "issue": "5",
      "pages": "504-8",
      "authors": "Bowyer SE et al",
      "elocationId": "doi: 10.1097/CMR.0000000000000099",
      "link": null,
      "reference": "Bowyer SE et al. Melanoma research. 2014 Oct;24(5)504-8.",
      "abstract": null
    },
    {
      "pmid": "23248257",
      "title": "Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Feb 1",
      "volume": "31",
      "issue": "4",
      "pages": "482-9",
      "authors": "Kim KB et al",
      "elocationId": "doi: 10.1200/JCO.2012.43.5966",
      "link": null,
      "reference": "Kim KB et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Feb 1;31(4)482-9.",
      "abstract": null
    },
    {
      "pmid": "28344857",
      "title": "Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months.",
      "journal": "Experimental hematology & oncology",
      "pubDate": "2017",
      "volume": "6",
      "issue": "",
      "pages": "6",
      "authors": "Marconcini R et al",
      "elocationId": "doi: 10.1186/s40164-017-0067-4",
      "link": null,
      "reference": "Marconcini R et al. Experimental hematology & oncology. 2017;6()6.",
      "abstract": null
    },
    {
      "pmid": "22798288",
      "title": "BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.",
      "journal": "Cancer discovery",
      "pubDate": "2012 Sep",
      "volume": "2",
      "issue": "9",
      "pages": "791-7",
      "authors": "Dahlman KB et al",
      "elocationId": "",
      "link": null,
      "reference": "Dahlman KB et al. Cancer discovery. 2012 Sep;2(9)791-7.",
      "abstract": null
    },
    {
      "pmid": "29903896",
      "title": "Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2018 Dec 15",
      "volume": "24",
      "issue": "24",
      "pages": "6483-6494",
      "authors": "Dankner M et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-17-3384",
      "link": null,
      "reference": "Dankner M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Dec 15;24(24)6483-6494.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faba7"
  },
  "level": "LEVEL_3A",
  "gene": "RET",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Vandetanib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27803005",
      "title": "Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2017 Feb 1",
      "volume": "28",
      "issue": "2",
      "pages": "292-297",
      "authors": "Lee SH et al",
      "elocationId": "doi: 10.1093/annonc/mdw559",
      "link": null,
      "reference": "Lee SH et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Feb 1;28(2)292-297.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faba8"
  },
  "level": "LEVEL_3A",
  "gene": "NTRK2",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Repotrectinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/mct/article/20/12_Supplement/P02-01/675917/Abstract-P02-01-Repotrectinib-in-patients-with",
      "reference": "null. null. .",
      "abstract": "Besse et al. Abstract# P02-01, AACR-NCI-EORTC MTCT 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faba9"
  },
  "level": "LEVEL_3A",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Talazoparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30110579",
      "title": "Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Aug 23",
      "volume": "379",
      "issue": "8",
      "pages": "753-763",
      "authors": "Litton JK et al",
      "elocationId": "doi: 10.1056/NEJMoa1802905",
      "link": null,
      "reference": "Litton JK et al. The New England journal of medicine. 2018 Aug 23;379(8)753-763.",
      "abstract": null
    },
    {
      "pmid": "36394867",
      "title": "Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2023 Jan 1",
      "volume": "9",
      "issue": "1",
      "pages": "29-39",
      "authors": "Schram AM et al",
      "elocationId": "doi: 10.1001/jamaoncol.2022.5218",
      "link": null,
      "reference": "Schram AM et al. JAMA oncology. 2023 Jan 1;9(1)29-39.",
      "abstract": null
    },
    {
      "pmid": "30563931",
      "title": "A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO).",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2717-2724",
      "authors": "Turner NC et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1891",
      "link": null,
      "reference": "Turner NC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2717-2724.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabaa"
  },
  "level": "LEVEL_3A",
  "gene": "EGFR",
  "alteration": "762_823ins",
  "alteration_name": "Exon 20 in-frame insertions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Poziotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://wclc2018.iaslc.org/wp-content/uploads/2018/09/WCLC2018-Abstract-Book_vF-LR-REV-SEPT-25-2018.pdf",
      "reference": "null. null. .",
      "abstract": "Heymach et al. Abstract# OA02.06, WCLC 2018"
    },
    {
      "pmid": "29686424",
      "title": "Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.",
      "journal": "Nature medicine",
      "pubDate": "2018 May",
      "volume": "24",
      "issue": "5",
      "pages": "638-646",
      "authors": "Robichaux JP et al",
      "elocationId": "doi: 10.1038/s41591-018-0007-9",
      "link": null,
      "reference": "Robichaux JP et al. Nature medicine. 2018 May;24(5)638-646.",
      "abstract": null
    },
    {
      "pmid": "35820397",
      "title": "Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.",
      "journal": "Cancer cell",
      "pubDate": "2022 Jul 11",
      "volume": "40",
      "issue": "7",
      "pages": "754-767.e6",
      "authors": "Elamin YY et al",
      "elocationId": "doi: 10.1016/j.ccell.2022.06.006",
      "link": null,
      "reference": "Elamin YY et al. Cancer cell. 2022 Jul 11;40(7)754-767.e6.",
      "abstract": null
    },
    {
      "pmid": "27188206",
      "title": "A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (<i>EGFR</i>)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors.",
      "journal": "Cancer research and treatment : official journal of Korean Cancer Association",
      "pubDate": "2017 Jan",
      "volume": "49",
      "issue": "1",
      "pages": "10-19",
      "authors": "Han JY et al",
      "elocationId": "doi: 10.4143/crt.2016.058",
      "link": null,
      "reference": "Han JY et al. Cancer research and treatment : official journal of Korean Cancer Association. 2017 Jan;49(1)10-19.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabab"
  },
  "level": "LEVEL_3A",
  "gene": "MAP2K2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30361829",
      "title": "A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.",
      "journal": "International journal of hematology",
      "pubDate": "2019 Feb",
      "volume": "109",
      "issue": "2",
      "pages": "228-232",
      "authors": "Kumamoto T et al",
      "elocationId": "doi: 10.1007/s12185-018-2553-9",
      "link": null,
      "reference": "Kumamoto T et al. International journal of hematology. 2019 Feb;109(2)228-232.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabac"
  },
  "level": "LEVEL_3A",
  "gene": "MAP2K2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30361829",
      "title": "A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.",
      "journal": "International journal of hematology",
      "pubDate": "2019 Feb",
      "volume": "109",
      "issue": "2",
      "pages": "228-232",
      "authors": "Kumamoto T et al",
      "elocationId": "doi: 10.1007/s12185-018-2553-9",
      "link": null,
      "reference": "Kumamoto T et al. International journal of hematology. 2019 Feb;109(2)228-232.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabad"
  },
  "level": "LEVEL_3A",
  "gene": "EGFR",
  "alteration": "729_761ins",
  "alteration_name": "Exon 19 in-frame insertions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erlotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29340050",
      "title": "Molecular characteristics and clinical outcomes of <i>EGFR</i> exon 19 indel subtypes to EGFR TKIs in NSCLC patients.",
      "journal": "Oncotarget",
      "pubDate": "2017 Dec 19",
      "volume": "8",
      "issue": "67",
      "pages": "111246-111257",
      "authors": "Su J et al",
      "elocationId": "doi: 10.18632/oncotarget.22768",
      "link": null,
      "reference": "Su J et al. Oncotarget. 2017 Dec 19;8(67)111246-111257.",
      "abstract": null
    },
    {
      "pmid": "31562956",
      "title": "Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.",
      "journal": "Seminars in cancer biology",
      "pubDate": "2020 Apr",
      "volume": "61",
      "issue": "",
      "pages": "167-179",
      "authors": "Harrison PT et al",
      "elocationId": "doi: 10.1016/j.semcancer.2019.09.015",
      "link": null,
      "reference": "Harrison PT et al. Seminars in cancer biology. 2020 Apr;61()167-179.",
      "abstract": null
    },
    {
      "pmid": "22190593",
      "title": "EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Mar 15",
      "volume": "18",
      "issue": "6",
      "pages": "1790-7",
      "authors": "He M et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-11-2361",
      "link": null,
      "reference": "He M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Mar 15;18(6)1790-7.",
      "abstract": null
    },
    {
      "pmid": "21841502",
      "title": "Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2011 Nov",
      "volume": "6",
      "issue": "11",
      "pages": "1895-901",
      "authors": "De Pas T et al",
      "elocationId": "doi: 10.1097/JTO.0b013e318227e8c6",
      "link": null,
      "reference": "De Pas T et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011 Nov;6(11)1895-901.",
      "abstract": null
    },
    {
      "pmid": "24389445",
      "title": "An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2013 Dec",
      "volume": "8",
      "issue": "12",
      "pages": "e107-8",
      "authors": "Chan AW et al",
      "elocationId": "doi: 10.1097/JTO.0b013e3182a471e0",
      "link": null,
      "reference": "Chan AW et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Dec;8(12)e107-8.",
      "abstract": null
    },
    {
      "pmid": "25279299",
      "title": "Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib.",
      "journal": "SpringerPlus",
      "pubDate": "2014",
      "volume": "3",
      "issue": "",
      "pages": "507",
      "authors": "Agbarya A et al",
      "elocationId": "doi: 10.1186/2193-1801-3-507",
      "link": null,
      "reference": "Agbarya A et al. SpringerPlus. 2014;3()507.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabae"
  },
  "level": "LEVEL_3A",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Pancreatic Cancer",
  "cancer_sub_type": "Pancreatic Adenocarcinoma",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31157963",
      "title": "Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "317-327",
      "authors": "Golan T et al",
      "elocationId": "doi: 10.1056/NEJMoa1903387",
      "link": null,
      "reference": "Golan T et al. The New England journal of medicine. 2019 Jul 25;381(4)317-327.",
      "abstract": null
    },
    {
      "pmid": "32444418",
      "title": "Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2020 Jul 1",
      "volume": "26",
      "issue": "13",
      "pages": "3239-3247",
      "authors": "Park W et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-20-0418",
      "link": null,
      "reference": "Park W et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Jul 1;26(13)3239-3247.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabaf"
  },
  "level": "LEVEL_3A",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Pancreatic Cancer",
  "cancer_sub_type": "Acinar Cell Carcinoma of the Pancreas",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31157963",
      "title": "Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "317-327",
      "authors": "Golan T et al",
      "elocationId": "doi: 10.1056/NEJMoa1903387",
      "link": null,
      "reference": "Golan T et al. The New England journal of medicine. 2019 Jul 25;381(4)317-327.",
      "abstract": null
    },
    {
      "pmid": "32444418",
      "title": "Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2020 Jul 1",
      "volume": "26",
      "issue": "13",
      "pages": "3239-3247",
      "authors": "Park W et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-20-0418",
      "link": null,
      "reference": "Park W et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Jul 1;26(13)3239-3247.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabb0"
  },
  "level": "LEVEL_3A",
  "gene": "ERBB2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Neratinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23220880",
      "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2013 Feb",
      "volume": "3",
      "issue": "2",
      "pages": "224-37",
      "authors": "Bose R et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-12-0349",
      "link": null,
      "reference": "Bose R et al. Cancer discovery. 2013 Feb;3(2)224-37.",
      "abstract": null
    },
    {
      "pmid": "17311002",
      "title": "The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.",
      "journal": "Oncogene",
      "pubDate": "2007 Jul 26",
      "volume": "26",
      "issue": "34",
      "pages": "5023-7",
      "authors": "Minami Y et al",
      "elocationId": "",
      "link": null,
      "reference": "Minami Y et al. Oncogene. 2007 Jul 26;26(34)5023-7.",
      "abstract": null
    },
    {
      "pmid": "29420467",
      "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
      "journal": "Nature",
      "pubDate": "2018 Feb 8",
      "volume": "554",
      "issue": "7691",
      "pages": "189-194",
      "authors": "Hyman DM et al",
      "elocationId": "doi: 10.1038/nature25475",
      "link": null,
      "reference": "Hyman DM et al. Nature. 2018 Feb 8;554(7691)189-194.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabb1"
  },
  "level": "LEVEL_3A",
  "gene": "ERCC2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Bladder Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Cisplatin"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29980530",
      "title": "<i>ERCC2</i> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Feb 1",
      "volume": "25",
      "issue": "3",
      "pages": "977-988",
      "authors": "Li Q et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1001",
      "link": null,
      "reference": "Li Q et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Feb 1;25(3)977-988.",
      "abstract": null
    },
    {
      "pmid": "25096233",
      "title": "Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma.",
      "journal": "Cancer discovery",
      "pubDate": "2014 Oct",
      "volume": "4",
      "issue": "10",
      "pages": "1140-53",
      "authors": "Van Allen EM et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-14-0623",
      "link": null,
      "reference": "Van Allen EM et al. Cancer discovery. 2014 Oct;4(10)1140-53.",
      "abstract": null
    },
    {
      "pmid": "12208738",
      "title": "Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells.",
      "journal": "Cancer research",
      "pubDate": "2002 Sep 1",
      "volume": "62",
      "issue": "17",
      "pages": "4899-902",
      "authors": "Furuta T et al",
      "elocationId": "",
      "link": null,
      "reference": "Furuta T et al. Cancer research. 2002 Sep 1;62(17)4899-902.",
      "abstract": null
    },
    {
      "pmid": "27310333",
      "title": "Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.",
      "journal": "JAMA oncology",
      "pubDate": "2016 Aug 1",
      "volume": "2",
      "issue": "8",
      "pages": "1094-6",
      "authors": "Liu D et al",
      "elocationId": "doi: 10.1001/jamaoncol.2016.1056",
      "link": null,
      "reference": "Liu D et al. JAMA oncology. 2016 Aug 1;2(8)1094-6.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabb2"
  },
  "level": "LEVEL_3A",
  "gene": "AKT1",
  "alteration": "E17K",
  "alteration_name": "E17K",
  "cancer_main_type": "Ovarian Cancer",
  "cancer_sub_type": "",
  "drug": [
    "AZD5363"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22294718",
      "title": "Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2012 Apr",
      "volume": "11",
      "issue": "4",
      "pages": "873-87",
      "authors": "Davies BR et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-11-0824-T",
      "link": null,
      "reference": "Davies BR et al. Molecular cancer therapeutics. 2012 Apr;11(4)873-87.",
      "abstract": null
    },
    {
      "pmid": "28489509",
      "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jul 10",
      "volume": "35",
      "issue": "20",
      "pages": "2251-2259",
      "authors": "Hyman DM et al",
      "elocationId": "doi: 10.1200/JCO.2017.73.0143",
      "link": null,
      "reference": "Hyman DM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jul 10;35(20)2251-2259.",
      "abstract": null
    },
    {
      "pmid": "23394218",
      "title": "Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.",
      "journal": "Journal of medicinal chemistry",
      "pubDate": "2013 Mar 14",
      "volume": "56",
      "issue": "5",
      "pages": "2059-73",
      "authors": "Addie M et al",
      "elocationId": "doi: 10.1021/jm301762v",
      "link": null,
      "reference": "Addie M et al. Journal of medicinal chemistry. 2013 Mar 14;56(5)2059-73.",
      "abstract": null
    },
    {
      "pmid": "26351323",
      "title": "Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Nov",
      "volume": "14",
      "issue": "11",
      "pages": "2441-51",
      "authors": "Davies BR et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0230",
      "link": null,
      "reference": "Davies BR et al. Molecular cancer therapeutics. 2015 Nov;14(11)2441-51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabb3"
  },
  "level": "LEVEL_3A",
  "gene": "AKT1",
  "alteration": "E17K",
  "alteration_name": "E17K",
  "cancer_main_type": "Endometrial Cancer",
  "cancer_sub_type": "",
  "drug": [
    "AZD5363"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22294718",
      "title": "Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2012 Apr",
      "volume": "11",
      "issue": "4",
      "pages": "873-87",
      "authors": "Davies BR et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-11-0824-T",
      "link": null,
      "reference": "Davies BR et al. Molecular cancer therapeutics. 2012 Apr;11(4)873-87.",
      "abstract": null
    },
    {
      "pmid": "28489509",
      "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jul 10",
      "volume": "35",
      "issue": "20",
      "pages": "2251-2259",
      "authors": "Hyman DM et al",
      "elocationId": "doi: 10.1200/JCO.2017.73.0143",
      "link": null,
      "reference": "Hyman DM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jul 10;35(20)2251-2259.",
      "abstract": null
    },
    {
      "pmid": "23394218",
      "title": "Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.",
      "journal": "Journal of medicinal chemistry",
      "pubDate": "2013 Mar 14",
      "volume": "56",
      "issue": "5",
      "pages": "2059-73",
      "authors": "Addie M et al",
      "elocationId": "doi: 10.1021/jm301762v",
      "link": null,
      "reference": "Addie M et al. Journal of medicinal chemistry. 2013 Mar 14;56(5)2059-73.",
      "abstract": null
    },
    {
      "pmid": "26351323",
      "title": "Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Nov",
      "volume": "14",
      "issue": "11",
      "pages": "2441-51",
      "authors": "Davies BR et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0230",
      "link": null,
      "reference": "Davies BR et al. Molecular cancer therapeutics. 2015 Nov;14(11)2441-51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabb4"
  },
  "level": "LEVEL_3A",
  "gene": "KMT2A",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "SNDX-5613"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ash.confex.com/ash/2021/webprogram/Paper146944.html",
      "reference": "null. null. .",
      "abstract": "Stein et al. Abstract# 699, ASH 2021"
    },
    {
      "pmid": "31855575",
      "title": "Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2020 Feb 3",
      "volume": "130",
      "issue": "2",
      "pages": "981-997",
      "authors": "Klossowski S et al",
      "elocationId": "doi: 10.1172/JCI129126",
      "link": null,
      "reference": "Klossowski S et al. The Journal of clinical investigation. 2020 Feb 3;130(2)981-997.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabb5"
  },
  "level": "LEVEL_3A",
  "gene": "JAK2",
  "alteration": "PCM1-JAK2 Fusion",
  "alteration_name": "PCM1-JAK2 Fusion",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Eosinophilic Leukemia, NOS",
  "drug": [
    "Ruxolitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "25207766",
      "title": "Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.",
      "journal": "The New England journal of medicine",
      "pubDate": "2014 Sep 11",
      "volume": "371",
      "issue": "11",
      "pages": "1005-15",
      "authors": "Roberts KG et al",
      "elocationId": "doi: 10.1056/NEJMoa1403088",
      "link": null,
      "reference": "Roberts KG et al. The New England journal of medicine. 2014 Sep 11;371(11)1005-15.",
      "abstract": null
    },
    {
      "pmid": "25515960",
      "title": "The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.",
      "journal": "Blood",
      "pubDate": "2015 Feb 19",
      "volume": "125",
      "issue": "8",
      "pages": "1282-91",
      "authors": "Schinnerl D et al",
      "elocationId": "doi: 10.1182/blood-2014-04-570960",
      "link": null,
      "reference": "Schinnerl D et al. Blood. 2015 Feb 19;125(8)1282-91.",
      "abstract": null
    },
    {
      "pmid": "23630205",
      "title": "Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Jun 10",
      "volume": "31",
      "issue": "17",
      "pages": "e269-71",
      "authors": "Rumi E et al",
      "elocationId": "doi: 10.1200/JCO.2012.46.4370",
      "link": null,
      "reference": "Rumi E et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jun 10;31(17)e269-71.",
      "abstract": null
    },
    {
      "pmid": "23400675",
      "title": "Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.",
      "journal": "Annals of hematology",
      "pubDate": "2013 Jun",
      "volume": "92",
      "issue": "6",
      "pages": "759-69",
      "authors": "Patterer V et al",
      "elocationId": "doi: 10.1007/s00277-013-1695-3",
      "link": null,
      "reference": "Patterer V et al. Annals of hematology. 2013 Jun;92(6)759-69.",
      "abstract": null
    },
    {
      "pmid": "22875628",
      "title": "Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements.",
      "journal": "Haematologica",
      "pubDate": "2013 Mar",
      "volume": "98",
      "issue": "3",
      "pages": "404-8",
      "authors": "Chase A et al",
      "elocationId": "doi: 10.3324/haematol.2012.067959",
      "link": null,
      "reference": "Chase A et al. Haematologica. 2013 Mar;98(3)404-8.",
      "abstract": null
    },
    {
      "pmid": "26202607",
      "title": "Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.",
      "journal": "Annals of hematology",
      "pubDate": "2015 Nov",
      "volume": "94",
      "issue": "11",
      "pages": "1927-8",
      "authors": "Rumi E et al",
      "elocationId": "doi: 10.1007/s00277-015-2451-7",
      "link": null,
      "reference": "Rumi E et al. Annals of hematology. 2015 Nov;94(11)1927-8.",
      "abstract": null
    },
    {
      "pmid": "25260694",
      "title": "Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.",
      "journal": "Annals of hematology",
      "pubDate": "2015 Feb",
      "volume": "94",
      "issue": "2",
      "pages": "233-8",
      "authors": "Schwaab J et al",
      "elocationId": "doi: 10.1007/s00277-014-2221-y",
      "link": null,
      "reference": "Schwaab J et al. Annals of hematology. 2015 Feb;94(2)233-8.",
      "abstract": null
    },
    {
      "pmid": "22899477",
      "title": "Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia.",
      "journal": "Blood",
      "pubDate": "2012 Aug 16",
      "volume": "120",
      "issue": "7",
      "pages": "1529-31",
      "authors": "Lierman E et al",
      "elocationId": "doi: 10.1182/blood-2012-06-433821",
      "link": null,
      "reference": "Lierman E et al. Blood. 2012 Aug 16;120(7)1529-31.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabb6"
  },
  "level": "LEVEL_3A",
  "gene": "NRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Thyroid Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Iodine I 131-6-Beta-Iodomethyl-19-Norcholesterol",
    "Selumetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22105174",
      "title": "Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2011 Dec",
      "volume": "121",
      "issue": "12",
      "pages": "4700-11",
      "authors": "Chakravarty D et al",
      "elocationId": "doi: 10.1172/JCI46382",
      "link": null,
      "reference": "Chakravarty D et al. The Journal of clinical investigation. 2011 Dec;121(12)4700-11.",
      "abstract": null
    },
    {
      "pmid": "23406027",
      "title": "Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2013 Feb 14",
      "volume": "368",
      "issue": "7",
      "pages": "623-32",
      "authors": "Ho AL et al",
      "elocationId": "doi: 10.1056/NEJMoa1209288",
      "link": null,
      "reference": "Ho AL et al. The New England journal of medicine. 2013 Feb 14;368(7)623-32.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabb7"
  },
  "level": "LEVEL_3A",
  "gene": "KRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    },
    {
      "pmid": "30361829",
      "title": "A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.",
      "journal": "International journal of hematology",
      "pubDate": "2019 Feb",
      "volume": "109",
      "issue": "2",
      "pages": "228-232",
      "authors": "Kumamoto T et al",
      "elocationId": "doi: 10.1007/s12185-018-2553-9",
      "link": null,
      "reference": "Kumamoto T et al. International journal of hematology. 2019 Feb;109(2)228-232.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabb8"
  },
  "level": "LEVEL_3A",
  "gene": "KRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29236635",
      "title": "Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Dec 14",
      "volume": "377",
      "issue": "24",
      "pages": "2398-2399",
      "authors": "Jacobsen E et al",
      "elocationId": "doi: 10.1056/NEJMc1713676",
      "link": null,
      "reference": "Jacobsen E et al. The New England journal of medicine. 2017 Dec 14;377(24)2398-2399.",
      "abstract": null
    },
    {
      "pmid": "30361829",
      "title": "A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.",
      "journal": "International journal of hematology",
      "pubDate": "2019 Feb",
      "volume": "109",
      "issue": "2",
      "pages": "228-232",
      "authors": "Kumamoto T et al",
      "elocationId": "doi: 10.1007/s12185-018-2553-9",
      "link": null,
      "reference": "Kumamoto T et al. International journal of hematology. 2019 Feb;109(2)228-232.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabb9"
  },
  "level": "LEVEL_3A",
  "gene": "FLT3",
  "alteration": "572_630ins",
  "alteration_name": "Internal tandem duplication",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Sorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "18230792",
      "title": "Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.",
      "journal": "Journal of the National Cancer Institute",
      "pubDate": "2008 Feb 6",
      "volume": "100",
      "issue": "3",
      "pages": "184-98",
      "authors": "Zhang W et al",
      "elocationId": "doi: 10.1093/jnci/djm328",
      "link": null,
      "reference": "Zhang W et al. Journal of the National Cancer Institute. 2008 Feb 6;100(3)184-98.",
      "abstract": null
    },
    {
      "pmid": "22368270",
      "title": "Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.",
      "journal": "Blood",
      "pubDate": "2012 May 31",
      "volume": "119",
      "issue": "22",
      "pages": "5133-43",
      "authors": "Man CH et al",
      "elocationId": "doi: 10.1182/blood-2011-06-363960",
      "link": null,
      "reference": "Man CH et al. Blood. 2012 May 31;119(22)5133-43.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabba"
  },
  "level": "LEVEL_3A",
  "gene": "KRAS",
  "alteration": "G12C",
  "alteration_name": "G12C",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Adagrasib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://oncologypro.esmo.org/meeting-resources/esmo-congress/krystal-1-updated-efficacy-and-safety-of-adagrasib-mrtx849-with-or-without-cetuximab-in-patients-with-advanced-colorectal-cancer-crc-harboring",
      "reference": "null. null. .",
      "abstract": "Weiss et al. Abstract #LBA24, ESMO 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabbb"
  },
  "level": "LEVEL_3A",
  "gene": "KRAS",
  "alteration": "G12C",
  "alteration_name": "G12C",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Adagrasib",
    "Cetuximab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://oncologypro.esmo.org/meeting-resources/esmo-congress/krystal-1-updated-efficacy-and-safety-of-adagrasib-mrtx849-with-or-without-cetuximab-in-patients-with-advanced-colorectal-cancer-crc-harboring",
      "reference": "null. null. .",
      "abstract": "Weiss et al. Abstract #LBA24, ESMO 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabbc"
  },
  "level": "LEVEL_3A",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2527",
      "reference": "null. null. .",
      "abstract": "Dhawan, MS et al. JCO. Abstract# 2527"
    },
    {
      "pmid": "28578601",
      "title": "Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Aug 10",
      "volume": "377",
      "issue": "6",
      "pages": "523-533",
      "authors": "Robson M et al",
      "elocationId": "doi: 10.1056/NEJMoa1706450",
      "link": null,
      "reference": "Robson M et al. The New England journal of medicine. 2017 Aug 10;377(6)523-533.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabbd"
  },
  "level": "LEVEL_3A",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Pancreatic Cancer",
  "cancer_sub_type": "Pancreatic Adenocarcinoma",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31157963",
      "title": "Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "317-327",
      "authors": "Golan T et al",
      "elocationId": "doi: 10.1056/NEJMoa1903387",
      "link": null,
      "reference": "Golan T et al. The New England journal of medicine. 2019 Jul 25;381(4)317-327.",
      "abstract": null
    },
    {
      "pmid": "32444418",
      "title": "Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2020 Jul 1",
      "volume": "26",
      "issue": "13",
      "pages": "3239-3247",
      "authors": "Park W et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-20-0418",
      "link": null,
      "reference": "Park W et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Jul 1;26(13)3239-3247.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabbe"
  },
  "level": "LEVEL_3A",
  "gene": "BRCA2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Pancreatic Cancer",
  "cancer_sub_type": "Acinar Cell Carcinoma of the Pancreas",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31157963",
      "title": "Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "317-327",
      "authors": "Golan T et al",
      "elocationId": "doi: 10.1056/NEJMoa1903387",
      "link": null,
      "reference": "Golan T et al. The New England journal of medicine. 2019 Jul 25;381(4)317-327.",
      "abstract": null
    },
    {
      "pmid": "32444418",
      "title": "Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2020 Jul 1",
      "volume": "26",
      "issue": "13",
      "pages": "3239-3247",
      "authors": "Park W et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-20-0418",
      "link": null,
      "reference": "Park W et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Jul 1;26(13)3239-3247.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabbf"
  },
  "level": "LEVEL_3A",
  "gene": "FGFR1",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "Lung Squamous Cell Carcinoma",
  "drug": [
    "Erdafitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabc0"
  },
  "level": "LEVEL_3A",
  "gene": "FGFR1",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "Lung Squamous Cell Carcinoma",
  "drug": [
    "Infigratinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabc1"
  },
  "level": "LEVEL_3A",
  "gene": "FGFR1",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "Lung Squamous Cell Carcinoma",
  "drug": [
    "Debio1347"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabc2"
  },
  "level": "LEVEL_3A",
  "gene": "NRG1",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Seribantumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3006",
      "reference": "null. null. .",
      "abstract": "Carrizosa et al. Abstract# 3006, ASCO 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabc3"
  },
  "level": "LEVEL_3A",
  "gene": "MTOR",
  "alteration": "E2014K",
  "alteration_name": "E2014K",
  "cancer_main_type": "Bladder Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Everolimus"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24625776",
      "title": "Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.",
      "journal": "Cancer discovery",
      "pubDate": "2014 May",
      "volume": "4",
      "issue": "5",
      "pages": "546-53",
      "authors": "Wagle N et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-13-0353",
      "link": null,
      "reference": "Wagle N et al. Cancer discovery. 2014 May;4(5)546-53.",
      "abstract": null
    },
    {
      "pmid": "23551593",
      "title": "Phase II study of everolimus in metastatic urothelial cancer.",
      "journal": "BJU international",
      "pubDate": "2013 Aug",
      "volume": "112",
      "issue": "4",
      "pages": "462-70",
      "authors": "Milowsky MI et al",
      "elocationId": "doi: 10.1111/j.1464-410X.2012.11720.x",
      "link": null,
      "reference": "Milowsky MI et al. BJU international. 2013 Aug;112(4)462-70.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabc4"
  },
  "level": "LEVEL_3A",
  "gene": "MTOR",
  "alteration": "E2419K",
  "alteration_name": "E2419K",
  "cancer_main_type": "Bladder Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Everolimus"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24625776",
      "title": "Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.",
      "journal": "Cancer discovery",
      "pubDate": "2014 May",
      "volume": "4",
      "issue": "5",
      "pages": "546-53",
      "authors": "Wagle N et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-13-0353",
      "link": null,
      "reference": "Wagle N et al. Cancer discovery. 2014 May;4(5)546-53.",
      "abstract": null
    },
    {
      "pmid": "23551593",
      "title": "Phase II study of everolimus in metastatic urothelial cancer.",
      "journal": "BJU international",
      "pubDate": "2013 Aug",
      "volume": "112",
      "issue": "4",
      "pages": "462-70",
      "authors": "Milowsky MI et al",
      "elocationId": "doi: 10.1111/j.1464-410X.2012.11720.x",
      "link": null,
      "reference": "Milowsky MI et al. BJU international. 2013 Aug;112(4)462-70.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabc5"
  },
  "level": "LEVEL_3A",
  "gene": "TSC2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Soft Tissue Sarcoma",
  "cancer_sub_type": "Perivascular Epithelioid Cell Tumor",
  "drug": [
    "ABI-009"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.11005",
      "reference": "null. null. .",
      "abstract": "Wagner et al. Abstract# 11005, ASCO 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.11516",
      "reference": "null. null. .",
      "abstract": "Wagner et al. Abstract# 11516, ASCO 2020"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabc6"
  },
  "level": "LEVEL_3A",
  "gene": "TSC2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Uterine Sarcoma",
  "cancer_sub_type": "Uterine Perivascular Epithelioid Cell Tumor",
  "drug": [
    "ABI-009"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.11005",
      "reference": "null. null. .",
      "abstract": "Wagner et al. Abstract# 11005, ASCO 2019"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.11516",
      "reference": "null. null. .",
      "abstract": "Wagner et al. Abstract# 11516, ASCO 2020"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabc7"
  },
  "level": "LEVEL_3A",
  "gene": "EGFR",
  "alteration": "L858R",
  "alteration_name": "L858R",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Patritumab Deruxtecan"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31661465",
      "title": "U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2020 Jan 2",
      "volume": "130",
      "issue": "1",
      "pages": "374-388",
      "authors": "Haratani K et al",
      "elocationId": "doi: 10.1172/JCI126598",
      "link": null,
      "reference": "Haratani K et al. The Journal of clinical investigation. 2020 Jan 2;130(1)374-388.",
      "abstract": null
    },
    {
      "pmid": "34548309",
      "title": "Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2022 Jan",
      "volume": "12",
      "issue": "1",
      "pages": "74-89",
      "authors": "Jänne PA et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-21-0715",
      "link": null,
      "reference": "Jänne PA et al. Cancer discovery. 2022 Jan;12(1)74-89.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabc8"
  },
  "level": "LEVEL_3A",
  "gene": "EGFR",
  "alteration": "S768I",
  "alteration_name": "S768I",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Patritumab Deruxtecan"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31661465",
      "title": "U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2020 Jan 2",
      "volume": "130",
      "issue": "1",
      "pages": "374-388",
      "authors": "Haratani K et al",
      "elocationId": "doi: 10.1172/JCI126598",
      "link": null,
      "reference": "Haratani K et al. The Journal of clinical investigation. 2020 Jan 2;130(1)374-388.",
      "abstract": null
    },
    {
      "pmid": "34548309",
      "title": "Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2022 Jan",
      "volume": "12",
      "issue": "1",
      "pages": "74-89",
      "authors": "Jänne PA et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-21-0715",
      "link": null,
      "reference": "Jänne PA et al. Cancer discovery. 2022 Jan;12(1)74-89.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabc9"
  },
  "level": "LEVEL_3A",
  "gene": "EGFR",
  "alteration": "G719",
  "alteration_name": "G719",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Patritumab Deruxtecan"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31661465",
      "title": "U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2020 Jan 2",
      "volume": "130",
      "issue": "1",
      "pages": "374-388",
      "authors": "Haratani K et al",
      "elocationId": "doi: 10.1172/JCI126598",
      "link": null,
      "reference": "Haratani K et al. The Journal of clinical investigation. 2020 Jan 2;130(1)374-388.",
      "abstract": null
    },
    {
      "pmid": "34548309",
      "title": "Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2022 Jan",
      "volume": "12",
      "issue": "1",
      "pages": "74-89",
      "authors": "Jänne PA et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-21-0715",
      "link": null,
      "reference": "Jänne PA et al. Cancer discovery. 2022 Jan;12(1)74-89.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabca"
  },
  "level": "LEVEL_3A",
  "gene": "EGFR",
  "alteration": "L861Q",
  "alteration_name": "L861Q",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Patritumab Deruxtecan"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31661465",
      "title": "U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2020 Jan 2",
      "volume": "130",
      "issue": "1",
      "pages": "374-388",
      "authors": "Haratani K et al",
      "elocationId": "doi: 10.1172/JCI126598",
      "link": null,
      "reference": "Haratani K et al. The Journal of clinical investigation. 2020 Jan 2;130(1)374-388.",
      "abstract": null
    },
    {
      "pmid": "34548309",
      "title": "Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2022 Jan",
      "volume": "12",
      "issue": "1",
      "pages": "74-89",
      "authors": "Jänne PA et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-21-0715",
      "link": null,
      "reference": "Jänne PA et al. Cancer discovery. 2022 Jan;12(1)74-89.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabcb"
  },
  "level": "LEVEL_3A",
  "gene": "EGFR",
  "alteration": "729_761del",
  "alteration_name": "Exon 19 in-frame deletions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Patritumab Deruxtecan"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31661465",
      "title": "U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2020 Jan 2",
      "volume": "130",
      "issue": "1",
      "pages": "374-388",
      "authors": "Haratani K et al",
      "elocationId": "doi: 10.1172/JCI126598",
      "link": null,
      "reference": "Haratani K et al. The Journal of clinical investigation. 2020 Jan 2;130(1)374-388.",
      "abstract": null
    },
    {
      "pmid": "34548309",
      "title": "Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2022 Jan",
      "volume": "12",
      "issue": "1",
      "pages": "74-89",
      "authors": "Jänne PA et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-21-0715",
      "link": null,
      "reference": "Jänne PA et al. Cancer discovery. 2022 Jan;12(1)74-89.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabcc"
  },
  "level": "LEVEL_3A",
  "gene": "EGFR",
  "alteration": "729_761ins",
  "alteration_name": "Exon 19 in-frame insertions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Patritumab Deruxtecan"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31661465",
      "title": "U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2020 Jan 2",
      "volume": "130",
      "issue": "1",
      "pages": "374-388",
      "authors": "Haratani K et al",
      "elocationId": "doi: 10.1172/JCI126598",
      "link": null,
      "reference": "Haratani K et al. The Journal of clinical investigation. 2020 Jan 2;130(1)374-388.",
      "abstract": null
    },
    {
      "pmid": "34548309",
      "title": "Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2022 Jan",
      "volume": "12",
      "issue": "1",
      "pages": "74-89",
      "authors": "Jänne PA et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-21-0715",
      "link": null,
      "reference": "Jänne PA et al. Cancer discovery. 2022 Jan;12(1)74-89.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabcd"
  },
  "level": "LEVEL_3A",
  "gene": "PTCH1",
  "alteration": "Truncating Mutations",
  "alteration_name": "Truncating Mutations",
  "cancer_main_type": "Embryonal Tumor",
  "cancer_sub_type": "Medulloblastoma",
  "drug": [
    "Sonidegib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24900187",
      "title": "Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.",
      "journal": "ACS medicinal chemistry letters",
      "pubDate": "2010 Jun 10",
      "volume": "1",
      "issue": "3",
      "pages": "130-4",
      "authors": "Pan S et al",
      "elocationId": "doi: 10.1021/ml1000307",
      "link": null,
      "reference": "Pan S et al. ACS medicinal chemistry letters. 2010 Jun 10;1(3)130-4.",
      "abstract": null
    },
    {
      "pmid": "26169613",
      "title": "Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Aug 20",
      "volume": "33",
      "issue": "24",
      "pages": "2646-54",
      "authors": "Robinson GW et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.1591",
      "link": null,
      "reference": "Robinson GW et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Aug 20;33(24)2646-54.",
      "abstract": null
    },
    {
      "pmid": "24523439",
      "title": "A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Apr 1",
      "volume": "20",
      "issue": "7",
      "pages": "1900-9",
      "authors": "Rodon J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-13-1710",
      "link": null,
      "reference": "Rodon J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Apr 1;20(7)1900-9.",
      "abstract": null
    },
    {
      "pmid": "29515801",
      "title": "Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression.",
      "journal": "Oncotarget",
      "pubDate": "2018 Feb 9",
      "volume": "9",
      "issue": "11",
      "pages": "10175-10183",
      "authors": "Petrirena GJ et al",
      "elocationId": "doi: 10.18632/oncotarget.23699",
      "link": null,
      "reference": "Petrirena GJ et al. Oncotarget. 2018 Feb 9;9(11)10175-10183.",
      "abstract": null
    },
    {
      "pmid": "32923880",
      "title": "Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma.",
      "journal": "JCO precision oncology",
      "pubDate": "2020",
      "volume": "4",
      "issue": "",
      "pages": "",
      "authors": "Kian W et al",
      "elocationId": "pii: PO.19.00264. doi: 10.1200/PO.19.00264",
      "link": null,
      "reference": "Kian W et al. JCO precision oncology. 2020;4().",
      "abstract": null
    },
    {
      "pmid": "31362788",
      "title": "Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.",
      "journal": "Acta neuropathologica communications",
      "pubDate": "2019 Jul 30",
      "volume": "7",
      "issue": "1",
      "pages": "123",
      "authors": "Li Y et al",
      "elocationId": "doi: 10.1186/s40478-019-0773-8",
      "link": null,
      "reference": "Li Y et al. Acta neuropathologica communications. 2019 Jul 30;7(1)123.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabce"
  },
  "level": "LEVEL_3A",
  "gene": "PTCH1",
  "alteration": "Truncating Mutations",
  "alteration_name": "Truncating Mutations",
  "cancer_main_type": "Embryonal Tumor",
  "cancer_sub_type": "Medulloblastoma",
  "drug": [
    "Vismodegib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24900187",
      "title": "Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist.",
      "journal": "ACS medicinal chemistry letters",
      "pubDate": "2010 Jun 10",
      "volume": "1",
      "issue": "3",
      "pages": "130-4",
      "authors": "Pan S et al",
      "elocationId": "doi: 10.1021/ml1000307",
      "link": null,
      "reference": "Pan S et al. ACS medicinal chemistry letters. 2010 Jun 10;1(3)130-4.",
      "abstract": null
    },
    {
      "pmid": "26169613",
      "title": "Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Aug 20",
      "volume": "33",
      "issue": "24",
      "pages": "2646-54",
      "authors": "Robinson GW et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.1591",
      "link": null,
      "reference": "Robinson GW et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Aug 20;33(24)2646-54.",
      "abstract": null
    },
    {
      "pmid": "24523439",
      "title": "A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Apr 1",
      "volume": "20",
      "issue": "7",
      "pages": "1900-9",
      "authors": "Rodon J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-13-1710",
      "link": null,
      "reference": "Rodon J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Apr 1;20(7)1900-9.",
      "abstract": null
    },
    {
      "pmid": "29515801",
      "title": "Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression.",
      "journal": "Oncotarget",
      "pubDate": "2018 Feb 9",
      "volume": "9",
      "issue": "11",
      "pages": "10175-10183",
      "authors": "Petrirena GJ et al",
      "elocationId": "doi: 10.18632/oncotarget.23699",
      "link": null,
      "reference": "Petrirena GJ et al. Oncotarget. 2018 Feb 9;9(11)10175-10183.",
      "abstract": null
    },
    {
      "pmid": "32923880",
      "title": "Vismodegib as First-Line Treatment of Mutated Sonic Hedgehog Pathway in Adult Medulloblastoma.",
      "journal": "JCO precision oncology",
      "pubDate": "2020",
      "volume": "4",
      "issue": "",
      "pages": "",
      "authors": "Kian W et al",
      "elocationId": "pii: PO.19.00264. doi: 10.1200/PO.19.00264",
      "link": null,
      "reference": "Kian W et al. JCO precision oncology. 2020;4().",
      "abstract": null
    },
    {
      "pmid": "31362788",
      "title": "Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.",
      "journal": "Acta neuropathologica communications",
      "pubDate": "2019 Jul 30",
      "volume": "7",
      "issue": "1",
      "pages": "123",
      "authors": "Li Y et al",
      "elocationId": "doi: 10.1186/s40478-019-0773-8",
      "link": null,
      "reference": "Li Y et al. Acta neuropathologica communications. 2019 Jul 30;7(1)123.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabcf"
  },
  "level": "LEVEL_3A",
  "gene": "KMT2A",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "SNDX-5613"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ash.confex.com/ash/2021/webprogram/Paper146944.html",
      "reference": "null. null. .",
      "abstract": "Stein et al. Abstract# 699, ASH 2021"
    },
    {
      "pmid": "31855575",
      "title": "Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2020 Feb 3",
      "volume": "130",
      "issue": "2",
      "pages": "981-997",
      "authors": "Klossowski S et al",
      "elocationId": "doi: 10.1172/JCI129126",
      "link": null,
      "reference": "Klossowski S et al. The Journal of clinical investigation. 2020 Feb 3;130(2)981-997.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabd0"
  },
  "level": "LEVEL_3A",
  "gene": "MTOR",
  "alteration": "L2427Q",
  "alteration_name": "L2427Q",
  "cancer_main_type": "Renal Cell Carcinoma",
  "cancer_sub_type": "",
  "drug": [
    "Temsirolimus"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26831717",
      "title": "Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2016 May 15",
      "volume": "22",
      "issue": "10",
      "pages": "2445-2452",
      "authors": "Kwiatkowski DJ et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-15-2631",
      "link": null,
      "reference": "Kwiatkowski DJ et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 May 15;22(10)2445-2452.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabd1"
  },
  "level": "LEVEL_3A",
  "gene": "MTOR",
  "alteration": "L2209V",
  "alteration_name": "L2209V",
  "cancer_main_type": "Renal Cell Carcinoma",
  "cancer_sub_type": "",
  "drug": [
    "Temsirolimus"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26831717",
      "title": "Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2016 May 15",
      "volume": "22",
      "issue": "10",
      "pages": "2445-2452",
      "authors": "Kwiatkowski DJ et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-15-2631",
      "link": null,
      "reference": "Kwiatkowski DJ et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 May 15;22(10)2445-2452.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabd2"
  },
  "level": "LEVEL_3A",
  "gene": "NRG1",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Zenocutuzumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.105",
      "reference": "null. null. .",
      "abstract": "Schram et al. Abstract#  105, ASCO 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabd3"
  },
  "level": "LEVEL_3A",
  "gene": "BRAF",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26072686",
      "title": "Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.",
      "journal": "Pigment cell & melanoma research",
      "pubDate": "2015 Sep",
      "volume": "28",
      "issue": "5",
      "pages": "607-10",
      "authors": "Menzies AM et al",
      "elocationId": "doi: 10.1111/pcmr.12388",
      "link": null,
      "reference": "Menzies AM et al. Pigment cell & melanoma research. 2015 Sep;28(5)607-10.",
      "abstract": null
    },
    {
      "pmid": "24345920",
      "title": "BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2013 Dec 15",
      "volume": "19",
      "issue": "24",
      "pages": "6696-702",
      "authors": "Hutchinson KE et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-13-1746",
      "link": null,
      "reference": "Hutchinson KE et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Dec 15;19(24)6696-702.",
      "abstract": null
    },
    {
      "pmid": "26314551",
      "title": "The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.",
      "journal": "International journal of cancer",
      "pubDate": "2016 Feb 15",
      "volume": "138",
      "issue": "4",
      "pages": "881-90",
      "authors": "Ross JS et al",
      "elocationId": "doi: 10.1002/ijc.29825",
      "link": null,
      "reference": "Ross JS et al. International journal of cancer. 2016 Feb 15;138(4)881-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabd4"
  },
  "level": "LEVEL_3A",
  "gene": "BRAF",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26072686",
      "title": "Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.",
      "journal": "Pigment cell & melanoma research",
      "pubDate": "2015 Sep",
      "volume": "28",
      "issue": "5",
      "pages": "607-10",
      "authors": "Menzies AM et al",
      "elocationId": "doi: 10.1111/pcmr.12388",
      "link": null,
      "reference": "Menzies AM et al. Pigment cell & melanoma research. 2015 Sep;28(5)607-10.",
      "abstract": null
    },
    {
      "pmid": "24345920",
      "title": "BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2013 Dec 15",
      "volume": "19",
      "issue": "24",
      "pages": "6696-702",
      "authors": "Hutchinson KE et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-13-1746",
      "link": null,
      "reference": "Hutchinson KE et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Dec 15;19(24)6696-702.",
      "abstract": null
    },
    {
      "pmid": "26314551",
      "title": "The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.",
      "journal": "International journal of cancer",
      "pubDate": "2016 Feb 15",
      "volume": "138",
      "issue": "4",
      "pages": "881-90",
      "authors": "Ross JS et al",
      "elocationId": "doi: 10.1002/ijc.29825",
      "link": null,
      "reference": "Ross JS et al. International journal of cancer. 2016 Feb 15;138(4)881-90.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabd5"
  },
  "level": "LEVEL_3A",
  "gene": "RAF1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30361829",
      "title": "A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.",
      "journal": "International journal of hematology",
      "pubDate": "2019 Feb",
      "volume": "109",
      "issue": "2",
      "pages": "228-232",
      "authors": "Kumamoto T et al",
      "elocationId": "doi: 10.1007/s12185-018-2553-9",
      "link": null,
      "reference": "Kumamoto T et al. International journal of hematology. 2019 Feb;109(2)228-232.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabd6"
  },
  "level": "LEVEL_3A",
  "gene": "RAF1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30361829",
      "title": "A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.",
      "journal": "International journal of hematology",
      "pubDate": "2019 Feb",
      "volume": "109",
      "issue": "2",
      "pages": "228-232",
      "authors": "Kumamoto T et al",
      "elocationId": "doi: 10.1007/s12185-018-2553-9",
      "link": null,
      "reference": "Kumamoto T et al. International journal of hematology. 2019 Feb;109(2)228-232.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabd7"
  },
  "level": "LEVEL_3A",
  "gene": "TP53",
  "alteration": "Y220C",
  "alteration_name": "Y220C",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "PC14586"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3003",
      "reference": "null. null. .",
      "abstract": "Dumbrava et al. Abstract# 3003, ASCO 2022"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/cancerres/article/81/13_Supplement/LB006/669897/Abstract-LB006-PC14586-The-first-orally",
      "reference": "null. null. .",
      "abstract": "Dumble et al. Abstract# LB006, AACR 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabd8"
  },
  "level": "LEVEL_3A",
  "gene": "NTRK1",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Repotrectinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/mct/article/20/12_Supplement/P02-01/675917/Abstract-P02-01-Repotrectinib-in-patients-with",
      "reference": "null. null. .",
      "abstract": "Besse et al. Abstract# P02-01, AACR-NCI-EORTC MTCT 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabd9"
  },
  "level": "LEVEL_3A",
  "gene": "IDH1",
  "alteration": "R132",
  "alteration_name": "R132",
  "cancer_main_type": "Glioma",
  "cancer_sub_type": "",
  "drug": [
    "Ivosidenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29670690",
      "title": "Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.",
      "journal": "ACS medicinal chemistry letters",
      "pubDate": "2018 Apr 12",
      "volume": "9",
      "issue": "4",
      "pages": "300-305",
      "authors": "Popovici-Muller J et al",
      "elocationId": "doi: 10.1021/acsmedchemlett.7b00421",
      "link": null,
      "reference": "Popovici-Muller J et al. ACS medicinal chemistry letters. 2018 Apr 12;9(4)300-305.",
      "abstract": null
    },
    {
      "pmid": "32530764",
      "title": "Ivosidenib in Isocitrate Dehydrogenase 1<i>-</i>Mutated Advanced Glioma.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2020 Oct 10",
      "volume": "38",
      "issue": "29",
      "pages": "3398-3406",
      "authors": "Mellinghoff IK et al",
      "elocationId": "doi: 10.1200/JCO.19.03327",
      "link": null,
      "reference": "Mellinghoff IK et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Oct 10;38(29)3398-3406.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabda"
  },
  "level": "LEVEL_3A",
  "gene": "BRAF",
  "alteration": "Oncogenic Mutations {excluding V600}",
  "alteration_name": "Oncogenic Mutations (excluding V600)",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30361829",
      "title": "A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.",
      "journal": "International journal of hematology",
      "pubDate": "2019 Feb",
      "volume": "109",
      "issue": "2",
      "pages": "228-232",
      "authors": "Kumamoto T et al",
      "elocationId": "doi: 10.1007/s12185-018-2553-9",
      "link": null,
      "reference": "Kumamoto T et al. International journal of hematology. 2019 Feb;109(2)228-232.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabdb"
  },
  "level": "LEVEL_3A",
  "gene": "BRAF",
  "alteration": "Oncogenic Mutations {excluding V600}",
  "alteration_name": "Oncogenic Mutations (excluding V600)",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30361829",
      "title": "A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.",
      "journal": "International journal of hematology",
      "pubDate": "2019 Feb",
      "volume": "109",
      "issue": "2",
      "pages": "228-232",
      "authors": "Kumamoto T et al",
      "elocationId": "doi: 10.1007/s12185-018-2553-9",
      "link": null,
      "reference": "Kumamoto T et al. International journal of hematology. 2019 Feb;109(2)228-232.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabdc"
  },
  "level": "LEVEL_3A",
  "gene": "ROS1",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Repotrectinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.ejcancer.com/article/S0959-8049(22",
      "reference": "null. null. .",
      "abstract": "Cho et al. Abstract# 2LBA, EJC 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabdd"
  },
  "level": "LEVEL_3A",
  "gene": "BRAF",
  "alteration": "V600",
  "alteration_name": "V600",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Vemurafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31376203",
      "title": "Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: A case report and review of the literature.",
      "journal": "European journal of haematology",
      "pubDate": "2019 Oct",
      "volume": "103",
      "issue": "4",
      "pages": "444-448",
      "authors": "Branco B et al",
      "elocationId": "doi: 10.1111/ejh.13303",
      "link": null,
      "reference": "Branco B et al. European journal of haematology. 2019 Oct;103(4)444-448.",
      "abstract": null
    },
    {
      "pmid": "31213430",
      "title": "<i>BRAF</i>-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor.",
      "journal": "Blood advances",
      "pubDate": "2019 Jun 25",
      "volume": "3",
      "issue": "12",
      "pages": "1848-1853",
      "authors": "Mastropolo R et al",
      "elocationId": "doi: 10.1182/bloodadvances.2019000093",
      "link": null,
      "reference": "Mastropolo R et al. Blood advances. 2019 Jun 25;3(12)1848-1853.",
      "abstract": null
    },
    {
      "pmid": "25209580",
      "title": "Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.",
      "journal": "Neurology",
      "pubDate": "2014 Oct 14",
      "volume": "83",
      "issue": "16",
      "pages": "1478-80",
      "authors": "Idbaih A et al",
      "elocationId": "doi: 10.1212/WNL.0000000000000880",
      "link": null,
      "reference": "Idbaih A et al. Neurology. 2014 Oct 14;83(16)1478-80.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabde"
  },
  "level": "LEVEL_3A",
  "gene": "BRAF",
  "alteration": "V600",
  "alteration_name": "V600",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Dabrafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31376203",
      "title": "Targeted therapy of BRAF V600E-mutant histiocytic sarcoma: A case report and review of the literature.",
      "journal": "European journal of haematology",
      "pubDate": "2019 Oct",
      "volume": "103",
      "issue": "4",
      "pages": "444-448",
      "authors": "Branco B et al",
      "elocationId": "doi: 10.1111/ejh.13303",
      "link": null,
      "reference": "Branco B et al. European journal of haematology. 2019 Oct;103(4)444-448.",
      "abstract": null
    },
    {
      "pmid": "31213430",
      "title": "<i>BRAF</i>-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor.",
      "journal": "Blood advances",
      "pubDate": "2019 Jun 25",
      "volume": "3",
      "issue": "12",
      "pages": "1848-1853",
      "authors": "Mastropolo R et al",
      "elocationId": "doi: 10.1182/bloodadvances.2019000093",
      "link": null,
      "reference": "Mastropolo R et al. Blood advances. 2019 Jun 25;3(12)1848-1853.",
      "abstract": null
    },
    {
      "pmid": "25209580",
      "title": "Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.",
      "journal": "Neurology",
      "pubDate": "2014 Oct 14",
      "volume": "83",
      "issue": "16",
      "pages": "1478-80",
      "authors": "Idbaih A et al",
      "elocationId": "doi: 10.1212/WNL.0000000000000880",
      "link": null,
      "reference": "Idbaih A et al. Neurology. 2014 Oct 14;83(16)1478-80.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabdf"
  },
  "level": "LEVEL_3A",
  "gene": "MET",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Telisotuzumab Vedotin"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9016",
      "reference": "null. null. .",
      "abstract": "Camidge et al. Abstract# 9016, ASCO 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabe0"
  },
  "level": "LEVEL_3A",
  "gene": "KRAS",
  "alteration": "G12C",
  "alteration_name": "G12C",
  "cancer_main_type": "Pancreatic Cancer",
  "cancer_sub_type": "Pancreatic Adenocarcinoma",
  "drug": [
    "Adagrasib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.519",
      "reference": "null. null. .",
      "abstract": "Bekaii-Saab et al. Abstract# 519, ASCO GI Symposium, 2022"
    },
    {
      "pmid": "31658955",
      "title": "The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
      "journal": "Cancer discovery",
      "pubDate": "2020 Jan",
      "volume": "10",
      "issue": "1",
      "pages": "54-71",
      "authors": "Hallin J et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-19-1167",
      "link": null,
      "reference": "Hallin J et al. Cancer discovery. 2020 Jan;10(1)54-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabe1"
  },
  "level": "LEVEL_3A",
  "gene": "MAP2K1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30361829",
      "title": "A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.",
      "journal": "International journal of hematology",
      "pubDate": "2019 Feb",
      "volume": "109",
      "issue": "2",
      "pages": "228-232",
      "authors": "Kumamoto T et al",
      "elocationId": "doi: 10.1007/s12185-018-2553-9",
      "link": null,
      "reference": "Kumamoto T et al. International journal of hematology. 2019 Feb;109(2)228-232.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabe2"
  },
  "level": "LEVEL_3A",
  "gene": "MAP2K1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30361829",
      "title": "A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.",
      "journal": "International journal of hematology",
      "pubDate": "2019 Feb",
      "volume": "109",
      "issue": "2",
      "pages": "228-232",
      "authors": "Kumamoto T et al",
      "elocationId": "doi: 10.1007/s12185-018-2553-9",
      "link": null,
      "reference": "Kumamoto T et al. International journal of hematology. 2019 Feb;109(2)228-232.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabe3"
  },
  "level": "LEVEL_3A",
  "gene": "NRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30361829",
      "title": "A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.",
      "journal": "International journal of hematology",
      "pubDate": "2019 Feb",
      "volume": "109",
      "issue": "2",
      "pages": "228-232",
      "authors": "Kumamoto T et al",
      "elocationId": "doi: 10.1007/s12185-018-2553-9",
      "link": null,
      "reference": "Kumamoto T et al. International journal of hematology. 2019 Feb;109(2)228-232.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabe4"
  },
  "level": "LEVEL_3A",
  "gene": "NRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30361829",
      "title": "A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.",
      "journal": "International journal of hematology",
      "pubDate": "2019 Feb",
      "volume": "109",
      "issue": "2",
      "pages": "228-232",
      "authors": "Kumamoto T et al",
      "elocationId": "doi: 10.1007/s12185-018-2553-9",
      "link": null,
      "reference": "Kumamoto T et al. International journal of hematology. 2019 Feb;109(2)228-232.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabe5"
  },
  "level": "LEVEL_3A",
  "gene": "FLT3",
  "alteration": "572_630ins",
  "alteration_name": "Internal tandem duplication",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Quizartinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://library.ehaweb.org/eha/2022/eha2022-congress/356965/",
      "reference": "null. null. .",
      "abstract": "Erba et al. Abstract# S100, EHA 2022 Congress"
    },
    {
      "pmid": "29859851",
      "title": "Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2018 Jul",
      "volume": "19",
      "issue": "7",
      "pages": "889-903",
      "authors": "Cortes J et al",
      "elocationId": "doi: 10.1016/S1470-2045(18)30240-7",
      "link": null,
      "reference": "Cortes J et al. The Lancet. Oncology. 2018 Jul;19(7)889-903.",
      "abstract": null
    },
    {
      "pmid": "31175001",
      "title": "Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 Jul",
      "volume": "20",
      "issue": "7",
      "pages": "984-997",
      "authors": "Cortes JE et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30150-0",
      "link": null,
      "reference": "Cortes JE et al. The Lancet. Oncology. 2019 Jul;20(7)984-997.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabe6"
  },
  "level": "LEVEL_3A",
  "gene": "NRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Binimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28284557",
      "title": "Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2017 Apr",
      "volume": "18",
      "issue": "4",
      "pages": "435-445",
      "authors": "Dummer R et al",
      "elocationId": "doi: 10.1016/S1470-2045(17)30180-8",
      "link": null,
      "reference": "Dummer R et al. The Lancet. Oncology. 2017 Apr;18(4)435-445.",
      "abstract": null
    },
    {
      "pmid": "16273091",
      "title": "BRAF mutation predicts sensitivity to MEK inhibition.",
      "journal": "Nature",
      "pubDate": "2006 Jan 19",
      "volume": "439",
      "issue": "7074",
      "pages": "358-62",
      "authors": "Solit DB et al",
      "elocationId": "",
      "link": null,
      "reference": "Solit DB et al. Nature. 2006 Jan 19;439(7074)358-62.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabe7"
  },
  "level": "LEVEL_3A",
  "gene": "AKT1",
  "alteration": "E17K",
  "alteration_name": "E17K",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "AZD5363"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22294718",
      "title": "Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2012 Apr",
      "volume": "11",
      "issue": "4",
      "pages": "873-87",
      "authors": "Davies BR et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-11-0824-T",
      "link": null,
      "reference": "Davies BR et al. Molecular cancer therapeutics. 2012 Apr;11(4)873-87.",
      "abstract": null
    },
    {
      "pmid": "28489509",
      "title": "AKT Inhibition in Solid Tumors With AKT1 Mutations.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jul 10",
      "volume": "35",
      "issue": "20",
      "pages": "2251-2259",
      "authors": "Hyman DM et al",
      "elocationId": "doi: 10.1200/JCO.2017.73.0143",
      "link": null,
      "reference": "Hyman DM et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jul 10;35(20)2251-2259.",
      "abstract": null
    },
    {
      "pmid": "23394218",
      "title": "Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.",
      "journal": "Journal of medicinal chemistry",
      "pubDate": "2013 Mar 14",
      "volume": "56",
      "issue": "5",
      "pages": "2059-73",
      "authors": "Addie M et al",
      "elocationId": "doi: 10.1021/jm301762v",
      "link": null,
      "reference": "Addie M et al. Journal of medicinal chemistry. 2013 Mar 14;56(5)2059-73.",
      "abstract": null
    },
    {
      "pmid": "26351323",
      "title": "Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Nov",
      "volume": "14",
      "issue": "11",
      "pages": "2441-51",
      "authors": "Davies BR et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0230",
      "link": null,
      "reference": "Davies BR et al. Molecular cancer therapeutics. 2015 Nov;14(11)2441-51.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabe8"
  },
  "level": "LEVEL_3A",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Talazoparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30110579",
      "title": "Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Aug 23",
      "volume": "379",
      "issue": "8",
      "pages": "753-763",
      "authors": "Litton JK et al",
      "elocationId": "doi: 10.1056/NEJMoa1802905",
      "link": null,
      "reference": "Litton JK et al. The New England journal of medicine. 2018 Aug 23;379(8)753-763.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2527",
      "reference": "null. null. .",
      "abstract": "Dhawan, MS et al. JCO. Abstract# 2527"
    },
    {
      "pmid": "36394867",
      "title": "Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2023 Jan 1",
      "volume": "9",
      "issue": "1",
      "pages": "29-39",
      "authors": "Schram AM et al",
      "elocationId": "doi: 10.1001/jamaoncol.2022.5218",
      "link": null,
      "reference": "Schram AM et al. JAMA oncology. 2023 Jan 1;9(1)29-39.",
      "abstract": null
    },
    {
      "pmid": "30563931",
      "title": "A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline <i>BRCA1/2</i> Mutations (ABRAZO).",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2717-2724",
      "authors": "Turner NC et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1891",
      "link": null,
      "reference": "Turner NC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2717-2724.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabe9"
  },
  "level": "LEVEL_3A",
  "gene": "BRAF",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Ovarian Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24345920",
      "title": "BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2013 Dec 15",
      "volume": "19",
      "issue": "24",
      "pages": "6696-702",
      "authors": "Hutchinson KE et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-13-1746",
      "link": null,
      "reference": "Hutchinson KE et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Dec 15;19(24)6696-702.",
      "abstract": null
    },
    {
      "pmid": "26324360",
      "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Dec 1",
      "volume": "33",
      "issue": "34",
      "pages": "4099-105",
      "authors": "Grisham RN et al",
      "elocationId": "doi: 10.1200/JCO.2015.62.4726",
      "link": null,
      "reference": "Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabea"
  },
  "level": "LEVEL_3A",
  "gene": "BRAF",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "Ovarian Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24345920",
      "title": "BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2013 Dec 15",
      "volume": "19",
      "issue": "24",
      "pages": "6696-702",
      "authors": "Hutchinson KE et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-13-1746",
      "link": null,
      "reference": "Hutchinson KE et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Dec 15;19(24)6696-702.",
      "abstract": null
    },
    {
      "pmid": "26324360",
      "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Dec 1",
      "volume": "33",
      "issue": "34",
      "pages": "4099-105",
      "authors": "Grisham RN et al",
      "elocationId": "doi: 10.1200/JCO.2015.62.4726",
      "link": null,
      "reference": "Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabeb"
  },
  "level": "LEVEL_3A",
  "gene": "HRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Head and Neck Cancer",
  "cancer_sub_type": "Head and Neck Squamous Cell Carcinoma",
  "drug": [
    "Tipifarnib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24240680",
      "title": "Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.",
      "journal": "Oncogene",
      "pubDate": "2014 Nov 20",
      "volume": "33",
      "issue": "47",
      "pages": "5442-9",
      "authors": "Chen X et al",
      "elocationId": "doi: 10.1038/onc.2013.489",
      "link": null,
      "reference": "Chen X et al. Oncogene. 2014 Nov 20;33(47)5442-9.",
      "abstract": null
    },
    {
      "pmid": "33750196",
      "title": "Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2021 Jun 10",
      "volume": "39",
      "issue": "17",
      "pages": "1856-1864",
      "authors": "Ho AL et al",
      "elocationId": "doi: 10.1200/JCO.20.02903",
      "link": null,
      "reference": "Ho AL et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Jun 10;39(17)1856-1864.",
      "abstract": null
    },
    {
      "pmid": "12497061",
      "title": "Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer.",
      "journal": "Prostate cancer and prostatic diseases",
      "pubDate": "2001",
      "volume": "4",
      "issue": "1",
      "pages": "33-43",
      "authors": "Sepp-Lorenzino L et al",
      "elocationId": "",
      "link": null,
      "reference": "Sepp-Lorenzino L et al. Prostate cancer and prostatic diseases. 2001;4(1)33-43.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.TPS2618",
      "reference": "null. null. .",
      "abstract": "Ho et al. Abstract# TPS2618, JCO 2017"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://mct.aacrjournals.org/content/18/12_Supplement/PR08",
      "reference": "null. null. .",
      "abstract": "Ho et al. Abstract# PR08, Molecular Cancer Therapeutics, 2019"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabec"
  },
  "level": "LEVEL_3A",
  "gene": "ESR1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Fulvestrant"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31563959",
      "title": "The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2019 Sep 29",
      "volume": "",
      "issue": "",
      "pages": "",
      "authors": "Sledge GW Jr et al",
      "elocationId": "doi: 10.1001/jamaoncol.2019.4782",
      "link": null,
      "reference": "Sledge GW Jr et al. JAMA oncology. 2019 Sep 29;().",
      "abstract": null
    },
    {
      "pmid": "36183733",
      "title": "Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2022 Nov",
      "volume": "23",
      "issue": "11",
      "pages": "1367-1377",
      "authors": "Bidard FC et al",
      "elocationId": "doi: 10.1016/S1470-2045(22)00555-1",
      "link": null,
      "reference": "Bidard FC et al. The Lancet. Oncology. 2022 Nov;23(11)1367-1377.",
      "abstract": null
    },
    {
      "pmid": "27269946",
      "title": "Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2016 Sep 1",
      "volume": "34",
      "issue": "25",
      "pages": "2961-8",
      "authors": "Fribbens C et al",
      "elocationId": "doi: 10.1200/JCO.2016.67.3061",
      "link": null,
      "reference": "Fribbens C et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Sep 1;34(25)2961-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabed"
  },
  "level": "LEVEL_3A",
  "gene": "FGFR3",
  "alteration": "S371C",
  "alteration_name": "S371C",
  "cancer_main_type": "Bladder Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erdafitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/160559/abstract",
      "reference": "null. null. .",
      "abstract": "Siefker-Radtke et al. Abstract#4503, ASCO 2018"
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "21119661",
      "title": "Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.",
      "journal": "British journal of cancer",
      "pubDate": "2011 Jan 4",
      "volume": "104",
      "issue": "1",
      "pages": "75-82",
      "authors": "Lamont FR et al",
      "elocationId": "doi: 10.1038/sj.bjc.6606016",
      "link": null,
      "reference": "Lamont FR et al. British journal of cancer. 2011 Jan 4;104(1)75-82.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    },
    {
      "pmid": "26324363",
      "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Oct 20",
      "volume": "33",
      "issue": "30",
      "pages": "3401-8",
      "authors": "Tabernero J et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.7341",
      "link": null,
      "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.",
      "abstract": null
    },
    {
      "pmid": "29848605",
      "title": "Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations.",
      "journal": "Cancer discovery",
      "pubDate": "2018 Jul",
      "volume": "8",
      "issue": "7",
      "pages": "812-821",
      "authors": "Pal SK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0229",
      "link": null,
      "reference": "Pal SK et al. Cancer discovery. 2018 Jul;8(7)812-821.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabee"
  },
  "level": "LEVEL_3A",
  "gene": "FGFR3",
  "alteration": "K650",
  "alteration_name": "K650",
  "cancer_main_type": "Bladder Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erdafitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/160559/abstract",
      "reference": "null. null. .",
      "abstract": "Siefker-Radtke et al. Abstract#4503, ASCO 2018"
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "21119661",
      "title": "Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.",
      "journal": "British journal of cancer",
      "pubDate": "2011 Jan 4",
      "volume": "104",
      "issue": "1",
      "pages": "75-82",
      "authors": "Lamont FR et al",
      "elocationId": "doi: 10.1038/sj.bjc.6606016",
      "link": null,
      "reference": "Lamont FR et al. British journal of cancer. 2011 Jan 4;104(1)75-82.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    },
    {
      "pmid": "26324363",
      "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Oct 20",
      "volume": "33",
      "issue": "30",
      "pages": "3401-8",
      "authors": "Tabernero J et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.7341",
      "link": null,
      "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.",
      "abstract": null
    },
    {
      "pmid": "29848605",
      "title": "Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations.",
      "journal": "Cancer discovery",
      "pubDate": "2018 Jul",
      "volume": "8",
      "issue": "7",
      "pages": "812-821",
      "authors": "Pal SK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0229",
      "link": null,
      "reference": "Pal SK et al. Cancer discovery. 2018 Jul;8(7)812-821.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabef"
  },
  "level": "LEVEL_3A",
  "gene": "FGFR3",
  "alteration": "G380R",
  "alteration_name": "G380R",
  "cancer_main_type": "Bladder Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erdafitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/160559/abstract",
      "reference": "null. null. .",
      "abstract": "Siefker-Radtke et al. Abstract#4503, ASCO 2018"
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "21119661",
      "title": "Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.",
      "journal": "British journal of cancer",
      "pubDate": "2011 Jan 4",
      "volume": "104",
      "issue": "1",
      "pages": "75-82",
      "authors": "Lamont FR et al",
      "elocationId": "doi: 10.1038/sj.bjc.6606016",
      "link": null,
      "reference": "Lamont FR et al. British journal of cancer. 2011 Jan 4;104(1)75-82.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    },
    {
      "pmid": "26324363",
      "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Oct 20",
      "volume": "33",
      "issue": "30",
      "pages": "3401-8",
      "authors": "Tabernero J et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.7341",
      "link": null,
      "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.",
      "abstract": null
    },
    {
      "pmid": "29848605",
      "title": "Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations.",
      "journal": "Cancer discovery",
      "pubDate": "2018 Jul",
      "volume": "8",
      "issue": "7",
      "pages": "812-821",
      "authors": "Pal SK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0229",
      "link": null,
      "reference": "Pal SK et al. Cancer discovery. 2018 Jul;8(7)812-821.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabf0"
  },
  "level": "LEVEL_3A",
  "gene": "MET",
  "alteration": "Y1003",
  "alteration_name": "Y1003",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "11741535",
      "title": "Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.",
      "journal": "Molecular cell",
      "pubDate": "2001 Nov",
      "volume": "8",
      "issue": "5",
      "pages": "995-1004",
      "authors": "Peschard P et al",
      "elocationId": "",
      "link": null,
      "reference": "Peschard P et al. Molecular cell. 2001 Nov;8(5)995-1004.",
      "abstract": null
    },
    {
      "pmid": "25971938",
      "title": "Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.",
      "journal": "Cancer discovery",
      "pubDate": "2015 Aug",
      "volume": "5",
      "issue": "8",
      "pages": "850-9",
      "authors": "Frampton GM et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0285",
      "link": null,
      "reference": "Frampton GM et al. Cancer discovery. 2015 Aug;5(8)850-9.",
      "abstract": null
    },
    {
      "pmid": "30885356",
      "title": "MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2019 Apr",
      "volume": "130",
      "issue": "",
      "pages": "84-86",
      "authors": "Miao YL et al",
      "elocationId": "doi: 10.1016/j.lungcan.2019.02.002",
      "link": null,
      "reference": "Miao YL et al. Lung cancer (Amsterdam, Netherlands). 2019 Apr;130()84-86.",
      "abstract": null
    },
    {
      "pmid": "27343443",
      "title": "Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2016 Sep",
      "volume": "11",
      "issue": "9",
      "pages": "1493-502",
      "authors": "Schrock AB et al",
      "elocationId": "doi: 10.1016/j.jtho.2016.06.004",
      "link": null,
      "reference": "Schrock AB et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Sep;11(9)1493-502.",
      "abstract": null
    },
    {
      "pmid": "16397241",
      "title": "Somatic mutations lead to an oncogenic deletion of met in lung cancer.",
      "journal": "Cancer research",
      "pubDate": "2006 Jan 1",
      "volume": "66",
      "issue": "1",
      "pages": "283-9",
      "authors": "Kong-Beltran M et al",
      "elocationId": "",
      "link": null,
      "reference": "Kong-Beltran M et al. Cancer research. 2006 Jan 1;66(1)283-9.",
      "abstract": null
    },
    {
      "pmid": "25079552",
      "title": "Comprehensive molecular profiling of lung adenocarcinoma.",
      "journal": "Nature",
      "pubDate": "2014 Jul 31",
      "volume": "511",
      "issue": "7511",
      "pages": "543-50",
      "authors": "Cancer Genome Atlas Research Network.",
      "elocationId": "doi: 10.1038/nature13385",
      "link": null,
      "reference": "Cancer Genome Atlas Research Network.. Nature. 2014 Jul 31;511(7511)543-50.",
      "abstract": null
    },
    {
      "pmid": "16227611",
      "title": "Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation.",
      "journal": "Molecular and cellular biology",
      "pubDate": "2005 Nov",
      "volume": "25",
      "issue": "21",
      "pages": "9632-45",
      "authors": "Abella JV et al",
      "elocationId": "",
      "link": null,
      "reference": "Abella JV et al. Molecular and cellular biology. 2005 Nov;25(21)9632-45.",
      "abstract": null
    },
    {
      "pmid": "15123609",
      "title": "A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation.",
      "journal": "The Journal of biological chemistry",
      "pubDate": "2004 Jul 9",
      "volume": "279",
      "issue": "28",
      "pages": "29565-71",
      "authors": "Peschard P et al",
      "elocationId": "",
      "link": null,
      "reference": "Peschard P et al. The Journal of biological chemistry. 2004 Jul 9;279(28)29565-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabf1"
  },
  "level": "LEVEL_3A",
  "gene": "MET",
  "alteration": "Y1003",
  "alteration_name": "Y1003",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Tepotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "11741535",
      "title": "Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.",
      "journal": "Molecular cell",
      "pubDate": "2001 Nov",
      "volume": "8",
      "issue": "5",
      "pages": "995-1004",
      "authors": "Peschard P et al",
      "elocationId": "",
      "link": null,
      "reference": "Peschard P et al. Molecular cell. 2001 Nov;8(5)995-1004.",
      "abstract": null
    },
    {
      "pmid": "25971938",
      "title": "Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.",
      "journal": "Cancer discovery",
      "pubDate": "2015 Aug",
      "volume": "5",
      "issue": "8",
      "pages": "850-9",
      "authors": "Frampton GM et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0285",
      "link": null,
      "reference": "Frampton GM et al. Cancer discovery. 2015 Aug;5(8)850-9.",
      "abstract": null
    },
    {
      "pmid": "30885356",
      "title": "MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2019 Apr",
      "volume": "130",
      "issue": "",
      "pages": "84-86",
      "authors": "Miao YL et al",
      "elocationId": "doi: 10.1016/j.lungcan.2019.02.002",
      "link": null,
      "reference": "Miao YL et al. Lung cancer (Amsterdam, Netherlands). 2019 Apr;130()84-86.",
      "abstract": null
    },
    {
      "pmid": "27343443",
      "title": "Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2016 Sep",
      "volume": "11",
      "issue": "9",
      "pages": "1493-502",
      "authors": "Schrock AB et al",
      "elocationId": "doi: 10.1016/j.jtho.2016.06.004",
      "link": null,
      "reference": "Schrock AB et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Sep;11(9)1493-502.",
      "abstract": null
    },
    {
      "pmid": "16397241",
      "title": "Somatic mutations lead to an oncogenic deletion of met in lung cancer.",
      "journal": "Cancer research",
      "pubDate": "2006 Jan 1",
      "volume": "66",
      "issue": "1",
      "pages": "283-9",
      "authors": "Kong-Beltran M et al",
      "elocationId": "",
      "link": null,
      "reference": "Kong-Beltran M et al. Cancer research. 2006 Jan 1;66(1)283-9.",
      "abstract": null
    },
    {
      "pmid": "25079552",
      "title": "Comprehensive molecular profiling of lung adenocarcinoma.",
      "journal": "Nature",
      "pubDate": "2014 Jul 31",
      "volume": "511",
      "issue": "7511",
      "pages": "543-50",
      "authors": "Cancer Genome Atlas Research Network.",
      "elocationId": "doi: 10.1038/nature13385",
      "link": null,
      "reference": "Cancer Genome Atlas Research Network.. Nature. 2014 Jul 31;511(7511)543-50.",
      "abstract": null
    },
    {
      "pmid": "16227611",
      "title": "Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation.",
      "journal": "Molecular and cellular biology",
      "pubDate": "2005 Nov",
      "volume": "25",
      "issue": "21",
      "pages": "9632-45",
      "authors": "Abella JV et al",
      "elocationId": "",
      "link": null,
      "reference": "Abella JV et al. Molecular and cellular biology. 2005 Nov;25(21)9632-45.",
      "abstract": null
    },
    {
      "pmid": "15123609",
      "title": "A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation.",
      "journal": "The Journal of biological chemistry",
      "pubDate": "2004 Jul 9",
      "volume": "279",
      "issue": "28",
      "pages": "29565-71",
      "authors": "Peschard P et al",
      "elocationId": "",
      "link": null,
      "reference": "Peschard P et al. The Journal of biological chemistry. 2004 Jul 9;279(28)29565-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabf2"
  },
  "level": "LEVEL_3A",
  "gene": "MET",
  "alteration": "Y1003",
  "alteration_name": "Y1003",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Capmatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "11741535",
      "title": "Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.",
      "journal": "Molecular cell",
      "pubDate": "2001 Nov",
      "volume": "8",
      "issue": "5",
      "pages": "995-1004",
      "authors": "Peschard P et al",
      "elocationId": "",
      "link": null,
      "reference": "Peschard P et al. Molecular cell. 2001 Nov;8(5)995-1004.",
      "abstract": null
    },
    {
      "pmid": "25971938",
      "title": "Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.",
      "journal": "Cancer discovery",
      "pubDate": "2015 Aug",
      "volume": "5",
      "issue": "8",
      "pages": "850-9",
      "authors": "Frampton GM et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0285",
      "link": null,
      "reference": "Frampton GM et al. Cancer discovery. 2015 Aug;5(8)850-9.",
      "abstract": null
    },
    {
      "pmid": "30885356",
      "title": "MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2019 Apr",
      "volume": "130",
      "issue": "",
      "pages": "84-86",
      "authors": "Miao YL et al",
      "elocationId": "doi: 10.1016/j.lungcan.2019.02.002",
      "link": null,
      "reference": "Miao YL et al. Lung cancer (Amsterdam, Netherlands). 2019 Apr;130()84-86.",
      "abstract": null
    },
    {
      "pmid": "27343443",
      "title": "Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2016 Sep",
      "volume": "11",
      "issue": "9",
      "pages": "1493-502",
      "authors": "Schrock AB et al",
      "elocationId": "doi: 10.1016/j.jtho.2016.06.004",
      "link": null,
      "reference": "Schrock AB et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Sep;11(9)1493-502.",
      "abstract": null
    },
    {
      "pmid": "16397241",
      "title": "Somatic mutations lead to an oncogenic deletion of met in lung cancer.",
      "journal": "Cancer research",
      "pubDate": "2006 Jan 1",
      "volume": "66",
      "issue": "1",
      "pages": "283-9",
      "authors": "Kong-Beltran M et al",
      "elocationId": "",
      "link": null,
      "reference": "Kong-Beltran M et al. Cancer research. 2006 Jan 1;66(1)283-9.",
      "abstract": null
    },
    {
      "pmid": "25079552",
      "title": "Comprehensive molecular profiling of lung adenocarcinoma.",
      "journal": "Nature",
      "pubDate": "2014 Jul 31",
      "volume": "511",
      "issue": "7511",
      "pages": "543-50",
      "authors": "Cancer Genome Atlas Research Network.",
      "elocationId": "doi: 10.1038/nature13385",
      "link": null,
      "reference": "Cancer Genome Atlas Research Network.. Nature. 2014 Jul 31;511(7511)543-50.",
      "abstract": null
    },
    {
      "pmid": "16227611",
      "title": "Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation.",
      "journal": "Molecular and cellular biology",
      "pubDate": "2005 Nov",
      "volume": "25",
      "issue": "21",
      "pages": "9632-45",
      "authors": "Abella JV et al",
      "elocationId": "",
      "link": null,
      "reference": "Abella JV et al. Molecular and cellular biology. 2005 Nov;25(21)9632-45.",
      "abstract": null
    },
    {
      "pmid": "15123609",
      "title": "A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation.",
      "journal": "The Journal of biological chemistry",
      "pubDate": "2004 Jul 9",
      "volume": "279",
      "issue": "28",
      "pages": "29565-71",
      "authors": "Peschard P et al",
      "elocationId": "",
      "link": null,
      "reference": "Peschard P et al. The Journal of biological chemistry. 2004 Jul 9;279(28)29565-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabf3"
  },
  "level": "LEVEL_3A",
  "gene": "ARAF",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Sorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24569458",
      "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2014 Apr",
      "volume": "124",
      "issue": "4",
      "pages": "1582-6",
      "authors": "Imielinski M et al",
      "elocationId": "doi: 10.1172/JCI72763",
      "link": null,
      "reference": "Imielinski M et al. The Journal of clinical investigation. 2014 Apr;124(4)1582-6.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabf4"
  },
  "level": "LEVEL_3A",
  "gene": "EGFR",
  "alteration": "762_823ins",
  "alteration_name": "Exon 20 in-frame insertions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "CLN-081"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9007",
      "reference": "null. null. .",
      "abstract": "Yu et al. Abstract# 9007, ASCO 2022"
    },
    {
      "pmid": "31467113",
      "title": "TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant <i>EGFR</i> Mutations.",
      "journal": "Molecular cancer research : MCR",
      "pubDate": "2019 Nov",
      "volume": "17",
      "issue": "11",
      "pages": "2233-2243",
      "authors": "Udagawa H et al",
      "elocationId": "doi: 10.1158/1541-7786.MCR-19-0419",
      "link": null,
      "reference": "Udagawa H et al. Molecular cancer research : MCR. 2019 Nov;17(11)2233-2243.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabf5"
  },
  "level": "LEVEL_3A",
  "gene": "BRCA1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Olaparib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28578601",
      "title": "Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.",
      "journal": "The New England journal of medicine",
      "pubDate": "2017 Aug 10",
      "volume": "377",
      "issue": "6",
      "pages": "523-533",
      "authors": "Robson M et al",
      "elocationId": "doi: 10.1056/NEJMoa1706450",
      "link": null,
      "reference": "Robson M et al. The New England journal of medicine. 2017 Aug 10;377(6)523-533.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/full/10.1200/PO.19.00012",
      "reference": "null. null. .",
      "abstract": "Pascual et al. JCOPO, 2019"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabf6"
  },
  "level": "LEVEL_3A",
  "gene": "KRAS",
  "alteration": "G12C",
  "alteration_name": "G12C",
  "cancer_main_type": "Pancreatic Cancer",
  "cancer_sub_type": "Pancreatic Adenocarcinoma",
  "drug": [
    "Sotorasib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.36_suppl.360490",
      "reference": "null. null. .",
      "abstract": "Strickler et al. Abstract# 360490, ASCO GI 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabf7"
  },
  "level": "LEVEL_3A",
  "gene": "ARAF",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Sorafenib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26566875",
      "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.",
      "journal": "Cancer discovery",
      "pubDate": "2016 Feb",
      "volume": "6",
      "issue": "2",
      "pages": "154-65",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0913",
      "link": null,
      "reference": "Diamond EL et al. Cancer discovery. 2016 Feb;6(2)154-65.",
      "abstract": null
    },
    {
      "pmid": "24569458",
      "title": "Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2014 Apr",
      "volume": "124",
      "issue": "4",
      "pages": "1582-6",
      "authors": "Imielinski M et al",
      "elocationId": "doi: 10.1172/JCI72763",
      "link": null,
      "reference": "Imielinski M et al. The Journal of clinical investigation. 2014 Apr;124(4)1582-6.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabf8"
  },
  "level": "LEVEL_3A",
  "gene": "ERBB2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Docetaxel",
    "Pertuzumab",
    "Trastuzumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "28959366",
      "title": "Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model.",
      "journal": "Oncology letters",
      "pubDate": "2017 Oct",
      "volume": "14",
      "issue": "4",
      "pages": "4197-4205",
      "authors": "Yamashita-Kashima Y et al",
      "elocationId": "doi: 10.3892/ol.2017.6679",
      "link": null,
      "reference": "Yamashita-Kashima Y et al. Oncology letters. 2017 Oct;14(4)4197-4205.",
      "abstract": null
    },
    {
      "pmid": "15059883",
      "title": "The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.",
      "journal": "Cancer research",
      "pubDate": "2004 Apr 1",
      "volume": "64",
      "issue": "7",
      "pages": "2343-6",
      "authors": "Nahta R et al",
      "elocationId": "",
      "link": null,
      "reference": "Nahta R et al. Cancer research. 2004 Apr 1;64(7)2343-6.",
      "abstract": null
    },
    {
      "pmid": "35073148",
      "title": "Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Mutations: Results From the IFCT-1703 R2D2 Trial.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2022 Jan 24",
      "volume": "",
      "issue": "",
      "pages": "JCO2101455",
      "authors": "Mazieres J et al",
      "elocationId": "doi: 10.1200/JCO.21.01455",
      "link": null,
      "reference": "Mazieres J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Jan 24;()JCO2101455.",
      "abstract": null
    },
    {
      "pmid": "19934333",
      "title": "Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.",
      "journal": "Cancer research",
      "pubDate": "2009 Dec 15",
      "volume": "69",
      "issue": "24",
      "pages": "9330-6",
      "authors": "Scheuer W et al",
      "elocationId": "doi: 10.1158/0008-5472.CAN-08-4597",
      "link": null,
      "reference": "Scheuer W et al. Cancer research. 2009 Dec 15;69(24)9330-6.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabf9"
  },
  "level": "LEVEL_3A",
  "gene": "HRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Bladder Cancer",
  "cancer_sub_type": "Bladder Urothelial Carcinoma",
  "drug": [
    "Tipifarnib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "32636318",
      "title": "A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring <i>HRAS</i> Mutations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2020 Oct 1",
      "volume": "26",
      "issue": "19",
      "pages": "5113-5119",
      "authors": "Lee HW et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-20-1246",
      "link": null,
      "reference": "Lee HW et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Oct 1;26(19)5113-5119.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabfa"
  },
  "level": "LEVEL_3A",
  "gene": "MAP2K1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26566875",
      "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.",
      "journal": "Cancer discovery",
      "pubDate": "2016 Feb",
      "volume": "6",
      "issue": "2",
      "pages": "154-65",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0913",
      "link": null,
      "reference": "Diamond EL et al. Cancer discovery. 2016 Feb;6(2)154-65.",
      "abstract": null
    },
    {
      "pmid": "25370473",
      "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Jan 1",
      "volume": "21",
      "issue": "1",
      "pages": "98-105",
      "authors": "Carlino MS et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-0759",
      "link": null,
      "reference": "Carlino MS et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 1;21(1)98-105.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://ascopubs.org/doi/full/10.1200/PO.16.00070",
      "reference": "null. null. .",
      "abstract": "Papapanagiotou et al. JCOPO, 2017"
    },
    {
      "pmid": "26324360",
      "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Dec 1",
      "volume": "33",
      "issue": "34",
      "pages": "4099-105",
      "authors": "Grisham RN et al",
      "elocationId": "doi: 10.1200/JCO.2015.62.4726",
      "link": null,
      "reference": "Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    },
    {
      "pmid": "25351745",
      "title": "MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Apr 15",
      "volume": "21",
      "issue": "8",
      "pages": "1935-43",
      "authors": "Arcila ME et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-2124",
      "link": null,
      "reference": "Arcila ME et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Apr 15;21(8)1935-43.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabfb"
  },
  "level": "LEVEL_3A",
  "gene": "MAP2K1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26566875",
      "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.",
      "journal": "Cancer discovery",
      "pubDate": "2016 Feb",
      "volume": "6",
      "issue": "2",
      "pages": "154-65",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0913",
      "link": null,
      "reference": "Diamond EL et al. Cancer discovery. 2016 Feb;6(2)154-65.",
      "abstract": null
    },
    {
      "pmid": "25370473",
      "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Jan 1",
      "volume": "21",
      "issue": "1",
      "pages": "98-105",
      "authors": "Carlino MS et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-0759",
      "link": null,
      "reference": "Carlino MS et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 1;21(1)98-105.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://ascopubs.org/doi/full/10.1200/PO.16.00070",
      "reference": "null. null. .",
      "abstract": "Papapanagiotou et al. JCOPO, 2017"
    },
    {
      "pmid": "26324360",
      "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Dec 1",
      "volume": "33",
      "issue": "34",
      "pages": "4099-105",
      "authors": "Grisham RN et al",
      "elocationId": "doi: 10.1200/JCO.2015.62.4726",
      "link": null,
      "reference": "Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    },
    {
      "pmid": "25351745",
      "title": "MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Apr 15",
      "volume": "21",
      "issue": "8",
      "pages": "1935-43",
      "authors": "Arcila ME et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-2124",
      "link": null,
      "reference": "Arcila ME et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Apr 15;21(8)1935-43.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabfc"
  },
  "level": "LEVEL_3A",
  "gene": "MAP2K1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26566875",
      "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.",
      "journal": "Cancer discovery",
      "pubDate": "2016 Feb",
      "volume": "6",
      "issue": "2",
      "pages": "154-65",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0913",
      "link": null,
      "reference": "Diamond EL et al. Cancer discovery. 2016 Feb;6(2)154-65.",
      "abstract": null
    },
    {
      "pmid": "25370473",
      "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Jan 1",
      "volume": "21",
      "issue": "1",
      "pages": "98-105",
      "authors": "Carlino MS et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-0759",
      "link": null,
      "reference": "Carlino MS et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 1;21(1)98-105.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://ascopubs.org/doi/full/10.1200/PO.16.00070",
      "reference": "null. null. .",
      "abstract": "Papapanagiotou et al. JCOPO, 2017"
    },
    {
      "pmid": "26324360",
      "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Dec 1",
      "volume": "33",
      "issue": "34",
      "pages": "4099-105",
      "authors": "Grisham RN et al",
      "elocationId": "doi: 10.1200/JCO.2015.62.4726",
      "link": null,
      "reference": "Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    },
    {
      "pmid": "25351745",
      "title": "MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Apr 15",
      "volume": "21",
      "issue": "8",
      "pages": "1935-43",
      "authors": "Arcila ME et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-2124",
      "link": null,
      "reference": "Arcila ME et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Apr 15;21(8)1935-43.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabfd"
  },
  "level": "LEVEL_3A",
  "gene": "MAP2K1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26566875",
      "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.",
      "journal": "Cancer discovery",
      "pubDate": "2016 Feb",
      "volume": "6",
      "issue": "2",
      "pages": "154-65",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0913",
      "link": null,
      "reference": "Diamond EL et al. Cancer discovery. 2016 Feb;6(2)154-65.",
      "abstract": null
    },
    {
      "pmid": "25370473",
      "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Jan 1",
      "volume": "21",
      "issue": "1",
      "pages": "98-105",
      "authors": "Carlino MS et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-0759",
      "link": null,
      "reference": "Carlino MS et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 1;21(1)98-105.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://ascopubs.org/doi/full/10.1200/PO.16.00070",
      "reference": "null. null. .",
      "abstract": "Papapanagiotou et al. JCOPO, 2017"
    },
    {
      "pmid": "26324360",
      "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Dec 1",
      "volume": "33",
      "issue": "34",
      "pages": "4099-105",
      "authors": "Grisham RN et al",
      "elocationId": "doi: 10.1200/JCO.2015.62.4726",
      "link": null,
      "reference": "Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    },
    {
      "pmid": "25351745",
      "title": "MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Apr 15",
      "volume": "21",
      "issue": "8",
      "pages": "1935-43",
      "authors": "Arcila ME et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-2124",
      "link": null,
      "reference": "Arcila ME et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Apr 15;21(8)1935-43.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabfe"
  },
  "level": "LEVEL_3A",
  "gene": "MAP2K1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian Cancer",
  "cancer_sub_type": "Low-Grade Serous Ovarian Cancer",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26566875",
      "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.",
      "journal": "Cancer discovery",
      "pubDate": "2016 Feb",
      "volume": "6",
      "issue": "2",
      "pages": "154-65",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0913",
      "link": null,
      "reference": "Diamond EL et al. Cancer discovery. 2016 Feb;6(2)154-65.",
      "abstract": null
    },
    {
      "pmid": "25370473",
      "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Jan 1",
      "volume": "21",
      "issue": "1",
      "pages": "98-105",
      "authors": "Carlino MS et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-0759",
      "link": null,
      "reference": "Carlino MS et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 1;21(1)98-105.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://ascopubs.org/doi/full/10.1200/PO.16.00070",
      "reference": "null. null. .",
      "abstract": "Papapanagiotou et al. JCOPO, 2017"
    },
    {
      "pmid": "26324360",
      "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Dec 1",
      "volume": "33",
      "issue": "34",
      "pages": "4099-105",
      "authors": "Grisham RN et al",
      "elocationId": "doi: 10.1200/JCO.2015.62.4726",
      "link": null,
      "reference": "Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    },
    {
      "pmid": "25351745",
      "title": "MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Apr 15",
      "volume": "21",
      "issue": "8",
      "pages": "1935-43",
      "authors": "Arcila ME et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-2124",
      "link": null,
      "reference": "Arcila ME et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Apr 15;21(8)1935-43.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fabff"
  },
  "level": "LEVEL_3A",
  "gene": "MAP2K1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Ovarian Cancer",
  "cancer_sub_type": "Low-Grade Serous Ovarian Cancer",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26566875",
      "title": "Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.",
      "journal": "Cancer discovery",
      "pubDate": "2016 Feb",
      "volume": "6",
      "issue": "2",
      "pages": "154-65",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0913",
      "link": null,
      "reference": "Diamond EL et al. Cancer discovery. 2016 Feb;6(2)154-65.",
      "abstract": null
    },
    {
      "pmid": "25370473",
      "title": "Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Jan 1",
      "volume": "21",
      "issue": "1",
      "pages": "98-105",
      "authors": "Carlino MS et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-0759",
      "link": null,
      "reference": "Carlino MS et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jan 1;21(1)98-105.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://ascopubs.org/doi/full/10.1200/PO.16.00070",
      "reference": "null. null. .",
      "abstract": "Papapanagiotou et al. JCOPO, 2017"
    },
    {
      "pmid": "26324360",
      "title": "Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Dec 1",
      "volume": "33",
      "issue": "34",
      "pages": "4099-105",
      "authors": "Grisham RN et al",
      "elocationId": "doi: 10.1200/JCO.2015.62.4726",
      "link": null,
      "reference": "Grisham RN et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Dec 1;33(34)4099-105.",
      "abstract": null
    },
    {
      "pmid": "30867592",
      "title": "Efficacy of MEK inhibition in patients with histiocytic neoplasms.",
      "journal": "Nature",
      "pubDate": "2019 Mar",
      "volume": "567",
      "issue": "7749",
      "pages": "521-524",
      "authors": "Diamond EL et al",
      "elocationId": "doi: 10.1038/s41586-019-1012-y",
      "link": null,
      "reference": "Diamond EL et al. Nature. 2019 Mar;567(7749)521-524.",
      "abstract": null
    },
    {
      "pmid": "25351745",
      "title": "MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Apr 15",
      "volume": "21",
      "issue": "8",
      "pages": "1935-43",
      "authors": "Arcila ME et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-2124",
      "link": null,
      "reference": "Arcila ME et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Apr 15;21(8)1935-43.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac00"
  },
  "level": "LEVEL_3A",
  "gene": "KRAS",
  "alteration": "G12C",
  "alteration_name": "G12C",
  "cancer_main_type": "Hepatobiliary Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Adagrasib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.519",
      "reference": "null. null. .",
      "abstract": "Bekaii-Saab et al. Abstract# 519, ASCO GI Symposium, 2022"
    },
    {
      "pmid": "31658955",
      "title": "The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
      "journal": "Cancer discovery",
      "pubDate": "2020 Jan",
      "volume": "10",
      "issue": "1",
      "pages": "54-71",
      "authors": "Hallin J et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-19-1167",
      "link": null,
      "reference": "Hallin J et al. Cancer discovery. 2020 Jan;10(1)54-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac01"
  },
  "level": "LEVEL_3A",
  "gene": "KRAS",
  "alteration": "G12C",
  "alteration_name": "G12C",
  "cancer_main_type": "Tubular Adenoma of the Colon",
  "cancer_sub_type": "",
  "drug": [
    "Adagrasib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.519",
      "reference": "null. null. .",
      "abstract": "Bekaii-Saab et al. Abstract# 519, ASCO GI Symposium, 2022"
    },
    {
      "pmid": "31658955",
      "title": "The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
      "journal": "Cancer discovery",
      "pubDate": "2020 Jan",
      "volume": "10",
      "issue": "1",
      "pages": "54-71",
      "authors": "Hallin J et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-19-1167",
      "link": null,
      "reference": "Hallin J et al. Cancer discovery. 2020 Jan;10(1)54-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac02"
  },
  "level": "LEVEL_3A",
  "gene": "KRAS",
  "alteration": "G12C",
  "alteration_name": "G12C",
  "cancer_main_type": "Esophagogastric Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Adagrasib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.519",
      "reference": "null. null. .",
      "abstract": "Bekaii-Saab et al. Abstract# 519, ASCO GI Symposium, 2022"
    },
    {
      "pmid": "31658955",
      "title": "The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
      "journal": "Cancer discovery",
      "pubDate": "2020 Jan",
      "volume": "10",
      "issue": "1",
      "pages": "54-71",
      "authors": "Hallin J et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-19-1167",
      "link": null,
      "reference": "Hallin J et al. Cancer discovery. 2020 Jan;10(1)54-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac03"
  },
  "level": "LEVEL_3A",
  "gene": "KRAS",
  "alteration": "G12C",
  "alteration_name": "G12C",
  "cancer_main_type": "Anal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Adagrasib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.519",
      "reference": "null. null. .",
      "abstract": "Bekaii-Saab et al. Abstract# 519, ASCO GI Symposium, 2022"
    },
    {
      "pmid": "31658955",
      "title": "The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
      "journal": "Cancer discovery",
      "pubDate": "2020 Jan",
      "volume": "10",
      "issue": "1",
      "pages": "54-71",
      "authors": "Hallin J et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-19-1167",
      "link": null,
      "reference": "Hallin J et al. Cancer discovery. 2020 Jan;10(1)54-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac04"
  },
  "level": "LEVEL_3A",
  "gene": "KRAS",
  "alteration": "G12C",
  "alteration_name": "G12C",
  "cancer_main_type": "Small Bowel Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Adagrasib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.519",
      "reference": "null. null. .",
      "abstract": "Bekaii-Saab et al. Abstract# 519, ASCO GI Symposium, 2022"
    },
    {
      "pmid": "31658955",
      "title": "The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
      "journal": "Cancer discovery",
      "pubDate": "2020 Jan",
      "volume": "10",
      "issue": "1",
      "pages": "54-71",
      "authors": "Hallin J et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-19-1167",
      "link": null,
      "reference": "Hallin J et al. Cancer discovery. 2020 Jan;10(1)54-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac05"
  },
  "level": "LEVEL_3A",
  "gene": "KRAS",
  "alteration": "G12C",
  "alteration_name": "G12C",
  "cancer_main_type": "Gastrointestinal Neuroendocrine Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Adagrasib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.519",
      "reference": "null. null. .",
      "abstract": "Bekaii-Saab et al. Abstract# 519, ASCO GI Symposium, 2022"
    },
    {
      "pmid": "31658955",
      "title": "The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.",
      "journal": "Cancer discovery",
      "pubDate": "2020 Jan",
      "volume": "10",
      "issue": "1",
      "pages": "54-71",
      "authors": "Hallin J et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-19-1167",
      "link": null,
      "reference": "Hallin J et al. Cancer discovery. 2020 Jan;10(1)54-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac06"
  },
  "level": "LEVEL_3A",
  "gene": "MTOR",
  "alteration": "Q2223K",
  "alteration_name": "Q2223K",
  "cancer_main_type": "Renal Cell Carcinoma",
  "cancer_sub_type": "",
  "drug": [
    "Everolimus"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24622468",
      "title": "Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Apr 1",
      "volume": "20",
      "issue": "7",
      "pages": "1955-64",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-13-2345",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Apr 1;20(7)1955-64.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac07"
  },
  "level": "LEVEL_3A",
  "gene": "FLT3",
  "alteration": "572_630ins",
  "alteration_name": "Internal tandem duplication",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "Crenolanib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://learningcenter.ehaweb.org/eha/2017/22nd/181839/eunice.wang.variant.flt3.mutations.can.be.eradicated.by.cytarabine.html",
      "reference": "null. null. .",
      "abstract": "Wang E. et al. Abstract# P552, EHA Congress 2017"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetings.asco.org/abstracts-presentations/209027",
      "reference": "null. null. .",
      "abstract": "Wang E. et al. Abstract# 7007, ASCO 2022"
    },
    {
      "pmid": "24227820",
      "title": "Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.",
      "journal": "Blood",
      "pubDate": "2014 Jan 2",
      "volume": "123",
      "issue": "1",
      "pages": "94-100",
      "authors": "Galanis A et al",
      "elocationId": "doi: 10.1182/blood-2013-10-529313",
      "link": null,
      "reference": "Galanis A et al. Blood. 2014 Jan 2;123(1)94-100.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac08"
  },
  "level": "LEVEL_3A",
  "gene": "ARAF",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30361829",
      "title": "A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.",
      "journal": "International journal of hematology",
      "pubDate": "2019 Feb",
      "volume": "109",
      "issue": "2",
      "pages": "228-232",
      "authors": "Kumamoto T et al",
      "elocationId": "doi: 10.1007/s12185-018-2553-9",
      "link": null,
      "reference": "Kumamoto T et al. International journal of hematology. 2019 Feb;109(2)228-232.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac09"
  },
  "level": "LEVEL_3A",
  "gene": "ARAF",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Histiocytosis",
  "cancer_sub_type": "",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30361829",
      "title": "A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.",
      "journal": "International journal of hematology",
      "pubDate": "2019 Feb",
      "volume": "109",
      "issue": "2",
      "pages": "228-232",
      "authors": "Kumamoto T et al",
      "elocationId": "doi: 10.1007/s12185-018-2553-9",
      "link": null,
      "reference": "Kumamoto T et al. International journal of hematology. 2019 Feb;109(2)228-232.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac0a"
  },
  "level": "LEVEL_3A",
  "gene": "EGFR",
  "alteration": "E709_T710delinsD",
  "alteration_name": "E709_T710delinsD",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Afatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26206867",
      "title": "EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Dec 1",
      "volume": "21",
      "issue": "23",
      "pages": "5305-13",
      "authors": "Kobayashi Y et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-15-1046",
      "link": null,
      "reference": "Kobayashi Y et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Dec 1;21(23)5305-13.",
      "abstract": null
    },
    {
      "pmid": "31686847",
      "title": "Great efficacy of afatinib on a patient with lung adenocarcinoma harboring uncommon EGFR delE709_T710insD mutations: a case report.",
      "journal": "OncoTargets and therapy",
      "pubDate": "2019",
      "volume": "12",
      "issue": "",
      "pages": "7399-7404",
      "authors": "An N et al",
      "elocationId": "doi: 10.2147/OTT.S221638",
      "link": null,
      "reference": "An N et al. OncoTargets and therapy. 2019;12()7399-7404.",
      "abstract": null
    },
    {
      "pmid": "28625646",
      "title": "EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2017 Jun",
      "volume": "108",
      "issue": "",
      "pages": "45-47",
      "authors": "Ibrahim U et al",
      "elocationId": "doi: 10.1016/j.lungcan.2017.02.023",
      "link": null,
      "reference": "Ibrahim U et al. Lung cancer (Amsterdam, Netherlands). 2017 Jun;108()45-47.",
      "abstract": null
    },
    {
      "pmid": "31187861",
      "title": "Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.",
      "journal": "Japanese journal of clinical oncology",
      "pubDate": "2019 Aug 1",
      "volume": "49",
      "issue": "8",
      "pages": "786-788",
      "authors": "Iwamoto Y et al",
      "elocationId": "doi: 10.1093/jjco/hyz086",
      "link": null,
      "reference": "Iwamoto Y et al. Japanese journal of clinical oncology. 2019 Aug 1;49(8)786-788.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac0b"
  },
  "level": "LEVEL_3A",
  "gene": "EGFR",
  "alteration": "729_761ins",
  "alteration_name": "Exon 19 in-frame insertions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Gefitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29340050",
      "title": "Molecular characteristics and clinical outcomes of <i>EGFR</i> exon 19 indel subtypes to EGFR TKIs in NSCLC patients.",
      "journal": "Oncotarget",
      "pubDate": "2017 Dec 19",
      "volume": "8",
      "issue": "67",
      "pages": "111246-111257",
      "authors": "Su J et al",
      "elocationId": "doi: 10.18632/oncotarget.22768",
      "link": null,
      "reference": "Su J et al. Oncotarget. 2017 Dec 19;8(67)111246-111257.",
      "abstract": null
    },
    {
      "pmid": "22190593",
      "title": "EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Mar 15",
      "volume": "18",
      "issue": "6",
      "pages": "1790-7",
      "authors": "He M et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-11-2361",
      "link": null,
      "reference": "He M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Mar 15;18(6)1790-7.",
      "abstract": null
    },
    {
      "pmid": "28089594",
      "title": "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer.",
      "journal": "Clinical lung cancer",
      "pubDate": "2017 May",
      "volume": "18",
      "issue": "3",
      "pages": "324-332.e1",
      "authors": "Lin YT et al",
      "elocationId": "doi: 10.1016/j.cllc.2016.12.014",
      "link": null,
      "reference": "Lin YT et al. Clinical lung cancer. 2017 May;18(3)324-332.e1.",
      "abstract": null
    },
    {
      "pmid": "20075572",
      "title": "Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis.",
      "journal": "Internal medicine (Tokyo, Japan)",
      "pubDate": "2010",
      "volume": "49",
      "issue": "2",
      "pages": "103-7",
      "authors": "Uruga H et al",
      "elocationId": "",
      "link": null,
      "reference": "Uruga H et al. Internal medicine (Tokyo, Japan). 2010;49(2)103-7.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac0c"
  },
  "level": "LEVEL_3A",
  "gene": "ERBB2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Neratinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23220880",
      "title": "Activating HER2 mutations in HER2 gene amplification negative breast cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2013 Feb",
      "volume": "3",
      "issue": "2",
      "pages": "224-37",
      "authors": "Bose R et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-12-0349",
      "link": null,
      "reference": "Bose R et al. Cancer discovery. 2013 Feb;3(2)224-37.",
      "abstract": null
    },
    {
      "pmid": "29420467",
      "title": "HER kinase inhibition in patients with HER2- and HER3-mutant cancers.",
      "journal": "Nature",
      "pubDate": "2018 Feb 8",
      "volume": "554",
      "issue": "7691",
      "pages": "189-194",
      "authors": "Hyman DM et al",
      "elocationId": "doi: 10.1038/nature25475",
      "link": null,
      "reference": "Hyman DM et al. Nature. 2018 Feb 8;554(7691)189-194.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac0d"
  },
  "level": "LEVEL_4",
  "gene": "ARID1A",
  "alteration": "Truncating Mutations",
  "alteration_name": "Truncating Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "PLX2853"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31913353",
      "title": "ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.",
      "journal": "Nature genetics",
      "pubDate": "2020 Feb",
      "volume": "52",
      "issue": "2",
      "pages": "187-197",
      "authors": "Nagarajan S et al",
      "elocationId": "doi: 10.1038/s41588-019-0541-5",
      "link": null,
      "reference": "Nagarajan S et al. Nature genetics. 2020 Feb;52(2)187-197.",
      "abstract": null
    },
    {
      "pmid": "29760405",
      "title": "ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.",
      "journal": "Oncogene",
      "pubDate": "2018 Aug",
      "volume": "37",
      "issue": "33",
      "pages": "4611-4625",
      "authors": "Berns K et al",
      "elocationId": "doi: 10.1038/s41388-018-0300-6",
      "link": null,
      "reference": "Berns K et al. Oncogene. 2018 Aug;37(33)4611-4625.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac0e"
  },
  "level": "LEVEL_4",
  "gene": "FLI1",
  "alteration": "EWSR1-FLI1 Fusion",
  "alteration_name": "EWSR1-FLI1 Fusion",
  "cancer_main_type": "Bone Cancer",
  "cancer_sub_type": "Ewing Sarcoma",
  "drug": [
    "TK216"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/694",
      "reference": "null. null. .",
      "abstract": "Selvanathan et al. Abstract# 694, AACR 2017"
    },
    {
      "pmid": "19584866",
      "title": "A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma.",
      "journal": "Nature medicine",
      "pubDate": "2009 Jul",
      "volume": "15",
      "issue": "7",
      "pages": "750-6",
      "authors": "Erkizan HV et al",
      "elocationId": "doi: 10.1038/nm.1983",
      "link": null,
      "reference": "Erkizan HV et al. Nature medicine. 2009 Jul;15(7)750-6.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac0f"
  },
  "level": "LEVEL_4",
  "gene": "FLI1",
  "alteration": "EWSR1-FLI1 Fusion",
  "alteration_name": "EWSR1-FLI1 Fusion",
  "cancer_main_type": "Soft Tissue Sarcoma",
  "cancer_sub_type": "Ewing Sarcoma of Soft Tissue",
  "drug": [
    "TK216"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/694",
      "reference": "null. null. .",
      "abstract": "Selvanathan et al. Abstract# 694, AACR 2017"
    },
    {
      "pmid": "19584866",
      "title": "A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma.",
      "journal": "Nature medicine",
      "pubDate": "2009 Jul",
      "volume": "15",
      "issue": "7",
      "pages": "750-6",
      "authors": "Erkizan HV et al",
      "elocationId": "doi: 10.1038/nm.1983",
      "link": null,
      "reference": "Erkizan HV et al. Nature medicine. 2009 Jul;15(7)750-6.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac10"
  },
  "level": "LEVEL_4",
  "gene": "KDM6A",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Bladder Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Tazemetostat"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24123378",
      "title": "EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification.",
      "journal": "Stem cells (Dayton, Ohio)",
      "pubDate": "2014 Mar",
      "volume": "32",
      "issue": "3",
      "pages": "802-15",
      "authors": "Hemming S et al",
      "elocationId": "doi: 10.1002/stem.1573",
      "link": null,
      "reference": "Hemming S et al. Stem cells (Dayton, Ohio). 2014 Mar;32(3)802-15.",
      "abstract": null
    },
    {
      "pmid": "28228601",
      "title": "Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.",
      "journal": "Science translational medicine",
      "pubDate": "2017 Feb 22",
      "volume": "9",
      "issue": "378",
      "pages": "",
      "authors": "Ler LD et al",
      "elocationId": "pii: eaai8312. doi: 10.1126/scitranslmed.aai8312",
      "link": null,
      "reference": "Ler LD et al. Science translational medicine. 2017 Feb 22;9(378).",
      "abstract": null
    },
    {
      "pmid": "29045832",
      "title": "UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.",
      "journal": "Cell reports",
      "pubDate": "2017 Oct 17",
      "volume": "21",
      "issue": "3",
      "pages": "628-640",
      "authors": "Ezponda T et al",
      "elocationId": "doi: 10.1016/j.celrep.2017.09.078",
      "link": null,
      "reference": "Ezponda T et al. Cell reports. 2017 Oct 17;21(3)628-640.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac11"
  },
  "level": "LEVEL_4",
  "gene": "ARID1A",
  "alteration": "Truncating Mutations",
  "alteration_name": "Truncating Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Tazemetostat"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "25686104",
      "title": "Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.",
      "journal": "Nature medicine",
      "pubDate": "2015 Mar",
      "volume": "21",
      "issue": "3",
      "pages": "231-8",
      "authors": "Bitler BG et al",
      "elocationId": "doi: 10.1038/nm.3799",
      "link": null,
      "reference": "Bitler BG et al. Nature medicine. 2015 Mar;21(3)231-8.",
      "abstract": null
    },
    {
      "pmid": "32506298",
      "title": "Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer.",
      "journal": "Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association",
      "pubDate": "2021 Jan",
      "volume": "24",
      "issue": "1",
      "pages": "60-71",
      "authors": "Yamada L et al",
      "elocationId": "doi: 10.1007/s10120-020-01094-0",
      "link": null,
      "reference": "Yamada L et al. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2021 Jan;24(1)60-71.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac12"
  },
  "level": "LEVEL_4",
  "gene": "SF3B1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "H3B-8800"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29457796",
      "title": "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.",
      "journal": "Nature medicine",
      "pubDate": "2018 May",
      "volume": "24",
      "issue": "4",
      "pages": "497-504",
      "authors": "Seiler M et al",
      "elocationId": "doi: 10.1038/nm.4493",
      "link": null,
      "reference": "Seiler M et al. Nature medicine. 2018 May;24(4)497-504.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/128/22/966?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Buonamici, S. et al. Abstract# Blood 128:966, 2016"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac13"
  },
  "level": "LEVEL_4",
  "gene": "EGFR",
  "alteration": "L718V",
  "alteration_name": "L718V",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "Non-Small Cell Lung Cancer",
  "drug": [
    "Afatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31757379",
      "title": "Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2019 Dec",
      "volume": "14",
      "issue": "12",
      "pages": "e274-e275",
      "authors": "Fang W et al",
      "elocationId": "doi: 10.1016/j.jtho.2019.07.018",
      "link": null,
      "reference": "Fang W et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Dec;14(12)e274-e275.",
      "abstract": null
    },
    {
      "pmid": "29571986",
      "title": "Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2018 Apr",
      "volume": "118",
      "issue": "",
      "pages": "1-5",
      "authors": "Liu Y et al",
      "elocationId": "doi: 10.1016/j.lungcan.2018.01.015",
      "link": null,
      "reference": "Liu Y et al. Lung cancer (Amsterdam, Netherlands). 2018 Apr;118()1-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac14"
  },
  "level": "LEVEL_4",
  "gene": "MTOR",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Everolimus"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26831717",
      "title": "Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2016 May 15",
      "volume": "22",
      "issue": "10",
      "pages": "2445-2452",
      "authors": "Kwiatkowski DJ et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-15-2631",
      "link": null,
      "reference": "Kwiatkowski DJ et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 May 15;22(10)2445-2452.",
      "abstract": null
    },
    {
      "pmid": "30327302",
      "title": "PTEN Expression, Not Mutation Status in <i>TSC1, TSC2</i>, or <i>mTOR</i>, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Jan 15",
      "volume": "25",
      "issue": "2",
      "pages": "506-514",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1833",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jan 15;25(2)506-514.",
      "abstract": null
    },
    {
      "pmid": "24631838",
      "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
      "journal": "Cancer discovery",
      "pubDate": "2014 May",
      "volume": "4",
      "issue": "5",
      "pages": "554-63",
      "authors": "Grabiner BC et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-13-0929",
      "link": null,
      "reference": "Grabiner BC et al. Cancer discovery. 2014 May;4(5)554-63.",
      "abstract": null
    },
    {
      "pmid": "27482884",
      "title": "Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2016 Sep 1",
      "volume": "126",
      "issue": "9",
      "pages": "3526-40",
      "authors": "Xu J et al",
      "elocationId": "doi: 10.1172/JCI86120",
      "link": null,
      "reference": "Xu J et al. The Journal of clinical investigation. 2016 Sep 1;126(9)3526-40.",
      "abstract": null
    },
    {
      "pmid": "24622468",
      "title": "Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Apr 1",
      "volume": "20",
      "issue": "7",
      "pages": "1955-64",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-13-2345",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Apr 1;20(7)1955-64.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac15"
  },
  "level": "LEVEL_4",
  "gene": "MTOR",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Temsirolimus"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26831717",
      "title": "Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2016 May 15",
      "volume": "22",
      "issue": "10",
      "pages": "2445-2452",
      "authors": "Kwiatkowski DJ et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-15-2631",
      "link": null,
      "reference": "Kwiatkowski DJ et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 May 15;22(10)2445-2452.",
      "abstract": null
    },
    {
      "pmid": "30327302",
      "title": "PTEN Expression, Not Mutation Status in <i>TSC1, TSC2</i>, or <i>mTOR</i>, Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Jan 15",
      "volume": "25",
      "issue": "2",
      "pages": "506-514",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1833",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Jan 15;25(2)506-514.",
      "abstract": null
    },
    {
      "pmid": "24631838",
      "title": "A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.",
      "journal": "Cancer discovery",
      "pubDate": "2014 May",
      "volume": "4",
      "issue": "5",
      "pages": "554-63",
      "authors": "Grabiner BC et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-13-0929",
      "link": null,
      "reference": "Grabiner BC et al. Cancer discovery. 2014 May;4(5)554-63.",
      "abstract": null
    },
    {
      "pmid": "27482884",
      "title": "Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2016 Sep 1",
      "volume": "126",
      "issue": "9",
      "pages": "3526-40",
      "authors": "Xu J et al",
      "elocationId": "doi: 10.1172/JCI86120",
      "link": null,
      "reference": "Xu J et al. The Journal of clinical investigation. 2016 Sep 1;126(9)3526-40.",
      "abstract": null
    },
    {
      "pmid": "24622468",
      "title": "Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2014 Apr 1",
      "volume": "20",
      "issue": "7",
      "pages": "1955-64",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-13-2345",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Apr 1;20(7)1955-64.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac16"
  },
  "level": "LEVEL_4",
  "gene": "BRAF",
  "alteration": "G464",
  "alteration_name": "G464",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "PLX8394"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26466569",
      "title": "RAF inhibitors that evade paradoxical MAPK pathway activation.",
      "journal": "Nature",
      "pubDate": "2015 Oct 22",
      "volume": "526",
      "issue": "7574",
      "pages": "583-6",
      "authors": "Zhang C et al",
      "elocationId": "doi: 10.1038/nature14982",
      "link": null,
      "reference": "Zhang C et al. Nature. 2015 Oct 22;526(7574)583-6.",
      "abstract": null
    },
    {
      "pmid": "28659148",
      "title": "PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.",
      "journal": "Molecular cancer",
      "pubDate": "2017 Jun 28",
      "volume": "16",
      "issue": "1",
      "pages": "112",
      "authors": "Tutuka CSA et al",
      "elocationId": "doi: 10.1186/s12943-017-0684-x",
      "link": null,
      "reference": "Tutuka CSA et al. Molecular cancer. 2017 Jun 28;16(1)112.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://mct.aacrjournals.org/content/17/1_Supplement/B176",
      "reference": "null. null. .",
      "abstract": "Janku et al. Abstract# B176, AACR-NCI-EORTC 2017"
    },
    {
      "pmid": "28783719",
      "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
      "journal": "Nature",
      "pubDate": "2017 Aug 10",
      "volume": "548",
      "issue": "7666",
      "pages": "234-238",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/nature23291",
      "link": null,
      "reference": "Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.",
      "abstract": null
    },
    {
      "pmid": "30559419",
      "title": "RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.",
      "journal": "Nature medicine",
      "pubDate": "2019 Feb",
      "volume": "25",
      "issue": "2",
      "pages": "284-291",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/s41591-018-0274-5",
      "link": null,
      "reference": "Yao Z et al. Nature medicine. 2019 Feb;25(2)284-291.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac17"
  },
  "level": "LEVEL_4",
  "gene": "BRAF",
  "alteration": "G469A",
  "alteration_name": "G469A",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "PLX8394"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26466569",
      "title": "RAF inhibitors that evade paradoxical MAPK pathway activation.",
      "journal": "Nature",
      "pubDate": "2015 Oct 22",
      "volume": "526",
      "issue": "7574",
      "pages": "583-6",
      "authors": "Zhang C et al",
      "elocationId": "doi: 10.1038/nature14982",
      "link": null,
      "reference": "Zhang C et al. Nature. 2015 Oct 22;526(7574)583-6.",
      "abstract": null
    },
    {
      "pmid": "28659148",
      "title": "PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.",
      "journal": "Molecular cancer",
      "pubDate": "2017 Jun 28",
      "volume": "16",
      "issue": "1",
      "pages": "112",
      "authors": "Tutuka CSA et al",
      "elocationId": "doi: 10.1186/s12943-017-0684-x",
      "link": null,
      "reference": "Tutuka CSA et al. Molecular cancer. 2017 Jun 28;16(1)112.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://mct.aacrjournals.org/content/17/1_Supplement/B176",
      "reference": "null. null. .",
      "abstract": "Janku et al. Abstract# B176, AACR-NCI-EORTC 2017"
    },
    {
      "pmid": "28783719",
      "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
      "journal": "Nature",
      "pubDate": "2017 Aug 10",
      "volume": "548",
      "issue": "7666",
      "pages": "234-238",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/nature23291",
      "link": null,
      "reference": "Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.",
      "abstract": null
    },
    {
      "pmid": "30559419",
      "title": "RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.",
      "journal": "Nature medicine",
      "pubDate": "2019 Feb",
      "volume": "25",
      "issue": "2",
      "pages": "284-291",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/s41591-018-0274-5",
      "link": null,
      "reference": "Yao Z et al. Nature medicine. 2019 Feb;25(2)284-291.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac18"
  },
  "level": "LEVEL_4",
  "gene": "BRAF",
  "alteration": "G469R",
  "alteration_name": "G469R",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "PLX8394"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26466569",
      "title": "RAF inhibitors that evade paradoxical MAPK pathway activation.",
      "journal": "Nature",
      "pubDate": "2015 Oct 22",
      "volume": "526",
      "issue": "7574",
      "pages": "583-6",
      "authors": "Zhang C et al",
      "elocationId": "doi: 10.1038/nature14982",
      "link": null,
      "reference": "Zhang C et al. Nature. 2015 Oct 22;526(7574)583-6.",
      "abstract": null
    },
    {
      "pmid": "28659148",
      "title": "PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.",
      "journal": "Molecular cancer",
      "pubDate": "2017 Jun 28",
      "volume": "16",
      "issue": "1",
      "pages": "112",
      "authors": "Tutuka CSA et al",
      "elocationId": "doi: 10.1186/s12943-017-0684-x",
      "link": null,
      "reference": "Tutuka CSA et al. Molecular cancer. 2017 Jun 28;16(1)112.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://mct.aacrjournals.org/content/17/1_Supplement/B176",
      "reference": "null. null. .",
      "abstract": "Janku et al. Abstract# B176, AACR-NCI-EORTC 2017"
    },
    {
      "pmid": "28783719",
      "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
      "journal": "Nature",
      "pubDate": "2017 Aug 10",
      "volume": "548",
      "issue": "7666",
      "pages": "234-238",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/nature23291",
      "link": null,
      "reference": "Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.",
      "abstract": null
    },
    {
      "pmid": "30559419",
      "title": "RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.",
      "journal": "Nature medicine",
      "pubDate": "2019 Feb",
      "volume": "25",
      "issue": "2",
      "pages": "284-291",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/s41591-018-0274-5",
      "link": null,
      "reference": "Yao Z et al. Nature medicine. 2019 Feb;25(2)284-291.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac19"
  },
  "level": "LEVEL_4",
  "gene": "BRAF",
  "alteration": "G469V",
  "alteration_name": "G469V",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "PLX8394"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26466569",
      "title": "RAF inhibitors that evade paradoxical MAPK pathway activation.",
      "journal": "Nature",
      "pubDate": "2015 Oct 22",
      "volume": "526",
      "issue": "7574",
      "pages": "583-6",
      "authors": "Zhang C et al",
      "elocationId": "doi: 10.1038/nature14982",
      "link": null,
      "reference": "Zhang C et al. Nature. 2015 Oct 22;526(7574)583-6.",
      "abstract": null
    },
    {
      "pmid": "28659148",
      "title": "PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.",
      "journal": "Molecular cancer",
      "pubDate": "2017 Jun 28",
      "volume": "16",
      "issue": "1",
      "pages": "112",
      "authors": "Tutuka CSA et al",
      "elocationId": "doi: 10.1186/s12943-017-0684-x",
      "link": null,
      "reference": "Tutuka CSA et al. Molecular cancer. 2017 Jun 28;16(1)112.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://mct.aacrjournals.org/content/17/1_Supplement/B176",
      "reference": "null. null. .",
      "abstract": "Janku et al. Abstract# B176, AACR-NCI-EORTC 2017"
    },
    {
      "pmid": "28783719",
      "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
      "journal": "Nature",
      "pubDate": "2017 Aug 10",
      "volume": "548",
      "issue": "7666",
      "pages": "234-238",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/nature23291",
      "link": null,
      "reference": "Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.",
      "abstract": null
    },
    {
      "pmid": "30559419",
      "title": "RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.",
      "journal": "Nature medicine",
      "pubDate": "2019 Feb",
      "volume": "25",
      "issue": "2",
      "pages": "284-291",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/s41591-018-0274-5",
      "link": null,
      "reference": "Yao Z et al. Nature medicine. 2019 Feb;25(2)284-291.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac1a"
  },
  "level": "LEVEL_4",
  "gene": "SF3B1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Myelodysplastic/Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelomonocytic Leukemia",
  "drug": [
    "H3B-8800"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29457796",
      "title": "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.",
      "journal": "Nature medicine",
      "pubDate": "2018 May",
      "volume": "24",
      "issue": "4",
      "pages": "497-504",
      "authors": "Seiler M et al",
      "elocationId": "doi: 10.1038/nm.4493",
      "link": null,
      "reference": "Seiler M et al. Nature medicine. 2018 May;24(4)497-504.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/128/22/966?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Buonamici, S. et al. Abstract# Blood 128:966, 2016"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac1b"
  },
  "level": "LEVEL_4",
  "gene": "EGFR",
  "alteration": "Kinase Domain Duplication",
  "alteration_name": "Kinase Domain Duplication",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erlotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30255937",
      "title": "Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC.",
      "journal": "International journal of cancer",
      "pubDate": "2019 Jun 1",
      "volume": "144",
      "issue": "11",
      "pages": "2677-2682",
      "authors": "Wang J et al",
      "elocationId": "doi: 10.1002/ijc.31895",
      "link": null,
      "reference": "Wang J et al. International journal of cancer. 2019 Jun 1;144(11)2677-2682.",
      "abstract": null
    },
    {
      "pmid": "28336552",
      "title": "Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.",
      "journal": "Cancer discovery",
      "pubDate": "2017 Jun",
      "volume": "7",
      "issue": "6",
      "pages": "596-609",
      "authors": "Jordan EJ et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-16-1337",
      "link": null,
      "reference": "Jordan EJ et al. Cancer discovery. 2017 Jun;7(6)596-609.",
      "abstract": null
    },
    {
      "pmid": "26398831",
      "title": "Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2015 Oct",
      "volume": "10",
      "issue": "10",
      "pages": "e97-9",
      "authors": "Baik CS et al",
      "elocationId": "doi: 10.1097/JTO.0000000000000586",
      "link": null,
      "reference": "Baik CS et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Oct;10(10)e97-9.",
      "abstract": null
    },
    {
      "pmid": "26286086",
      "title": "EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.",
      "journal": "Cancer discovery",
      "pubDate": "2015 Nov",
      "volume": "5",
      "issue": "11",
      "pages": "1155-63",
      "authors": "Gallant JN et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0654",
      "link": null,
      "reference": "Gallant JN et al. Cancer discovery. 2015 Nov;5(11)1155-63.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac1c"
  },
  "level": "LEVEL_4",
  "gene": "PIK3CA",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "RLY-2608"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/cancerres/article/82/4_Supplement/P5-16-10/681459",
      "reference": "null. null. .",
      "abstract": "Pazolli et al. Abstract# P5-16-10, SABCS 2021"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/mct/article/20/12_Supplement/P251/676005/Abstract-P251-Discovery-and-characterization-of",
      "reference": "null. null. .",
      "abstract": "Pazolli et al. Abstract# P251, TARG 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac1d"
  },
  "level": "LEVEL_4",
  "gene": "ZRSR2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Myelodysplastic/Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelomonocytic Leukemia",
  "drug": [
    "H3B-8800"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29457796",
      "title": "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.",
      "journal": "Nature medicine",
      "pubDate": "2018 May",
      "volume": "24",
      "issue": "4",
      "pages": "497-504",
      "authors": "Seiler M et al",
      "elocationId": "doi: 10.1038/nm.4493",
      "link": null,
      "reference": "Seiler M et al. Nature medicine. 2018 May;24(4)497-504.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/128/22/966?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Buonamici, S. et al. Abstract# Blood 128:966, 2016"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac1e"
  },
  "level": "LEVEL_4",
  "gene": "PTEN",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "GSK2636771"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2570",
      "reference": "null. null. .",
      "abstract": "Hansen et al. Abstract# 2570, ASCO 2017"
    },
    {
      "pmid": "28645941",
      "title": "A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2017 Oct 1",
      "volume": "23",
      "issue": "19",
      "pages": "5981-5992",
      "authors": "Mateo J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-17-0725",
      "link": null,
      "reference": "Mateo J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Oct 1;23(19)5981-5992.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac1f"
  },
  "level": "LEVEL_4",
  "gene": "PTEN",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "AZD8186"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.2570",
      "reference": "null. null. .",
      "abstract": "Hansen et al. Abstract# 2570, ASCO 2017"
    },
    {
      "pmid": "28645941",
      "title": "A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2017 Oct 1",
      "volume": "23",
      "issue": "19",
      "pages": "5981-5992",
      "authors": "Mateo J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-17-0725",
      "link": null,
      "reference": "Mateo J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Oct 1;23(19)5981-5992.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac20"
  },
  "level": "LEVEL_4",
  "gene": "EGFR",
  "alteration": "D761Y",
  "alteration_name": "D761Y",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Osimertinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "17085664",
      "title": "Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Nov 1",
      "volume": "12",
      "issue": "21",
      "pages": "6494-501",
      "authors": "Balak MN et al",
      "elocationId": "",
      "link": null,
      "reference": "Balak MN et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Nov 1;12(21)6494-501.",
      "abstract": null
    },
    {
      "pmid": "28424065",
      "title": "Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.",
      "journal": "BMC cancer",
      "pubDate": "2017 Apr 19",
      "volume": "17",
      "issue": "1",
      "pages": "281",
      "authors": "Chiba M et al",
      "elocationId": "doi: 10.1186/s12885-017-3263-z",
      "link": null,
      "reference": "Chiba M et al. BMC cancer. 2017 Apr 19;17(1)281.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac21"
  },
  "level": "LEVEL_4",
  "gene": "U2AF1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Myelodysplastic/Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelomonocytic Leukemia",
  "drug": [
    "H3B-8800"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29457796",
      "title": "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.",
      "journal": "Nature medicine",
      "pubDate": "2018 May",
      "volume": "24",
      "issue": "4",
      "pages": "497-504",
      "authors": "Seiler M et al",
      "elocationId": "doi: 10.1038/nm.4493",
      "link": null,
      "reference": "Seiler M et al. Nature medicine. 2018 May;24(4)497-504.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/128/22/966?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Buonamici, S. et al. Abstract# Blood 128:966, 2016"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac22"
  },
  "level": "LEVEL_4",
  "gene": "SF3B1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Myelodysplastic Syndromes",
  "cancer_sub_type": "Myelodysplastic Syndromes",
  "drug": [
    "H3B-8800"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29457796",
      "title": "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.",
      "journal": "Nature medicine",
      "pubDate": "2018 May",
      "volume": "24",
      "issue": "4",
      "pages": "497-504",
      "authors": "Seiler M et al",
      "elocationId": "doi: 10.1038/nm.4493",
      "link": null,
      "reference": "Seiler M et al. Nature medicine. 2018 May;24(4)497-504.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/128/22/966?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Buonamici, S. et al. Abstract# Blood 128:966, 2016"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac23"
  },
  "level": "LEVEL_4",
  "gene": "KIT",
  "alteration": "D816",
  "alteration_name": "D816",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21456006",
      "title": "Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.",
      "journal": "Cancer",
      "pubDate": "2011 Oct 15",
      "volume": "117",
      "issue": "20",
      "pages": "4633-41",
      "authors": "Sawaki A et al",
      "elocationId": "doi: 10.1002/cncr.26120",
      "link": null,
      "reference": "Sawaki A et al. Cancer. 2011 Oct 15;117(20)4633-41.",
      "abstract": null
    },
    {
      "pmid": "19467857",
      "title": "Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.",
      "journal": "European journal of cancer (Oxford, England : 1990)",
      "pubDate": "2009 Sep",
      "volume": "45",
      "issue": "13",
      "pages": "2293-7",
      "authors": "Montemurro M et al",
      "elocationId": "doi: 10.1016/j.ejca.2009.04.030",
      "link": null,
      "reference": "Montemurro M et al. European journal of cancer (Oxford, England : 1990). 2009 Sep;45(13)2293-7.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac24"
  },
  "level": "LEVEL_4",
  "gene": "KIT",
  "alteration": "D820",
  "alteration_name": "D820",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21456006",
      "title": "Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.",
      "journal": "Cancer",
      "pubDate": "2011 Oct 15",
      "volume": "117",
      "issue": "20",
      "pages": "4633-41",
      "authors": "Sawaki A et al",
      "elocationId": "doi: 10.1002/cncr.26120",
      "link": null,
      "reference": "Sawaki A et al. Cancer. 2011 Oct 15;117(20)4633-41.",
      "abstract": null
    },
    {
      "pmid": "19467857",
      "title": "Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.",
      "journal": "European journal of cancer (Oxford, England : 1990)",
      "pubDate": "2009 Sep",
      "volume": "45",
      "issue": "13",
      "pages": "2293-7",
      "authors": "Montemurro M et al",
      "elocationId": "doi: 10.1016/j.ejca.2009.04.030",
      "link": null,
      "reference": "Montemurro M et al. European journal of cancer (Oxford, England : 1990). 2009 Sep;45(13)2293-7.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac25"
  },
  "level": "LEVEL_4",
  "gene": "KIT",
  "alteration": "N822",
  "alteration_name": "N822",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21456006",
      "title": "Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.",
      "journal": "Cancer",
      "pubDate": "2011 Oct 15",
      "volume": "117",
      "issue": "20",
      "pages": "4633-41",
      "authors": "Sawaki A et al",
      "elocationId": "doi: 10.1002/cncr.26120",
      "link": null,
      "reference": "Sawaki A et al. Cancer. 2011 Oct 15;117(20)4633-41.",
      "abstract": null
    },
    {
      "pmid": "19467857",
      "title": "Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.",
      "journal": "European journal of cancer (Oxford, England : 1990)",
      "pubDate": "2009 Sep",
      "volume": "45",
      "issue": "13",
      "pages": "2293-7",
      "authors": "Montemurro M et al",
      "elocationId": "doi: 10.1016/j.ejca.2009.04.030",
      "link": null,
      "reference": "Montemurro M et al. European journal of cancer (Oxford, England : 1990). 2009 Sep;45(13)2293-7.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac26"
  },
  "level": "LEVEL_4",
  "gene": "KIT",
  "alteration": "Y823D",
  "alteration_name": "Y823D",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21456006",
      "title": "Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.",
      "journal": "Cancer",
      "pubDate": "2011 Oct 15",
      "volume": "117",
      "issue": "20",
      "pages": "4633-41",
      "authors": "Sawaki A et al",
      "elocationId": "doi: 10.1002/cncr.26120",
      "link": null,
      "reference": "Sawaki A et al. Cancer. 2011 Oct 15;117(20)4633-41.",
      "abstract": null
    },
    {
      "pmid": "19467857",
      "title": "Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.",
      "journal": "European journal of cancer (Oxford, England : 1990)",
      "pubDate": "2009 Sep",
      "volume": "45",
      "issue": "13",
      "pages": "2293-7",
      "authors": "Montemurro M et al",
      "elocationId": "doi: 10.1016/j.ejca.2009.04.030",
      "link": null,
      "reference": "Montemurro M et al. European journal of cancer (Oxford, England : 1990). 2009 Sep;45(13)2293-7.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac27"
  },
  "level": "LEVEL_4",
  "gene": "KIT",
  "alteration": "C809G",
  "alteration_name": "C809G",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21456006",
      "title": "Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.",
      "journal": "Cancer",
      "pubDate": "2011 Oct 15",
      "volume": "117",
      "issue": "20",
      "pages": "4633-41",
      "authors": "Sawaki A et al",
      "elocationId": "doi: 10.1002/cncr.26120",
      "link": null,
      "reference": "Sawaki A et al. Cancer. 2011 Oct 15;117(20)4633-41.",
      "abstract": null
    },
    {
      "pmid": "19467857",
      "title": "Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.",
      "journal": "European journal of cancer (Oxford, England : 1990)",
      "pubDate": "2009 Sep",
      "volume": "45",
      "issue": "13",
      "pages": "2293-7",
      "authors": "Montemurro M et al",
      "elocationId": "doi: 10.1016/j.ejca.2009.04.030",
      "link": null,
      "reference": "Montemurro M et al. European journal of cancer (Oxford, England : 1990). 2009 Sep;45(13)2293-7.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac28"
  },
  "level": "LEVEL_4",
  "gene": "KIT",
  "alteration": "A829P",
  "alteration_name": "A829P",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "21456006",
      "title": "Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.",
      "journal": "Cancer",
      "pubDate": "2011 Oct 15",
      "volume": "117",
      "issue": "20",
      "pages": "4633-41",
      "authors": "Sawaki A et al",
      "elocationId": "doi: 10.1002/cncr.26120",
      "link": null,
      "reference": "Sawaki A et al. Cancer. 2011 Oct 15;117(20)4633-41.",
      "abstract": null
    },
    {
      "pmid": "19467857",
      "title": "Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib.",
      "journal": "European journal of cancer (Oxford, England : 1990)",
      "pubDate": "2009 Sep",
      "volume": "45",
      "issue": "13",
      "pages": "2293-7",
      "authors": "Montemurro M et al",
      "elocationId": "doi: 10.1016/j.ejca.2009.04.030",
      "link": null,
      "reference": "Montemurro M et al. European journal of cancer (Oxford, England : 1990). 2009 Sep;45(13)2293-7.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac29"
  },
  "level": "LEVEL_4",
  "gene": "FGFR1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Infigratinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23082000",
      "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Dec 15",
      "volume": "18",
      "issue": "24",
      "pages": "6658-67",
      "authors": "Zhang J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-12-2694",
      "link": null,
      "reference": "Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.",
      "abstract": null
    },
    {
      "pmid": "25169980",
      "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2014 Nov",
      "volume": "13",
      "issue": "11",
      "pages": "2547-58",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-14-0248",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.",
      "abstract": null
    },
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "26438159",
      "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Dec",
      "volume": "14",
      "issue": "12",
      "pages": "2831-9",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0497",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/2088",
      "reference": "null. null. .",
      "abstract": "Brichory F et al. Abstract# 2088, AACR 2017"
    },
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    },
    {
      "pmid": "35344029",
      "title": "Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2022 Jun 1",
      "volume": "28",
      "issue": "11",
      "pages": "2270-2277",
      "authors": "Lassman AB et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-21-2664",
      "link": null,
      "reference": "Lassman AB et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Jun 1;28(11)2270-2277.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac2a"
  },
  "level": "LEVEL_4",
  "gene": "FGFR1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Debio1347"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23082000",
      "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Dec 15",
      "volume": "18",
      "issue": "24",
      "pages": "6658-67",
      "authors": "Zhang J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-12-2694",
      "link": null,
      "reference": "Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.",
      "abstract": null
    },
    {
      "pmid": "25169980",
      "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2014 Nov",
      "volume": "13",
      "issue": "11",
      "pages": "2547-58",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-14-0248",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.",
      "abstract": null
    },
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "26438159",
      "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Dec",
      "volume": "14",
      "issue": "12",
      "pages": "2831-9",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0497",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/2088",
      "reference": "null. null. .",
      "abstract": "Brichory F et al. Abstract# 2088, AACR 2017"
    },
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    },
    {
      "pmid": "35344029",
      "title": "Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2022 Jun 1",
      "volume": "28",
      "issue": "11",
      "pages": "2270-2277",
      "authors": "Lassman AB et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-21-2664",
      "link": null,
      "reference": "Lassman AB et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Jun 1;28(11)2270-2277.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac2b"
  },
  "level": "LEVEL_4",
  "gene": "FGFR1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "AZD4547"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23082000",
      "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Dec 15",
      "volume": "18",
      "issue": "24",
      "pages": "6658-67",
      "authors": "Zhang J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-12-2694",
      "link": null,
      "reference": "Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.",
      "abstract": null
    },
    {
      "pmid": "25169980",
      "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2014 Nov",
      "volume": "13",
      "issue": "11",
      "pages": "2547-58",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-14-0248",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.",
      "abstract": null
    },
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "26438159",
      "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Dec",
      "volume": "14",
      "issue": "12",
      "pages": "2831-9",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0497",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/2088",
      "reference": "null. null. .",
      "abstract": "Brichory F et al. Abstract# 2088, AACR 2017"
    },
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    },
    {
      "pmid": "35344029",
      "title": "Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2022 Jun 1",
      "volume": "28",
      "issue": "11",
      "pages": "2270-2277",
      "authors": "Lassman AB et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-21-2664",
      "link": null,
      "reference": "Lassman AB et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Jun 1;28(11)2270-2277.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac2c"
  },
  "level": "LEVEL_4",
  "gene": "FGFR1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Erdafitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23082000",
      "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Dec 15",
      "volume": "18",
      "issue": "24",
      "pages": "6658-67",
      "authors": "Zhang J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-12-2694",
      "link": null,
      "reference": "Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.",
      "abstract": null
    },
    {
      "pmid": "25169980",
      "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2014 Nov",
      "volume": "13",
      "issue": "11",
      "pages": "2547-58",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-14-0248",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.",
      "abstract": null
    },
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "26438159",
      "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Dec",
      "volume": "14",
      "issue": "12",
      "pages": "2831-9",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0497",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/2088",
      "reference": "null. null. .",
      "abstract": "Brichory F et al. Abstract# 2088, AACR 2017"
    },
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    },
    {
      "pmid": "35344029",
      "title": "Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2022 Jun 1",
      "volume": "28",
      "issue": "11",
      "pages": "2270-2277",
      "authors": "Lassman AB et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-21-2664",
      "link": null,
      "reference": "Lassman AB et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Jun 1;28(11)2270-2277.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac2d"
  },
  "level": "LEVEL_4",
  "gene": "FGFR2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Erdafitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23082000",
      "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Dec 15",
      "volume": "18",
      "issue": "24",
      "pages": "6658-67",
      "authors": "Zhang J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-12-2694",
      "link": null,
      "reference": "Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.",
      "abstract": null
    },
    {
      "pmid": "25169980",
      "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2014 Nov",
      "volume": "13",
      "issue": "11",
      "pages": "2547-58",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-14-0248",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.",
      "abstract": null
    },
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "26438159",
      "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Dec",
      "volume": "14",
      "issue": "12",
      "pages": "2831-9",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0497",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/2088",
      "reference": "null. null. .",
      "abstract": "Brichory F et al. Abstract# 2088, AACR 2017"
    },
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    },
    {
      "pmid": "35344029",
      "title": "Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2022 Jun 1",
      "volume": "28",
      "issue": "11",
      "pages": "2270-2277",
      "authors": "Lassman AB et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-21-2664",
      "link": null,
      "reference": "Lassman AB et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Jun 1;28(11)2270-2277.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac2e"
  },
  "level": "LEVEL_4",
  "gene": "FGFR2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Debio1347"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23082000",
      "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Dec 15",
      "volume": "18",
      "issue": "24",
      "pages": "6658-67",
      "authors": "Zhang J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-12-2694",
      "link": null,
      "reference": "Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.",
      "abstract": null
    },
    {
      "pmid": "25169980",
      "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2014 Nov",
      "volume": "13",
      "issue": "11",
      "pages": "2547-58",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-14-0248",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.",
      "abstract": null
    },
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "26438159",
      "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Dec",
      "volume": "14",
      "issue": "12",
      "pages": "2831-9",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0497",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/2088",
      "reference": "null. null. .",
      "abstract": "Brichory F et al. Abstract# 2088, AACR 2017"
    },
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    },
    {
      "pmid": "35344029",
      "title": "Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2022 Jun 1",
      "volume": "28",
      "issue": "11",
      "pages": "2270-2277",
      "authors": "Lassman AB et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-21-2664",
      "link": null,
      "reference": "Lassman AB et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Jun 1;28(11)2270-2277.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac2f"
  },
  "level": "LEVEL_4",
  "gene": "FGFR2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "AZD4547"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23082000",
      "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Dec 15",
      "volume": "18",
      "issue": "24",
      "pages": "6658-67",
      "authors": "Zhang J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-12-2694",
      "link": null,
      "reference": "Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.",
      "abstract": null
    },
    {
      "pmid": "25169980",
      "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2014 Nov",
      "volume": "13",
      "issue": "11",
      "pages": "2547-58",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-14-0248",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.",
      "abstract": null
    },
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "26438159",
      "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Dec",
      "volume": "14",
      "issue": "12",
      "pages": "2831-9",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0497",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/2088",
      "reference": "null. null. .",
      "abstract": "Brichory F et al. Abstract# 2088, AACR 2017"
    },
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    },
    {
      "pmid": "35344029",
      "title": "Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2022 Jun 1",
      "volume": "28",
      "issue": "11",
      "pages": "2270-2277",
      "authors": "Lassman AB et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-21-2664",
      "link": null,
      "reference": "Lassman AB et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Jun 1;28(11)2270-2277.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac30"
  },
  "level": "LEVEL_4",
  "gene": "FGFR2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Infigratinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23082000",
      "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Dec 15",
      "volume": "18",
      "issue": "24",
      "pages": "6658-67",
      "authors": "Zhang J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-12-2694",
      "link": null,
      "reference": "Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.",
      "abstract": null
    },
    {
      "pmid": "25169980",
      "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2014 Nov",
      "volume": "13",
      "issue": "11",
      "pages": "2547-58",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-14-0248",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.",
      "abstract": null
    },
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "26438159",
      "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Dec",
      "volume": "14",
      "issue": "12",
      "pages": "2831-9",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0497",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/2088",
      "reference": "null. null. .",
      "abstract": "Brichory F et al. Abstract# 2088, AACR 2017"
    },
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    },
    {
      "pmid": "35344029",
      "title": "Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2022 Jun 1",
      "volume": "28",
      "issue": "11",
      "pages": "2270-2277",
      "authors": "Lassman AB et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-21-2664",
      "link": null,
      "reference": "Lassman AB et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Jun 1;28(11)2270-2277.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac31"
  },
  "level": "LEVEL_4",
  "gene": "SMARCB1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Liquid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Tazemetostat"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27391784",
      "title": "Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.",
      "journal": "PloS one",
      "pubDate": "2016",
      "volume": "11",
      "issue": "7",
      "pages": "e0158888",
      "authors": "Kawano S et al",
      "elocationId": "doi: 10.1371/journal.pone.0158888",
      "link": null,
      "reference": "Kawano S et al. PloS one. 2016;11(7)e0158888.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.abstractsonline.com/pp8/#!/4557/presentation/616",
      "reference": "null. null. .",
      "abstract": "Chi et al. Abstract# A175, AACR-NCI-EORTC 2017"
    },
    {
      "pmid": "20951942",
      "title": "Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation.",
      "journal": "Cancer cell",
      "pubDate": "2010 Oct 19",
      "volume": "18",
      "issue": "4",
      "pages": "316-28",
      "authors": "Wilson BG et al",
      "elocationId": "doi: 10.1016/j.ccr.2010.09.006",
      "link": null,
      "reference": "Wilson BG et al. Cancer cell. 2010 Oct 19;18(4)316-28.",
      "abstract": null
    },
    {
      "pmid": "23620515",
      "title": "Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.",
      "journal": "Proceedings of the National Academy of Sciences of the United States of America",
      "pubDate": "2013 May 7",
      "volume": "110",
      "issue": "19",
      "pages": "7922-7",
      "authors": "Knutson SK et al",
      "elocationId": "doi: 10.1073/pnas.1303800110",
      "link": null,
      "reference": "Knutson SK et al. Proceedings of the National Academy of Sciences of the United States of America. 2013 May 7;110(19)7922-7.",
      "abstract": null
    },
    {
      "pmid": "29650362",
      "title": "Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2018 May",
      "volume": "19",
      "issue": "5",
      "pages": "649-659",
      "authors": "Italiano A et al",
      "elocationId": "doi: 10.1016/S1470-2045(18)30145-1",
      "link": null,
      "reference": "Italiano A et al. The Lancet. Oncology. 2018 May;19(5)649-659.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac32"
  },
  "level": "LEVEL_4",
  "gene": "KIT",
  "alteration": "D816",
  "alteration_name": "D816",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Pazopanib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24356634",
      "title": "A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2014 Jan",
      "volume": "25",
      "issue": "1",
      "pages": "236-40",
      "authors": "Ganjoo KN et al",
      "elocationId": "doi: 10.1093/annonc/mdt484",
      "link": null,
      "reference": "Ganjoo KN et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Jan;25(1)236-40.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac33"
  },
  "level": "LEVEL_4",
  "gene": "KIT",
  "alteration": "D820",
  "alteration_name": "D820",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Pazopanib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24356634",
      "title": "A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2014 Jan",
      "volume": "25",
      "issue": "1",
      "pages": "236-40",
      "authors": "Ganjoo KN et al",
      "elocationId": "doi: 10.1093/annonc/mdt484",
      "link": null,
      "reference": "Ganjoo KN et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Jan;25(1)236-40.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac34"
  },
  "level": "LEVEL_4",
  "gene": "KIT",
  "alteration": "N822",
  "alteration_name": "N822",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Pazopanib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24356634",
      "title": "A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2014 Jan",
      "volume": "25",
      "issue": "1",
      "pages": "236-40",
      "authors": "Ganjoo KN et al",
      "elocationId": "doi: 10.1093/annonc/mdt484",
      "link": null,
      "reference": "Ganjoo KN et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Jan;25(1)236-40.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac35"
  },
  "level": "LEVEL_4",
  "gene": "KIT",
  "alteration": "Y823D",
  "alteration_name": "Y823D",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Pazopanib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24356634",
      "title": "A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2014 Jan",
      "volume": "25",
      "issue": "1",
      "pages": "236-40",
      "authors": "Ganjoo KN et al",
      "elocationId": "doi: 10.1093/annonc/mdt484",
      "link": null,
      "reference": "Ganjoo KN et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Jan;25(1)236-40.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac36"
  },
  "level": "LEVEL_4",
  "gene": "KIT",
  "alteration": "C809G",
  "alteration_name": "C809G",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Pazopanib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24356634",
      "title": "A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2014 Jan",
      "volume": "25",
      "issue": "1",
      "pages": "236-40",
      "authors": "Ganjoo KN et al",
      "elocationId": "doi: 10.1093/annonc/mdt484",
      "link": null,
      "reference": "Ganjoo KN et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Jan;25(1)236-40.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac37"
  },
  "level": "LEVEL_4",
  "gene": "KIT",
  "alteration": "A829P",
  "alteration_name": "A829P",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Pazopanib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24356634",
      "title": "A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2014 Jan",
      "volume": "25",
      "issue": "1",
      "pages": "236-40",
      "authors": "Ganjoo KN et al",
      "elocationId": "doi: 10.1093/annonc/mdt484",
      "link": null,
      "reference": "Ganjoo KN et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Jan;25(1)236-40.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac38"
  },
  "level": "LEVEL_4",
  "gene": "MDM2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Soft Tissue Sarcoma",
  "cancer_sub_type": "Dedifferentiated Liposarcoma",
  "drug": [
    "Milademetan"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://meetinglibrary.asco.org/content/166204-176",
      "reference": "null. null. .",
      "abstract": "Gounder et al. Abstract# 2581, ASCO 2016"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B27",
      "reference": "null. null. .",
      "abstract": "Bauer T et al. Abstract# B27, AACR 2015"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.retesarcoma.it/wp-content/uploads/2018/10/2018-ctos-final-program.pdf",
      "reference": "null. null. .",
      "abstract": "Gounder et al. Abstract# 19 3025592, CTOS 2018"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.ejcancer.com/article/S0959-8049(20",
      "reference": "null. null. .",
      "abstract": "Gounder, M.M. et al. Abstract# S2-S3, European Journal of Cancer, 2020"
    },
    {
      "pmid": "23400593",
      "title": "MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.",
      "journal": "Cancer research",
      "pubDate": "2013 Apr 15",
      "volume": "73",
      "issue": "8",
      "pages": "2587-97",
      "authors": "Tovar C et al",
      "elocationId": "doi: 10.1158/0008-5472.CAN-12-2807",
      "link": null,
      "reference": "Tovar C et al. Cancer research. 2013 Apr 15;73(8)2587-97.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac39"
  },
  "level": "LEVEL_4",
  "gene": "MDM2",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Soft Tissue Sarcoma",
  "cancer_sub_type": "Well-Differentiated Liposarcoma",
  "drug": [
    "Milademetan"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://meetinglibrary.asco.org/content/166204-176",
      "reference": "null. null. .",
      "abstract": "Gounder et al. Abstract# 2581, ASCO 2016"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://mct.aacrjournals.org/content/14/12_Supplement_2/B27",
      "reference": "null. null. .",
      "abstract": "Bauer T et al. Abstract# B27, AACR 2015"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.retesarcoma.it/wp-content/uploads/2018/10/2018-ctos-final-program.pdf",
      "reference": "null. null. .",
      "abstract": "Gounder et al. Abstract# 19 3025592, CTOS 2018"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://www.ejcancer.com/article/S0959-8049(20",
      "reference": "null. null. .",
      "abstract": "Gounder, M.M. et al. Abstract# S2-S3, European Journal of Cancer, 2020"
    },
    {
      "pmid": "23400593",
      "title": "MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.",
      "journal": "Cancer research",
      "pubDate": "2013 Apr 15",
      "volume": "73",
      "issue": "8",
      "pages": "2587-97",
      "authors": "Tovar C et al",
      "elocationId": "doi: 10.1158/0008-5472.CAN-12-2807",
      "link": null,
      "reference": "Tovar C et al. Cancer research. 2013 Apr 15;73(8)2587-97.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac3a"
  },
  "level": "LEVEL_4",
  "gene": "CCNE1",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "RP-6306"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/cancerres/article/82/12_Supplement/2306/703534",
      "reference": "null. null. .",
      "abstract": "Brown et al. Abstract# 2306, AACR 2022"
    },
    {
      "pmid": "35444283",
      "title": "CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.",
      "journal": "Nature",
      "pubDate": "2022 Apr",
      "volume": "604",
      "issue": "7907",
      "pages": "749-756",
      "authors": "Gallo D et al",
      "elocationId": "doi: 10.1038/s41586-022-04638-9",
      "link": null,
      "reference": "Gallo D et al. Nature. 2022 Apr;604(7907)749-756.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac3b"
  },
  "level": "LEVEL_4",
  "gene": "CCNE1",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "BLU-222"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/cancerres/article/82/12_Supplement/2306/703534",
      "reference": "null. null. .",
      "abstract": "Brown et al. Abstract# 2306, AACR 2022"
    },
    {
      "pmid": "35444283",
      "title": "CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.",
      "journal": "Nature",
      "pubDate": "2022 Apr",
      "volume": "604",
      "issue": "7907",
      "pages": "749-756",
      "authors": "Gallo D et al",
      "elocationId": "doi: 10.1038/s41586-022-04638-9",
      "link": null,
      "reference": "Gallo D et al. Nature. 2022 Apr;604(7907)749-756.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac3c"
  },
  "level": "LEVEL_4",
  "gene": "CDK4",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Soft Tissue Sarcoma",
  "cancer_sub_type": "Dedifferentiated Liposarcoma",
  "drug": [
    "Abemaciclib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27124835",
      "title": "Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2016 Jul 1",
      "volume": "2",
      "issue": "7",
      "pages": "937-40",
      "authors": "Dickson MA et al",
      "elocationId": "doi: 10.1001/jamaoncol.2016.0264",
      "link": null,
      "reference": "Dickson MA et al. JAMA oncology. 2016 Jul 1;2(7)937-40.",
      "abstract": null
    },
    {
      "pmid": "23569312",
      "title": "Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Jun 1",
      "volume": "31",
      "issue": "16",
      "pages": "2024-8",
      "authors": "Dickson MA et al",
      "elocationId": "doi: 10.1200/JCO.2012.46.5476",
      "link": null,
      "reference": "Dickson MA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jun 1;31(16)2024-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac3d"
  },
  "level": "LEVEL_4",
  "gene": "CDK4",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Soft Tissue Sarcoma",
  "cancer_sub_type": "Dedifferentiated Liposarcoma",
  "drug": [
    "Palbociclib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27124835",
      "title": "Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2016 Jul 1",
      "volume": "2",
      "issue": "7",
      "pages": "937-40",
      "authors": "Dickson MA et al",
      "elocationId": "doi: 10.1001/jamaoncol.2016.0264",
      "link": null,
      "reference": "Dickson MA et al. JAMA oncology. 2016 Jul 1;2(7)937-40.",
      "abstract": null
    },
    {
      "pmid": "23569312",
      "title": "Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Jun 1",
      "volume": "31",
      "issue": "16",
      "pages": "2024-8",
      "authors": "Dickson MA et al",
      "elocationId": "doi: 10.1200/JCO.2012.46.5476",
      "link": null,
      "reference": "Dickson MA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jun 1;31(16)2024-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac3e"
  },
  "level": "LEVEL_4",
  "gene": "CDK4",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Soft Tissue Sarcoma",
  "cancer_sub_type": "Well-Differentiated Liposarcoma",
  "drug": [
    "Abemaciclib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27124835",
      "title": "Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2016 Jul 1",
      "volume": "2",
      "issue": "7",
      "pages": "937-40",
      "authors": "Dickson MA et al",
      "elocationId": "doi: 10.1001/jamaoncol.2016.0264",
      "link": null,
      "reference": "Dickson MA et al. JAMA oncology. 2016 Jul 1;2(7)937-40.",
      "abstract": null
    },
    {
      "pmid": "23569312",
      "title": "Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Jun 1",
      "volume": "31",
      "issue": "16",
      "pages": "2024-8",
      "authors": "Dickson MA et al",
      "elocationId": "doi: 10.1200/JCO.2012.46.5476",
      "link": null,
      "reference": "Dickson MA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jun 1;31(16)2024-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac3f"
  },
  "level": "LEVEL_4",
  "gene": "CDK4",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Soft Tissue Sarcoma",
  "cancer_sub_type": "Well-Differentiated Liposarcoma",
  "drug": [
    "Palbociclib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "27124835",
      "title": "Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.",
      "journal": "JAMA oncology",
      "pubDate": "2016 Jul 1",
      "volume": "2",
      "issue": "7",
      "pages": "937-40",
      "authors": "Dickson MA et al",
      "elocationId": "doi: 10.1001/jamaoncol.2016.0264",
      "link": null,
      "reference": "Dickson MA et al. JAMA oncology. 2016 Jul 1;2(7)937-40.",
      "abstract": null
    },
    {
      "pmid": "23569312",
      "title": "Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Jun 1",
      "volume": "31",
      "issue": "16",
      "pages": "2024-8",
      "authors": "Dickson MA et al",
      "elocationId": "doi: 10.1200/JCO.2012.46.5476",
      "link": null,
      "reference": "Dickson MA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Jun 1;31(16)2024-8.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac40"
  },
  "level": "LEVEL_4",
  "gene": "BRAF",
  "alteration": "K601",
  "alteration_name": "K601",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "PLX8394"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26466569",
      "title": "RAF inhibitors that evade paradoxical MAPK pathway activation.",
      "journal": "Nature",
      "pubDate": "2015 Oct 22",
      "volume": "526",
      "issue": "7574",
      "pages": "583-6",
      "authors": "Zhang C et al",
      "elocationId": "doi: 10.1038/nature14982",
      "link": null,
      "reference": "Zhang C et al. Nature. 2015 Oct 22;526(7574)583-6.",
      "abstract": null
    },
    {
      "pmid": "28659148",
      "title": "PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.",
      "journal": "Molecular cancer",
      "pubDate": "2017 Jun 28",
      "volume": "16",
      "issue": "1",
      "pages": "112",
      "authors": "Tutuka CSA et al",
      "elocationId": "doi: 10.1186/s12943-017-0684-x",
      "link": null,
      "reference": "Tutuka CSA et al. Molecular cancer. 2017 Jun 28;16(1)112.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://mct.aacrjournals.org/content/17/1_Supplement/B176",
      "reference": "null. null. .",
      "abstract": "Janku et al. Abstract# B176, AACR-NCI-EORTC 2017"
    },
    {
      "pmid": "28783719",
      "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
      "journal": "Nature",
      "pubDate": "2017 Aug 10",
      "volume": "548",
      "issue": "7666",
      "pages": "234-238",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/nature23291",
      "link": null,
      "reference": "Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.",
      "abstract": null
    },
    {
      "pmid": "30559419",
      "title": "RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.",
      "journal": "Nature medicine",
      "pubDate": "2019 Feb",
      "volume": "25",
      "issue": "2",
      "pages": "284-291",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/s41591-018-0274-5",
      "link": null,
      "reference": "Yao Z et al. Nature medicine. 2019 Feb;25(2)284-291.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac41"
  },
  "level": "LEVEL_4",
  "gene": "EGFR",
  "alteration": "Kinase Domain Duplication",
  "alteration_name": "Kinase Domain Duplication",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Gefitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "30255937",
      "title": "Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC.",
      "journal": "International journal of cancer",
      "pubDate": "2019 Jun 1",
      "volume": "144",
      "issue": "11",
      "pages": "2677-2682",
      "authors": "Wang J et al",
      "elocationId": "doi: 10.1002/ijc.31895",
      "link": null,
      "reference": "Wang J et al. International journal of cancer. 2019 Jun 1;144(11)2677-2682.",
      "abstract": null
    },
    {
      "pmid": "26398831",
      "title": "Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2015 Oct",
      "volume": "10",
      "issue": "10",
      "pages": "e97-9",
      "authors": "Baik CS et al",
      "elocationId": "doi: 10.1097/JTO.0000000000000586",
      "link": null,
      "reference": "Baik CS et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 Oct;10(10)e97-9.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac42"
  },
  "level": "LEVEL_4",
  "gene": "NRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Melanoma",
  "cancer_sub_type": "Melanoma",
  "drug": [
    "Binimetinib",
    "Ribociclib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22983396",
      "title": "Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.",
      "journal": "Nature medicine",
      "pubDate": "2012 Oct",
      "volume": "18",
      "issue": "10",
      "pages": "1503-10",
      "authors": "Kwong LN et al",
      "elocationId": "doi: 10.1038/nm.2941",
      "link": null,
      "reference": "Kwong LN et al. Nature medicine. 2012 Oct;18(10)1503-10.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9519",
      "reference": "null. null. .",
      "abstract": "Schuler et al. Abstract #9519, ASCO 2017"
    },
    {
      "pmid": "29496665",
      "title": "A Preexisting Rare <i>PIK3CA</i><sup>E545K</sup> Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in <i>NRAS</i> Melanoma and Is Dependent on S6K1 Signaling.",
      "journal": "Cancer discovery",
      "pubDate": "2018 May",
      "volume": "8",
      "issue": "5",
      "pages": "556-567",
      "authors": "Romano G et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-17-0745",
      "link": null,
      "reference": "Romano G et al. Cancer discovery. 2018 May;8(5)556-567.",
      "abstract": null
    },
    {
      "pmid": "30819666",
      "title": "A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.",
      "journal": "Cancer research",
      "pubDate": "2019 May 1",
      "volume": "79",
      "issue": "9",
      "pages": "2352-2366",
      "authors": "Hayes TK et al",
      "elocationId": "doi: 10.1158/0008-5472.CAN-18-2711",
      "link": null,
      "reference": "Hayes TK et al. Cancer research. 2019 May 1;79(9)2352-2366.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac43"
  },
  "level": "LEVEL_4",
  "gene": "BRAF",
  "alteration": "L597",
  "alteration_name": "L597",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "PLX8394"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26466569",
      "title": "RAF inhibitors that evade paradoxical MAPK pathway activation.",
      "journal": "Nature",
      "pubDate": "2015 Oct 22",
      "volume": "526",
      "issue": "7574",
      "pages": "583-6",
      "authors": "Zhang C et al",
      "elocationId": "doi: 10.1038/nature14982",
      "link": null,
      "reference": "Zhang C et al. Nature. 2015 Oct 22;526(7574)583-6.",
      "abstract": null
    },
    {
      "pmid": "28659148",
      "title": "PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.",
      "journal": "Molecular cancer",
      "pubDate": "2017 Jun 28",
      "volume": "16",
      "issue": "1",
      "pages": "112",
      "authors": "Tutuka CSA et al",
      "elocationId": "doi: 10.1186/s12943-017-0684-x",
      "link": null,
      "reference": "Tutuka CSA et al. Molecular cancer. 2017 Jun 28;16(1)112.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://mct.aacrjournals.org/content/17/1_Supplement/B176",
      "reference": "null. null. .",
      "abstract": "Janku et al. Abstract# B176, AACR-NCI-EORTC 2017"
    },
    {
      "pmid": "28783719",
      "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
      "journal": "Nature",
      "pubDate": "2017 Aug 10",
      "volume": "548",
      "issue": "7666",
      "pages": "234-238",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/nature23291",
      "link": null,
      "reference": "Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.",
      "abstract": null
    },
    {
      "pmid": "30559419",
      "title": "RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.",
      "journal": "Nature medicine",
      "pubDate": "2019 Feb",
      "volume": "25",
      "issue": "2",
      "pages": "284-291",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/s41591-018-0274-5",
      "link": null,
      "reference": "Yao Z et al. Nature medicine. 2019 Feb;25(2)284-291.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac44"
  },
  "level": "LEVEL_4",
  "gene": "FGFR3",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Erdafitinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23082000",
      "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Dec 15",
      "volume": "18",
      "issue": "24",
      "pages": "6658-67",
      "authors": "Zhang J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-12-2694",
      "link": null,
      "reference": "Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/2088",
      "reference": "null. null. .",
      "abstract": "Brichory F et al. Abstract# 2088, AACR 2017"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/160559/abstract",
      "reference": "null. null. .",
      "abstract": "Siefker-Radtke et al. Abstract#4503, ASCO 2018"
    },
    {
      "pmid": "35344029",
      "title": "Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2022 Jun 1",
      "volume": "28",
      "issue": "11",
      "pages": "2270-2277",
      "authors": "Lassman AB et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-21-2664",
      "link": null,
      "reference": "Lassman AB et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Jun 1;28(11)2270-2277.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "21119661",
      "title": "Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.",
      "journal": "British journal of cancer",
      "pubDate": "2011 Jan 4",
      "volume": "104",
      "issue": "1",
      "pages": "75-82",
      "authors": "Lamont FR et al",
      "elocationId": "doi: 10.1038/sj.bjc.6606016",
      "link": null,
      "reference": "Lamont FR et al. British journal of cancer. 2011 Jan 4;104(1)75-82.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    },
    {
      "pmid": "26324363",
      "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Oct 20",
      "volume": "33",
      "issue": "30",
      "pages": "3401-8",
      "authors": "Tabernero J et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.7341",
      "link": null,
      "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.",
      "abstract": null
    },
    {
      "pmid": "29848605",
      "title": "Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations.",
      "journal": "Cancer discovery",
      "pubDate": "2018 Jul",
      "volume": "8",
      "issue": "7",
      "pages": "812-821",
      "authors": "Pal SK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0229",
      "link": null,
      "reference": "Pal SK et al. Cancer discovery. 2018 Jul;8(7)812-821.",
      "abstract": null
    },
    {
      "pmid": "25169980",
      "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2014 Nov",
      "volume": "13",
      "issue": "11",
      "pages": "2547-58",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-14-0248",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.",
      "abstract": null
    },
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "26438159",
      "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Dec",
      "volume": "14",
      "issue": "12",
      "pages": "2831-9",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0497",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.",
      "abstract": null
    },
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac45"
  },
  "level": "LEVEL_4",
  "gene": "FGFR3",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Debio1347"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23082000",
      "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Dec 15",
      "volume": "18",
      "issue": "24",
      "pages": "6658-67",
      "authors": "Zhang J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-12-2694",
      "link": null,
      "reference": "Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/2088",
      "reference": "null. null. .",
      "abstract": "Brichory F et al. Abstract# 2088, AACR 2017"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/160559/abstract",
      "reference": "null. null. .",
      "abstract": "Siefker-Radtke et al. Abstract#4503, ASCO 2018"
    },
    {
      "pmid": "35344029",
      "title": "Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2022 Jun 1",
      "volume": "28",
      "issue": "11",
      "pages": "2270-2277",
      "authors": "Lassman AB et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-21-2664",
      "link": null,
      "reference": "Lassman AB et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Jun 1;28(11)2270-2277.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "21119661",
      "title": "Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.",
      "journal": "British journal of cancer",
      "pubDate": "2011 Jan 4",
      "volume": "104",
      "issue": "1",
      "pages": "75-82",
      "authors": "Lamont FR et al",
      "elocationId": "doi: 10.1038/sj.bjc.6606016",
      "link": null,
      "reference": "Lamont FR et al. British journal of cancer. 2011 Jan 4;104(1)75-82.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    },
    {
      "pmid": "26324363",
      "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Oct 20",
      "volume": "33",
      "issue": "30",
      "pages": "3401-8",
      "authors": "Tabernero J et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.7341",
      "link": null,
      "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.",
      "abstract": null
    },
    {
      "pmid": "29848605",
      "title": "Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations.",
      "journal": "Cancer discovery",
      "pubDate": "2018 Jul",
      "volume": "8",
      "issue": "7",
      "pages": "812-821",
      "authors": "Pal SK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0229",
      "link": null,
      "reference": "Pal SK et al. Cancer discovery. 2018 Jul;8(7)812-821.",
      "abstract": null
    },
    {
      "pmid": "25169980",
      "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2014 Nov",
      "volume": "13",
      "issue": "11",
      "pages": "2547-58",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-14-0248",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.",
      "abstract": null
    },
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "26438159",
      "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Dec",
      "volume": "14",
      "issue": "12",
      "pages": "2831-9",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0497",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.",
      "abstract": null
    },
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac46"
  },
  "level": "LEVEL_4",
  "gene": "FGFR3",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "AZD4547"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23082000",
      "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Dec 15",
      "volume": "18",
      "issue": "24",
      "pages": "6658-67",
      "authors": "Zhang J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-12-2694",
      "link": null,
      "reference": "Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/2088",
      "reference": "null. null. .",
      "abstract": "Brichory F et al. Abstract# 2088, AACR 2017"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/160559/abstract",
      "reference": "null. null. .",
      "abstract": "Siefker-Radtke et al. Abstract#4503, ASCO 2018"
    },
    {
      "pmid": "35344029",
      "title": "Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2022 Jun 1",
      "volume": "28",
      "issue": "11",
      "pages": "2270-2277",
      "authors": "Lassman AB et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-21-2664",
      "link": null,
      "reference": "Lassman AB et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Jun 1;28(11)2270-2277.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "21119661",
      "title": "Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.",
      "journal": "British journal of cancer",
      "pubDate": "2011 Jan 4",
      "volume": "104",
      "issue": "1",
      "pages": "75-82",
      "authors": "Lamont FR et al",
      "elocationId": "doi: 10.1038/sj.bjc.6606016",
      "link": null,
      "reference": "Lamont FR et al. British journal of cancer. 2011 Jan 4;104(1)75-82.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    },
    {
      "pmid": "26324363",
      "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Oct 20",
      "volume": "33",
      "issue": "30",
      "pages": "3401-8",
      "authors": "Tabernero J et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.7341",
      "link": null,
      "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.",
      "abstract": null
    },
    {
      "pmid": "29848605",
      "title": "Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations.",
      "journal": "Cancer discovery",
      "pubDate": "2018 Jul",
      "volume": "8",
      "issue": "7",
      "pages": "812-821",
      "authors": "Pal SK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0229",
      "link": null,
      "reference": "Pal SK et al. Cancer discovery. 2018 Jul;8(7)812-821.",
      "abstract": null
    },
    {
      "pmid": "25169980",
      "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2014 Nov",
      "volume": "13",
      "issue": "11",
      "pages": "2547-58",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-14-0248",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.",
      "abstract": null
    },
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "26438159",
      "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Dec",
      "volume": "14",
      "issue": "12",
      "pages": "2831-9",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0497",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.",
      "abstract": null
    },
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac47"
  },
  "level": "LEVEL_4",
  "gene": "FGFR3",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Infigratinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "23082000",
      "title": "Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Dec 15",
      "volume": "18",
      "issue": "24",
      "pages": "6658-67",
      "authors": "Zhang J et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-12-2694",
      "link": null,
      "reference": "Zhang J et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Dec 15;18(24)6658-67.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://cancerres.aacrjournals.org/content/77/13_Supplement/2088",
      "reference": "null. null. .",
      "abstract": "Brichory F et al. Abstract# 2088, AACR 2017"
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://meetinglibrary.asco.org/record/160559/abstract",
      "reference": "null. null. .",
      "abstract": "Siefker-Radtke et al. Abstract#4503, ASCO 2018"
    },
    {
      "pmid": "35344029",
      "title": "Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2022 Jun 1",
      "volume": "28",
      "issue": "11",
      "pages": "2270-2277",
      "authors": "Lassman AB et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-21-2664",
      "link": null,
      "reference": "Lassman AB et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Jun 1;28(11)2270-2277.",
      "abstract": null
    },
    {
      "pmid": "30745300",
      "title": "A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 May 1",
      "volume": "25",
      "issue": "9",
      "pages": "2699-2707",
      "authors": "Voss MH et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-1959",
      "link": null,
      "reference": "Voss MH et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 May 1;25(9)2699-2707.",
      "abstract": null
    },
    {
      "pmid": "21119661",
      "title": "Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.",
      "journal": "British journal of cancer",
      "pubDate": "2011 Jan 4",
      "volume": "104",
      "issue": "1",
      "pages": "75-82",
      "authors": "Lamont FR et al",
      "elocationId": "doi: 10.1038/sj.bjc.6606016",
      "link": null,
      "reference": "Lamont FR et al. British journal of cancer. 2011 Jan 4;104(1)75-82.",
      "abstract": null
    },
    {
      "pmid": "31088831",
      "title": "Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2019 Aug 15",
      "volume": "25",
      "issue": "16",
      "pages": "4888-4897",
      "authors": "Bahleda R et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-18-3334",
      "link": null,
      "reference": "Bahleda R et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Aug 15;25(16)4888-4897.",
      "abstract": null
    },
    {
      "pmid": "26324363",
      "title": "Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2015 Oct 20",
      "volume": "33",
      "issue": "30",
      "pages": "3401-8",
      "authors": "Tabernero J et al",
      "elocationId": "doi: 10.1200/JCO.2014.60.7341",
      "link": null,
      "reference": "Tabernero J et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Oct 20;33(30)3401-8.",
      "abstract": null
    },
    {
      "pmid": "29848605",
      "title": "Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations.",
      "journal": "Cancer discovery",
      "pubDate": "2018 Jul",
      "volume": "8",
      "issue": "7",
      "pages": "812-821",
      "authors": "Pal SK et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0229",
      "link": null,
      "reference": "Pal SK et al. Cancer discovery. 2018 Jul;8(7)812-821.",
      "abstract": null
    },
    {
      "pmid": "25169980",
      "title": "The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2014 Nov",
      "volume": "13",
      "issue": "11",
      "pages": "2547-58",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-14-0248",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2014 Nov;13(11)2547-58.",
      "abstract": null
    },
    {
      "pmid": "27870574",
      "title": "Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 Jan 10",
      "volume": "35",
      "issue": "2",
      "pages": "157-165",
      "authors": "Nogova L et al",
      "elocationId": "",
      "link": null,
      "reference": "Nogova L et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Jan 10;35(2)157-165.",
      "abstract": null
    },
    {
      "pmid": "26438159",
      "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2015 Dec",
      "volume": "14",
      "issue": "12",
      "pages": "2831-9",
      "authors": "Nakanishi Y et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-15-0497",
      "link": null,
      "reference": "Nakanishi Y et al. Molecular cancer therapeutics. 2015 Dec;14(12)2831-9.",
      "abstract": null
    },
    {
      "pmid": "31340094",
      "title": "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.",
      "journal": "The New England journal of medicine",
      "pubDate": "2019 Jul 25",
      "volume": "381",
      "issue": "4",
      "pages": "338-348",
      "authors": "Loriot Y et al",
      "elocationId": "doi: 10.1056/NEJMoa1817323",
      "link": null,
      "reference": "Loriot Y et al. The New England journal of medicine. 2019 Jul 25;381(4)338-348.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac48"
  },
  "level": "LEVEL_4",
  "gene": "U2AF1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Myelodysplastic Syndromes",
  "cancer_sub_type": "Myelodysplastic Syndromes",
  "drug": [
    "H3B-8800"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29457796",
      "title": "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.",
      "journal": "Nature medicine",
      "pubDate": "2018 May",
      "volume": "24",
      "issue": "4",
      "pages": "497-504",
      "authors": "Seiler M et al",
      "elocationId": "doi: 10.1038/nm.4493",
      "link": null,
      "reference": "Seiler M et al. Nature medicine. 2018 May;24(4)497-504.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/128/22/966?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Buonamici, S. et al. Abstract# Blood 128:966, 2016"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac49"
  },
  "level": "LEVEL_4",
  "gene": "SRSF2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Myelodysplastic Syndromes",
  "cancer_sub_type": "Myelodysplastic Syndromes",
  "drug": [
    "H3B-8800"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29457796",
      "title": "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.",
      "journal": "Nature medicine",
      "pubDate": "2018 May",
      "volume": "24",
      "issue": "4",
      "pages": "497-504",
      "authors": "Seiler M et al",
      "elocationId": "doi: 10.1038/nm.4493",
      "link": null,
      "reference": "Seiler M et al. Nature medicine. 2018 May;24(4)497-504.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/128/22/966?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Buonamici, S. et al. Abstract# Blood 128:966, 2016"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac4a"
  },
  "level": "LEVEL_4",
  "gene": "SRSF2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Myelodysplastic/Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelomonocytic Leukemia",
  "drug": [
    "H3B-8800"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29457796",
      "title": "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.",
      "journal": "Nature medicine",
      "pubDate": "2018 May",
      "volume": "24",
      "issue": "4",
      "pages": "497-504",
      "authors": "Seiler M et al",
      "elocationId": "doi: 10.1038/nm.4493",
      "link": null,
      "reference": "Seiler M et al. Nature medicine. 2018 May;24(4)497-504.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/128/22/966?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Buonamici, S. et al. Abstract# Blood 128:966, 2016"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac4b"
  },
  "level": "LEVEL_4",
  "gene": "KRAS",
  "alteration": "G12D",
  "alteration_name": "G12D",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "RMC-6236"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/cancerres/article/82/12_Supplement/3597/702320",
      "reference": "null. null. .",
      "abstract": "Koltun et al. Abstract# 3597, AACR 2022"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac4c"
  },
  "level": "LEVEL_4",
  "gene": "PIK3CA",
  "alteration": "H1047R",
  "alteration_name": "H1047R",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "LOXO-783"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/mct/article/20/12_Supplement/P142/675896/Abstract-P142-Preclinical-characterization-of-LOX",
      "reference": "null. null. .",
      "abstract": "Klippel et al. Abstract# P142, AACR-NCI-EORTC 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac4d"
  },
  "level": "LEVEL_4",
  "gene": "KRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Binimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33933896",
      "title": "Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2021 Jun",
      "volume": "156",
      "issue": "",
      "pages": "91-99",
      "authors": "Froesch P et al",
      "elocationId": "doi: 10.1016/j.lungcan.2021.04.002",
      "link": null,
      "reference": "Froesch P et al. Lung cancer (Amsterdam, Netherlands). 2021 Jun;156()91-99.",
      "abstract": null
    },
    {
      "pmid": "24746704",
      "title": "Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.",
      "journal": "Cancer cell",
      "pubDate": "2014 May 12",
      "volume": "25",
      "issue": "5",
      "pages": "697-710",
      "authors": "Lito P et al",
      "elocationId": "doi: 10.1016/j.ccr.2014.03.011",
      "link": null,
      "reference": "Lito P et al. Cancer cell. 2014 May 12;25(5)697-710.",
      "abstract": null
    },
    {
      "pmid": "23934108",
      "title": "Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.",
      "journal": "Nature",
      "pubDate": "2013 Sep 12",
      "volume": "501",
      "issue": "7466",
      "pages": "232-6",
      "authors": "Hatzivassiliou G et al",
      "elocationId": "doi: 10.1038/nature12441",
      "link": null,
      "reference": "Hatzivassiliou G et al. Nature. 2013 Sep 12;501(7466)232-6.",
      "abstract": null
    },
    {
      "pmid": "28783719",
      "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
      "journal": "Nature",
      "pubDate": "2017 Aug 10",
      "volume": "548",
      "issue": "7666",
      "pages": "234-238",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/nature23291",
      "link": null,
      "reference": "Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.",
      "abstract": null
    },
    {
      "pmid": "25435214",
      "title": "Targeting RAS-ERK signalling in cancer: promises and challenges.",
      "journal": "Nature reviews. Drug discovery",
      "pubDate": "2014 Dec",
      "volume": "13",
      "issue": "12",
      "pages": "928-42",
      "authors": "Samatar AA et al",
      "elocationId": "doi: 10.1038/nrd4281",
      "link": null,
      "reference": "Samatar AA et al. Nature reviews. Drug discovery. 2014 Dec;13(12)928-42.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac4e"
  },
  "level": "LEVEL_4",
  "gene": "KRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33933896",
      "title": "Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2021 Jun",
      "volume": "156",
      "issue": "",
      "pages": "91-99",
      "authors": "Froesch P et al",
      "elocationId": "doi: 10.1016/j.lungcan.2021.04.002",
      "link": null,
      "reference": "Froesch P et al. Lung cancer (Amsterdam, Netherlands). 2021 Jun;156()91-99.",
      "abstract": null
    },
    {
      "pmid": "24746704",
      "title": "Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.",
      "journal": "Cancer cell",
      "pubDate": "2014 May 12",
      "volume": "25",
      "issue": "5",
      "pages": "697-710",
      "authors": "Lito P et al",
      "elocationId": "doi: 10.1016/j.ccr.2014.03.011",
      "link": null,
      "reference": "Lito P et al. Cancer cell. 2014 May 12;25(5)697-710.",
      "abstract": null
    },
    {
      "pmid": "23934108",
      "title": "Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.",
      "journal": "Nature",
      "pubDate": "2013 Sep 12",
      "volume": "501",
      "issue": "7466",
      "pages": "232-6",
      "authors": "Hatzivassiliou G et al",
      "elocationId": "doi: 10.1038/nature12441",
      "link": null,
      "reference": "Hatzivassiliou G et al. Nature. 2013 Sep 12;501(7466)232-6.",
      "abstract": null
    },
    {
      "pmid": "28783719",
      "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
      "journal": "Nature",
      "pubDate": "2017 Aug 10",
      "volume": "548",
      "issue": "7666",
      "pages": "234-238",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/nature23291",
      "link": null,
      "reference": "Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.",
      "abstract": null
    },
    {
      "pmid": "25435214",
      "title": "Targeting RAS-ERK signalling in cancer: promises and challenges.",
      "journal": "Nature reviews. Drug discovery",
      "pubDate": "2014 Dec",
      "volume": "13",
      "issue": "12",
      "pages": "928-42",
      "authors": "Samatar AA et al",
      "elocationId": "doi: 10.1038/nrd4281",
      "link": null,
      "reference": "Samatar AA et al. Nature reviews. Drug discovery. 2014 Dec;13(12)928-42.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac4f"
  },
  "level": "LEVEL_4",
  "gene": "KRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "33933896",
      "title": "Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2021 Jun",
      "volume": "156",
      "issue": "",
      "pages": "91-99",
      "authors": "Froesch P et al",
      "elocationId": "doi: 10.1016/j.lungcan.2021.04.002",
      "link": null,
      "reference": "Froesch P et al. Lung cancer (Amsterdam, Netherlands). 2021 Jun;156()91-99.",
      "abstract": null
    },
    {
      "pmid": "24746704",
      "title": "Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.",
      "journal": "Cancer cell",
      "pubDate": "2014 May 12",
      "volume": "25",
      "issue": "5",
      "pages": "697-710",
      "authors": "Lito P et al",
      "elocationId": "doi: 10.1016/j.ccr.2014.03.011",
      "link": null,
      "reference": "Lito P et al. Cancer cell. 2014 May 12;25(5)697-710.",
      "abstract": null
    },
    {
      "pmid": "23934108",
      "title": "Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers.",
      "journal": "Nature",
      "pubDate": "2013 Sep 12",
      "volume": "501",
      "issue": "7466",
      "pages": "232-6",
      "authors": "Hatzivassiliou G et al",
      "elocationId": "doi: 10.1038/nature12441",
      "link": null,
      "reference": "Hatzivassiliou G et al. Nature. 2013 Sep 12;501(7466)232-6.",
      "abstract": null
    },
    {
      "pmid": "28783719",
      "title": "Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.",
      "journal": "Nature",
      "pubDate": "2017 Aug 10",
      "volume": "548",
      "issue": "7666",
      "pages": "234-238",
      "authors": "Yao Z et al",
      "elocationId": "doi: 10.1038/nature23291",
      "link": null,
      "reference": "Yao Z et al. Nature. 2017 Aug 10;548(7666)234-238.",
      "abstract": null
    },
    {
      "pmid": "25435214",
      "title": "Targeting RAS-ERK signalling in cancer: promises and challenges.",
      "journal": "Nature reviews. Drug discovery",
      "pubDate": "2014 Dec",
      "volume": "13",
      "issue": "12",
      "pages": "928-42",
      "authors": "Samatar AA et al",
      "elocationId": "doi: 10.1038/nrd4281",
      "link": null,
      "reference": "Samatar AA et al. Nature reviews. Drug discovery. 2014 Dec;13(12)928-42.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac50"
  },
  "level": "LEVEL_4",
  "gene": "CDKN2A",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Palbociclib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24495407",
      "title": "Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.",
      "journal": "Pigment cell & melanoma research",
      "pubDate": "2014 Jul",
      "volume": "27",
      "issue": "4",
      "pages": "590-600",
      "authors": "Young RJ et al",
      "elocationId": "doi: 10.1111/pcmr.12228",
      "link": null,
      "reference": "Young RJ et al. Pigment cell & melanoma research. 2014 Jul;27(4)590-600.",
      "abstract": null
    },
    {
      "pmid": "19874578",
      "title": "PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially   inhibits proliferation of luminal estrogen receptor-positive human   breast cancer cell lines in vitro.",
      "journal": "Breast cancer research : BCR",
      "pubDate": "2009",
      "volume": "11",
      "issue": "5",
      "pages": "R77",
      "authors": "Finn RS et al",
      "elocationId": "doi: 10.1186/bcr2419",
      "link": null,
      "reference": "Finn RS et al. Breast cancer research : BCR. 2009;11(5)R77.",
      "abstract": null
    },
    {
      "pmid": "28283584",
      "title": "Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common <i>CDKN2A</i> Alteration.",
      "journal": "The oncologist",
      "pubDate": "2017 Apr",
      "volume": "22",
      "issue": "4",
      "pages": "416-421",
      "authors": "Elvin JA et al",
      "elocationId": "doi: 10.1634/theoncologist.2016-0310",
      "link": null,
      "reference": "Elvin JA et al. The oncologist. 2017 Apr;22(4)416-421.",
      "abstract": null
    },
    {
      "pmid": "29232554",
      "title": "Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.",
      "journal": "Cancer cell",
      "pubDate": "2017 Dec 11",
      "volume": "32",
      "issue": "6",
      "pages": "761-776.e6",
      "authors": "Gong X et al",
      "elocationId": "doi: 10.1016/j.ccell.2017.11.006",
      "link": null,
      "reference": "Gong X et al. Cancer cell. 2017 Dec 11;32(6)761-776.e6.",
      "abstract": null
    },
    {
      "pmid": "25941111",
      "title": "Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Jul 1",
      "volume": "21",
      "issue": "13",
      "pages": "2905-10",
      "authors": "VanArsdale T et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-0816",
      "link": null,
      "reference": "VanArsdale T et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jul 1;21(13)2905-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac51"
  },
  "level": "LEVEL_4",
  "gene": "CDKN2A",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Ribociclib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24495407",
      "title": "Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.",
      "journal": "Pigment cell & melanoma research",
      "pubDate": "2014 Jul",
      "volume": "27",
      "issue": "4",
      "pages": "590-600",
      "authors": "Young RJ et al",
      "elocationId": "doi: 10.1111/pcmr.12228",
      "link": null,
      "reference": "Young RJ et al. Pigment cell & melanoma research. 2014 Jul;27(4)590-600.",
      "abstract": null
    },
    {
      "pmid": "19874578",
      "title": "PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially   inhibits proliferation of luminal estrogen receptor-positive human   breast cancer cell lines in vitro.",
      "journal": "Breast cancer research : BCR",
      "pubDate": "2009",
      "volume": "11",
      "issue": "5",
      "pages": "R77",
      "authors": "Finn RS et al",
      "elocationId": "doi: 10.1186/bcr2419",
      "link": null,
      "reference": "Finn RS et al. Breast cancer research : BCR. 2009;11(5)R77.",
      "abstract": null
    },
    {
      "pmid": "28283584",
      "title": "Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common <i>CDKN2A</i> Alteration.",
      "journal": "The oncologist",
      "pubDate": "2017 Apr",
      "volume": "22",
      "issue": "4",
      "pages": "416-421",
      "authors": "Elvin JA et al",
      "elocationId": "doi: 10.1634/theoncologist.2016-0310",
      "link": null,
      "reference": "Elvin JA et al. The oncologist. 2017 Apr;22(4)416-421.",
      "abstract": null
    },
    {
      "pmid": "29232554",
      "title": "Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.",
      "journal": "Cancer cell",
      "pubDate": "2017 Dec 11",
      "volume": "32",
      "issue": "6",
      "pages": "761-776.e6",
      "authors": "Gong X et al",
      "elocationId": "doi: 10.1016/j.ccell.2017.11.006",
      "link": null,
      "reference": "Gong X et al. Cancer cell. 2017 Dec 11;32(6)761-776.e6.",
      "abstract": null
    },
    {
      "pmid": "25941111",
      "title": "Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Jul 1",
      "volume": "21",
      "issue": "13",
      "pages": "2905-10",
      "authors": "VanArsdale T et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-0816",
      "link": null,
      "reference": "VanArsdale T et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jul 1;21(13)2905-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac52"
  },
  "level": "LEVEL_4",
  "gene": "CDKN2A",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Abemaciclib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "24495407",
      "title": "Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.",
      "journal": "Pigment cell & melanoma research",
      "pubDate": "2014 Jul",
      "volume": "27",
      "issue": "4",
      "pages": "590-600",
      "authors": "Young RJ et al",
      "elocationId": "doi: 10.1111/pcmr.12228",
      "link": null,
      "reference": "Young RJ et al. Pigment cell & melanoma research. 2014 Jul;27(4)590-600.",
      "abstract": null
    },
    {
      "pmid": "19874578",
      "title": "PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially   inhibits proliferation of luminal estrogen receptor-positive human   breast cancer cell lines in vitro.",
      "journal": "Breast cancer research : BCR",
      "pubDate": "2009",
      "volume": "11",
      "issue": "5",
      "pages": "R77",
      "authors": "Finn RS et al",
      "elocationId": "doi: 10.1186/bcr2419",
      "link": null,
      "reference": "Finn RS et al. Breast cancer research : BCR. 2009;11(5)R77.",
      "abstract": null
    },
    {
      "pmid": "28283584",
      "title": "Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common <i>CDKN2A</i> Alteration.",
      "journal": "The oncologist",
      "pubDate": "2017 Apr",
      "volume": "22",
      "issue": "4",
      "pages": "416-421",
      "authors": "Elvin JA et al",
      "elocationId": "doi: 10.1634/theoncologist.2016-0310",
      "link": null,
      "reference": "Elvin JA et al. The oncologist. 2017 Apr;22(4)416-421.",
      "abstract": null
    },
    {
      "pmid": "29232554",
      "title": "Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.",
      "journal": "Cancer cell",
      "pubDate": "2017 Dec 11",
      "volume": "32",
      "issue": "6",
      "pages": "761-776.e6",
      "authors": "Gong X et al",
      "elocationId": "doi: 10.1016/j.ccell.2017.11.006",
      "link": null,
      "reference": "Gong X et al. Cancer cell. 2017 Dec 11;32(6)761-776.e6.",
      "abstract": null
    },
    {
      "pmid": "25941111",
      "title": "Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2015 Jul 1",
      "volume": "21",
      "issue": "13",
      "pages": "2905-10",
      "authors": "VanArsdale T et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-14-0816",
      "link": null,
      "reference": "VanArsdale T et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Jul 1;21(13)2905-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac53"
  },
  "level": "LEVEL_4",
  "gene": "U2AF1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "H3B-8800"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29457796",
      "title": "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.",
      "journal": "Nature medicine",
      "pubDate": "2018 May",
      "volume": "24",
      "issue": "4",
      "pages": "497-504",
      "authors": "Seiler M et al",
      "elocationId": "doi: 10.1038/nm.4493",
      "link": null,
      "reference": "Seiler M et al. Nature medicine. 2018 May;24(4)497-504.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/128/22/966?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Buonamici, S. et al. Abstract# Blood 128:966, 2016"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac54"
  },
  "level": "LEVEL_4",
  "gene": "CDK12",
  "alteration": "Truncating Mutations",
  "alteration_name": "Truncating Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Pembrolizumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29906450",
      "title": "Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.",
      "journal": "Cell",
      "pubDate": "2018 Jun 14",
      "volume": "173",
      "issue": "7",
      "pages": "1770-1782.e14",
      "authors": "Wu YM et al",
      "elocationId": "doi: 10.1016/j.cell.2018.04.034",
      "link": null,
      "reference": "Wu YM et al. Cell. 2018 Jun 14;173(7)1770-1782.e14.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac55"
  },
  "level": "LEVEL_4",
  "gene": "CDK12",
  "alteration": "Truncating Mutations",
  "alteration_name": "Truncating Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Cemiplimab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29906450",
      "title": "Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.",
      "journal": "Cell",
      "pubDate": "2018 Jun 14",
      "volume": "173",
      "issue": "7",
      "pages": "1770-1782.e14",
      "authors": "Wu YM et al",
      "elocationId": "doi: 10.1016/j.cell.2018.04.034",
      "link": null,
      "reference": "Wu YM et al. Cell. 2018 Jun 14;173(7)1770-1782.e14.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac56"
  },
  "level": "LEVEL_4",
  "gene": "CDK12",
  "alteration": "Truncating Mutations",
  "alteration_name": "Truncating Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Nivolumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29906450",
      "title": "Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.",
      "journal": "Cell",
      "pubDate": "2018 Jun 14",
      "volume": "173",
      "issue": "7",
      "pages": "1770-1782.e14",
      "authors": "Wu YM et al",
      "elocationId": "doi: 10.1016/j.cell.2018.04.034",
      "link": null,
      "reference": "Wu YM et al. Cell. 2018 Jun 14;173(7)1770-1782.e14.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac57"
  },
  "level": "LEVEL_4",
  "gene": "PIK3CA",
  "alteration": "H1047R",
  "alteration_name": "H1047R",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Abemaciclib",
    "Aromatase Inhibition Therapy",
    "LOXO-783"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/mct/article/20/12_Supplement/P142/675896/Abstract-P142-Preclinical-characterization-of-LOX",
      "reference": "null. null. .",
      "abstract": "Klippel et al. Abstract# P142, AACR-NCI-EORTC 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac58"
  },
  "level": "LEVEL_4",
  "gene": "PIK3CA",
  "alteration": "H1047R",
  "alteration_name": "H1047R",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Abemaciclib",
    "LOXO-783",
    "LY3484356"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/mct/article/20/12_Supplement/P142/675896/Abstract-P142-Preclinical-characterization-of-LOX",
      "reference": "null. null. .",
      "abstract": "Klippel et al. Abstract# P142, AACR-NCI-EORTC 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac59"
  },
  "level": "LEVEL_4",
  "gene": "PIK3CA",
  "alteration": "H1047R",
  "alteration_name": "H1047R",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Abemaciclib",
    "Fulvestrant",
    "LOXO-783"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/mct/article/20/12_Supplement/P142/675896/Abstract-P142-Preclinical-characterization-of-LOX",
      "reference": "null. null. .",
      "abstract": "Klippel et al. Abstract# P142, AACR-NCI-EORTC 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac5a"
  },
  "level": "LEVEL_4",
  "gene": "PIK3CA",
  "alteration": "H1047R",
  "alteration_name": "H1047R",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "LOXO-783",
    "Paclitaxel"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/mct/article/20/12_Supplement/P142/675896/Abstract-P142-Preclinical-characterization-of-LOX",
      "reference": "null. null. .",
      "abstract": "Klippel et al. Abstract# P142, AACR-NCI-EORTC 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac5b"
  },
  "level": "LEVEL_4",
  "gene": "PIK3CA",
  "alteration": "H1047R",
  "alteration_name": "H1047R",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "LOXO-783",
    "LY3484356"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/mct/article/20/12_Supplement/P142/675896/Abstract-P142-Preclinical-characterization-of-LOX",
      "reference": "null. null. .",
      "abstract": "Klippel et al. Abstract# P142, AACR-NCI-EORTC 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac5c"
  },
  "level": "LEVEL_4",
  "gene": "PIK3CA",
  "alteration": "H1047R",
  "alteration_name": "H1047R",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Fulvestrant",
    "LOXO-783"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/mct/article/20/12_Supplement/P142/675896/Abstract-P142-Preclinical-characterization-of-LOX",
      "reference": "null. null. .",
      "abstract": "Klippel et al. Abstract# P142, AACR-NCI-EORTC 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac5d"
  },
  "level": "LEVEL_4",
  "gene": "STK11",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Bemcentinib",
    "Pembrolizumab"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://jitc.bmj.com/content/9/Suppl_2/A632.altmetrics",
      "reference": "null. null. .",
      "abstract": "Li et al. Abstract # 602, JITC 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac5e"
  },
  "level": "LEVEL_4",
  "gene": "MET",
  "alteration": "Fusions",
  "alteration_name": "Fusions",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Crizotinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29284707",
      "title": "Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2018 Mar 15",
      "volume": "24",
      "issue": "6",
      "pages": "1337-1343",
      "authors": "Plenker D et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-17-3001",
      "link": null,
      "reference": "Plenker D et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Mar 15;24(6)1337-1343.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e13539",
      "reference": "null. null. .",
      "abstract": "Wang et al. Abstract#e13539, ASCO 2018"
    },
    {
      "pmid": "29527595",
      "title": "Dramatic Response to Crizotinib in a Patient with Lung Cancer Positive for an <i>HLA-DRB1-MET</i> Gene Fusion.",
      "journal": "JCO precision oncology",
      "pubDate": "2017",
      "volume": "2017",
      "issue": "1",
      "pages": "",
      "authors": "Davies KD et al",
      "elocationId": "doi: 10.1200/PO.17.00117",
      "link": null,
      "reference": "Davies KD et al. JCO precision oncology. 2017;2017(1).",
      "abstract": null
    },
    {
      "pmid": "29102694",
      "title": "KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2018 Mar",
      "volume": "13",
      "issue": "3",
      "pages": "e29-e31",
      "authors": "Cho JH et al",
      "elocationId": "doi: 10.1016/j.jtho.2017.10.014",
      "link": null,
      "reference": "Cho JH et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2018 Mar;13(3)e29-e31.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac5f"
  },
  "level": "LEVEL_4",
  "gene": "SRSF2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "H3B-8800"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29457796",
      "title": "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.",
      "journal": "Nature medicine",
      "pubDate": "2018 May",
      "volume": "24",
      "issue": "4",
      "pages": "497-504",
      "authors": "Seiler M et al",
      "elocationId": "doi: 10.1038/nm.4493",
      "link": null,
      "reference": "Seiler M et al. Nature medicine. 2018 May;24(4)497-504.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/128/22/966?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Buonamici, S. et al. Abstract# Blood 128:966, 2016"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac60"
  },
  "level": "LEVEL_4",
  "gene": "EGFR",
  "alteration": "R108K",
  "alteration_name": "R108K",
  "cancer_main_type": "Glioma",
  "cancer_sub_type": "",
  "drug": [
    "Lapatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22588883",
      "title": "Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.",
      "journal": "Cancer discovery",
      "pubDate": "2012 May",
      "volume": "2",
      "issue": "5",
      "pages": "458-71",
      "authors": "Vivanco I et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-11-0284",
      "link": null,
      "reference": "Vivanco I et al. Cancer discovery. 2012 May;2(5)458-71.",
      "abstract": null
    },
    {
      "pmid": "20459769",
      "title": "Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.",
      "journal": "BMC cancer",
      "pubDate": "2010 May 11",
      "volume": "10",
      "issue": "",
      "pages": "188",
      "authors": "Diaz R et al",
      "elocationId": "doi: 10.1186/1471-2407-10-188",
      "link": null,
      "reference": "Diaz R et al. BMC cancer. 2010 May 11;10()188.",
      "abstract": null
    },
    {
      "pmid": "18334972",
      "title": "Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.",
      "journal": "British journal of cancer",
      "pubDate": "2008 Mar 25",
      "volume": "98",
      "issue": "6",
      "pages": "1076-84",
      "authors": "Konecny GE et al",
      "elocationId": "doi: 10.1038/sj.bjc.6604278",
      "link": null,
      "reference": "Konecny GE et al. British journal of cancer. 2008 Mar 25;98(6)1076-84.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac61"
  },
  "level": "LEVEL_4",
  "gene": "EGFR",
  "alteration": "T263P",
  "alteration_name": "T263P",
  "cancer_main_type": "Glioma",
  "cancer_sub_type": "",
  "drug": [
    "Lapatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22588883",
      "title": "Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.",
      "journal": "Cancer discovery",
      "pubDate": "2012 May",
      "volume": "2",
      "issue": "5",
      "pages": "458-71",
      "authors": "Vivanco I et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-11-0284",
      "link": null,
      "reference": "Vivanco I et al. Cancer discovery. 2012 May;2(5)458-71.",
      "abstract": null
    },
    {
      "pmid": "20459769",
      "title": "Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.",
      "journal": "BMC cancer",
      "pubDate": "2010 May 11",
      "volume": "10",
      "issue": "",
      "pages": "188",
      "authors": "Diaz R et al",
      "elocationId": "doi: 10.1186/1471-2407-10-188",
      "link": null,
      "reference": "Diaz R et al. BMC cancer. 2010 May 11;10()188.",
      "abstract": null
    },
    {
      "pmid": "18334972",
      "title": "Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.",
      "journal": "British journal of cancer",
      "pubDate": "2008 Mar 25",
      "volume": "98",
      "issue": "6",
      "pages": "1076-84",
      "authors": "Konecny GE et al",
      "elocationId": "doi: 10.1038/sj.bjc.6604278",
      "link": null,
      "reference": "Konecny GE et al. British journal of cancer. 2008 Mar 25;98(6)1076-84.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac62"
  },
  "level": "LEVEL_4",
  "gene": "EGFR",
  "alteration": "A289V",
  "alteration_name": "A289V",
  "cancer_main_type": "Glioma",
  "cancer_sub_type": "",
  "drug": [
    "Lapatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22588883",
      "title": "Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.",
      "journal": "Cancer discovery",
      "pubDate": "2012 May",
      "volume": "2",
      "issue": "5",
      "pages": "458-71",
      "authors": "Vivanco I et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-11-0284",
      "link": null,
      "reference": "Vivanco I et al. Cancer discovery. 2012 May;2(5)458-71.",
      "abstract": null
    },
    {
      "pmid": "20459769",
      "title": "Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.",
      "journal": "BMC cancer",
      "pubDate": "2010 May 11",
      "volume": "10",
      "issue": "",
      "pages": "188",
      "authors": "Diaz R et al",
      "elocationId": "doi: 10.1186/1471-2407-10-188",
      "link": null,
      "reference": "Diaz R et al. BMC cancer. 2010 May 11;10()188.",
      "abstract": null
    },
    {
      "pmid": "18334972",
      "title": "Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.",
      "journal": "British journal of cancer",
      "pubDate": "2008 Mar 25",
      "volume": "98",
      "issue": "6",
      "pages": "1076-84",
      "authors": "Konecny GE et al",
      "elocationId": "doi: 10.1038/sj.bjc.6604278",
      "link": null,
      "reference": "Konecny GE et al. British journal of cancer. 2008 Mar 25;98(6)1076-84.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac63"
  },
  "level": "LEVEL_4",
  "gene": "EGFR",
  "alteration": "L747P",
  "alteration_name": "L747P",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Afatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "31200815",
      "title": "Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2019 Jul",
      "volume": "133",
      "issue": "",
      "pages": "103-109",
      "authors": "Liang SK et al",
      "elocationId": "doi: 10.1016/j.lungcan.2019.05.019",
      "link": null,
      "reference": "Liang SK et al. Lung cancer (Amsterdam, Netherlands). 2019 Jul;133()103-109.",
      "abstract": null
    },
    {
      "pmid": "30746257",
      "title": "EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report.",
      "journal": "Journal of thoracic disease",
      "pubDate": "2018 Dec",
      "volume": "10",
      "issue": "12",
      "pages": "E802-E805",
      "authors": "Zhou T et al",
      "elocationId": "doi: 10.21037/jtd.2018.12.26",
      "link": null,
      "reference": "Zhou T et al. Journal of thoracic disease. 2018 Dec;10(12)E802-E805.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac64"
  },
  "level": "LEVEL_4",
  "gene": "EGFR",
  "alteration": "A763_Y764insFQEA",
  "alteration_name": "A763_Y764insFQEA",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Afatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "26515464",
      "title": "In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.",
      "journal": "Oncotarget",
      "pubDate": "2015 Nov 17",
      "volume": "6",
      "issue": "36",
      "pages": "38789-803",
      "authors": "Hirano T et al",
      "elocationId": "doi: 10.18632/oncotarget.5887",
      "link": null,
      "reference": "Hirano T et al. Oncotarget. 2015 Nov 17;6(36)38789-803.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac65"
  },
  "level": "LEVEL_4",
  "gene": "ZRSR2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Leukemia",
  "cancer_sub_type": "Acute Myeloid Leukemia",
  "drug": [
    "H3B-8800"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29457796",
      "title": "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.",
      "journal": "Nature medicine",
      "pubDate": "2018 May",
      "volume": "24",
      "issue": "4",
      "pages": "497-504",
      "authors": "Seiler M et al",
      "elocationId": "doi: 10.1038/nm.4493",
      "link": null,
      "reference": "Seiler M et al. Nature medicine. 2018 May;24(4)497-504.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/128/22/966?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Buonamici, S. et al. Abstract# Blood 128:966, 2016"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac66"
  },
  "level": "LEVEL_4",
  "gene": "EGFR",
  "alteration": "Amplification",
  "alteration_name": "Amplification",
  "cancer_main_type": "Glioma",
  "cancer_sub_type": "",
  "drug": [
    "Lapatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22588883",
      "title": "Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.",
      "journal": "Cancer discovery",
      "pubDate": "2012 May",
      "volume": "2",
      "issue": "5",
      "pages": "458-71",
      "authors": "Vivanco I et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-11-0284",
      "link": null,
      "reference": "Vivanco I et al. Cancer discovery. 2012 May;2(5)458-71.",
      "abstract": null
    },
    {
      "pmid": "20459769",
      "title": "Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.",
      "journal": "BMC cancer",
      "pubDate": "2010 May 11",
      "volume": "10",
      "issue": "",
      "pages": "188",
      "authors": "Diaz R et al",
      "elocationId": "doi: 10.1186/1471-2407-10-188",
      "link": null,
      "reference": "Diaz R et al. BMC cancer. 2010 May 11;10()188.",
      "abstract": null
    },
    {
      "pmid": "18334972",
      "title": "Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.",
      "journal": "British journal of cancer",
      "pubDate": "2008 Mar 25",
      "volume": "98",
      "issue": "6",
      "pages": "1076-84",
      "authors": "Konecny GE et al",
      "elocationId": "doi: 10.1038/sj.bjc.6604278",
      "link": null,
      "reference": "Konecny GE et al. British journal of cancer. 2008 Mar 25;98(6)1076-84.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac67"
  },
  "level": "LEVEL_4",
  "gene": "EGFR",
  "alteration": "729_761ins",
  "alteration_name": "Exon 19 in-frame insertions",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Afatinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "22190593",
      "title": "EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Mar 15",
      "volume": "18",
      "issue": "6",
      "pages": "1790-7",
      "authors": "He M et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-11-2361",
      "link": null,
      "reference": "He M et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Mar 15;18(6)1790-7.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac68"
  },
  "level": "LEVEL_4",
  "gene": "NF1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Trametinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e13562",
      "reference": "null. null. .",
      "abstract": "Romo et al. Abstract# e13562, ASCO 2019"
    },
    {
      "pmid": "24576830",
      "title": "Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.",
      "journal": "Cancer research",
      "pubDate": "2014 Apr 15",
      "volume": "74",
      "issue": "8",
      "pages": "2340-50",
      "authors": "Nissan MH et al",
      "elocationId": "doi: 10.1158/0008-5472.CAN-13-2625",
      "link": null,
      "reference": "Nissan MH et al. Cancer research. 2014 Apr 15;74(8)2340-50.",
      "abstract": null
    },
    {
      "pmid": "24535670",
      "title": "Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2014 May",
      "volume": "4",
      "issue": "5",
      "pages": "606-19",
      "authors": "de Bruin EC et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-13-0741",
      "link": null,
      "reference": "de Bruin EC et al. Cancer discovery. 2014 May;4(5)606-19.",
      "abstract": null
    },
    {
      "pmid": "31151904",
      "title": "Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 Jul",
      "volume": "20",
      "issue": "7",
      "pages": "1011-1022",
      "authors": "Fangusaro J et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30277-3",
      "link": null,
      "reference": "Fangusaro J et al. The Lancet. Oncology. 2019 Jul;20(7)1011-1022.",
      "abstract": null
    },
    {
      "pmid": "26936308",
      "title": "Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma.",
      "journal": "Journal of clinical pharmacy and therapeutics",
      "pubDate": "2016 Jun",
      "volume": "41",
      "issue": "3",
      "pages": "357-359",
      "authors": "Ameratunga M et al",
      "elocationId": "doi: 10.1111/jcpt.12378",
      "link": null,
      "reference": "Ameratunga M et al. Journal of clinical pharmacy and therapeutics. 2016 Jun;41(3)357-359.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac69"
  },
  "level": "LEVEL_4",
  "gene": "NF1",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Cobimetinib"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e13562",
      "reference": "null. null. .",
      "abstract": "Romo et al. Abstract# e13562, ASCO 2019"
    },
    {
      "pmid": "24576830",
      "title": "Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.",
      "journal": "Cancer research",
      "pubDate": "2014 Apr 15",
      "volume": "74",
      "issue": "8",
      "pages": "2340-50",
      "authors": "Nissan MH et al",
      "elocationId": "doi: 10.1158/0008-5472.CAN-13-2625",
      "link": null,
      "reference": "Nissan MH et al. Cancer research. 2014 Apr 15;74(8)2340-50.",
      "abstract": null
    },
    {
      "pmid": "24535670",
      "title": "Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2014 May",
      "volume": "4",
      "issue": "5",
      "pages": "606-19",
      "authors": "de Bruin EC et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-13-0741",
      "link": null,
      "reference": "de Bruin EC et al. Cancer discovery. 2014 May;4(5)606-19.",
      "abstract": null
    },
    {
      "pmid": "31151904",
      "title": "Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 Jul",
      "volume": "20",
      "issue": "7",
      "pages": "1011-1022",
      "authors": "Fangusaro J et al",
      "elocationId": "doi: 10.1016/S1470-2045(19)30277-3",
      "link": null,
      "reference": "Fangusaro J et al. The Lancet. Oncology. 2019 Jul;20(7)1011-1022.",
      "abstract": null
    },
    {
      "pmid": "26936308",
      "title": "Prolonged disease control with MEK inhibitor in neurofibromatosis type I-associated glioblastoma.",
      "journal": "Journal of clinical pharmacy and therapeutics",
      "pubDate": "2016 Jun",
      "volume": "41",
      "issue": "3",
      "pages": "357-359",
      "authors": "Ameratunga M et al",
      "elocationId": "doi: 10.1111/jcpt.12378",
      "link": null,
      "reference": "Ameratunga M et al. Journal of clinical pharmacy and therapeutics. 2016 Jun;41(3)357-359.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac6a"
  },
  "level": "LEVEL_4",
  "gene": "ZRSR2",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Myelodysplastic Syndromes",
  "cancer_sub_type": "Myelodysplastic Syndromes",
  "drug": [
    "H3B-8800"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": "29457796",
      "title": "H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers.",
      "journal": "Nature medicine",
      "pubDate": "2018 May",
      "volume": "24",
      "issue": "4",
      "pages": "497-504",
      "authors": "Seiler M et al",
      "elocationId": "doi: 10.1038/nm.4493",
      "link": null,
      "reference": "Seiler M et al. Nature medicine. 2018 May;24(4)497-504.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://www.bloodjournal.org/content/128/22/966?sso-checked=true",
      "reference": "null. null. .",
      "abstract": "Buonamici, S. et al. Abstract# Blood 128:966, 2016"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac6b"
  },
  "level": "LEVEL_4",
  "gene": "PIK3CA",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Breast Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Fulvestrant",
    "RLY-2608"
  ],
  "knownEffect": "Sensitive",
  "articles": [
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://aacrjournals.org/cancerres/article/82/4_Supplement/P5-16-10/681459",
      "reference": "null. null. .",
      "abstract": "Pazolli et al. Abstract# P5-16-10, SABCS 2021"
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac6c"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F359I",
  "alteration_name": "F359I",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "19652056",
      "title": "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Sep 1",
      "volume": "27",
      "issue": "25",
      "pages": "4204-10",
      "authors": "Hughes T et al",
      "elocationId": "doi: 10.1200/JCO.2009.21.8230",
      "link": null,
      "reference": "Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac6d"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "E255K",
  "alteration_name": "E255K",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "19652056",
      "title": "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Sep 1",
      "volume": "27",
      "issue": "25",
      "pages": "4204-10",
      "authors": "Hughes T et al",
      "elocationId": "doi: 10.1200/JCO.2009.21.8230",
      "link": null,
      "reference": "Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac6e"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "E255V",
  "alteration_name": "E255V",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "19652056",
      "title": "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Sep 1",
      "volume": "27",
      "issue": "25",
      "pages": "4204-10",
      "authors": "Hughes T et al",
      "elocationId": "doi: 10.1200/JCO.2009.21.8230",
      "link": null,
      "reference": "Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac6f"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "Y253H",
  "alteration_name": "Y253H",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "19652056",
      "title": "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Sep 1",
      "volume": "27",
      "issue": "25",
      "pages": "4204-10",
      "authors": "Hughes T et al",
      "elocationId": "doi: 10.1200/JCO.2009.21.8230",
      "link": null,
      "reference": "Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac70"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F359V",
  "alteration_name": "F359V",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "19652056",
      "title": "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Sep 1",
      "volume": "27",
      "issue": "25",
      "pages": "4204-10",
      "authors": "Hughes T et al",
      "elocationId": "doi: 10.1200/JCO.2009.21.8230",
      "link": null,
      "reference": "Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac71"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "G250E",
  "alteration_name": "G250E",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "19652056",
      "title": "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Sep 1",
      "volume": "27",
      "issue": "25",
      "pages": "4204-10",
      "authors": "Hughes T et al",
      "elocationId": "doi: 10.1200/JCO.2009.21.8230",
      "link": null,
      "reference": "Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac72"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F359C",
  "alteration_name": "F359C",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "19652056",
      "title": "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Sep 1",
      "volume": "27",
      "issue": "25",
      "pages": "4204-10",
      "authors": "Hughes T et al",
      "elocationId": "doi: 10.1200/JCO.2009.21.8230",
      "link": null,
      "reference": "Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac73"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "T315I",
  "alteration_name": "T315I",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "17768119",
      "title": "Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.",
      "journal": "Haematologica",
      "pubDate": "2007 Sep",
      "volume": "92",
      "issue": "9",
      "pages": "1238-41",
      "authors": "Nicolini FE et al",
      "elocationId": "",
      "link": null,
      "reference": "Nicolini FE et al. Haematologica. 2007 Sep;92(9)1238-41.",
      "abstract": null
    },
    {
      "pmid": "18403620",
      "title": "Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.",
      "journal": "Blood",
      "pubDate": "2008 Jul 1",
      "volume": "112",
      "issue": "1",
      "pages": "53-5",
      "authors": "Jabbour E et al",
      "elocationId": "doi: 10.1182/blood-2007-11-123950",
      "link": null,
      "reference": "Jabbour E et al. Blood. 2008 Jul 1;112(1)53-5.",
      "abstract": null
    },
    {
      "pmid": "17339191",
      "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
      "journal": "Haematologica",
      "pubDate": "2007 Mar",
      "volume": "92",
      "issue": "3",
      "pages": "401-4",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac74"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "T315I",
  "alteration_name": "T315I",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "17768119",
      "title": "Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.",
      "journal": "Haematologica",
      "pubDate": "2007 Sep",
      "volume": "92",
      "issue": "9",
      "pages": "1238-41",
      "authors": "Nicolini FE et al",
      "elocationId": "",
      "link": null,
      "reference": "Nicolini FE et al. Haematologica. 2007 Sep;92(9)1238-41.",
      "abstract": null
    },
    {
      "pmid": "18403620",
      "title": "Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.",
      "journal": "Blood",
      "pubDate": "2008 Jul 1",
      "volume": "112",
      "issue": "1",
      "pages": "53-5",
      "authors": "Jabbour E et al",
      "elocationId": "doi: 10.1182/blood-2007-11-123950",
      "link": null,
      "reference": "Jabbour E et al. Blood. 2008 Jul 1;112(1)53-5.",
      "abstract": null
    },
    {
      "pmid": "17339191",
      "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
      "journal": "Haematologica",
      "pubDate": "2007 Mar",
      "volume": "92",
      "issue": "3",
      "pages": "401-4",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac75"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "T315I",
  "alteration_name": "T315I",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "17768119",
      "title": "Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.",
      "journal": "Haematologica",
      "pubDate": "2007 Sep",
      "volume": "92",
      "issue": "9",
      "pages": "1238-41",
      "authors": "Nicolini FE et al",
      "elocationId": "",
      "link": null,
      "reference": "Nicolini FE et al. Haematologica. 2007 Sep;92(9)1238-41.",
      "abstract": null
    },
    {
      "pmid": "18403620",
      "title": "Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.",
      "journal": "Blood",
      "pubDate": "2008 Jul 1",
      "volume": "112",
      "issue": "1",
      "pages": "53-5",
      "authors": "Jabbour E et al",
      "elocationId": "doi: 10.1182/blood-2007-11-123950",
      "link": null,
      "reference": "Jabbour E et al. Blood. 2008 Jul 1;112(1)53-5.",
      "abstract": null
    },
    {
      "pmid": "17339191",
      "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
      "journal": "Haematologica",
      "pubDate": "2007 Mar",
      "volume": "92",
      "issue": "3",
      "pages": "401-4",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac76"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "T315I",
  "alteration_name": "T315I",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "17768119",
      "title": "Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.",
      "journal": "Haematologica",
      "pubDate": "2007 Sep",
      "volume": "92",
      "issue": "9",
      "pages": "1238-41",
      "authors": "Nicolini FE et al",
      "elocationId": "",
      "link": null,
      "reference": "Nicolini FE et al. Haematologica. 2007 Sep;92(9)1238-41.",
      "abstract": null
    },
    {
      "pmid": "18403620",
      "title": "Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.",
      "journal": "Blood",
      "pubDate": "2008 Jul 1",
      "volume": "112",
      "issue": "1",
      "pages": "53-5",
      "authors": "Jabbour E et al",
      "elocationId": "doi: 10.1182/blood-2007-11-123950",
      "link": null,
      "reference": "Jabbour E et al. Blood. 2008 Jul 1;112(1)53-5.",
      "abstract": null
    },
    {
      "pmid": "17339191",
      "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
      "journal": "Haematologica",
      "pubDate": "2007 Mar",
      "volume": "92",
      "issue": "3",
      "pages": "401-4",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac77"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "T315I",
  "alteration_name": "T315I",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "17768119",
      "title": "Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.",
      "journal": "Haematologica",
      "pubDate": "2007 Sep",
      "volume": "92",
      "issue": "9",
      "pages": "1238-41",
      "authors": "Nicolini FE et al",
      "elocationId": "",
      "link": null,
      "reference": "Nicolini FE et al. Haematologica. 2007 Sep;92(9)1238-41.",
      "abstract": null
    },
    {
      "pmid": "18403620",
      "title": "Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.",
      "journal": "Blood",
      "pubDate": "2008 Jul 1",
      "volume": "112",
      "issue": "1",
      "pages": "53-5",
      "authors": "Jabbour E et al",
      "elocationId": "doi: 10.1182/blood-2007-11-123950",
      "link": null,
      "reference": "Jabbour E et al. Blood. 2008 Jul 1;112(1)53-5.",
      "abstract": null
    },
    {
      "pmid": "17339191",
      "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
      "journal": "Haematologica",
      "pubDate": "2007 Mar",
      "volume": "92",
      "issue": "3",
      "pages": "401-4",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac78"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "T315I",
  "alteration_name": "T315I",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "17768119",
      "title": "Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.",
      "journal": "Haematologica",
      "pubDate": "2007 Sep",
      "volume": "92",
      "issue": "9",
      "pages": "1238-41",
      "authors": "Nicolini FE et al",
      "elocationId": "",
      "link": null,
      "reference": "Nicolini FE et al. Haematologica. 2007 Sep;92(9)1238-41.",
      "abstract": null
    },
    {
      "pmid": "18403620",
      "title": "Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.",
      "journal": "Blood",
      "pubDate": "2008 Jul 1",
      "volume": "112",
      "issue": "1",
      "pages": "53-5",
      "authors": "Jabbour E et al",
      "elocationId": "doi: 10.1182/blood-2007-11-123950",
      "link": null,
      "reference": "Jabbour E et al. Blood. 2008 Jul 1;112(1)53-5.",
      "abstract": null
    },
    {
      "pmid": "17339191",
      "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
      "journal": "Haematologica",
      "pubDate": "2007 Mar",
      "volume": "92",
      "issue": "3",
      "pages": "401-4",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac79"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "T315I",
  "alteration_name": "T315I",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "17768119",
      "title": "Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.",
      "journal": "Haematologica",
      "pubDate": "2007 Sep",
      "volume": "92",
      "issue": "9",
      "pages": "1238-41",
      "authors": "Nicolini FE et al",
      "elocationId": "",
      "link": null,
      "reference": "Nicolini FE et al. Haematologica. 2007 Sep;92(9)1238-41.",
      "abstract": null
    },
    {
      "pmid": "18403620",
      "title": "Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.",
      "journal": "Blood",
      "pubDate": "2008 Jul 1",
      "volume": "112",
      "issue": "1",
      "pages": "53-5",
      "authors": "Jabbour E et al",
      "elocationId": "doi: 10.1182/blood-2007-11-123950",
      "link": null,
      "reference": "Jabbour E et al. Blood. 2008 Jul 1;112(1)53-5.",
      "abstract": null
    },
    {
      "pmid": "17339191",
      "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
      "journal": "Haematologica",
      "pubDate": "2007 Mar",
      "volume": "92",
      "issue": "3",
      "pages": "401-4",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac7a"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "T315I",
  "alteration_name": "T315I",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "19075254",
      "title": "Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Jan 20",
      "volume": "27",
      "issue": "3",
      "pages": "469-71",
      "authors": "Redaelli S et al",
      "elocationId": "doi: 10.1200/JCO.2008.19.8853",
      "link": null,
      "reference": "Redaelli S et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Jan 20;27(3)469-71.",
      "abstract": null
    },
    {
      "pmid": "17768119",
      "title": "Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.",
      "journal": "Haematologica",
      "pubDate": "2007 Sep",
      "volume": "92",
      "issue": "9",
      "pages": "1238-41",
      "authors": "Nicolini FE et al",
      "elocationId": "",
      "link": null,
      "reference": "Nicolini FE et al. Haematologica. 2007 Sep;92(9)1238-41.",
      "abstract": null
    },
    {
      "pmid": "18403620",
      "title": "Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.",
      "journal": "Blood",
      "pubDate": "2008 Jul 1",
      "volume": "112",
      "issue": "1",
      "pages": "53-5",
      "authors": "Jabbour E et al",
      "elocationId": "doi: 10.1182/blood-2007-11-123950",
      "link": null,
      "reference": "Jabbour E et al. Blood. 2008 Jul 1;112(1)53-5.",
      "abstract": null
    },
    {
      "pmid": "17339191",
      "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
      "journal": "Haematologica",
      "pubDate": "2007 Mar",
      "volume": "92",
      "issue": "3",
      "pages": "401-4",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac7b"
  },
  "level": "LEVEL_R1",
  "gene": "NTRK1",
  "alteration": "G595R",
  "alteration_name": "G595R",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Larotrectinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "28578312",
      "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
      "journal": "Cancer discovery",
      "pubDate": "2017 Sep",
      "volume": "7",
      "issue": "9",
      "pages": "963-972",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-17-0507",
      "link": null,
      "reference": "Drilon A et al. Cancer discovery. 2017 Sep;7(9)963-972.",
      "abstract": null
    },
    {
      "pmid": "31406350",
      "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
      "journal": "Nature medicine",
      "pubDate": "2019 Sep",
      "volume": "25",
      "issue": "9",
      "pages": "1422-1427",
      "authors": "Cocco E et al",
      "elocationId": "doi: 10.1038/s41591-019-0542-z",
      "link": null,
      "reference": "Cocco E et al. Nature medicine. 2019 Sep;25(9)1422-1427.",
      "abstract": null
    },
    {
      "pmid": "32133433",
      "title": "Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of <i>NTRK1</i>.",
      "journal": "JCO precision oncology",
      "pubDate": "2020",
      "volume": "4",
      "issue": "",
      "pages": "79-90",
      "authors": "Hemming ML et al",
      "elocationId": "doi: 10.1200/po.19.00287",
      "link": null,
      "reference": "Hemming ML et al. JCO precision oncology. 2020;4()79-90.",
      "abstract": null
    },
    {
      "pmid": "26546295",
      "title": "Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2016 Jan",
      "volume": "6",
      "issue": "1",
      "pages": "36-44",
      "authors": "Russo M et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0940",
      "link": null,
      "reference": "Russo M et al. Cancer discovery. 2016 Jan;6(1)36-44.",
      "abstract": null
    },
    {
      "pmid": "30624546",
      "title": "Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2019 Feb 1",
      "volume": "30",
      "issue": "2",
      "pages": "325-331",
      "authors": "Hong DS et al",
      "elocationId": "doi: 10.1093/annonc/mdy539",
      "link": null,
      "reference": "Hong DS et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Feb 1;30(2)325-331.",
      "abstract": null
    },
    {
      "pmid": "29466156",
      "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Feb 22",
      "volume": "378",
      "issue": "8",
      "pages": "731-739",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1056/NEJMoa1714448",
      "link": null,
      "reference": "Drilon A et al. The New England journal of medicine. 2018 Feb 22;378(8)731-739.",
      "abstract": null
    },
    {
      "pmid": "28751539",
      "title": "Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2017 Oct",
      "volume": "16",
      "issue": "10",
      "pages": "2130-2143",
      "authors": "Fuse MJ et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-16-0909",
      "link": null,
      "reference": "Fuse MJ et al. Molecular cancer therapeutics. 2017 Oct;16(10)2130-2143.",
      "abstract": null
    },
    {
      "pmid": "33328556",
      "title": "NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.",
      "journal": "Communications biology",
      "pubDate": "2020 Dec 16",
      "volume": "3",
      "issue": "1",
      "pages": "776",
      "authors": "Somwar R et al",
      "elocationId": "doi: 10.1038/s42003-020-01508-w",
      "link": null,
      "reference": "Somwar R et al. Communications biology. 2020 Dec 16;3(1)776.",
      "abstract": null
    },
    {
      "pmid": "30093503",
      "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
      "journal": "Cancer discovery",
      "pubDate": "2018 Oct",
      "volume": "8",
      "issue": "10",
      "pages": "1227-1236",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0484",
      "link": null,
      "reference": "Drilon A et al. Cancer discovery. 2018 Oct;8(10)1227-1236.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac7c"
  },
  "level": "LEVEL_R1",
  "gene": "KRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Trastuzumab",
    "Tucatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "30857956",
      "title": "Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 Apr",
      "volume": "20",
      "issue": "4",
      "pages": "518-530",
      "authors": "Meric-Bernstam F et al",
      "elocationId": "doi: 10.1016/S1470-2045(18)30904-5",
      "link": null,
      "reference": "Meric-Bernstam F et al. The Lancet. Oncology. 2019 Apr;20(4)518-530.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac7d"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "V299L",
  "alteration_name": "V299L",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac7e"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317L",
  "alteration_name": "F317L",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac7f"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "G250E",
  "alteration_name": "G250E",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac80"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "V299L",
  "alteration_name": "V299L",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac81"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317L",
  "alteration_name": "F317L",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac82"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "G250E",
  "alteration_name": "G250E",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Bosutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "26040495",
      "title": "Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.",
      "journal": "American journal of hematology",
      "pubDate": "2015 Sep",
      "volume": "90",
      "issue": "9",
      "pages": "755-68",
      "authors": "Gambacorti-Passerini C et al",
      "elocationId": "doi: 10.1002/ajh.24034",
      "link": null,
      "reference": "Gambacorti-Passerini C et al. American journal of hematology. 2015 Sep;90(9)755-68.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac83"
  },
  "level": "LEVEL_R1",
  "gene": "EGFR",
  "alteration": "762_823ins {excluding A763_Y764insFQEA}",
  "alteration_name": "Exon 20 in-frame insertions (excluding A763_Y764insFQEA)",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erlotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "15897572",
      "title": "Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2005 May 15",
      "volume": "11",
      "issue": "10",
      "pages": "3750-7",
      "authors": "Chou TY et al",
      "elocationId": "",
      "link": null,
      "reference": "Chou TY et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 May 15;11(10)3750-7.",
      "abstract": null
    },
    {
      "pmid": "24065731",
      "title": "Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.",
      "journal": "Cancer discovery",
      "pubDate": "2013 Dec",
      "volume": "3",
      "issue": "12",
      "pages": "1404-15",
      "authors": "Walter AO et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-13-0314",
      "link": null,
      "reference": "Walter AO et al. Cancer discovery. 2013 Dec;3(12)1404-15.",
      "abstract": null
    },
    {
      "pmid": "18676761",
      "title": "Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2008 Aug 1",
      "volume": "14",
      "issue": "15",
      "pages": "4877-82",
      "authors": "Wu JY et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-07-5123",
      "link": null,
      "reference": "Wu JY et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Aug 1;14(15)4877-82.",
      "abstract": null
    },
    {
      "pmid": "19536777",
      "title": "Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.",
      "journal": "International journal of cancer",
      "pubDate": "2010 Jan 1",
      "volume": "126",
      "issue": "1",
      "pages": "247-55",
      "authors": "Wu JY et al",
      "elocationId": "doi: 10.1002/ijc.24657",
      "link": null,
      "reference": "Wu JY et al. International journal of cancer. 2010 Jan 1;126(1)247-55.",
      "abstract": null
    },
    {
      "pmid": "24353160",
      "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2013 Dec 18",
      "volume": "5",
      "issue": "216",
      "pages": "216ra177",
      "authors": "Yasuda H et al",
      "elocationId": "doi: 10.1126/scitranslmed.3007205",
      "link": null,
      "reference": "Yasuda H et al. Science translational medicine. 2013 Dec 18;5(216)216ra177.",
      "abstract": null
    },
    {
      "pmid": "21764376",
      "title": "EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2012 Jan",
      "volume": "13",
      "issue": "1",
      "pages": "e23-31",
      "authors": "Yasuda H et al",
      "elocationId": "doi: 10.1016/S1470-2045(11)70129-2",
      "link": null,
      "reference": "Yasuda H et al. The Lancet. Oncology. 2012 Jan;13(1)e23-31.",
      "abstract": null
    },
    {
      "pmid": "17686547",
      "title": "EGFR exon 20 insertion mutation in Japanese lung cancer.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2007 Dec",
      "volume": "58",
      "issue": "3",
      "pages": "324-8",
      "authors": "Sasaki H et al",
      "elocationId": "",
      "link": null,
      "reference": "Sasaki H et al. Lung cancer (Amsterdam, Netherlands). 2007 Dec;58(3)324-8.",
      "abstract": null
    },
    {
      "pmid": "24893891",
      "title": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2014 Sep",
      "volume": "4",
      "issue": "9",
      "pages": "1046-61",
      "authors": "Cross DA et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-14-0337",
      "link": null,
      "reference": "Cross DA et al. Cancer discovery. 2014 Sep;4(9)1046-61.",
      "abstract": null
    },
    {
      "pmid": "23371856",
      "title": "EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2013 Feb",
      "volume": "12",
      "issue": "2",
      "pages": "220-9",
      "authors": "Arcila ME et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-12-0620",
      "link": null,
      "reference": "Arcila ME et al. Molecular cancer therapeutics. 2013 Feb;12(2)220-9.",
      "abstract": null
    },
    {
      "pmid": "23328547",
      "title": "Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2013 Feb",
      "volume": "8",
      "issue": "2",
      "pages": "179-84",
      "authors": "Oxnard GR et al",
      "elocationId": "doi: 10.1097/JTO.0b013e3182779d18",
      "link": null,
      "reference": "Oxnard GR et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Feb;8(2)179-84.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac84"
  },
  "level": "LEVEL_R1",
  "gene": "EGFR",
  "alteration": "762_823ins {excluding A763_Y764insFQEA}",
  "alteration_name": "Exon 20 in-frame insertions (excluding A763_Y764insFQEA)",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Afatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "15897572",
      "title": "Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2005 May 15",
      "volume": "11",
      "issue": "10",
      "pages": "3750-7",
      "authors": "Chou TY et al",
      "elocationId": "",
      "link": null,
      "reference": "Chou TY et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 May 15;11(10)3750-7.",
      "abstract": null
    },
    {
      "pmid": "24065731",
      "title": "Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.",
      "journal": "Cancer discovery",
      "pubDate": "2013 Dec",
      "volume": "3",
      "issue": "12",
      "pages": "1404-15",
      "authors": "Walter AO et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-13-0314",
      "link": null,
      "reference": "Walter AO et al. Cancer discovery. 2013 Dec;3(12)1404-15.",
      "abstract": null
    },
    {
      "pmid": "18676761",
      "title": "Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2008 Aug 1",
      "volume": "14",
      "issue": "15",
      "pages": "4877-82",
      "authors": "Wu JY et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-07-5123",
      "link": null,
      "reference": "Wu JY et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Aug 1;14(15)4877-82.",
      "abstract": null
    },
    {
      "pmid": "19536777",
      "title": "Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.",
      "journal": "International journal of cancer",
      "pubDate": "2010 Jan 1",
      "volume": "126",
      "issue": "1",
      "pages": "247-55",
      "authors": "Wu JY et al",
      "elocationId": "doi: 10.1002/ijc.24657",
      "link": null,
      "reference": "Wu JY et al. International journal of cancer. 2010 Jan 1;126(1)247-55.",
      "abstract": null
    },
    {
      "pmid": "24353160",
      "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2013 Dec 18",
      "volume": "5",
      "issue": "216",
      "pages": "216ra177",
      "authors": "Yasuda H et al",
      "elocationId": "doi: 10.1126/scitranslmed.3007205",
      "link": null,
      "reference": "Yasuda H et al. Science translational medicine. 2013 Dec 18;5(216)216ra177.",
      "abstract": null
    },
    {
      "pmid": "21764376",
      "title": "EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2012 Jan",
      "volume": "13",
      "issue": "1",
      "pages": "e23-31",
      "authors": "Yasuda H et al",
      "elocationId": "doi: 10.1016/S1470-2045(11)70129-2",
      "link": null,
      "reference": "Yasuda H et al. The Lancet. Oncology. 2012 Jan;13(1)e23-31.",
      "abstract": null
    },
    {
      "pmid": "17686547",
      "title": "EGFR exon 20 insertion mutation in Japanese lung cancer.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2007 Dec",
      "volume": "58",
      "issue": "3",
      "pages": "324-8",
      "authors": "Sasaki H et al",
      "elocationId": "",
      "link": null,
      "reference": "Sasaki H et al. Lung cancer (Amsterdam, Netherlands). 2007 Dec;58(3)324-8.",
      "abstract": null
    },
    {
      "pmid": "24893891",
      "title": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2014 Sep",
      "volume": "4",
      "issue": "9",
      "pages": "1046-61",
      "authors": "Cross DA et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-14-0337",
      "link": null,
      "reference": "Cross DA et al. Cancer discovery. 2014 Sep;4(9)1046-61.",
      "abstract": null
    },
    {
      "pmid": "23371856",
      "title": "EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2013 Feb",
      "volume": "12",
      "issue": "2",
      "pages": "220-9",
      "authors": "Arcila ME et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-12-0620",
      "link": null,
      "reference": "Arcila ME et al. Molecular cancer therapeutics. 2013 Feb;12(2)220-9.",
      "abstract": null
    },
    {
      "pmid": "23328547",
      "title": "Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2013 Feb",
      "volume": "8",
      "issue": "2",
      "pages": "179-84",
      "authors": "Oxnard GR et al",
      "elocationId": "doi: 10.1097/JTO.0b013e3182779d18",
      "link": null,
      "reference": "Oxnard GR et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Feb;8(2)179-84.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac85"
  },
  "level": "LEVEL_R1",
  "gene": "EGFR",
  "alteration": "762_823ins {excluding A763_Y764insFQEA}",
  "alteration_name": "Exon 20 in-frame insertions (excluding A763_Y764insFQEA)",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Gefitinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "15897572",
      "title": "Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2005 May 15",
      "volume": "11",
      "issue": "10",
      "pages": "3750-7",
      "authors": "Chou TY et al",
      "elocationId": "",
      "link": null,
      "reference": "Chou TY et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 May 15;11(10)3750-7.",
      "abstract": null
    },
    {
      "pmid": "24065731",
      "title": "Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.",
      "journal": "Cancer discovery",
      "pubDate": "2013 Dec",
      "volume": "3",
      "issue": "12",
      "pages": "1404-15",
      "authors": "Walter AO et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-13-0314",
      "link": null,
      "reference": "Walter AO et al. Cancer discovery. 2013 Dec;3(12)1404-15.",
      "abstract": null
    },
    {
      "pmid": "18676761",
      "title": "Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2008 Aug 1",
      "volume": "14",
      "issue": "15",
      "pages": "4877-82",
      "authors": "Wu JY et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-07-5123",
      "link": null,
      "reference": "Wu JY et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Aug 1;14(15)4877-82.",
      "abstract": null
    },
    {
      "pmid": "19536777",
      "title": "Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.",
      "journal": "International journal of cancer",
      "pubDate": "2010 Jan 1",
      "volume": "126",
      "issue": "1",
      "pages": "247-55",
      "authors": "Wu JY et al",
      "elocationId": "doi: 10.1002/ijc.24657",
      "link": null,
      "reference": "Wu JY et al. International journal of cancer. 2010 Jan 1;126(1)247-55.",
      "abstract": null
    },
    {
      "pmid": "24353160",
      "title": "Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.",
      "journal": "Science translational medicine",
      "pubDate": "2013 Dec 18",
      "volume": "5",
      "issue": "216",
      "pages": "216ra177",
      "authors": "Yasuda H et al",
      "elocationId": "doi: 10.1126/scitranslmed.3007205",
      "link": null,
      "reference": "Yasuda H et al. Science translational medicine. 2013 Dec 18;5(216)216ra177.",
      "abstract": null
    },
    {
      "pmid": "21764376",
      "title": "EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2012 Jan",
      "volume": "13",
      "issue": "1",
      "pages": "e23-31",
      "authors": "Yasuda H et al",
      "elocationId": "doi: 10.1016/S1470-2045(11)70129-2",
      "link": null,
      "reference": "Yasuda H et al. The Lancet. Oncology. 2012 Jan;13(1)e23-31.",
      "abstract": null
    },
    {
      "pmid": "17686547",
      "title": "EGFR exon 20 insertion mutation in Japanese lung cancer.",
      "journal": "Lung cancer (Amsterdam, Netherlands)",
      "pubDate": "2007 Dec",
      "volume": "58",
      "issue": "3",
      "pages": "324-8",
      "authors": "Sasaki H et al",
      "elocationId": "",
      "link": null,
      "reference": "Sasaki H et al. Lung cancer (Amsterdam, Netherlands). 2007 Dec;58(3)324-8.",
      "abstract": null
    },
    {
      "pmid": "24893891",
      "title": "AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2014 Sep",
      "volume": "4",
      "issue": "9",
      "pages": "1046-61",
      "authors": "Cross DA et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-14-0337",
      "link": null,
      "reference": "Cross DA et al. Cancer discovery. 2014 Sep;4(9)1046-61.",
      "abstract": null
    },
    {
      "pmid": "23371856",
      "title": "EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.",
      "journal": "Molecular cancer therapeutics",
      "pubDate": "2013 Feb",
      "volume": "12",
      "issue": "2",
      "pages": "220-9",
      "authors": "Arcila ME et al",
      "elocationId": "doi: 10.1158/1535-7163.MCT-12-0620",
      "link": null,
      "reference": "Arcila ME et al. Molecular cancer therapeutics. 2013 Feb;12(2)220-9.",
      "abstract": null
    },
    {
      "pmid": "23328547",
      "title": "Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.",
      "journal": "Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer",
      "pubDate": "2013 Feb",
      "volume": "8",
      "issue": "2",
      "pages": "179-84",
      "authors": "Oxnard GR et al",
      "elocationId": "doi: 10.1097/JTO.0b013e3182779d18",
      "link": null,
      "reference": "Oxnard GR et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Feb;8(2)179-84.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac86"
  },
  "level": "LEVEL_R1",
  "gene": "NTRK3",
  "alteration": "F617L",
  "alteration_name": "F617L",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Larotrectinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "30624546",
      "title": "Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2019 Feb 1",
      "volume": "30",
      "issue": "2",
      "pages": "325-331",
      "authors": "Hong DS et al",
      "elocationId": "doi: 10.1093/annonc/mdy539",
      "link": null,
      "reference": "Hong DS et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Feb 1;30(2)325-331.",
      "abstract": null
    },
    {
      "pmid": "31738426",
      "title": "TRK inhibitors in TRK fusion-positive cancers.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2019 Nov 1",
      "volume": "30",
      "issue": "Suppl_8",
      "pages": "viii23-viii30",
      "authors": "Drilon A",
      "elocationId": "doi: 10.1093/annonc/mdz282",
      "link": null,
      "reference": "Drilon A. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Nov 1;30(Suppl_8)viii23-viii30.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac87"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317I",
  "alteration_name": "F317I",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "19779040",
      "title": "Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.",
      "journal": "Blood",
      "pubDate": "2009 Dec 3",
      "volume": "114",
      "issue": "24",
      "pages": "4944-53",
      "authors": "Müller MC et al",
      "elocationId": "doi: 10.1182/blood-2009-04-214221",
      "link": null,
      "reference": "Müller MC et al. Blood. 2009 Dec 3;114(24)4944-53.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "17710227",
      "title": "Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2007 Sep",
      "volume": "117",
      "issue": "9",
      "pages": "2562-9",
      "authors": "Shah NP et al",
      "elocationId": "",
      "link": null,
      "reference": "Shah NP et al. The Journal of clinical investigation. 2007 Sep;117(9)2562-9.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac88"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317C",
  "alteration_name": "F317C",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "19779040",
      "title": "Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.",
      "journal": "Blood",
      "pubDate": "2009 Dec 3",
      "volume": "114",
      "issue": "24",
      "pages": "4944-53",
      "authors": "Müller MC et al",
      "elocationId": "doi: 10.1182/blood-2009-04-214221",
      "link": null,
      "reference": "Müller MC et al. Blood. 2009 Dec 3;114(24)4944-53.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "17710227",
      "title": "Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2007 Sep",
      "volume": "117",
      "issue": "9",
      "pages": "2562-9",
      "authors": "Shah NP et al",
      "elocationId": "",
      "link": null,
      "reference": "Shah NP et al. The Journal of clinical investigation. 2007 Sep;117(9)2562-9.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac89"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "T315A",
  "alteration_name": "T315A",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "19779040",
      "title": "Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.",
      "journal": "Blood",
      "pubDate": "2009 Dec 3",
      "volume": "114",
      "issue": "24",
      "pages": "4944-53",
      "authors": "Müller MC et al",
      "elocationId": "doi: 10.1182/blood-2009-04-214221",
      "link": null,
      "reference": "Müller MC et al. Blood. 2009 Dec 3;114(24)4944-53.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "17710227",
      "title": "Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2007 Sep",
      "volume": "117",
      "issue": "9",
      "pages": "2562-9",
      "authors": "Shah NP et al",
      "elocationId": "",
      "link": null,
      "reference": "Shah NP et al. The Journal of clinical investigation. 2007 Sep;117(9)2562-9.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac8a"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317V",
  "alteration_name": "F317V",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "19779040",
      "title": "Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.",
      "journal": "Blood",
      "pubDate": "2009 Dec 3",
      "volume": "114",
      "issue": "24",
      "pages": "4944-53",
      "authors": "Müller MC et al",
      "elocationId": "doi: 10.1182/blood-2009-04-214221",
      "link": null,
      "reference": "Müller MC et al. Blood. 2009 Dec 3;114(24)4944-53.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "17710227",
      "title": "Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2007 Sep",
      "volume": "117",
      "issue": "9",
      "pages": "2562-9",
      "authors": "Shah NP et al",
      "elocationId": "",
      "link": null,
      "reference": "Shah NP et al. The Journal of clinical investigation. 2007 Sep;117(9)2562-9.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac8b"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "V299L",
  "alteration_name": "V299L",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "19779040",
      "title": "Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.",
      "journal": "Blood",
      "pubDate": "2009 Dec 3",
      "volume": "114",
      "issue": "24",
      "pages": "4944-53",
      "authors": "Müller MC et al",
      "elocationId": "doi: 10.1182/blood-2009-04-214221",
      "link": null,
      "reference": "Müller MC et al. Blood. 2009 Dec 3;114(24)4944-53.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "17710227",
      "title": "Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2007 Sep",
      "volume": "117",
      "issue": "9",
      "pages": "2562-9",
      "authors": "Shah NP et al",
      "elocationId": "",
      "link": null,
      "reference": "Shah NP et al. The Journal of clinical investigation. 2007 Sep;117(9)2562-9.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac8c"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317L",
  "alteration_name": "F317L",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "19779040",
      "title": "Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.",
      "journal": "Blood",
      "pubDate": "2009 Dec 3",
      "volume": "114",
      "issue": "24",
      "pages": "4944-53",
      "authors": "Müller MC et al",
      "elocationId": "doi: 10.1182/blood-2009-04-214221",
      "link": null,
      "reference": "Müller MC et al. Blood. 2009 Dec 3;114(24)4944-53.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "17710227",
      "title": "Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.",
      "journal": "The Journal of clinical investigation",
      "pubDate": "2007 Sep",
      "volume": "117",
      "issue": "9",
      "pages": "2562-9",
      "authors": "Shah NP et al",
      "elocationId": "",
      "link": null,
      "reference": "Shah NP et al. The Journal of clinical investigation. 2007 Sep;117(9)2562-9.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac8d"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317I",
  "alteration_name": "F317I",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "20131302",
      "title": "Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.",
      "journal": "American journal of hematology",
      "pubDate": "2010 Mar",
      "volume": "85",
      "issue": "3",
      "pages": "164-70",
      "authors": "Lilly MB et al",
      "elocationId": "doi: 10.1002/ajh.21615",
      "link": null,
      "reference": "Lilly MB et al. American journal of hematology. 2010 Mar;85(3)164-70.",
      "abstract": null
    },
    {
      "pmid": "17496201",
      "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.",
      "journal": "Blood",
      "pubDate": "2007 Oct 1",
      "volume": "110",
      "issue": "7",
      "pages": "2309-15",
      "authors": "Ottmann O et al",
      "elocationId": "",
      "link": null,
      "reference": "Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.",
      "abstract": null
    },
    {
      "pmid": "17339191",
      "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
      "journal": "Haematologica",
      "pubDate": "2007 Mar",
      "volume": "92",
      "issue": "3",
      "pages": "401-4",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac8e"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317C",
  "alteration_name": "F317C",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "20131302",
      "title": "Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.",
      "journal": "American journal of hematology",
      "pubDate": "2010 Mar",
      "volume": "85",
      "issue": "3",
      "pages": "164-70",
      "authors": "Lilly MB et al",
      "elocationId": "doi: 10.1002/ajh.21615",
      "link": null,
      "reference": "Lilly MB et al. American journal of hematology. 2010 Mar;85(3)164-70.",
      "abstract": null
    },
    {
      "pmid": "17496201",
      "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.",
      "journal": "Blood",
      "pubDate": "2007 Oct 1",
      "volume": "110",
      "issue": "7",
      "pages": "2309-15",
      "authors": "Ottmann O et al",
      "elocationId": "",
      "link": null,
      "reference": "Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.",
      "abstract": null
    },
    {
      "pmid": "17339191",
      "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
      "journal": "Haematologica",
      "pubDate": "2007 Mar",
      "volume": "92",
      "issue": "3",
      "pages": "401-4",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac8f"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "T315A",
  "alteration_name": "T315A",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "20131302",
      "title": "Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.",
      "journal": "American journal of hematology",
      "pubDate": "2010 Mar",
      "volume": "85",
      "issue": "3",
      "pages": "164-70",
      "authors": "Lilly MB et al",
      "elocationId": "doi: 10.1002/ajh.21615",
      "link": null,
      "reference": "Lilly MB et al. American journal of hematology. 2010 Mar;85(3)164-70.",
      "abstract": null
    },
    {
      "pmid": "17496201",
      "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.",
      "journal": "Blood",
      "pubDate": "2007 Oct 1",
      "volume": "110",
      "issue": "7",
      "pages": "2309-15",
      "authors": "Ottmann O et al",
      "elocationId": "",
      "link": null,
      "reference": "Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.",
      "abstract": null
    },
    {
      "pmid": "17339191",
      "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
      "journal": "Haematologica",
      "pubDate": "2007 Mar",
      "volume": "92",
      "issue": "3",
      "pages": "401-4",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac90"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317V",
  "alteration_name": "F317V",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "20131302",
      "title": "Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.",
      "journal": "American journal of hematology",
      "pubDate": "2010 Mar",
      "volume": "85",
      "issue": "3",
      "pages": "164-70",
      "authors": "Lilly MB et al",
      "elocationId": "doi: 10.1002/ajh.21615",
      "link": null,
      "reference": "Lilly MB et al. American journal of hematology. 2010 Mar;85(3)164-70.",
      "abstract": null
    },
    {
      "pmid": "17496201",
      "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.",
      "journal": "Blood",
      "pubDate": "2007 Oct 1",
      "volume": "110",
      "issue": "7",
      "pages": "2309-15",
      "authors": "Ottmann O et al",
      "elocationId": "",
      "link": null,
      "reference": "Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.",
      "abstract": null
    },
    {
      "pmid": "17339191",
      "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
      "journal": "Haematologica",
      "pubDate": "2007 Mar",
      "volume": "92",
      "issue": "3",
      "pages": "401-4",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac91"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "V299L",
  "alteration_name": "V299L",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "20131302",
      "title": "Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.",
      "journal": "American journal of hematology",
      "pubDate": "2010 Mar",
      "volume": "85",
      "issue": "3",
      "pages": "164-70",
      "authors": "Lilly MB et al",
      "elocationId": "doi: 10.1002/ajh.21615",
      "link": null,
      "reference": "Lilly MB et al. American journal of hematology. 2010 Mar;85(3)164-70.",
      "abstract": null
    },
    {
      "pmid": "17496201",
      "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.",
      "journal": "Blood",
      "pubDate": "2007 Oct 1",
      "volume": "110",
      "issue": "7",
      "pages": "2309-15",
      "authors": "Ottmann O et al",
      "elocationId": "",
      "link": null,
      "reference": "Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.",
      "abstract": null
    },
    {
      "pmid": "17339191",
      "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
      "journal": "Haematologica",
      "pubDate": "2007 Mar",
      "volume": "92",
      "issue": "3",
      "pages": "401-4",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac92"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317L",
  "alteration_name": "F317L",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Dasatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "20131302",
      "title": "Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.",
      "journal": "American journal of hematology",
      "pubDate": "2010 Mar",
      "volume": "85",
      "issue": "3",
      "pages": "164-70",
      "authors": "Lilly MB et al",
      "elocationId": "doi: 10.1002/ajh.21615",
      "link": null,
      "reference": "Lilly MB et al. American journal of hematology. 2010 Mar;85(3)164-70.",
      "abstract": null
    },
    {
      "pmid": "17496201",
      "title": "Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.",
      "journal": "Blood",
      "pubDate": "2007 Oct 1",
      "volume": "110",
      "issue": "7",
      "pages": "2309-15",
      "authors": "Ottmann O et al",
      "elocationId": "",
      "link": null,
      "reference": "Ottmann O et al. Blood. 2007 Oct 1;110(7)2309-15.",
      "abstract": null
    },
    {
      "pmid": "17339191",
      "title": "Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.",
      "journal": "Haematologica",
      "pubDate": "2007 Mar",
      "volume": "92",
      "issue": "3",
      "pages": "401-4",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Haematologica. 2007 Mar;92(3)401-4.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac93"
  },
  "level": "LEVEL_R1",
  "gene": "KRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Panitumumab"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "24024839",
      "title": "Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2013 Sep 12",
      "volume": "369",
      "issue": "11",
      "pages": "1023-34",
      "authors": "Douillard JY et al",
      "elocationId": "doi: 10.1056/NEJMoa1305275",
      "link": null,
      "reference": "Douillard JY et al. The New England journal of medicine. 2013 Sep 12;369(11)1023-34.",
      "abstract": null
    },
    {
      "pmid": "21228335",
      "title": "Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2011 Jul",
      "volume": "22",
      "issue": "7",
      "pages": "1535-1546",
      "authors": "Bokemeyer C et al",
      "elocationId": "doi: 10.1093/annonc/mdq632",
      "link": null,
      "reference": "Bokemeyer C et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Jul;22(7)1535-1546.",
      "abstract": null
    },
    {
      "pmid": "20619739",
      "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2010 Aug",
      "volume": "11",
      "issue": "8",
      "pages": "753-62",
      "authors": "De Roock W et al",
      "elocationId": "doi: 10.1016/S1470-2045(10)70130-3",
      "link": null,
      "reference": "De Roock W et al. The Lancet. Oncology. 2010 Aug;11(8)753-62.",
      "abstract": null
    },
    {
      "pmid": "18316791",
      "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Apr 1",
      "volume": "26",
      "issue": "10",
      "pages": "1626-34",
      "authors": "Amado RG et al",
      "elocationId": "doi: 10.1200/JCO.2007.14.7116",
      "link": null,
      "reference": "Amado RG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Apr 1;26(10)1626-34.",
      "abstract": null
    },
    {
      "pmid": "20921465",
      "title": "Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2010 Nov 1",
      "volume": "28",
      "issue": "31",
      "pages": "4697-705",
      "authors": "Douillard JY et al",
      "elocationId": "doi: 10.1200/JCO.2009.27.4860",
      "link": null,
      "reference": "Douillard JY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Nov 1;28(31)4697-705.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac94"
  },
  "level": "LEVEL_R1",
  "gene": "KRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Cetuximab"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "24024839",
      "title": "Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2013 Sep 12",
      "volume": "369",
      "issue": "11",
      "pages": "1023-34",
      "authors": "Douillard JY et al",
      "elocationId": "doi: 10.1056/NEJMoa1305275",
      "link": null,
      "reference": "Douillard JY et al. The New England journal of medicine. 2013 Sep 12;369(11)1023-34.",
      "abstract": null
    },
    {
      "pmid": "21228335",
      "title": "Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2011 Jul",
      "volume": "22",
      "issue": "7",
      "pages": "1535-1546",
      "authors": "Bokemeyer C et al",
      "elocationId": "doi: 10.1093/annonc/mdq632",
      "link": null,
      "reference": "Bokemeyer C et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2011 Jul;22(7)1535-1546.",
      "abstract": null
    },
    {
      "pmid": "20619739",
      "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2010 Aug",
      "volume": "11",
      "issue": "8",
      "pages": "753-62",
      "authors": "De Roock W et al",
      "elocationId": "doi: 10.1016/S1470-2045(10)70130-3",
      "link": null,
      "reference": "De Roock W et al. The Lancet. Oncology. 2010 Aug;11(8)753-62.",
      "abstract": null
    },
    {
      "pmid": "18316791",
      "title": "Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Apr 1",
      "volume": "26",
      "issue": "10",
      "pages": "1626-34",
      "authors": "Amado RG et al",
      "elocationId": "doi: 10.1200/JCO.2007.14.7116",
      "link": null,
      "reference": "Amado RG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Apr 1;26(10)1626-34.",
      "abstract": null
    },
    {
      "pmid": "20921465",
      "title": "Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2010 Nov 1",
      "volume": "28",
      "issue": "31",
      "pages": "4697-705",
      "authors": "Douillard JY et al",
      "elocationId": "doi: 10.1200/JCO.2009.27.4860",
      "link": null,
      "reference": "Douillard JY et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Nov 1;28(31)4697-705.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac95"
  },
  "level": "LEVEL_R1",
  "gene": "EGFR",
  "alteration": "T790M",
  "alteration_name": "T790M",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Gefitinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "24478319",
      "title": "Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2014 Feb",
      "volume": "25",
      "issue": "2",
      "pages": "423-8",
      "authors": "Yu HA et al",
      "elocationId": "doi: 10.1093/annonc/mdt573",
      "link": null,
      "reference": "Yu HA et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Feb;25(2)423-8.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://library.iaslc.org/search-speaker?search_speaker=17991",
      "reference": "null. null. .",
      "abstract": "Yang et al. Abstract# O03.05, IASLC 2013"
    },
    {
      "pmid": "26051236",
      "title": "Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2015 Jul",
      "volume": "16",
      "issue": "7",
      "pages": "830-8",
      "authors": "Yang JC et al",
      "elocationId": "doi: 10.1016/S1470-2045(15)00026-1",
      "link": null,
      "reference": "Yang JC et al. The Lancet. Oncology. 2015 Jul;16(7)830-8.",
      "abstract": null
    },
    {
      "pmid": "23816963",
      "title": "LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 20",
      "volume": "31",
      "issue": "27",
      "pages": "3335-41",
      "authors": "Katakami N et al",
      "elocationId": "doi: 10.1200/JCO.2012.45.0981",
      "link": null,
      "reference": "Katakami N et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 20;31(27)3335-41.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac96"
  },
  "level": "LEVEL_R1",
  "gene": "EGFR",
  "alteration": "T790M",
  "alteration_name": "T790M",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Afatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "24478319",
      "title": "Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2014 Feb",
      "volume": "25",
      "issue": "2",
      "pages": "423-8",
      "authors": "Yu HA et al",
      "elocationId": "doi: 10.1093/annonc/mdt573",
      "link": null,
      "reference": "Yu HA et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Feb;25(2)423-8.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://library.iaslc.org/search-speaker?search_speaker=17991",
      "reference": "null. null. .",
      "abstract": "Yang et al. Abstract# O03.05, IASLC 2013"
    },
    {
      "pmid": "26051236",
      "title": "Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2015 Jul",
      "volume": "16",
      "issue": "7",
      "pages": "830-8",
      "authors": "Yang JC et al",
      "elocationId": "doi: 10.1016/S1470-2045(15)00026-1",
      "link": null,
      "reference": "Yang JC et al. The Lancet. Oncology. 2015 Jul;16(7)830-8.",
      "abstract": null
    },
    {
      "pmid": "23816963",
      "title": "LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 20",
      "volume": "31",
      "issue": "27",
      "pages": "3335-41",
      "authors": "Katakami N et al",
      "elocationId": "doi: 10.1200/JCO.2012.45.0981",
      "link": null,
      "reference": "Katakami N et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 20;31(27)3335-41.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac97"
  },
  "level": "LEVEL_R1",
  "gene": "EGFR",
  "alteration": "T790M",
  "alteration_name": "T790M",
  "cancer_main_type": "Non-Small Cell Lung Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Erlotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "24478319",
      "title": "Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.",
      "journal": "Annals of oncology : official journal of the European Society for Medical Oncology",
      "pubDate": "2014 Feb",
      "volume": "25",
      "issue": "2",
      "pages": "423-8",
      "authors": "Yu HA et al",
      "elocationId": "doi: 10.1093/annonc/mdt573",
      "link": null,
      "reference": "Yu HA et al. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Feb;25(2)423-8.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "http://library.iaslc.org/search-speaker?search_speaker=17991",
      "reference": "null. null. .",
      "abstract": "Yang et al. Abstract# O03.05, IASLC 2013"
    },
    {
      "pmid": "26051236",
      "title": "Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2015 Jul",
      "volume": "16",
      "issue": "7",
      "pages": "830-8",
      "authors": "Yang JC et al",
      "elocationId": "doi: 10.1016/S1470-2045(15)00026-1",
      "link": null,
      "reference": "Yang JC et al. The Lancet. Oncology. 2015 Jul;16(7)830-8.",
      "abstract": null
    },
    {
      "pmid": "23816963",
      "title": "LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2013 Sep 20",
      "volume": "31",
      "issue": "27",
      "pages": "3335-41",
      "authors": "Katakami N et al",
      "elocationId": "doi: 10.1200/JCO.2012.45.0981",
      "link": null,
      "reference": "Katakami N et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Sep 20;31(27)3335-41.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac98"
  },
  "level": "LEVEL_R1",
  "gene": "NRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Cetuximab"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "24024839",
      "title": "Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2013 Sep 12",
      "volume": "369",
      "issue": "11",
      "pages": "1023-34",
      "authors": "Douillard JY et al",
      "elocationId": "doi: 10.1056/NEJMoa1305275",
      "link": null,
      "reference": "Douillard JY et al. The New England journal of medicine. 2013 Sep 12;369(11)1023-34.",
      "abstract": null
    },
    {
      "pmid": "25110411",
      "title": "Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.",
      "journal": "World journal of gastroenterology",
      "pubDate": "2014 Aug 7",
      "volume": "20",
      "issue": "29",
      "pages": "9732-43",
      "authors": "De Stefano A et al",
      "elocationId": "doi: 10.3748/wjg.v20.i29.9732",
      "link": null,
      "reference": "De Stefano A et al. World journal of gastroenterology. 2014 Aug 7;20(29)9732-43.",
      "abstract": null
    },
    {
      "pmid": "20619739",
      "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2010 Aug",
      "volume": "11",
      "issue": "8",
      "pages": "753-62",
      "authors": "De Roock W et al",
      "elocationId": "doi: 10.1016/S1470-2045(10)70130-3",
      "link": null,
      "reference": "De Roock W et al. The Lancet. Oncology. 2010 Aug;11(8)753-62.",
      "abstract": null
    },
    {
      "pmid": "24024844",
      "title": "Beyond exon 2--the developing story of RAS mutations in colorectal cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2013 Sep 12",
      "volume": "369",
      "issue": "11",
      "pages": "1059-60",
      "authors": "Berlin J",
      "elocationId": "doi: 10.1056/NEJMe1307992",
      "link": null,
      "reference": "Berlin J. The New England journal of medicine. 2013 Sep 12;369(11)1059-60.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac99"
  },
  "level": "LEVEL_R1",
  "gene": "NRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Panitumumab"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "24024839",
      "title": "Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2013 Sep 12",
      "volume": "369",
      "issue": "11",
      "pages": "1023-34",
      "authors": "Douillard JY et al",
      "elocationId": "doi: 10.1056/NEJMoa1305275",
      "link": null,
      "reference": "Douillard JY et al. The New England journal of medicine. 2013 Sep 12;369(11)1023-34.",
      "abstract": null
    },
    {
      "pmid": "25110411",
      "title": "Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.",
      "journal": "World journal of gastroenterology",
      "pubDate": "2014 Aug 7",
      "volume": "20",
      "issue": "29",
      "pages": "9732-43",
      "authors": "De Stefano A et al",
      "elocationId": "doi: 10.3748/wjg.v20.i29.9732",
      "link": null,
      "reference": "De Stefano A et al. World journal of gastroenterology. 2014 Aug 7;20(29)9732-43.",
      "abstract": null
    },
    {
      "pmid": "20619739",
      "title": "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2010 Aug",
      "volume": "11",
      "issue": "8",
      "pages": "753-62",
      "authors": "De Roock W et al",
      "elocationId": "doi: 10.1016/S1470-2045(10)70130-3",
      "link": null,
      "reference": "De Roock W et al. The Lancet. Oncology. 2010 Aug;11(8)753-62.",
      "abstract": null
    },
    {
      "pmid": "24024844",
      "title": "Beyond exon 2--the developing story of RAS mutations in colorectal cancer.",
      "journal": "The New England journal of medicine",
      "pubDate": "2013 Sep 12",
      "volume": "369",
      "issue": "11",
      "pages": "1059-60",
      "authors": "Berlin J",
      "elocationId": "doi: 10.1056/NEJMe1307992",
      "link": null,
      "reference": "Berlin J. The New England journal of medicine. 2013 Sep 12;369(11)1059-60.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac9a"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F359I",
  "alteration_name": "F359I",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "19652056",
      "title": "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Sep 1",
      "volume": "27",
      "issue": "25",
      "pages": "4204-10",
      "authors": "Hughes T et al",
      "elocationId": "doi: 10.1200/JCO.2009.21.8230",
      "link": null,
      "reference": "Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac9b"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "E255K",
  "alteration_name": "E255K",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "19652056",
      "title": "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Sep 1",
      "volume": "27",
      "issue": "25",
      "pages": "4204-10",
      "authors": "Hughes T et al",
      "elocationId": "doi: 10.1200/JCO.2009.21.8230",
      "link": null,
      "reference": "Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac9c"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "E255V",
  "alteration_name": "E255V",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "19652056",
      "title": "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Sep 1",
      "volume": "27",
      "issue": "25",
      "pages": "4204-10",
      "authors": "Hughes T et al",
      "elocationId": "doi: 10.1200/JCO.2009.21.8230",
      "link": null,
      "reference": "Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac9d"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "Y253H",
  "alteration_name": "Y253H",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "19652056",
      "title": "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Sep 1",
      "volume": "27",
      "issue": "25",
      "pages": "4204-10",
      "authors": "Hughes T et al",
      "elocationId": "doi: 10.1200/JCO.2009.21.8230",
      "link": null,
      "reference": "Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac9e"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F359V",
  "alteration_name": "F359V",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "19652056",
      "title": "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Sep 1",
      "volume": "27",
      "issue": "25",
      "pages": "4204-10",
      "authors": "Hughes T et al",
      "elocationId": "doi: 10.1200/JCO.2009.21.8230",
      "link": null,
      "reference": "Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0fac9f"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "G250E",
  "alteration_name": "G250E",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "19652056",
      "title": "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Sep 1",
      "volume": "27",
      "issue": "25",
      "pages": "4204-10",
      "authors": "Hughes T et al",
      "elocationId": "doi: 10.1200/JCO.2009.21.8230",
      "link": null,
      "reference": "Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faca0"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F359C",
  "alteration_name": "F359C",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Nilotinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "23502220",
      "title": "Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.",
      "journal": "Blood",
      "pubDate": "2013 May 2",
      "volume": "121",
      "issue": "18",
      "pages": "3703-8",
      "authors": "Hochhaus A et al",
      "elocationId": "doi: 10.1182/blood-2012-04-423418",
      "link": null,
      "reference": "Hochhaus A et al. Blood. 2013 May 2;121(18)3703-8.",
      "abstract": null
    },
    {
      "pmid": "16775235",
      "title": "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.",
      "journal": "The New England journal of medicine",
      "pubDate": "2006 Jun 15",
      "volume": "354",
      "issue": "24",
      "pages": "2542-51",
      "authors": "Kantarjian H et al",
      "elocationId": "",
      "link": null,
      "reference": "Kantarjian H et al. The New England journal of medicine. 2006 Jun 15;354(24)2542-51.",
      "abstract": null
    },
    {
      "pmid": "19589924",
      "title": "Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2009 Sep 3",
      "volume": "114",
      "issue": "10",
      "pages": "2168-71",
      "authors": "Soverini S et al",
      "elocationId": "doi: 10.1182/blood-2009-01-197186",
      "link": null,
      "reference": "Soverini S et al. Blood. 2009 Sep 3;114(10)2168-71.",
      "abstract": null
    },
    {
      "pmid": "19652056",
      "title": "Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2009 Sep 1",
      "volume": "27",
      "issue": "25",
      "pages": "4204-10",
      "authors": "Hughes T et al",
      "elocationId": "doi: 10.1200/JCO.2009.21.8230",
      "link": null,
      "reference": "Hughes T et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Sep 1;27(25)4204-10.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faca1"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "V299L",
  "alteration_name": "V299L",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "20010464",
      "title": "Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.",
      "journal": "Polskie Archiwum Medycyny Wewnetrznej",
      "pubDate": "2009 Dec",
      "volume": "119",
      "issue": "12",
      "pages": "789-94",
      "authors": "Lewandowski K et al",
      "elocationId": "",
      "link": null,
      "reference": "Lewandowski K et al. Polskie Archiwum Medycyny Wewnetrznej. 2009 Dec;119(12)789-94.",
      "abstract": null
    },
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "12623848",
      "title": "Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.",
      "journal": "Blood",
      "pubDate": "2003 Jul 1",
      "volume": "102",
      "issue": "1",
      "pages": "276-83",
      "authors": "Branford S et al",
      "elocationId": "",
      "link": null,
      "reference": "Branford S et al. Blood. 2003 Jul 1;102(1)276-83.",
      "abstract": null
    },
    {
      "pmid": "19925053",
      "title": "Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.",
      "journal": "Leukemia & lymphoma",
      "pubDate": "2009 Dec",
      "volume": "50",
      "issue": "12",
      "pages": "2092-5",
      "authors": "Markose P et al",
      "elocationId": "doi: 10.3109/10428190903332486",
      "link": null,
      "reference": "Markose P et al. Leukemia & lymphoma. 2009 Dec;50(12)2092-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faca2"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "Y253H",
  "alteration_name": "Y253H",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "20010464",
      "title": "Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.",
      "journal": "Polskie Archiwum Medycyny Wewnetrznej",
      "pubDate": "2009 Dec",
      "volume": "119",
      "issue": "12",
      "pages": "789-94",
      "authors": "Lewandowski K et al",
      "elocationId": "",
      "link": null,
      "reference": "Lewandowski K et al. Polskie Archiwum Medycyny Wewnetrznej. 2009 Dec;119(12)789-94.",
      "abstract": null
    },
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "12623848",
      "title": "Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.",
      "journal": "Blood",
      "pubDate": "2003 Jul 1",
      "volume": "102",
      "issue": "1",
      "pages": "276-83",
      "authors": "Branford S et al",
      "elocationId": "",
      "link": null,
      "reference": "Branford S et al. Blood. 2003 Jul 1;102(1)276-83.",
      "abstract": null
    },
    {
      "pmid": "19925053",
      "title": "Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.",
      "journal": "Leukemia & lymphoma",
      "pubDate": "2009 Dec",
      "volume": "50",
      "issue": "12",
      "pages": "2092-5",
      "authors": "Markose P et al",
      "elocationId": "doi: 10.3109/10428190903332486",
      "link": null,
      "reference": "Markose P et al. Leukemia & lymphoma. 2009 Dec;50(12)2092-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faca3"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F359C",
  "alteration_name": "F359C",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "20010464",
      "title": "Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.",
      "journal": "Polskie Archiwum Medycyny Wewnetrznej",
      "pubDate": "2009 Dec",
      "volume": "119",
      "issue": "12",
      "pages": "789-94",
      "authors": "Lewandowski K et al",
      "elocationId": "",
      "link": null,
      "reference": "Lewandowski K et al. Polskie Archiwum Medycyny Wewnetrznej. 2009 Dec;119(12)789-94.",
      "abstract": null
    },
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "12623848",
      "title": "Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.",
      "journal": "Blood",
      "pubDate": "2003 Jul 1",
      "volume": "102",
      "issue": "1",
      "pages": "276-83",
      "authors": "Branford S et al",
      "elocationId": "",
      "link": null,
      "reference": "Branford S et al. Blood. 2003 Jul 1;102(1)276-83.",
      "abstract": null
    },
    {
      "pmid": "19925053",
      "title": "Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.",
      "journal": "Leukemia & lymphoma",
      "pubDate": "2009 Dec",
      "volume": "50",
      "issue": "12",
      "pages": "2092-5",
      "authors": "Markose P et al",
      "elocationId": "doi: 10.3109/10428190903332486",
      "link": null,
      "reference": "Markose P et al. Leukemia & lymphoma. 2009 Dec;50(12)2092-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faca4"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317I",
  "alteration_name": "F317I",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "20010464",
      "title": "Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.",
      "journal": "Polskie Archiwum Medycyny Wewnetrznej",
      "pubDate": "2009 Dec",
      "volume": "119",
      "issue": "12",
      "pages": "789-94",
      "authors": "Lewandowski K et al",
      "elocationId": "",
      "link": null,
      "reference": "Lewandowski K et al. Polskie Archiwum Medycyny Wewnetrznej. 2009 Dec;119(12)789-94.",
      "abstract": null
    },
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "12623848",
      "title": "Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.",
      "journal": "Blood",
      "pubDate": "2003 Jul 1",
      "volume": "102",
      "issue": "1",
      "pages": "276-83",
      "authors": "Branford S et al",
      "elocationId": "",
      "link": null,
      "reference": "Branford S et al. Blood. 2003 Jul 1;102(1)276-83.",
      "abstract": null
    },
    {
      "pmid": "19925053",
      "title": "Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.",
      "journal": "Leukemia & lymphoma",
      "pubDate": "2009 Dec",
      "volume": "50",
      "issue": "12",
      "pages": "2092-5",
      "authors": "Markose P et al",
      "elocationId": "doi: 10.3109/10428190903332486",
      "link": null,
      "reference": "Markose P et al. Leukemia & lymphoma. 2009 Dec;50(12)2092-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faca5"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317C",
  "alteration_name": "F317C",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "20010464",
      "title": "Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.",
      "journal": "Polskie Archiwum Medycyny Wewnetrznej",
      "pubDate": "2009 Dec",
      "volume": "119",
      "issue": "12",
      "pages": "789-94",
      "authors": "Lewandowski K et al",
      "elocationId": "",
      "link": null,
      "reference": "Lewandowski K et al. Polskie Archiwum Medycyny Wewnetrznej. 2009 Dec;119(12)789-94.",
      "abstract": null
    },
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "12623848",
      "title": "Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.",
      "journal": "Blood",
      "pubDate": "2003 Jul 1",
      "volume": "102",
      "issue": "1",
      "pages": "276-83",
      "authors": "Branford S et al",
      "elocationId": "",
      "link": null,
      "reference": "Branford S et al. Blood. 2003 Jul 1;102(1)276-83.",
      "abstract": null
    },
    {
      "pmid": "19925053",
      "title": "Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.",
      "journal": "Leukemia & lymphoma",
      "pubDate": "2009 Dec",
      "volume": "50",
      "issue": "12",
      "pages": "2092-5",
      "authors": "Markose P et al",
      "elocationId": "doi: 10.3109/10428190903332486",
      "link": null,
      "reference": "Markose P et al. Leukemia & lymphoma. 2009 Dec;50(12)2092-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faca6"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F359I",
  "alteration_name": "F359I",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "20010464",
      "title": "Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.",
      "journal": "Polskie Archiwum Medycyny Wewnetrznej",
      "pubDate": "2009 Dec",
      "volume": "119",
      "issue": "12",
      "pages": "789-94",
      "authors": "Lewandowski K et al",
      "elocationId": "",
      "link": null,
      "reference": "Lewandowski K et al. Polskie Archiwum Medycyny Wewnetrznej. 2009 Dec;119(12)789-94.",
      "abstract": null
    },
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "12623848",
      "title": "Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.",
      "journal": "Blood",
      "pubDate": "2003 Jul 1",
      "volume": "102",
      "issue": "1",
      "pages": "276-83",
      "authors": "Branford S et al",
      "elocationId": "",
      "link": null,
      "reference": "Branford S et al. Blood. 2003 Jul 1;102(1)276-83.",
      "abstract": null
    },
    {
      "pmid": "19925053",
      "title": "Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.",
      "journal": "Leukemia & lymphoma",
      "pubDate": "2009 Dec",
      "volume": "50",
      "issue": "12",
      "pages": "2092-5",
      "authors": "Markose P et al",
      "elocationId": "doi: 10.3109/10428190903332486",
      "link": null,
      "reference": "Markose P et al. Leukemia & lymphoma. 2009 Dec;50(12)2092-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faca7"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "T315A",
  "alteration_name": "T315A",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "20010464",
      "title": "Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.",
      "journal": "Polskie Archiwum Medycyny Wewnetrznej",
      "pubDate": "2009 Dec",
      "volume": "119",
      "issue": "12",
      "pages": "789-94",
      "authors": "Lewandowski K et al",
      "elocationId": "",
      "link": null,
      "reference": "Lewandowski K et al. Polskie Archiwum Medycyny Wewnetrznej. 2009 Dec;119(12)789-94.",
      "abstract": null
    },
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "12623848",
      "title": "Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.",
      "journal": "Blood",
      "pubDate": "2003 Jul 1",
      "volume": "102",
      "issue": "1",
      "pages": "276-83",
      "authors": "Branford S et al",
      "elocationId": "",
      "link": null,
      "reference": "Branford S et al. Blood. 2003 Jul 1;102(1)276-83.",
      "abstract": null
    },
    {
      "pmid": "19925053",
      "title": "Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.",
      "journal": "Leukemia & lymphoma",
      "pubDate": "2009 Dec",
      "volume": "50",
      "issue": "12",
      "pages": "2092-5",
      "authors": "Markose P et al",
      "elocationId": "doi: 10.3109/10428190903332486",
      "link": null,
      "reference": "Markose P et al. Leukemia & lymphoma. 2009 Dec;50(12)2092-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faca8"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317V",
  "alteration_name": "F317V",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "20010464",
      "title": "Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.",
      "journal": "Polskie Archiwum Medycyny Wewnetrznej",
      "pubDate": "2009 Dec",
      "volume": "119",
      "issue": "12",
      "pages": "789-94",
      "authors": "Lewandowski K et al",
      "elocationId": "",
      "link": null,
      "reference": "Lewandowski K et al. Polskie Archiwum Medycyny Wewnetrznej. 2009 Dec;119(12)789-94.",
      "abstract": null
    },
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "12623848",
      "title": "Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.",
      "journal": "Blood",
      "pubDate": "2003 Jul 1",
      "volume": "102",
      "issue": "1",
      "pages": "276-83",
      "authors": "Branford S et al",
      "elocationId": "",
      "link": null,
      "reference": "Branford S et al. Blood. 2003 Jul 1;102(1)276-83.",
      "abstract": null
    },
    {
      "pmid": "19925053",
      "title": "Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.",
      "journal": "Leukemia & lymphoma",
      "pubDate": "2009 Dec",
      "volume": "50",
      "issue": "12",
      "pages": "2092-5",
      "authors": "Markose P et al",
      "elocationId": "doi: 10.3109/10428190903332486",
      "link": null,
      "reference": "Markose P et al. Leukemia & lymphoma. 2009 Dec;50(12)2092-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0faca9"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "E255K",
  "alteration_name": "E255K",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "20010464",
      "title": "Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.",
      "journal": "Polskie Archiwum Medycyny Wewnetrznej",
      "pubDate": "2009 Dec",
      "volume": "119",
      "issue": "12",
      "pages": "789-94",
      "authors": "Lewandowski K et al",
      "elocationId": "",
      "link": null,
      "reference": "Lewandowski K et al. Polskie Archiwum Medycyny Wewnetrznej. 2009 Dec;119(12)789-94.",
      "abstract": null
    },
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "12623848",
      "title": "Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.",
      "journal": "Blood",
      "pubDate": "2003 Jul 1",
      "volume": "102",
      "issue": "1",
      "pages": "276-83",
      "authors": "Branford S et al",
      "elocationId": "",
      "link": null,
      "reference": "Branford S et al. Blood. 2003 Jul 1;102(1)276-83.",
      "abstract": null
    },
    {
      "pmid": "19925053",
      "title": "Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.",
      "journal": "Leukemia & lymphoma",
      "pubDate": "2009 Dec",
      "volume": "50",
      "issue": "12",
      "pages": "2092-5",
      "authors": "Markose P et al",
      "elocationId": "doi: 10.3109/10428190903332486",
      "link": null,
      "reference": "Markose P et al. Leukemia & lymphoma. 2009 Dec;50(12)2092-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facaa"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "E255V",
  "alteration_name": "E255V",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "20010464",
      "title": "Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.",
      "journal": "Polskie Archiwum Medycyny Wewnetrznej",
      "pubDate": "2009 Dec",
      "volume": "119",
      "issue": "12",
      "pages": "789-94",
      "authors": "Lewandowski K et al",
      "elocationId": "",
      "link": null,
      "reference": "Lewandowski K et al. Polskie Archiwum Medycyny Wewnetrznej. 2009 Dec;119(12)789-94.",
      "abstract": null
    },
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "12623848",
      "title": "Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.",
      "journal": "Blood",
      "pubDate": "2003 Jul 1",
      "volume": "102",
      "issue": "1",
      "pages": "276-83",
      "authors": "Branford S et al",
      "elocationId": "",
      "link": null,
      "reference": "Branford S et al. Blood. 2003 Jul 1;102(1)276-83.",
      "abstract": null
    },
    {
      "pmid": "19925053",
      "title": "Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.",
      "journal": "Leukemia & lymphoma",
      "pubDate": "2009 Dec",
      "volume": "50",
      "issue": "12",
      "pages": "2092-5",
      "authors": "Markose P et al",
      "elocationId": "doi: 10.3109/10428190903332486",
      "link": null,
      "reference": "Markose P et al. Leukemia & lymphoma. 2009 Dec;50(12)2092-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facab"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317L",
  "alteration_name": "F317L",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "20010464",
      "title": "Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.",
      "journal": "Polskie Archiwum Medycyny Wewnetrznej",
      "pubDate": "2009 Dec",
      "volume": "119",
      "issue": "12",
      "pages": "789-94",
      "authors": "Lewandowski K et al",
      "elocationId": "",
      "link": null,
      "reference": "Lewandowski K et al. Polskie Archiwum Medycyny Wewnetrznej. 2009 Dec;119(12)789-94.",
      "abstract": null
    },
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "12623848",
      "title": "Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.",
      "journal": "Blood",
      "pubDate": "2003 Jul 1",
      "volume": "102",
      "issue": "1",
      "pages": "276-83",
      "authors": "Branford S et al",
      "elocationId": "",
      "link": null,
      "reference": "Branford S et al. Blood. 2003 Jul 1;102(1)276-83.",
      "abstract": null
    },
    {
      "pmid": "19925053",
      "title": "Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.",
      "journal": "Leukemia & lymphoma",
      "pubDate": "2009 Dec",
      "volume": "50",
      "issue": "12",
      "pages": "2092-5",
      "authors": "Markose P et al",
      "elocationId": "doi: 10.3109/10428190903332486",
      "link": null,
      "reference": "Markose P et al. Leukemia & lymphoma. 2009 Dec;50(12)2092-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facac"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F359V",
  "alteration_name": "F359V",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "20010464",
      "title": "Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.",
      "journal": "Polskie Archiwum Medycyny Wewnetrznej",
      "pubDate": "2009 Dec",
      "volume": "119",
      "issue": "12",
      "pages": "789-94",
      "authors": "Lewandowski K et al",
      "elocationId": "",
      "link": null,
      "reference": "Lewandowski K et al. Polskie Archiwum Medycyny Wewnetrznej. 2009 Dec;119(12)789-94.",
      "abstract": null
    },
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "12623848",
      "title": "Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.",
      "journal": "Blood",
      "pubDate": "2003 Jul 1",
      "volume": "102",
      "issue": "1",
      "pages": "276-83",
      "authors": "Branford S et al",
      "elocationId": "",
      "link": null,
      "reference": "Branford S et al. Blood. 2003 Jul 1;102(1)276-83.",
      "abstract": null
    },
    {
      "pmid": "19925053",
      "title": "Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.",
      "journal": "Leukemia & lymphoma",
      "pubDate": "2009 Dec",
      "volume": "50",
      "issue": "12",
      "pages": "2092-5",
      "authors": "Markose P et al",
      "elocationId": "doi: 10.3109/10428190903332486",
      "link": null,
      "reference": "Markose P et al. Leukemia & lymphoma. 2009 Dec;50(12)2092-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facad"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "G250E",
  "alteration_name": "G250E",
  "cancer_main_type": "Myeloproliferative Neoplasms",
  "cancer_sub_type": "Chronic Myelogenous Leukemia",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17785585",
      "title": "Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.",
      "journal": "Blood",
      "pubDate": "2007 Dec 1",
      "volume": "110",
      "issue": "12",
      "pages": "4005-11",
      "authors": "Cortes J et al",
      "elocationId": "",
      "link": null,
      "reference": "Cortes J et al. Blood. 2007 Dec 1;110(12)4005-11.",
      "abstract": null
    },
    {
      "pmid": "20010464",
      "title": "Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.",
      "journal": "Polskie Archiwum Medycyny Wewnetrznej",
      "pubDate": "2009 Dec",
      "volume": "119",
      "issue": "12",
      "pages": "789-94",
      "authors": "Lewandowski K et al",
      "elocationId": "",
      "link": null,
      "reference": "Lewandowski K et al. Polskie Archiwum Medycyny Wewnetrznej. 2009 Dec;119(12)789-94.",
      "abstract": null
    },
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "12623848",
      "title": "Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.",
      "journal": "Blood",
      "pubDate": "2003 Jul 1",
      "volume": "102",
      "issue": "1",
      "pages": "276-83",
      "authors": "Branford S et al",
      "elocationId": "",
      "link": null,
      "reference": "Branford S et al. Blood. 2003 Jul 1;102(1)276-83.",
      "abstract": null
    },
    {
      "pmid": "19925053",
      "title": "Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.",
      "journal": "Leukemia & lymphoma",
      "pubDate": "2009 Dec",
      "volume": "50",
      "issue": "12",
      "pages": "2092-5",
      "authors": "Markose P et al",
      "elocationId": "doi: 10.3109/10428190903332486",
      "link": null,
      "reference": "Markose P et al. Leukemia & lymphoma. 2009 Dec;50(12)2092-5.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facae"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "V299L",
  "alteration_name": "V299L",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "11861307",
      "title": "Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.",
      "journal": "Blood",
      "pubDate": "2002 Mar 1",
      "volume": "99",
      "issue": "5",
      "pages": "1860-2",
      "authors": "Hofmann WK et al",
      "elocationId": "",
      "link": null,
      "reference": "Hofmann WK et al. Blood. 2002 Mar 1;99(5)1860-2.",
      "abstract": null
    },
    {
      "pmid": "17405907",
      "title": "Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).",
      "journal": "Blood",
      "pubDate": "2007 Jul 15",
      "volume": "110",
      "issue": "2",
      "pages": "727-34",
      "authors": "Pfeifer H et al",
      "elocationId": "",
      "link": null,
      "reference": "Pfeifer H et al. Blood. 2007 Jul 15;110(2)727-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facaf"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "Y253H",
  "alteration_name": "Y253H",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "11861307",
      "title": "Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.",
      "journal": "Blood",
      "pubDate": "2002 Mar 1",
      "volume": "99",
      "issue": "5",
      "pages": "1860-2",
      "authors": "Hofmann WK et al",
      "elocationId": "",
      "link": null,
      "reference": "Hofmann WK et al. Blood. 2002 Mar 1;99(5)1860-2.",
      "abstract": null
    },
    {
      "pmid": "17405907",
      "title": "Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).",
      "journal": "Blood",
      "pubDate": "2007 Jul 15",
      "volume": "110",
      "issue": "2",
      "pages": "727-34",
      "authors": "Pfeifer H et al",
      "elocationId": "",
      "link": null,
      "reference": "Pfeifer H et al. Blood. 2007 Jul 15;110(2)727-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facb0"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F359C",
  "alteration_name": "F359C",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "11861307",
      "title": "Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.",
      "journal": "Blood",
      "pubDate": "2002 Mar 1",
      "volume": "99",
      "issue": "5",
      "pages": "1860-2",
      "authors": "Hofmann WK et al",
      "elocationId": "",
      "link": null,
      "reference": "Hofmann WK et al. Blood. 2002 Mar 1;99(5)1860-2.",
      "abstract": null
    },
    {
      "pmid": "17405907",
      "title": "Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).",
      "journal": "Blood",
      "pubDate": "2007 Jul 15",
      "volume": "110",
      "issue": "2",
      "pages": "727-34",
      "authors": "Pfeifer H et al",
      "elocationId": "",
      "link": null,
      "reference": "Pfeifer H et al. Blood. 2007 Jul 15;110(2)727-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facb1"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317I",
  "alteration_name": "F317I",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "11861307",
      "title": "Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.",
      "journal": "Blood",
      "pubDate": "2002 Mar 1",
      "volume": "99",
      "issue": "5",
      "pages": "1860-2",
      "authors": "Hofmann WK et al",
      "elocationId": "",
      "link": null,
      "reference": "Hofmann WK et al. Blood. 2002 Mar 1;99(5)1860-2.",
      "abstract": null
    },
    {
      "pmid": "17405907",
      "title": "Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).",
      "journal": "Blood",
      "pubDate": "2007 Jul 15",
      "volume": "110",
      "issue": "2",
      "pages": "727-34",
      "authors": "Pfeifer H et al",
      "elocationId": "",
      "link": null,
      "reference": "Pfeifer H et al. Blood. 2007 Jul 15;110(2)727-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facb2"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317C",
  "alteration_name": "F317C",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "11861307",
      "title": "Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.",
      "journal": "Blood",
      "pubDate": "2002 Mar 1",
      "volume": "99",
      "issue": "5",
      "pages": "1860-2",
      "authors": "Hofmann WK et al",
      "elocationId": "",
      "link": null,
      "reference": "Hofmann WK et al. Blood. 2002 Mar 1;99(5)1860-2.",
      "abstract": null
    },
    {
      "pmid": "17405907",
      "title": "Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).",
      "journal": "Blood",
      "pubDate": "2007 Jul 15",
      "volume": "110",
      "issue": "2",
      "pages": "727-34",
      "authors": "Pfeifer H et al",
      "elocationId": "",
      "link": null,
      "reference": "Pfeifer H et al. Blood. 2007 Jul 15;110(2)727-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facb3"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F359I",
  "alteration_name": "F359I",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "11861307",
      "title": "Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.",
      "journal": "Blood",
      "pubDate": "2002 Mar 1",
      "volume": "99",
      "issue": "5",
      "pages": "1860-2",
      "authors": "Hofmann WK et al",
      "elocationId": "",
      "link": null,
      "reference": "Hofmann WK et al. Blood. 2002 Mar 1;99(5)1860-2.",
      "abstract": null
    },
    {
      "pmid": "17405907",
      "title": "Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).",
      "journal": "Blood",
      "pubDate": "2007 Jul 15",
      "volume": "110",
      "issue": "2",
      "pages": "727-34",
      "authors": "Pfeifer H et al",
      "elocationId": "",
      "link": null,
      "reference": "Pfeifer H et al. Blood. 2007 Jul 15;110(2)727-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facb4"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "T315A",
  "alteration_name": "T315A",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "11861307",
      "title": "Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.",
      "journal": "Blood",
      "pubDate": "2002 Mar 1",
      "volume": "99",
      "issue": "5",
      "pages": "1860-2",
      "authors": "Hofmann WK et al",
      "elocationId": "",
      "link": null,
      "reference": "Hofmann WK et al. Blood. 2002 Mar 1;99(5)1860-2.",
      "abstract": null
    },
    {
      "pmid": "17405907",
      "title": "Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).",
      "journal": "Blood",
      "pubDate": "2007 Jul 15",
      "volume": "110",
      "issue": "2",
      "pages": "727-34",
      "authors": "Pfeifer H et al",
      "elocationId": "",
      "link": null,
      "reference": "Pfeifer H et al. Blood. 2007 Jul 15;110(2)727-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facb5"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317V",
  "alteration_name": "F317V",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "11861307",
      "title": "Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.",
      "journal": "Blood",
      "pubDate": "2002 Mar 1",
      "volume": "99",
      "issue": "5",
      "pages": "1860-2",
      "authors": "Hofmann WK et al",
      "elocationId": "",
      "link": null,
      "reference": "Hofmann WK et al. Blood. 2002 Mar 1;99(5)1860-2.",
      "abstract": null
    },
    {
      "pmid": "17405907",
      "title": "Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).",
      "journal": "Blood",
      "pubDate": "2007 Jul 15",
      "volume": "110",
      "issue": "2",
      "pages": "727-34",
      "authors": "Pfeifer H et al",
      "elocationId": "",
      "link": null,
      "reference": "Pfeifer H et al. Blood. 2007 Jul 15;110(2)727-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facb6"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "E255K",
  "alteration_name": "E255K",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "11861307",
      "title": "Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.",
      "journal": "Blood",
      "pubDate": "2002 Mar 1",
      "volume": "99",
      "issue": "5",
      "pages": "1860-2",
      "authors": "Hofmann WK et al",
      "elocationId": "",
      "link": null,
      "reference": "Hofmann WK et al. Blood. 2002 Mar 1;99(5)1860-2.",
      "abstract": null
    },
    {
      "pmid": "17405907",
      "title": "Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).",
      "journal": "Blood",
      "pubDate": "2007 Jul 15",
      "volume": "110",
      "issue": "2",
      "pages": "727-34",
      "authors": "Pfeifer H et al",
      "elocationId": "",
      "link": null,
      "reference": "Pfeifer H et al. Blood. 2007 Jul 15;110(2)727-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facb7"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "E255V",
  "alteration_name": "E255V",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "11861307",
      "title": "Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.",
      "journal": "Blood",
      "pubDate": "2002 Mar 1",
      "volume": "99",
      "issue": "5",
      "pages": "1860-2",
      "authors": "Hofmann WK et al",
      "elocationId": "",
      "link": null,
      "reference": "Hofmann WK et al. Blood. 2002 Mar 1;99(5)1860-2.",
      "abstract": null
    },
    {
      "pmid": "17405907",
      "title": "Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).",
      "journal": "Blood",
      "pubDate": "2007 Jul 15",
      "volume": "110",
      "issue": "2",
      "pages": "727-34",
      "authors": "Pfeifer H et al",
      "elocationId": "",
      "link": null,
      "reference": "Pfeifer H et al. Blood. 2007 Jul 15;110(2)727-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facb8"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F317L",
  "alteration_name": "F317L",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "11861307",
      "title": "Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.",
      "journal": "Blood",
      "pubDate": "2002 Mar 1",
      "volume": "99",
      "issue": "5",
      "pages": "1860-2",
      "authors": "Hofmann WK et al",
      "elocationId": "",
      "link": null,
      "reference": "Hofmann WK et al. Blood. 2002 Mar 1;99(5)1860-2.",
      "abstract": null
    },
    {
      "pmid": "17405907",
      "title": "Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).",
      "journal": "Blood",
      "pubDate": "2007 Jul 15",
      "volume": "110",
      "issue": "2",
      "pages": "727-34",
      "authors": "Pfeifer H et al",
      "elocationId": "",
      "link": null,
      "reference": "Pfeifer H et al. Blood. 2007 Jul 15;110(2)727-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facb9"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "F359V",
  "alteration_name": "F359V",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "11861307",
      "title": "Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.",
      "journal": "Blood",
      "pubDate": "2002 Mar 1",
      "volume": "99",
      "issue": "5",
      "pages": "1860-2",
      "authors": "Hofmann WK et al",
      "elocationId": "",
      "link": null,
      "reference": "Hofmann WK et al. Blood. 2002 Mar 1;99(5)1860-2.",
      "abstract": null
    },
    {
      "pmid": "17405907",
      "title": "Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).",
      "journal": "Blood",
      "pubDate": "2007 Jul 15",
      "volume": "110",
      "issue": "2",
      "pages": "727-34",
      "authors": "Pfeifer H et al",
      "elocationId": "",
      "link": null,
      "reference": "Pfeifer H et al. Blood. 2007 Jul 15;110(2)727-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facba"
  },
  "level": "LEVEL_R1",
  "gene": "ABL1",
  "alteration": "G250E",
  "alteration_name": "G250E",
  "cancer_main_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "cancer_sub_type": "B-Lymphoblastic Leukemia/Lymphoma",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "17189410",
      "title": "Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2006 Dec 15",
      "volume": "12",
      "issue": "24",
      "pages": "7374-9",
      "authors": "Soverini S et al",
      "elocationId": "",
      "link": null,
      "reference": "Soverini S et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Dec 15;12(24)7374-9.",
      "abstract": null
    },
    {
      "pmid": "11861307",
      "title": "Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.",
      "journal": "Blood",
      "pubDate": "2002 Mar 1",
      "volume": "99",
      "issue": "5",
      "pages": "1860-2",
      "authors": "Hofmann WK et al",
      "elocationId": "",
      "link": null,
      "reference": "Hofmann WK et al. Blood. 2002 Mar 1;99(5)1860-2.",
      "abstract": null
    },
    {
      "pmid": "17405907",
      "title": "Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).",
      "journal": "Blood",
      "pubDate": "2007 Jul 15",
      "volume": "110",
      "issue": "2",
      "pages": "727-34",
      "authors": "Pfeifer H et al",
      "elocationId": "",
      "link": null,
      "reference": "Pfeifer H et al. Blood. 2007 Jul 15;110(2)727-34.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facbb"
  },
  "level": "LEVEL_R1",
  "gene": "NRAS",
  "alteration": "Oncogenic Mutations",
  "alteration_name": "Oncogenic Mutations",
  "cancer_main_type": "Colorectal Cancer",
  "cancer_sub_type": "",
  "drug": [
    "Trastuzumab",
    "Tucatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "30857956",
      "title": "Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.",
      "journal": "The Lancet. Oncology",
      "pubDate": "2019 Apr",
      "volume": "20",
      "issue": "4",
      "pages": "518-530",
      "authors": "Meric-Bernstam F et al",
      "elocationId": "doi: 10.1016/S1470-2045(18)30904-5",
      "link": null,
      "reference": "Meric-Bernstam F et al. The Lancet. Oncology. 2019 Apr;20(4)518-530.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facbc"
  },
  "level": "LEVEL_R1",
  "gene": "BTK",
  "alteration": "C481S",
  "alteration_name": "C481S",
  "cancer_main_type": "Mature B-Cell Neoplasms",
  "cancer_sub_type": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
  "drug": [
    "Ibrutinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "27282255",
      "title": "Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.",
      "journal": "Leukemia",
      "pubDate": "2017 Jan",
      "volume": "31",
      "issue": "1",
      "pages": "177-185",
      "authors": "Hamasy A et al",
      "elocationId": "doi: 10.1038/leu.2016.153",
      "link": null,
      "reference": "Hamasy A et al. Leukemia. 2017 Jan;31(1)177-185.",
      "abstract": null
    },
    {
      "pmid": "24869598",
      "title": "Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.",
      "journal": "The New England journal of medicine",
      "pubDate": "2014 Jun 12",
      "volume": "370",
      "issue": "24",
      "pages": "2286-94",
      "authors": "Woyach JA et al",
      "elocationId": "doi: 10.1056/NEJMoa1400029",
      "link": null,
      "reference": "Woyach JA et al. The New England journal of medicine. 2014 Jun 12;370(24)2286-94.",
      "abstract": null
    },
    {
      "pmid": "28418267",
      "title": "BTK<sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2017 May 1",
      "volume": "35",
      "issue": "13",
      "pages": "1437-1443",
      "authors": "Woyach JA et al",
      "elocationId": "doi: 10.1200/JCO.2016.70.2282",
      "link": null,
      "reference": "Woyach JA et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 May 1;35(13)1437-1443.",
      "abstract": null
    },
    {
      "pmid": "27626698",
      "title": "Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.",
      "journal": "Oncotarget",
      "pubDate": "2016 Oct 18",
      "volume": "7",
      "issue": "42",
      "pages": "68833-68841",
      "authors": "Sharma S et al",
      "elocationId": "doi: 10.18632/oncotarget.11932",
      "link": null,
      "reference": "Sharma S et al. Oncotarget. 2016 Oct 18;7(42)68833-68841.",
      "abstract": null
    },
    {
      "pmid": "29296715",
      "title": "Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL.",
      "journal": "Blood advances",
      "pubDate": "2017 May 9",
      "volume": "1",
      "issue": "12",
      "pages": "715-727",
      "authors": "Kadri S et al",
      "elocationId": "doi: 10.1182/bloodadvances.2016003632",
      "link": null,
      "reference": "Kadri S et al. Blood advances. 2017 May 9;1(12)715-727.",
      "abstract": null
    },
    {
      "pmid": "28049639",
      "title": "Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.",
      "journal": "Blood",
      "pubDate": "2017 Mar 16",
      "volume": "129",
      "issue": "11",
      "pages": "1469-1479",
      "authors": "Ahn IE et al",
      "elocationId": "doi: 10.1182/blood-2016-06-719294",
      "link": null,
      "reference": "Ahn IE et al. Blood. 2017 Mar 16;129(11)1469-1479.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facbd"
  },
  "level": "LEVEL_R1",
  "gene": "NTRK3",
  "alteration": "G696A",
  "alteration_name": "G696A",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Larotrectinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "28578312",
      "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
      "journal": "Cancer discovery",
      "pubDate": "2017 Sep",
      "volume": "7",
      "issue": "9",
      "pages": "963-972",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-17-0507",
      "link": null,
      "reference": "Drilon A et al. Cancer discovery. 2017 Sep;7(9)963-972.",
      "abstract": null
    },
    {
      "pmid": "26546295",
      "title": "Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.",
      "journal": "Cancer discovery",
      "pubDate": "2016 Jan",
      "volume": "6",
      "issue": "1",
      "pages": "36-44",
      "authors": "Russo M et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-15-0940",
      "link": null,
      "reference": "Russo M et al. Cancer discovery. 2016 Jan;6(1)36-44.",
      "abstract": null
    },
    {
      "pmid": "29466156",
      "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Feb 22",
      "volume": "378",
      "issue": "8",
      "pages": "731-739",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1056/NEJMoa1714448",
      "link": null,
      "reference": "Drilon A et al. The New England journal of medicine. 2018 Feb 22;378(8)731-739.",
      "abstract": null
    },
    {
      "pmid": "30333516",
      "title": "NTRK fusion-positive cancers and TRK inhibitor therapy.",
      "journal": "Nature reviews. Clinical oncology",
      "pubDate": "2018 Dec",
      "volume": "15",
      "issue": "12",
      "pages": "731-747",
      "authors": "Cocco E et al",
      "elocationId": "doi: 10.1038/s41571-018-0113-0",
      "link": null,
      "reference": "Cocco E et al. Nature reviews. Clinical oncology. 2018 Dec;15(12)731-747.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facbe"
  },
  "level": "LEVEL_R1",
  "gene": "NTRK3",
  "alteration": "G623R",
  "alteration_name": "G623R",
  "cancer_main_type": "All Solid Tumors",
  "cancer_sub_type": "",
  "drug": [
    "Larotrectinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "28578312",
      "title": "A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.",
      "journal": "Cancer discovery",
      "pubDate": "2017 Sep",
      "volume": "7",
      "issue": "9",
      "pages": "963-972",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-17-0507",
      "link": null,
      "reference": "Drilon A et al. Cancer discovery. 2017 Sep;7(9)963-972.",
      "abstract": null
    },
    {
      "pmid": null,
      "title": null,
      "journal": null,
      "pubDate": null,
      "volume": null,
      "issue": null,
      "pages": null,
      "authors": null,
      "elocationId": null,
      "link": "https://tptherapeutics.com/wp-content/uploads/AACR_2019_TRK_Final_S.pdf",
      "reference": "null. null. .",
      "abstract": "Drilon et al. Abstract# 4000, AACR 2019"
    },
    {
      "pmid": "29466156",
      "title": "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.",
      "journal": "The New England journal of medicine",
      "pubDate": "2018 Feb 22",
      "volume": "378",
      "issue": "8",
      "pages": "731-739",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1056/NEJMoa1714448",
      "link": null,
      "reference": "Drilon A et al. The New England journal of medicine. 2018 Feb 22;378(8)731-739.",
      "abstract": null
    },
    {
      "pmid": "33328556",
      "title": "NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.",
      "journal": "Communications biology",
      "pubDate": "2020 Dec 16",
      "volume": "3",
      "issue": "1",
      "pages": "776",
      "authors": "Somwar R et al",
      "elocationId": "doi: 10.1038/s42003-020-01508-w",
      "link": null,
      "reference": "Somwar R et al. Communications biology. 2020 Dec 16;3(1)776.",
      "abstract": null
    },
    {
      "pmid": "30093503",
      "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
      "journal": "Cancer discovery",
      "pubDate": "2018 Oct",
      "volume": "8",
      "issue": "10",
      "pages": "1227-1236",
      "authors": "Drilon A et al",
      "elocationId": "doi: 10.1158/2159-8290.CD-18-0484",
      "link": null,
      "reference": "Drilon A et al. Cancer discovery. 2018 Oct;8(10)1227-1236.",
      "abstract": null
    }
  ]
},{
  "_id": {
    "$oid": "63e345920717205c0e0facbf"
  },
  "level": "LEVEL_R1",
  "gene": "PDGFRA",
  "alteration": "D842V",
  "alteration_name": "D842V",
  "cancer_main_type": "Gastrointestinal Stromal Tumor",
  "cancer_sub_type": "",
  "drug": [
    "Imatinib"
  ],
  "knownEffect": "Resistant",
  "articles": [
    {
      "pmid": "22745105",
      "title": "Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Aug 15",
      "volume": "18",
      "issue": "16",
      "pages": "4375-84",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-12-0625",
      "link": null,
      "reference": "Heinrich MC et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Aug 15;18(16)4375-84.",
      "abstract": null
    },
    {
      "pmid": "12949711",
      "title": "Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.",
      "journal": "Gastroenterology",
      "pubDate": "2003 Sep",
      "volume": "125",
      "issue": "3",
      "pages": "660-7",
      "authors": "Hirota S et al",
      "elocationId": "",
      "link": null,
      "reference": "Hirota S et al. Gastroenterology. 2003 Sep;125(3)660-7.",
      "abstract": null
    },
    {
      "pmid": "18955458",
      "title": "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2008 Nov 20",
      "volume": "26",
      "issue": "33",
      "pages": "5352-9",
      "authors": "Heinrich MC et al",
      "elocationId": "doi: 10.1200/JCO.2007.15.7461",
      "link": null,
      "reference": "Heinrich MC et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Nov 20;26(33)5352-9.",
      "abstract": null
    },
    {
      "pmid": "23752188",
      "title": "PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.",
      "journal": "Oncogene",
      "pubDate": "2014 May 15",
      "volume": "33",
      "issue": "20",
      "pages": "2568-76",
      "authors": "Velghe AI et al",
      "elocationId": "doi: 10.1038/onc.2013.218",
      "link": null,
      "reference": "Velghe AI et al. Oncogene. 2014 May 15;33(20)2568-76.",
      "abstract": null
    },
    {
      "pmid": "15685537",
      "title": "Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.",
      "journal": "Gastroenterology",
      "pubDate": "2005 Feb",
      "volume": "128",
      "issue": "2",
      "pages": "270-9",
      "authors": "Debiec-Rychter M et al",
      "elocationId": "",
      "link": null,
      "reference": "Debiec-Rychter M et al. Gastroenterology. 2005 Feb;128(2)270-9.",
      "abstract": null
    },
    {
      "pmid": "18794084",
      "title": "Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2008 Sep 15",
      "volume": "14",
      "issue": "18",
      "pages": "5749-58",
      "authors": "Dewaele B et al",
      "elocationId": "doi: 10.1158/1078-0432.CCR-08-0533",
      "link": null,
      "reference": "Dewaele B et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Sep 15;14(18)5749-58.",
      "abstract": null
    },
    {
      "pmid": "24963404",
      "title": "Imatinib: a breakthrough of targeted therapy in cancer.",
      "journal": "Chemotherapy research and practice",
      "pubDate": "2014",
      "volume": "2014",
      "issue": "",
      "pages": "357027",
      "authors": "Iqbal N et al",
      "elocationId": "doi: 10.1155/2014/357027",
      "link": null,
      "reference": "Iqbal N et al. Chemotherapy research and practice. 2014;2014()357027.",
      "abstract": null
    },
    {
      "pmid": "22718859",
      "title": "Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.",
      "journal": "Clinical cancer research : an official journal of the American Association for Cancer Research",
      "pubDate": "2012 Aug 15",
      "volume": "18",
      "issue": "16",
      "pages": "4458-64",
      "authors": "Cassier PA et al",
      "elocationId": "",
      "link": null,
      "reference": "Cassier PA et al. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Aug 15;18(16)4458-64.",
      "abstract": null
    },
    {
      "pmid": "15928335",
      "title": "PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.",
      "journal": "Journal of clinical oncology : official journal of the American Society of Clinical Oncology",
      "pubDate": "2005 Aug 10",
      "volume": "23",
      "issue": "23",
      "pages": "5357-64",
      "authors": "Corless CL et al",
      "elocationId": "",
      "link": null,
      "reference": "Corless CL et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Aug 10;23(23)5357-64.",
      "abstract": null
    },
    {
      "pmid": "25905001",
      "title": "Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program.",
      "journal": "Clinical sarcoma research",
      "pubDate": "2014",
      "volume": "4",
      "issue": "",
      "pages": "17",
      "authors": "Kollàr A et al",
      "elocationId": "doi: 10.1186/2045-3329-4-17",
      "link": null,
      "reference": "Kollàr A et al. Clinical sarcoma research. 2014;4()17.",
      "abstract": null
    },
    {
      "pmid": "17087936",
      "title": "Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.",
      "journal": "Gastroenterology",
      "pubDate": "2006 Dec",
      "volume": "131",
      "issue": "6",
      "pages": "1734-42",
      "authors": "Weisberg E et al",
      "elocationId": "",
      "link": null,
      "reference": "Weisberg E et al. Gastroenterology. 2006 Dec;131(6)1734-42.",
      "abstract": null
    }
  ]
}]